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And a woman spoke, saying, Tell us of pain. 
And he said: 
Your pain is the breaking of the shell that encloses your understanding. 
Even as the stone of the fruit must break, that its heart may stand in the 
sun, so must you know pain. 
And could you keep your heart in wonder at the daily miracles of your 
life, your pain would not seem less wondrous than your joy ..... . 
And you would watch with serenity through the winters of your grief. 
F or much of your pain is self chosen. 
It is the bitter potion by which the physician within you heals your sick 
self. 
Therefore trust the physician, and drink his remedy in silence and 
tranquillity; 
F or his hand, though heavy and hard, is guided by the tender hand of the 
Unseen, 
and the cup he brings, though it bum your lips, has been fashioned of the 
clay which the Potter has moistened with his own tears. 
From: The Prophet, Kahlil Gibran 
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ABSTRACT 
The pain transmission system is inherently plastic in nature; plasticity of nociceptive 
processing in the dorsal hom of the spinal cord is believed to contribute to clinical states of 
post-injury pain hypersensitivity. Both enhancement and tachyphylaxis of nociceptive 
processing have been reported previously following repeated carrageenan-induced 
inflammation. The present study aimed to investigate central mechanisms involved in the 
transformation of pain transmission from 'physiological' to 'pathophysiological' in adult 
rats, using a model of mild intraplantar inflammation induced by intraplantar 
administration of carrageenan at doses markedly lower than those standardly used in 
research into central mechanisms of inflammatory pain transmission. Changes in plantar 
inflammation, thermal and mechanical sensitivity were assessed following intraplantar 
injection of repeated doses of carrageenan (0.5%, corresponding to a dose of 0.25 mg and 
0.1 %, corresponding to a dose of 0.05 mg), administered at weekly (0.5% and 0.1 %) and 
daily (0.1%) intervals. Expression of mRNA of key genes implicated in plasticity of 
central spinal pain transmission in laminae I, II and V of the dorsal hom of the lumbar 
spinal cord (laminae involved in central nociceptive transmission) was investigated using 
in-situ hybridisation techniques. The genes investigated were calcium calmodulin kinase 
IIa (CaMKIla), a key intracellular molecule instantaneously activated by neuronal 
stimulation; alterations in CaMKIla expression can rapidly induce nociceptive plasticity 
through modulation of many excitatory and inhibitory nociceptive mediators; the cyclo-
oxygenase enzymes COX-1 and COX-2, which catalyse prostaglandin synthesis and are 
implicated in the modulation of the central nociceptive response to inflammatory injury; 
the immediate early genes zif11268, junD and tissue plasminogen activator (tPA), which 
have been implicated in the induction and maintenance of neuronal plasticity in higher 
centres, and the precursors for the inhibitory neurotransmitter molecules y-amino butyric 
acid (GABA), enkephalin and dynorphin. A method for organotypic culture of neonatal 
spinal cord was developed and characterised with the aim of providing a useful technique 
for more detailed study of the molecular basis of nociceptive plasticity. 
Mild inflammatory injury induced by 0.5% and 0.1% carrageenan treatment induced 
consistent hyperalgesic behaviour, which did not change following weekly repeated 
xi 
injection. Temporary attenuation of hyperalgesia developed following daily repetitive 
administration of 0.1 % carrageenan, but hyperalgesia returned when this repetitive 
inflammatory stimulation was maintained. Preliminary studies on the role of NMDA 
receptors, opioid receptors and a 2A adrenoreceptors in the mediation of this tachyphylaxis 
suggest that these receptor systems did not playa major role in the observed tachyphylaxis 
In-situ hybridization studies did not identify changes in gene expression induced by 
repetitive carrageenan treatment in lamina V. In laminae I1II, changes were observed in 
expression of certain genes (notably CaMKIla, COX-2 and proenkephalin), but not of 
immediate early genes, GAD 67 or prodynorphin. Hyperalgesia associated with weekly 
carrageenan treatment correlated closely with significantly enhanced transcription of 
CaMKIla mRNA in laminae IIII; moreover, tachyphylaxis of hyperalgesic behaviour 
correlated with attenuation of CaMKIla upregulation. Since increased expression of 
CaMKIla, leading to regulation of expression of a range of kinase-dependent receptors and 
intracellular mediators, is a hallmark of neuronal plasticity in higher centers, this suggests 
that central plasticity of nociceptive transmission in the dorsal hom could have contributed 
to the development of hyperalgesia following carrageenan treatment. Weekly 
administration of carrageenan also consistently induced significant upregulation of COX-2 
and proenkephalin mRNA expression in laminae I1II, suggesting that ultimate modulation 
of pain sensation following inflammatory injury is determined by the interaction of 
excitatory and inhibitory transmitter pathways. COX-I, prodynorphin and GAD 67 mRNA 
expression were not significantly changed in relation to the intensity of inflammatory 
injury or in relation to changes in nociceptive responses. This would suggest that these 
mediators did not play a key role in the modulation of spinal nociceptive transmission 
associated with mild inflammatory injury. With the possible exception of CaMKIla, 
changes in gene expression did not correlate closely with plasticity of nociceptive 
behaviour induced by daily repeated carrageenan treatment. 
200 !lm transverse slices of postnatal spinal cord were cultured successfully for up to 5 
days using a simple interface culture system. Histochemical and immunocytochemical 
assays indicated that the architecture of organotypically cultured spinal cord closely 
resembled that observed in-vivo. 
This study presents a new approach to the investigation of neuronal plasticity associated 
with tissue injury and inflammation. Different mechanisms underlying plasticity of 
XlI 
nociceptive responses may be induced by induced by high intensity as opposed to low-
intensity injury. The observation of tachyphylaxis of hyperalgesia following daily repeated 
carrageenan treatment may represent engagement of endogenous 'anti-hyperalgesic' 
mechanisms. Further investigation of the molecular basis of endogenous 'anti-
hyperalgesia', facilitated by organotypic slice culture techniques, may identify new targets 
for the treatment and prevention of persistent pathological nociceptive transmission 
following inflammatory injury. 
Xlll 
CHAPTER 1: INTRODUCTION 
The truth is out there 
(Carter, 1999) 
1.1 'PHYSIOLOGICAL' PAIN TRANSMISSION: THE NOCICEPTIVE 
PATHWAY 
Mankind has struggled to understand the nature of pain since time immemorial. The 
conscious experience of 'pain' defies precise anatomical, physiological and or 
pharmacological definition; unlike any other sensory experience, it is a subjective emotion 
which can be experienced even in the absence of obvious external stimulation, and which 
can be enhanced or abolished by a wide range of behavioural experiences. It cannot be 
seen or directly measured, but its patterns can be recognised. While elusive and ill 
defined, 'pain' nonetheless has substance and specific characteristics. We now recognise 
that conscious perception of pain is not the result of a simple transfer of information via 
ascending nociceptive pathways from the periphery to the brain, but rather the result of 
interplay of facilitatory and inhibitory pathways, which use an orchestra of interacting 
neurotransmitter systems. The highly subjective nature of pain perception is one of the 
factors which make it difficult to define and treat clinically. 
The neuroanatomy of the pain system and of the pathways that modulate pain perception 
are illustrated in figure 1.1. 
Pain pathways 
Following tissue injury, nociceptive information is relayed from the periphery to the CNS 
by nociceptors, the peripheral endings of primary sensory neurons whose cell bodies are 
located in the dorsal root and trigeminal ganglia. The structure and functional 
characteristics of the peripheral nociceptor have been reviewed by Casey (1992), 
Handwerker & Reeh (1992) and Willis et al. (1995a). Nociceptors, first described by 
Sherrington in 1906, are the least differentiated of the cutaneous sensory receptors, 
existing as free nerve endings lacking peripheral structures to filter or transduce external 
stimuli. Three types of afferent fibre conduct nociceptive information: C-fibres, A8 fibres 
and A~ fibres. Their properties are reviewed by Jessell & Kelly (1997) and Millan (1999). 
Figure 1 : The pain transmission pathway 
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Unmyelinated polymodal C fibres are activated by intense mechanical, chemical and 
thermal stimuli and conduct impulses relatively slowly at approximately O.5m1s. Thermal 
and mechanical stimulation thresholds of C fibres are substantially higher than those of 
other types of afferent sensory fibre, requiring, for example, noxious thermal stimulation at 
temperatures above 45°C to elicit a response. Physiologically, the C-nociceptor responds 
directly to increasing intensity of noxious stimulation- the greater the stimulus strength, the 
more vigorous the response (reviewed by Besson & Chaouch, 1987). Repeated 
stimulation, however, enhances C-nociceptor responsivity to a given stimulus strength 
(LaMotte, 1984, reviewed by Campbell et al., 1989). In contrast to other sensory afferent 
fibres, C-nociceptors have no background discharge pattern under physiological conditions 
but can develop a tonic discharge pattern following a single vigorous stimulation (Perl 
1992). Pain in the absence of ongoing external stimulation has been associated with the 
development of background activity in sensitised C-nociceptors (Jessell & Kelly, 1997). 
Thermal and mechanical nociceptors may also be supplied by finely myelinated A8 fibres, 
which conduct impulses at 5-30mls. Larger diameter low-threshold A~ fibres (which 
normally relay sensory information from mechanoreceptors) are also capable of 
transmitting nociceptive signals to higher centres and are believed to contribute to the 
development of pathological pain sensation (reviewed by Ren, 1996) , although they are 
not normally involved in nociceptive transmission (Price & Dubner, 1977, Wiesenfeld-
Hallin et al., 1984). 
Axons of A8 and C nociceptive fibres bifurcate on entering the spinal cord as they pass 
through the dorsal root ganglia and ascend and descend for some segments as constituents 
of the dorsolateral fasciculus of Lissauer, while collaterals synapse with projection neurons 
in the dorsal hom of the spinal cord [reviewed by Grant (1995); Jessell and Kelly, 1997]. 
The division of the grey matter of the spinal cord into distinct laminae, according to 
neuronal type and function, was described by Rexed (1952; 1954) and reviewed by 
Molander & Grant (1995). Laminae I-V comprise the dorsal hom. Nociceptive fibres 
terminate primarily in the superficial dorsal hom (laminae IIII) although some fine 
nociceptor axons terminate in deeper laminae (notably laminae V-VI) and close to the 
central canal (lamina X). Nociceptive afferent neurons form direct or indirect connections 
with three major classes of neuron in the dorsal hom: projection neurons which relay 
incoming sensory information to higher centres in the brain; excitatory interneurons; and 
inhibitory interneurons which regulate and modulate the flow of nociceptive information to 
higher centres. 
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The neurons of the dorsal horn have been classified into three types according to the nature 
of their response to nociceptive input (reviewed by Millan, 1999). Non-nociceptive 
neurons occur predominantly in laminae II, III and IV, although a small number are 
present in lamina 1. Nociceptive-specific (NS) neurons are activated exclusively by high-
intensity noxious stimuli mediated by C and A8 fibres and are concentrated in laminae IIII 
(although also present in lamina V). These neurons have very limited capacity to encode 
stimulus intensity. Wide-dynamic range (WDR) neurons display considerable convergence 
from cutaneous, muscular and visceral input (Mense, 1986; 1995). WDR neurons are 
found predominantly in lamina V but also in laminae I, II, III,VI and X and also occur in 
the ventral horn. WDR neurons encode stimulus intensity (Dubner et at., 1989) and are 
excited by thermal, mechanical and thermal stimuli mediated by C, A8 and A~ fibres, 
producing a response which is directly related to the intensity of stimulation. 
Figure 1.2 illustrates the laminar arrangement of the rat spinal dorsal horn. 
Lamina I, classically named 'the marginal zone', contains a high density of projection 
neuronswhich process nociceptive information. It is composed principally of large 
horizontal neurons (the marginal cells of Waldeyer) and a plexus of horizontally arranged 
fine axons. Lamina I neurons have been divided into two populations on a functional 
basis (Jessell & Kelly, 1997): one 'nociceptor-specific' population is excited solely by C 
and A-8 nociceptor fibres, the second 'wide dynamic range' population receives input 
from low-threshold mechanoreceptors in addition to nociceptors. Axons of lamina I 
neurons project to other regions of the spinal cord and also to the thalamus, midbrain, 
reticular formation in the brain stern, and cerebellum. Lamina I receives input from both 
fine unmyelinated axons (C fibres) and larger myelinated A-8 axons )(Gobel et at., 1981) 
Lamina II, termed' the substantia gelatinosa' due to its distinctive gelatinous appearance, 
is composed predominantly of small neurons and their unmyelinated processes. Lamina II 
constitutes the main projection area for cutaneous C-fibres while also receiving sparse 
primary afferent input from A8 fibres (LaMotte, 1977; Sugiura et at., 1986). Lamina II 
also receives C-fibre input from visceral areas. Most lamina II neurons display extensive 
local axonal arborisation, such that even 'projection neurons', which relay information to 
Figure 1.2 
The termination of afferent fibres in the dorsal horn of the spinal cord 
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distant centres, also integrate locally. Lamina II neurons have multiple projection targets. 
Some 'true' projection neurons project out of the spinal cord; some 'propriospinal' 
neurons project to distant spinal segments; some project to other laminae in the same or 
adjacent spinal segments; and some neurons communicate with other neurons in lamina 
II(Millan, 1999). 
Lamina III forms a broad band across the dorsal hom, distinguished from lamina II by the 
presence of slightly larger neurons with myelinated axons. The predominant primary 
afferent input into lamina III is from fibres transmitting sensory information from hair 
follicles; other primary afferent fibres entering lamina III arise from pacinian corpuscles 
and A~ fibres; many cells in lamina III respond only to mild mechanical stimulation 
(Cervero et al., 1988) 
Laminae IV and V are similar in terms of their composition and the axonal destinations of 
their projections. Primary afferent input to lamina IV comes from large primary afferent 
(A~) fibres organised into a prominent longitudinal plexus; as in lamina III, many cells in 
lamina IV respond only to light mechanical stimulation, but nociceptive specific and wide 
dynamic range fibres (C and Ai)) are also present (Cervero et al., 1988). Some of the cells 
of lamina IV are post-synaptic dorsal column and spino-cervical tract cells which 
communicate with neurons located in superficial laminae. The axons of cells in lamina 
IV pass to the thalamus, the lateral cervical nucleus, the dorsal column nuclei, and other 
regions of the spinal cord. Lamina V forms a thick band across the narrowest part of the 
dorsal hom and is composed of a heterogeneous population of neuronswhich project 
principally to the thalamus, the lateral cervical nucleus, dorsal column nuclei and local 
destinations in the spinal cord. 
Lamina VI, described only in the cervical and lumbosacral enlargements of the spinal cord, 
is a transition between the primary afferent dominated dorsal hom, and the ventral hom in 
which motor activity is co-ordinated and ultimately initiated (Willis & Coggeshall, 1991b). 
Lamina VII corresponds to the intermediate grey matter, while laminae VIII and IX 
comprise the medial and lateral ventral hom respectively. These laminae have not been 
accorded an important role in the transmission of nociceptive information. Lamina X is 
the area surrounding the central canal. The cells are generally small and more densely 
packed than those in the adjacent lamina VII. Many lamina X cells respond to noxious 
stimuli (Nahin et al., 1982). Cells from lamina X project to the brainstem (Nahin et al., 
1983), the hypothalamus (Burstein et al., 1987) and the thalamus (Burstein et ai., 1990). 
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Nociceptive input into the dorsal hom originating from sensory stimulation of the body is 
relayed to higher centres by projection neurons, which are organised into so-called 
'ascending pathways'. Ascending pathways are species-specific, bilaterally symmetrical 
and for the most part cross to the contralateral cortex for perception and control. There are 
numerous differences between species in anatomical location and relative importance of 
ascending nociceptive pathways. The following description refers to the rat, where the 
major ascending nociceptive pathways in the spinal cord are the spinothalamic tract, the 
spinoreticular tract and the spinomesencephalic tract (reviewed by Willis (1985), Willis & 
Coggeshall (1991), Tracey (1995) and Willis et ai. (1995). 
The spinothalamic tract, the most prominent ascending pathway in the primate (Jessell and 
Kelly 1997), carries the axons of nociceptive-specific and wide-dynamic range neurons 
originating in laminae I, VI and VII to terminate in the thalamus. The spinoreticular tract 
in the rat originates from neurons concentrated in laminae V, VII, VIII and X (Chaoch et 
ai.} 1983) to terminate in the thalamus and the reticular formation (Willis 1985; Willis & 
Coggeshall, 1991). The spinomesencephalic tract, another major ascending tract in the 
primate (Jessell & Kelly, 1997) carries axons originating in laminae I and V up to the 
midbrain, notably the mesencephalic reticulum and the lateral periaqueductal grey matter 
(P AG, which makes reciprocal connections with the limbic system through the 
hypothalamus). In the rat the spinomesencephalic tract is believed to process 
motivational-affective aspects of pain perception and stimulate activity in descending 
control systems rather than processing sensory-discriminative aspects of pain (Willis et ai.} 
1995). 
Additional ascending tracts have been extensively studied in other species, notably 
primates and cats, but are less well documented in the rat (Willis et ai., 1995). The 
spinocervical tract, identified in the primate and the rat, carries axons from neurons 
originating in laminae III and IV (predominantly neurons which respond specifically to 
mechanical stimuli but also a small population of nociceptive neurons (Giesler et ai.} 1979) 
to the lateral cervical nucleus, a small cluster of neurons lateral to the dorsal hom in the 
upper cervical segments of the spinal cord. Axons from this nucleus ascend in the 
contralateral medial lemniscus of the brainstem to midbrain nuclei and the thalamus. 
Spinal hypothalamic and spinotelencephalic tracts have also been described and ascribed a 
role in nociceptive processing in the rat (Burstein et ai.} 1987, Burstein & Giesler, 1989). 
In the primate, a small number of nociceptive neurons in laminae III and IV project their 
axons, accompanied by the axon collaterals of large-diameter myelinated primary afferent 
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fibres, to the cuneate and gracile nuclei of the medulla (Jessell & Kelly, 1997) but this 
ascending pathway has not been reported in the rat. 
Nociceptive input into the central nervous system originating from sensory stimulation of 
the head is transmitted via the trigeminal nerve (reviewed by Ranson & Clark, 1959). 
The thalamus is the principal synaptic relay for information reaching the cerebral cortex 
and contains distinct sensory nuclei, divided into medial and lateral groups, which process 
input about different sensory modalities (reviewed by Lund & Webster, 1967). The 
medial nuclear group, whose neurons project widely to basal ganglia and many different 
cortical areas, is not concerned exclusively with processing nociceptive information, but is 
part of a non-specific arousal system, although many neurons in the medial thalamus do 
respond optimally to noxious stimuli. The lateral nuclear group, which includes the 
ventrobasal nucleus and the posterior thalamic nuclei - receives input primarily from 
nociceptive-specific and WDR neurons in laminae I and V. Certain neurons in the lateral 
thalamus respond exclusively to noxious stimuli while others respond to multiple sensory 
stimuli. In the rat, the most extensively studied thalamic nuclei associated with processing 
of nociceptive information are the ventral posteriolateral (VPL) nucleus, the posterior 
thalamic nuclear group, and the reticular thalamic nucleus (Guilbaud et al., 1980; 
Peschanski et al., 1981). 
In higher centres, conscious perception of pain results from activation of a complex 
network of structures, each of which participates differently in the multiple aspects of the 
pain experience. Brain imaging studies perfOlmed in humans using positron emission 
tomography (PET) and functional magnetic resonance (fMRI) have identified many 
cortical and subcortical sites which demonstrate a multifocal and predictable pattern of 
activation in response to noxious stimulation, and it has been suggested that there is at 
least partial functional segregation of regions involved in the sensory and affective 
dimensions of pain (reviewed by Treede et al., 1999; Bushnell et al., 1999; Davis et al., 
1999; Tolle et aI., 1999; Saab et aI., 1999; Rainville et al., 2000). Cortical activation has 
been identified predominantly in the contralateral hemisphere, in primary and secondary 
somatosensory areas (S 1 and S2); parietal operculum; insula; the anterior cingulate cortex 
and the prefrontal cortex. It is probable that these areas process different aspects of pain 
sensation in parallel. Subcortical foci of activation have been identified in brain stem, 
thalamus, hypothalamus, lenticular nuclei, and cerebellum. 
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Descending modulation of nociceptive transmission 
Ascending nociceptive transmission is subject to descending modulatory influences- both 
inhibitory and facilitatory- from supraspinal sites. These endogenous pain modulatory 
systems can be activated by numerous environmental stimuli, including stress, illness, 
cognitive behaviour and pain (reviewed by Urban & Gebhart, 1999). The functional 
anatomy of descending pain modulation was initially investigated using traumatic lesions, 
electrical stimulation or reversible local anaesthetic blocks of selected regions of the 
brains tern or fibre tracts (reviewed by Basbaum & Fields, 1984; Besson and Chaouch, 
1987; Beitz, 1992). More recently, stimulation-produced neuronal activity associated with 
antinociception has been mapped at a cellular level (reviewed by Sandkuhler, 1996) and 
using non-invasive imaging techniques (reviewed by Bushnell et ai., 1999; Tolle et ai., 
1999). 
Descending inhibition 
Many regions of the brain contribute to the modulation of excitatory nociceptive 
transmission (reviewed by Willis & Westlund, 1997). Early studies using electrical 
stimulation in rats identified numerous 'antinociceptive' regions in the forebrain, including 
the prefrontal cortex (Hardy, 1985; Hardy et ai., 1985); the septal area of the ventral 
forebrain (Mayer & Liebeskind, 1974), the amygdala (Rogers, 1977) and the caudate 
nucleus (Schmidek et ai., 1971, Lineberry & Vierck, 1975). In the brainstem and 
midbrain, the periaqueductal grey matter (P AG) and the rostral ventromedial medulla 
(RVM, which incorporates the nuclei raphe magnus (NRM), reticularis gigantocellularis 
and gigantocellularis pars alpha) have been accorded predominant roles in the endogenous 
modulation of excitatory nociceptive transmission, although many other regions also 
possess this capacity, including the midbrain reticular formation, locus coeruleus (LC ) and 
locus subcoeruleus (LSC) of the pons (reviewed by Behbehani, 1995; Willis & Westlund, 
1997). Of these supraspinal sites, the PAG was originally found to be the most effective 
site for stimulation-produced analgesia. The majority ofPAG efferent fibres project to the 
RVM, which in tum sends bilateral descending projections that terminate in the spinal 
dorsal hom. Stimulation of the P AG inhibits both simple nociceptive spinal reflexes and 
behavioural responses to noxious stimulation in both rats (Fardin et ai 1984 a,b) and 
humans (Hosobuchi, 1986). Stimulation of the dorsal raphe nucleus, adjacent to the P AG, 
also induces analgesia although it has been postulated that this antinociception is mediated 
through both ascending and descending pathways (reviewed by Wang & Nakai, 1994; 
Watkins et ai., 1998). Wei et al., (1999) recently showed that chemical ablation of the 
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NRM or LCILSC enhanced hyperalgesic behaviour associated with Freund's adjuvant 
induced intraplantar inflammation. 
Millan (1999) reviewed the spinal targets of descending 'antinociceptive' pathways. The 
terminals of descending projections occur in laminae I-III and V-VII of the dorsal hom, 
where they synapse on central terminals of primary afferent nociceptors and cell bodies of 
ascending projection neurons. Descending inhibitory pathways originating in higher 
centres modulate (generally by reducing) release of neurotransmitters from the terminals of 
nociceptor-responsive primary afferent fibres. They also inhibit projection neurons located 
in the spinal cord, both directly and indirectly, through inhibition of excitatory 
intemeurons and excitation of inhibitory intemeurons. Substantial evidence suggests that 
this effect of descending modulatory pathways- essentially post-synaptic relative to 
primary afferent fibres- is the predominant mechanism through which descending 
pathways modulate nociceptive transmission (Willis & Coggeshall, 1991; Fields & 
Basbaum, 1994; Sandkuhler, 1996; Millan, 1997). Some studies indicate that descending 
pathways preferentially inhibit excitation of WDR neurons by noxious as compared to 
innocuous stimuli (reviewed by Fields & Basbaum, 1994; Willis, 1994; Millan, 1997). 
However, eledrophysiological studies have indicated that under certain conditions, the 
inhibitory influence of descending systems on WDR neurons in deeper laminae can be 
non-selectively expressed against both noxious and innocuous (A~) input, suggesting 
direct monosynaptic inhibition of projection neuron excitability (Willis & Coggeshall, 
1991; Fields & Basbaum, 1994; Willis, 1994). 
Although descending pain modulatory systems were originally accorded an exclusively 
inhibitory role, it is now recognised that stimulation of supraspinal sites- including those 
implicated in descending inhibition- can also facilitate spinal nociceptive transmission. 
Chemical or electrical stimulation of the RVM, typically at lesser intensities than those 
used to produce descending inhibition, has been shown to enhance spinal behavioural 
responses to acute noxious stimuli, spontaneous responses and evoked responses of dorsal 
hom nociceptive neurons (Gebhart, 1993). Facilitatory and inhibitory pathways 
originating in the RVM are mediated by independent descending systems that are 
anatomically, pharmacologically and physiologically distinct (reviewed by Urban & 
Gebhart, 1999). 
The stimuli which activate descending pain modulation have been reviewed by Beitz 
(1992) and Urban & Gebhart (1999). Descending inhibitory pathways can be activated 
naturally in response to various environmental factors, including noxious stimulation, and 
11 
indirectly through the limbic system; it has been proposed that descending inhibition 
represents a beneficial adaptive modulation of nociceptor sensitivity in response to 
aversive or potentially aversive environmental stimuli. Pain inhibition by noxious somatic 
input has formed the basis for analgesia produced by counter-irritant techniques and may 
contribute to the analgesic effect produced by certain forms of acupuncture and 
transcutaneous nerve stimulation techniques. It is well recognised that nociceptive 
transmission can be profoundly modulated by the emotional and attentional state of the 
individual, presumably through connections with the limbic system. The most extensively 
investigated example of descending inhibition is stress-induced analgesia (or hypoalgesia), 
which represents an adaptive response to prepare and protect the body in potentially 
injurious situations (reviewed by Yamada & Nabeshima, 1995; Menendez et al., 1996). 
Antinociceptive mechanisms are also engaged in experimental models of conditioned fear 
in anticipation of noxious stimulation, or by other stressful situations, produced by both 
opioid and non-opioid mediated mechanisms (Millan, 1986; Wiertelak et al., 1992; 
Watkins et al., 1994; 1997). Opioid mediated stress-associated analgesia demonstrates 
tolerance with repeated stress, and cross-tolerance with morphine, while non-opioid 
mediated stress-induced analgesia demonstrates neither of these characteristics (Grau et 
al., 1981; Watkins et al., 1982; Terman et al' J 1984 a,b). Descending facilitation can also 
be activated by environmental factors, which are opposite to those which trigger 
descending inhibition, suggesting that descending facilitation similarly represents a 
beneficial adaptive response in which enhanced pain perception encourages reduced 
mobility during illness, to conserve energy and promote healing (Maier et aI., 1992). 
Extensive modulation of excitatory nociceptive transmission also occurs segmentally 
within the dorsal hom of the spinal cord through interaction of multiple excitatory and 
inhibitory transmitter systems, which shall be introduced and discussed in subsequent 
sections. 
It is important to recognise that the ascending excitatory nociceptive transmission, and 
descending modulatory pathways are intimately interconnected and interdependent. Thus, 
nociceptive input is subject to modulation through spinal cord neuroplasticity and 
descending influences, both facilitatory and inhibitory, from supraspinal sites. The 
activation of these pathways is critically dependent on the nature of acute or persistent 
injury or noxious input, but also upon a melee of behavioural and environmental stimuli. , 
which may combine to produce dominant facilitation or inhibition of ascending 
nociceptive transmission (reviewed by Millan, 1999). An improved understanding of tonic 
'antinociceptive' regulation of the induction of physiological and pathophysiological pain 
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may help to identify new strategies for the prevention and treatment of pathological .. -
hyperalgesia and persistent pam. 
1.2 PATHOPHYSIOLOGICAL NOCICEPTIVE TRANSMISSION: PAIN 
HYPERSENSITIVITY 
Peripheral inflammatory injury can enhance subsequent sensation of pain. This 
phenomenon is defined as hyperalgesia, an enhanced response to a stimulus which is 
normally painful, and allodynia, pain associated with an innocuous stimulus which does 
not normally provoke pain (Lindblom et al 1986). These are behavioural phenomena 
which develop subsequent to cutaneous (thermal, mechanical or chemical/inflammatory) 
injury. Cutaneous hyperalgesia can also develop in undamaged skin in neuropathic pain 
conditions, or as a consequence of somatic referral from 'visceral pain and injury (for 
example, from the heart) (Ruch 1961, reviewed by Ness & Gebhardt, 1990). Hyperalgesia 
and allodynia are illustrated diagrammatically in figure 1.3. 
Hyperalgesia and allodynia may provide 'self-protection' mechanisms whereby the 
peripheral and central nervous systems work in concert to discourage further stimulation, 
or exacerbation of injury, to an already damaged area, thus enhancing the potential for 
recovery and healing. However hyperalgesia and allodynia are also hallmarks of persistent 
pain syndromes. Recognition of hyperalgesia and allodynia, which reflect hypersensitivity 
of peripheral or central nociceptive transmission, has changed our approach to clinical pain 
management. 
The region of hyperalgesia which develops subsequent to cutaneous injury is commonly 
divided into primary and secondary components (reviewed by Woolf, 1995). Within the 
region of primary hyperalgesia, incorporating the actual injury site, 'peripheral 
sensitisation' develops, (reviewed by Treede et al., 1992). The region of secondary 
hyperalgesia extends far beyond the site of injury into undamaged skin, mediated by 
peripheral and central mechanisms distinct to those which mediate primary hyperalgesia 
(Cervero & Laird 1996 [a, b]; Ren, 1996). The relative contribution of peripheral and .. -
central mechanisms to post-injury hypersensitivity remains a contentious topic. 
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Figure 1.3 
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Peripheral sensitisation 
Peripheral sensitisation is defined as enhanced sensitivity of nociceptive sensory afferent 
neurons associated with modulation of transduction at peripheral terminals (Levine & 
Taiwo 1994). Inflammatory injury enhances peripheral afferent nociceptive transmission 
through a host of chemical and physical mechanisms (reviewed by Dickenson 1996;Yaksh 
1996; Woolf & Salter, 2000). A multitude of chemical mediators are released into the 
immediate vicinity of the injured cell, including hydrogen ions, potassium ions, histamine, 
purines, neuropeptides, bradykinin, serotonin, arachidonic acid metabolites, cytokines and 
growth factors (reviewed by Dray & Perkins, 1993; Dickenson, 1997), which are 
illustrated in figure 104. These mediators alter nociceptor transduction sensitivity both 
directly and indirectly (through altering ionic conductance across the peripheral terminal 
membrane) so that less intense stimuli are sufficient to activate nociceptive fibres, more 
nociceptors are activated by any given suprathreshold stimulus, and sensory fibres which 
were previously resistant to excitation can be activated by natural stimuli. Peripheral 
sensitisation can also result from phenotypic modification of peripheral nociceptors in 
response to inflammatory injury, through up-regUlation of expression of target-derived 
growth factors which results in altered expression of transmitters, synaptic 
neuromodulators, ion channels, G-protein-coupled receptors and structural proteins 
(reviewed by Woolf & Salter, 2000). 
Recent studies have focused on the molecular mechanisms which enhance the excitability 
of peripheral nociceptors following injury. The predominant mechanism appears to be 
phosphorylation of ion/receptor channels or associated regulatory proteins within the 
primary nociceptor, which alter its intrinsic functional properties or cell-surface expression 
of ion channels such as the tetrodotoxin-resistant sensory neuron-specific sodium ion 
channel (SNS) (Khasar et ai., 1998) and the vanilloid receptor VR1 (Fitzgerald et al., 
1999). Inflammatory injury results in up-regUlation of expression of VR1 receptors and 
SNS channels at peripheral nerve terminals, resulting in increased sensitivity to 
inflammatory mediators and enhanced peripheral sensitisation (reviewed by Wood et al., 
1999). Peripheral sensitisation may also result from enhanced expression of receptors in 
dorsal hom neurons for transmitters such as substance P which are then transported to the 
terminals of primary nociceptive neurons, priming the system to respond more strongly to 
any given stimulus (Woolf & Costigan, 1999). 
Central sensitisation 
Inflammatory injury can also induce changes in central nociceptive transmission. Ample 
evidence suggests that central plasticity of nociceptive transmission is mediated through 
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correlated alterations in the discharge rates in individual nociceptive neurons- in other 
words, by changing the strength and the duration of synchronisation of central neuronal 
responses-rather than by recruiting additional neuronal connections (Aertsen et al., 1989). 
A similar pattern of neural transmission operates in other sensory systems, including the 
visual cortex (Engel et al., 1991; Konig & Schillen, 1991) and the olfactory system 
(Jolmson et aI., 1991). 
Central sensitisation is classically defined as an increase in excitability of neurons within 
the spinal cord, triggered exclusively by C-fibres, and characterised by a decrease in 
response threshold, increased response to suprathreshold stimuli, and an increase in the 
receptive field area which may include recruitment of previously ineffective inputs 
(Woolf, 1983; 1984; Wall & Woolf 1984; Woolf and Wall 1986; Cook et al., 1987; Woolf 
& King, 1990). However, central sensitisation has also often been associated with an 
increased response to A~ fibre activity, which has been speculated to contribute to 
mechanical allodynia (Simone et al., 1991; Woolf & Doubell, 1994). Enhanced 
sensitivity of central nociceptive neurons to stimulation from peripheral nociceptive 
afferents can persist long after the original stimulus has disappeared. It has been 
postulated that central plasticity of nociceptive processing is the' common denominator' in 
a number of pathological persistent pain syndromes (Dickenson, 1991; Coderre et al., 
1993; Pockett, 1995; Randic, 1996). 
A key advance in appreciation of the inherent plasticity of central pain processing came 
with the observation by Mendell & Wall (1965) that constant frequency stimulation of 
peripheral nerves induced a progressive augmentation in central neuronal excitability 
(Mendell & Wall 1965, Mendell 1966), which they named 'wind-up'. Windup is an 
electrophysiological phenomenon induced in response to mild low-frequency electrical 
stimulation, which synchronously activates many C-fibres (Woolf 1996) and is mediated 
by an N-methyl-D-aspartate (NMDA) receptor mechanism (Thompson et al., 1990). 
Windup, which can amplify dorsal hom neuronal responses to a given peripheral input by 
a factor of 20, has been demonstrated in dorsal hom neurons (Mendell 1966) and in large 
motor neurons of the ventral hom (Thompson et al., 1990). 
Woolf (1983) demonstrated that conditioning stimulation of C-fibres could induce 
prolonged enhancement of the flexion withdrawal reflex in spinal-decerebrate rats, thus 
demonstrating central sensitisation of dorsal hom nociceptive neurons. Hallmarks of 
central sensitisation of dorsal hom nociceptive transmission (reviewed by Coderre et aI., 
1993) include: increased responsiveness to supra-threshold inputs (Kenshalo et al., 1979), 
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expansion of the receptive field size (Cook et al., 1987; Hylden et al., 1989), reduced 
response threshold (Simone et al., 1989); and prolonged after-discharge (Mendell 1966; 
Schoeunberg & Dickenson (1985). Central sensitisation may also reflect depression of 
spinal inhibitory mechanisms. Electrophysiological evidence suggests that tonic 
descending inhibitory systems contribute to maintenance of 'functional synchronicity' of 
'physiological' central nociceptive transmission in the dorsal hom by prolonging the 
synchronisation time between central nociceptive neurons (Eblen-Zajjur & Sandkuhler, 
1997). The demonstration of central sensitisation marked a milestone in appreciation of 
the potential plasticity of central neuronal responses to peripheral stimulation, and led to 
the hypothesis that pathophysiological pain syndromes, including persistent hyperalgesia 
and allodynia, could represent synaptic plasticity of central spinal nociceptive processing 
(Woolf, 1984). This advance led in tum to the application of existing knowledge about 
neuronal plasticity- developed most extensively through studies in the hippocampus and 
neocortex- to central nociceptive transmission, in an attempt to relate central neuronal 
plasticity to persistent pain syndromes. 
Persistent alteration of neuronal excitability is defined electrophysiologically as long-term 
potentiation (LTP) and long-term depression (LTD). LTP was first observed in the 
hippocampus following high frequency (lOOHz) electrical stimulation of a synaptic 
pathway (Bliss & Lomo, 1973; Bliss & Collingridge, 1993) and the phenomenon has been 
accorded a key role in establishing memory and 'learning' pathways (Bliss & Collingridge, 
1993). 'LTP' is a generic phrase used to describe a prolonged increase in the efficacy of 
synaptic plasticity, lasting for more than one hour. Many different types ofLTP have been 
described in different regions of the central nervous system (reviewed by Holscher, 1999). 
Forms of prolonged synaptic plasticity which persist for a shorter duration (20 -60 
minutes) are termed short-term potentiation. 
L TP is generated through complex intraneuronal molecular pathways (reviewed by Bliss & 
Collingridge, 1993). Briefly, LTP induction critically depends upon the precise 
characteristics of the stimulation of presynaptic fibres, with synchronous high-frequency 
bursts being most effective in its induction at many central synapses. While NMDA 
receptor activation, leading to dramatic intracellular Ca 2+ ion influx, plays a key role in the 
induction ofLTP in the hippocampus (Herron et aI., 1986), associated activation of AMPA 
and metabotropic glutamate receptors also occurs (Bliss & Collingridge, 1993; Bashir et 
al., 1993). The capability of dramatic Ca2+ ion influx alone to generate stable LTP remains 
a contentious issue. NMDA receptor-independent LTP has been documented in the 
hippocampus (Johnston et al.,1992), induced by multiple mechanisms, certain of which 
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involve metabotropic receptor activation or activation of non-NMDA-associated calcium 
channels by strong post-synaptic stimulation (reviewed by Johnston et al., 1992). It has 
been postulated that afferent synaptic activity in addition to Ca2+ ion influx may also be a 
prerequisite for the induction of stable L TP, through a mechanism which involves 
metabotropic glutamate receptors (Kullman, 1994). 
L TP has been observed in various regions of the spinal cord grey matter, including the 
dorsal hom (Liu & Sandkuh1er, 1995; 1996; 1997; Svendson et al., 1997), the intermediate 
grey matter (Pockett 1995) and the ventral hom (Pockett & Figurov, 1993). Sandkuhler & 
Liu (1998) demonstrated that afferent discharge patterns which occur during natural 
noxious stimulations (heat, mechano- or chemosensitive cutaneous nociceptor stimulation) 
or acute nerve injury produce robust LTP of C-fibre evoked field potentials in superficial 
spinal cord. Moreover, maintenance of LTP was not affected when afferent nerves were 
cut 1 hour or 5 minutes after noxious stimulation, indicating that ongoing afferent barrage 
was not required to maintain LTP. Notably, natural noxious stimuli induced LTP in 
animals which were spinalised but were ineffective in intact animals, suggesting that 
induction of L TP was tonically suppressed by supraspinal descending inhibition. Previous 
studies by Liu & Sandkuhler (1995; 1996) support this hypothesis. LTP was induced in 
spinalised rats through inflammatory injury [intense radiant skin heating, intraplantar 
formalin injection, and noxious mechanical stimulation using an artery clamp], sural nerve 
injury or superfusion of the spinal cord with substance P, but could not be induced using 
the same conditioning stimuli in rats with intact central circuitry. Consistent with findings 
in the hippocampus, the NMDA receptor is postulated to playa major role in the induction 
of many forms ofLTP in the dorsal hom (Randic et al., 1993). 
NMDA-receptor independent LTP has been described in the spinal cord dorsal hom (Ceme 
et al., 1991; Meller et ai., 1993; Kojic & Randic, 1993). Meller et al. (1993) reported that 
chemical irritant- induced mechanical hyperalgesia required co-activation of AMP A and 
metabotropic receptors while remaining independent of NMDA receptor antagonism. 
Kojic & Randic (1993) demonstrated that metabotropic receptor agonists could induce 
L TP in the spinal dorsal hom in the absence of tetanic stimulation, speculating that 
metabotropic receptors played an essential role in the induction of NMDA-independent 
L TP in the spinal cord. 
Long term depression of primary afferent neurotransmission, the central complement of 
LTP, has been identified in the hippocampus (Dudek & Bear, 1992; Mulkey & Malenka, 
1992). Both LTP and LTD are induced by highly specific changes in the post-synaptic 
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membrane potential; indeed, the same conditioning stimuli (intracellular Ca2+ influx, 
activation of glutamate receptors and tetanic stimulation of dorsal roots) can give rise to 
L TP or LTD depending on factors that have not yet been fully elucidated. LTD is broadly 
classified as homo synaptic or heterosynaptic depending on whether the decrease of 
synaptic efficiency occurs only at the stimulated synapses (homo synaptic ) or also at 
inactive synapses adjacent to the activated synaptic region (heterosynaptic ). LTD was first 
observed in the cerebellum (Ito et aI., 1982) and has since been demonstrated in many 
regions of the CNS, including the hippocampus (Mulkey & Malenka, 1992), visual cortex 
(Artola & Singer, 1987) and spinal cord (Randic et al., 1993; Pockett & Figurov, 1993). 
LTD has been elicited by a wide variety of both high frequency (HFS-LTD) and low 
frequency (LFS-LTD) conditioning stimuli (reviewed by Bindman et al., 1991; Artola & 
Singer, 1993; Malenka & Nicoll, 1993; Christie et al., 1994). 
In the spinal cord, LTD has been observed in both the dorsal and ventral horns following 
primary afferent stimulation (Cerne et at., 1991; Randic et al., 1993; Pockett & Figurov, 
1993; Pockett, 1995). Both HFS-LTD and LFS-LTD have been induced in lamina II 
neurons in vitro through stimulation of primary afferent AI) fibre input (Sandkuhler & 
Randic, 1996; Sandkuhler et al., 1997); in these studies it was postulated that LTD of 
synaptic transmission in the dorsal hom may provide an alternative mechanism for 
suppression of excitatory central nociceptive transmission. 
Distinctions between LTP/LTD and central sensitisation 
L TP and LTD occur in many regions of the brain and spinal cord. Since cerebral L TP and 
LTD are typically associated with the processes of learning and memory (Bliss & 
Collingridge, 1993), a popular dogma has emerged that their principal roles in the 
superficial spinal dorsal hom may be related to plasticity of spinal nociception (Randic, 
1993). However, as electrophysiological phenomena that cannot be studied (in the spinal 
cord) in free-moving animals, direct comparisons cannot be made between LTP/LTD and 
plasticity of nociceptive behaviour observed in-vivo, and the association between 
observations of L TP and LTD in the spinal cord, and plasticity of nociceptive transmission 
associated with inflammatory injury, remains ambiguous and inconclusive. 
Willis (1997) and Millan (1999) discussed characteristic differences between L TP IL TD, as 
they are classically defined in higher centres, and central sensitisation of dorsal hom 
neuronal responses. L TP and LTD describe activity-dependent modulation of neuronal 
excitability which persists for at least 1 hour, but is of indefinite duration and may be 
permanent. It is worthy of note that permanent alterations in gene expression and 
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phenotypic changes are not prerequisites for L TP and LTD. Central sensitisation IS 
similarly activity-dependent and of indefinite duration, but may theoretically persist for 
less than 1 hour following specific injury, although it is typically used to describe long-
lasting alterations in central neuronal excitability. 
L TP and LTD of central nociceptive transmission may represent transient and reversible 
alterations in central nociceptive transmission, associated with upregulation of expression 
of key nociceptive mediators but not associated with permanent alterations in gene 
expressIOn or phenotypic alterations in dorsal hom neurons; or they may represent 
permanent alterations in gene expression which will produce a persistent state of 
hyperexcitability in the dorsal hom (Pockett, 1995). 
It is important to recognise that while L TP and LTD in the spinal dorsal hom may be 
related to persistent states of enhanced excitability in the dorsal hom involving phenotypic 
alterations in central nociceptive neurons (a convincing explanation for certain 
pathological persistent pain states), they may also represent central nociceptive plasticity 
of shorter duration, mediated by stimulus-induced alterations in gene transcription which 
alter nociceptive transmission for a certain period in the absence of persisting stimulation, 
but subsequently subside, without the induction of permanent phenotypic alterations in 
dorsal hom neuronal excitability 
1.3 PHARMACOLOGY OF PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL 
NOCICEPTIVE TRANSMISSION 
Information about noxious peripheral stimulation is communicated to the spinal cord by a 
barrage of excitatory neurotransmitters released into the spinal cord from peripheral 
afferent neurons. Simultaneously, ascending excitatory nociceptive transmission is subject 
to modulation by descending inhibitory transmission originating within higher centres or 
within the spinal cord itself. The interaction of key excitatory and inhibitory 
neurotransmitter systems in nociceptive transmission is illustrated in Figure 1.4. The 
pharmacology of pain transmission and of central pain states has been reviewed by Yaksh 
(1996), Dickenson (1997) and Millan (1999). 
Excitatory transmission 
Neuropeptides 
The tachykinins (TKs) are a family of small peptides which share the common C-terminal 
sequence Phe-X-Gly-Leu-MetNH2• Three peptides of this family, substance P (SP), 
neurokinin A (NKA) and neurokinin B (NKB), have an established role as 
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neurotransmitters in mammals; SP and NKA have been extensively studied as 
pronociceptive neurotransmitters. Three receptors for TKs have been cloned: NKI (SP-
preferring), NK2 (NKA -preferring) and NK3 (NKB-preferring) although NKA may also 
exert actions at NKI sites and SP at NK2 sites (Maggi, 1995). NKI receptors are located 
throughout the spinal cord grey matter although they are concentrated in laminae I and II, 
while NK3 binding sites are limited to laminae I and II (Yashpal et ai., 1990). 
The distribution ofNK2 receptors remains controversial. Tsuchida et ai., (1990) reported 
that NK2 receptor expression was limited to peripheral tissues; however, numerous studies 
have demonstrated that NK2 receptors are involved in the spinal processing of nociceptive 
information (Fleetwood-Walker et ai., 1990; Thompson et ai., 1994; Neugebauer et ai., 
1996). 
It has been speculated that tachykinin receptors play a minimal role in physiological 
nociceptive transmission, but are important mediators involved in enhanced nociceptive 
transmission following inflammatory injury and in the induction of central sensitisation 
(Dickenson, 1996). 
It has been recently demonstrated, however, that tachykinin release from nociceptive 
primary afferent fibres is required to produce moderate to intense pain sensation (Cao et 
at., 1998). Substance P (SP) and NKA are rapidly released following stimulation of C 
fibres and local intrinsic neurons, and this release is enhanced following inflammatory 
injury (Moochala & Sawnok 1984; Go & Yaksh, 1987; Okhubo et ai., 1990). Ample 
evidence supports the involvement of neuropeptides in the induction and maintenance of 
central sensitisation. Intrathecal administration of SP and NKA reduces behavioural 
nociceptive thresholds (Cridland & Henry, 1986) and enhances spinal flexor motor 
neuronal responses to noxious stimuli (Wiesenfeld-Hallin, 1986), while neurokinin 
receptor antagonists can block the development of central sensitisation following injury 
(Xu et at., 1992; Ma & Woolf, 1995). 
A further pro-nociceptive peptide, calcitonin gene-releasing peptide (CGRP) has been 
extensively studied in association with both physiological and pathophysiological 
nociceptive transmission. Two CGRP receptors (CGRP 1 and CGRP 2) have been 
characterised to date. CGRP is released following noxious stimulation of C-fibres and has 
an excitatory effect on dorsal horn neurons; intrathecal injection of CGRP increases the 
excitability of spinal flexor motor neurons (Ryu et at., 1988). Substance P and CGRP are 
degraded by the same breakdown enzyme (CGRP preferentially) and thus in the presence 
of CGRP, SP diffuses more extensively in the spinal cord. 
... 1 
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Figure 1.4 
Transmitters and chemical mediators, released following tissue injury, implicated in the 
induction of peripheral sensitisation 
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Numerous other neuropeptides have been accorded potential roles in physiological and 
pathophysiological nociceptive transmission, notably neuropeptide Y (Hua et ai., 1991; 
Calza et ai., 1998; Yaksh et at., 1999; Honore et at., 2000;), nerve growth factor (NGF) 
(Lewin & Mendell, 1993; Bennet et at., 1998; Theodosiou et at., 1999); somatostatin and 
galanin (Calza et aI., 1998; Hokfeldt et at., 1999; Honore et ai., 2000). 
Excitatory amino acids (EAA's) 
Glutamate is the major excitatory neurotransmitter in the central nervous system. EAA's 
produce their effects through two broad categories of receptors, ionotropic and 
metabotropic (reviewed by Schoepp & Conn 1992; Rang et at., 1999a). Ionotropic 
receptors are classified into 3 subtypes based on selectivity of synthetic agonists, namely 
N-methyl-D-aspartate (NMDA); a-amino-3-hydroxy-5-0-methyl-4-isoxazolepropionic 
acid (AMP A); and kainate (KA) receptors. Activation of AMP A or KA receptors is 
essential for fast excitatory transmission in the CNS. Pathophysiologically, regulation of 
the voltage-dependent Mg2+ ion block of NMDA receptor calcium channels plays a major 
role in central sensitisation (Davies & Lodge, 1987; Woolf & Thompson, 1991; Chen & 
Huang, 1992). 
The mechanism of NMDA receptor activation and the cascade of intracellular events 
which ensue have been reviewed by Pockett (1995). In the quiescent state, the Ca 2+ 
channel of the NMDA receptor is blocked by physiological levels of Mg2+ ions. This 
channel block can only be removed by repeated depolarisation of the cell membrane. In 
the 'normal' situation, C-fibre stimulation following brief acute mechanical or thermal 
stimulation causes activation of AMP A receptors to give excitations of short duration. If 
this stimulation is maintained, or if the frequency or intensity of stimulation is increased, 
then the NMDA receptor will be activated to produce dramatic enhancement of neuronal 
responses. This is the mechanism by which the NMDA receptor is believed to induce 
central spinal hypersensitivity. The effects ofNMDA receptor activation are the results of 
transient massive Ca 2+ ion influx into the post-synaptic cell. 
The role of the NMDA receptor in physiological and pathophysiological central 
nociceptive transmission has been reviewed by Dickenson (1996) and Millan (1999). 
NMDA antagonists typically exert minimal effects on acute nociceptive transmission but 
attenuate 'facilitated' states of processing (Dickenson & Sullivan, 1987; Simone et at., 
1989; Woolf & Thompson, 1990; Coderre & Melzack, 1992; Coderre et at, 1993). 
Ample evidence supports the involvement of the NMDA receptor in central sensitisation. 
Neuronal responses implicated in the induction of central sensitisation can be attenuated 
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by both intrathecal (Haley et at., 1990; Nasstrom et at., 1992) and systemically delivered 
(Hudspith et at., 1999) NMDA antagonists. Hyperalgesic behaviour following 
inflammatory injury can be attenuated through intrathecal (Haley et at., 1990; Ren et at., 
1992) and systemic (Hudspith et at., 1999) administration ofNMDA receptor antagonists. 
Intrathecal delivery of NMDA agonists induces spontaneous agitation, thermal 
hyperalgesia and tactile allodynia (Aanonsen & Wilcox 1986; Coderre & Melzack, 1992; 
Malmberg & Yaksh, 1992). 
Controversy persists over the precise role of the NMDA receptor in different 
manifestations of pathophysiological pain transmission. There is evidence to suggest that 
the NMDA receptor mediates thermal hyperalgesia but not mechanical allodynia (Meller 
et at., 1993; Tal & Bennet, 1994; Leem et at., 1996). However there are several reports of 
NMDA mediation of mechanical hyperalgesia (Aanonsen et at., 1990; Schaible et at., 
1991; Ma & Woolf, 1994; Munglani et at., 1999; Chap Ian et at., 1997). It has also been 
proposed (Song and Zhao 1993) that while cutaneous hyperalgesia is mediated by NMDA 
receptor activation, muscular hyperalgesia is mediated by non-NMDA mediated 
mechanisms. 
In addition to their central effects, NMDA receptors localised peripherally on primary 
afferent terminals in the skin may playa role in inflammatory pain states (Carlton et at., 
1995; Zhou et al., 1996; Davidson et at., 1997; Davidson & Carlton, 1998), since local 
application of the NMDA antagonist MK-801 attenuates hyperalgesia induced by 
intraplantar injection of complete Freunds adjuvant (Jackson et at., 1995) or formalin 
(Davidson et at., 1997). 
Metabotropic receptors 
Eight subtypes of metabotropic glutamate receptors have been identified, grouped into 
three distinct groups (mGluR's 1, 2 and 3) according to their transduction mechanisms 
(reviewed by Pin & Duvoisin, 1995). Metabotropic receptors are coupled to GTP-binding 
proteins in the cell membrane, and act in conjunction with initial transient calcium influx 
to activate various second messenger systems. Group 1 mGluR's are coupled to 
phopsholipase C, while group 2 and group 3 mGluR's are negatively coupled to adenyl 
cyclase. Metabotropic receptors induce numerous effects on central neurons, including 
depression of excitatory (and inhibitory) post-synaptic potentials (Baskys & Malenka, 
1991; Hayashi et al., 1993) and enhancement (or attenuation) of glutamate release (Glaum 
& Miller, 1992). There is evidence to suggest that metabotropic receptors play an 
important role in the induction and/or maintenance of synaptic plasticity in the central 
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nervous system (Knopfel et al., 1995; reviewed by Conn & Pin, 1997) but this role is less 
well defined for metabotropic receptors than for NMDA receptors. 
Prostaglandins 
Prostaglandins are metabolites of arachidonic acid, produced by many different types of 
cell, which produce a multitude of effects throughout the body. PG receptors are present 
in peripheral tissues and in many organ systems (reviewed by Rang & Dale, 1999) and 
throughout the central nervous system (Watanebe et al., 1989; Matsumura et al., 1992). 
Four major prostaglandin receptors have been described (DP, EP, FP and IP), derived from 
predicted amino acid sequences and operational pharmacology (reviewed by Bley et aI., 
1998). Further subtypes of each prostaglandin receptor have been subsequently identified; 
for example, the PGE receptor has been further subtyped into EPI EP2, EP3 and EP4• In the 
spinal cord, the majority of binding sites for PGE2 are located in laminae I and II 
(Mastumura et al., 1992). 
Prostaglandins playa key role in peripheral transmission of nociceptive responses to injury 
and in the development of peripheral sensitisation (Ferreira, 1978a; Geisslinger & Yaksh, 
1999). Prostaglandin synthesis is a key component of the acute inflammatory response. 
Following acute injury PGE2 and PGI2 are generated by local tissues and blood vessels, 
while mast cells generate PGD2• In chronic inflammatory conditions monocyte-
macrophage cells also synthesise prostaglandins (reviewed by Vasko, 1995). Peripheral PG 
administration reduces the activation threshold of peripheral nociceptive neurons (Martin 
et al., 1987; Schaible et at., 1988) and induces hyperalgesic behaviour (Ferreira, 1978b; 
Taiwo & Levine, 1986). 
PG's also fulfill an important role as neurotransmitters within the central nervous system, 
playing a key role in central excitatory transmission of nociceptive responses to injury and 
in the development of central sensitisation (reviewed by Yamagata et al., 1993; 
Geisslinger & Yaksh, 1999). Prostaglandins are synthesised in the spinal cord following 
stimulation of fine-diameter (nociceptive) afferent fibres (Ramwell, 1966) and following 
noxious stimulation (Malmberg & Yaksh, 1995a,b; Scheuren et al., 1997). Intrathecal 
injection ofPGEI,PGE2, PGF2 and PGD2 induces dose-dependent hyperalgesia (Coceani & 
Viti, 1975; Ferreira, 1983; Taiwo & Levine 1986). Intrathecal delivery of non-steroidal 
anti-inflammatory drugs (NSAID's) which inhibit prostaglandin synthesis) induces dose-
dependent attenuation of hyperalgesia and attenuation of spinal nociceptive neuronal 
responses associated with inflammatory injury, although these agents do not alter acute 
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nociceptive thresholds (Malmberg & Yaksh, 1992a,b; Chapman & Dickenson 1992; Dirig 
et al., 1998). 
The two isoforms of COX (COX-l and COX-2) catalyse a key stage in PG synthesis, 
namely the oxygenation of free arachidonic acid to PGH2, which is then further converted 
into alternative prostaglandins or thromboxane A2 by specific synthase enzymes (Smith & 
Marnett, 1991; Xie et al., 1991). COX-I, classically referred to as the 'constitutive' 
isoform, is expressed in many cell types including gastro-intestinal and renal cells, where it 
is involved in physiological prostanoid-associated homeostatic mechanisms. COX-2 is 
cytokine-inducible and present in inflammatory cells (Crofford et al., 1994; Ristimaki et 
al., 1994) but is also constitutively expressed in numerous tissues including the macula 
densa of the kidney (Harris et al., 1994 ), developing ovarian follicles (Sirois & Richards, 
1992), the testes (Sirois & Richards, 1992), and the central nervous system (Yamagata et 
al., 1993; Herrting & Seregei, 1989). In the rat brain COX-2 represents the predominant 
constitutive isoform (Breder et al., 1995; Beiche et al., 1996; Kaufmann et al., 1996). In 
the spinal cord, constitutive expression of rnRNA and protein for both COX isoenzymes 
has been identified (Beiche et al., 1996; Hay & de Belleroche, 1997). COX-2 protein 
expression has previously been identified in neurons in laminae I-IV of the dorsal hom and 
lamina IX motorneurons (Struebe & Beiche, 1998). 
The factors which regulate COX-2 expression in the central nervous system remam 
undetermined and somewhat contentious. In the brain, COX-2 expression is dynamically 
regulated by specific forms of activity associated with long-term neuronal plasticity, and 
can be rapidly and transiently induced in neurons by seizures or NMDA-receptor 
activation Yamagata et al (1993). Immunocytochemical studies have identified high levels 
of COX-2 expression in dendrites and neuronal cell bodies, typically post-synaptic 
structures, in the cerebral cortex (Breder et aI1994). 
The precise role of each COX isoform in inflammatory pain is also a controversial topic. 
Studies in cyclo-oxygenase gene-knockout mice suggest a role for both isoenzymes in the 
generation of peripheral inflammation (Langenbach et al., 1995). Selective COX-2 
knockout only partially reduces prostaglandin concentration at sites of acute and chronic 
inflammation (Langenbach et al., 1995) while non-selective cyclo-oxygenase blockade 
using non-steroidal anti-inflammatory drugs prevents peripheral prostaglandin induction 
(Seibert et al., 1994; Portanova et al., 1996), suggesting that both isoenzymes are involved 
in the peripheral inflammatory response. Centrally, there is mounting evidence that COX-
2 is the dominant isoform associated with nociceptive transmission and the development 
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and maintenance of hyperalgesia associated with inflammatory injury (Beiche et al., 1996; 
Hay et at., 1997; Hay & de Belleroche, 1997; Ichitani et al., 1997). 
Inhibitory transmission 
Gamma-amino-butyric acid 
Gamma-amino-butyric acid (GABA) is the most ubiquitous inhibitory neurotransmitter in 
the central nervous system. The pharmacology of the GABAergic system has been 
reviewed by Rang et al., (1999b). GABA inhibits neuronal excitability and 
neurotransmitter release through two main classes of receptor, both of which have been 
cloned and subsequently subdivided into receptor subtypes. GABAA receptors are ligand-
gated ion-channels selectively permeable to Cl- ions (Stephenson 1995), which are located 
post-synaptically and mediate fast post-synaptic inhibition. GABAB receptors are coupled 
through G proteins to K+ and Ca2+ channels (Bowery, 1993) and are located both pre- and 
post-synaptically. Both receptor types are present in the dorsal hom, co-existing on A8 
and C primary afferent fibres (Desarmenien et al., 1984; Price et al., 1986; 1987). Both 
GABAA and GABAB receptors are concentrated in lamina II of the superficial dorsal hom 
of the spinal cord. In the spinal cord, GABA protein expression has been identified 
predominantly in intemeurons in the superficial dorsal hom which receive afferent input 
from small-diameter nociceptive fibres (Carlton & Hayes, 1990; Hayes & Carlton, 1992; 
Magoul et aI., 1987; Todd & McKenzie, 1989). 
These inhibitory intemeurons are themselves targeted by C and A8 nociceptive fibres, as 
well as by A~ fibres (Coggeshall & Carlton, 1992; Yoshimura & Nishi, 1992; 1995; Todd 
& Spike, 1993; Todd et aI., 1994; Bernardi et al., 1995). This targeting suggests that C 
and A 8 nociceptive fibres may exert 'counter-regulatory' inhibitory feedback control upon 
their parallel excitation of WDR and nociceptive specific projection neurons in the dorsal 
hom, so that the pain elicited by projection neuron stimulation by nociceptors, may be 
limited by simultaneous activation of GABAergic inhibitory interneurons, at least for short 
duration sub-maximal stimulation (Millan, 1999). Numerous behavioural studies support 
this hypothesis. Antagonism of spinal GABAA receptors using specific antagonists 
(Reeves et al., 1998; Roberts et al., 1986), and selective GABAA gene- knockout (Ugarte 
et al., 1999) induce mechanical allodynia accompanied by modest thermal hyperalgesia, 
suggesting that GABA acting at GABAA receptors tonically suppresses afferent 
transmission of noxious information in the spinal cord. Antagonism of spinal GABAA (but 
not spinal GABAB) receptors enhances allodynic responses in spinalised rats, suggesting 
that GABAA receptors mediate tonic GABAergic inhibition through 'local' segmental 
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spinal inhibitory circuitry (Sivilotti & Woolf, 1994). Buritova et al., (1996) demonstrated 
that systemic (but not intraplantar) administration of baclofen, a GABAB agonist, reduced 
cfos expression in the spinal dorsal hom and also attenuated paw and ankle oedema 
following high-dose intraplantar carrageenan treatment, suggesting that GABAB receptors 
may also mediate tonic inhibition of excitatory nociceptive transmission. Activation of 
spinal GABAergic neurons through stimulation of peripheral nociceptive fibres (A~, A8 
and C) has also been shown to inhibit spinothalamic tract neurotransmission (Carlton et 
al., 1992). 
Hammond (1999) has reviewed the role of GABA in pathological pain. Changes in 
GABAergic transmission are highly dependent on the type of injury and the duration of the 
post-injury period; while nerve injury attenuates GABAergic responses (Castro-Lopez et 
ai., 1995), intense inflammatory injury enhances GABAergic transmission (Castro-Lopes 
et al., 1992; 1994; Kaneko & Hammond, 1997). Intraplantar injection of CFA (Castro-
Lopes et aI., 1992) or carrageenan (Castro-Lopez et al., 1994) enhances spinal GABA 
protein expression and increases the number of GABA-immunoreactive cells in the 
superficial dorsal hom. Intraplantar injection of CF A induces prolonged ipsilateral 
enhancement of glutamate decarboxylase (GAD) mRNA expression and GAB A 
immunoreactivity, from 4 days following CFA injection (Nahin & Hylden, 1991; Castro-
Lopes et al., 1994). 
GABA and GABAA receptors are involved in the development and induction of synaptic 
plasticity in higher centres including the amygdala, (Watanebe et al., 1995), cortex (Kanter 
& Haberly, 1993), dentate gyrus (Tomasulu et al., 1993), and hippocampus (Yasui et al., 
1993). Thus modulation of GABAergic transmission may also be implicated in the 
induction and/or maintenance of L TP or LTD of spinal nociceptive processing, associated 
with central sensitisation. 
Endogenous opioids 
While the pain-relieving properties of papaver somniferum were familiar to Sumerians and 
pre-dynastic Egyptians some 5 millenia ago, the active analgesic and euphoric component 
of the humble poppy was not identified until the 19th century, when the German chemist 
Friedrich Sertuner isolated the principal active compound of opium and named it morphine 
in honour of Morpheus, God of dreams. Opioids remain the' gold standard' against which 
all other analgesic agents are compared. Our understanding of the mechanisms through 
which opioids induce analgesia has been obscured by the intrinsically complex nature of 
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'pain' sensation as a mixture of sensory transmission and subjective emotional experience, 
since opioids are able to alter both of these components of pain sensation. 
The pharmacology of the endogenous opioid system has been reviewed by Loughlan et 
al.(1995) and Feldman et al. (1996). Endogenous opioid ligands were first identified in 
1975 and differentiated into two 'families' of closely related peptides, enkephalins 
(Hughes et al., 1975) and dynorphins (Goldstein et al., 1979). Three distinct genes coding 
for endogenous opioid peptides have since been identified, each of which encodes a 
collection of peptides. These are prepro-opioimelanocortin (POMC), which encodes 
endorphin peptides, preproenkephalin, which encodes enkephalin peptides, and 
preprodynorphin, which encodes dynorphins. Expression of the precursor peptides varies 
markedly between different tissue types and regions of the CNS. POMC is concentrated in 
the pituitary gland and the hypothalamus, while proenkephalin and dynorphin peptides are 
distributed widely throughout the CNS. 
Three major opioid receptor types have been cloned, classified as I.l (MOR-l) (Chen et al., 
1993; Wang et al., 1993); 6 (DOR-l) (Evans et al., 1992, Kiefer et al., 1992) and K[ 
(KOR-l) (Chen et al., 1993; Li et al., 1993). It is now becoming evident that each of these 
main receptor types can be further subdivided into multiple splice variants (reviewed by 
Pasternak,2000). Receptor distribution in the central nervous system and elsewhere varies 
significantly between the different receptor types and is species specific. The distribution 
of endogenous opioid receptors in the rat spinal cord has been characterized by Morris & 
Herz, 1987, and Besse et al., 1990). While opioid receptors are present in all laminae of 
the spinal grey matter they are more abundant within the dorsal hom; the precise 
localisation of each receptor type is believed to reflect their particular mode of action. All 
three major receptor types occur within the dorsal hom, predominantly within lamina II. 
Besse et al. (1990) reported that 70% of opioid receptors in lamina II are I.l; 24% are 6, 
and 6% are K. Although enkephalin, dynorphin and ~-endorphin do show selectivity for I.l, 
K and 6 receptors respectively, there is no clear correspondence between the anatomical 
distribution of any opioid peptide and a particular receptor type. Hollt (1986) proposed 
that this mismatch may reflect the processing of propeptide precursors into a number of 
different peptides with differing receptor selectivities. Opioid receptors are also located in 
higher centres including the peri-aqueductal grey matter (Budai & Fields, 1998) and the 
forebrain (Grau 1987; Meagher et al., 1989; 1990); thus, endogenous opioids also regulate 
central nociceptive transmission through modulation of descending control systems located 
in the midbrain and brainstem (reviewed by Gogas et al., 1991; Duggan, 1992). While most 
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exogenously administered opioids interact with several different opioid receptors, 
morphine and the majority of opioid agents used in clinical analgesia act through Il-opioid 
receptors (Pasternak, 2000). Selective K opioid receptor activation produces numerous 
adverse behavioural side effects including psychomimetic behaviour and dysphoria in rats 
and humans and thus K selective agents have not been developed as clinical analgesic 
agents. Il-selective receptor activation produces the most potent and effective opioid-
mediated inhibition of excitatory nociceptive transmission (reviewed by Pasternak, 2000) 
All opioid receptors belong to the G-protein-coupled receptor superfamily and induce their 
intracellular effects through interaction with guanine nucleotide-binding proteins 
(reviewed by Childers, 1993 and Cox, 1993). The mechanisms through which opioids 
modulate spinal nociceptive transmission- principally by means of modulating synaptic 
transmission and neurotransmitter release- have been reviewed by Yaksh (1993)and 
Dickenson (1997). Opioids exert both pre- and post-synaptic influence on primary afferent 
nociceptive neurons and the spinal neurons on which they converge, and alter activity in 
ascending excitatory pathways and descending inhibitory pathways. It has been proposed 
that numerous central nociceptive circuits may exist under tonic opioid inhibitory control 
(reviewed by Dickenson, 1997). Opioids selectively inhibit synaptic transmission in A8 
and C nociceptive afferent fibres within the dorsal hom rather than generally inhibiting all 
sensory transmission, and modulate release of numerous key neurotransmitters involved in 
pain transmission pathways, including substance P, CGRP, noradrenaline, acetylcholine, 
dopamine and serotonin (5-HT). 
It is well established that endogenous opioids exert tonic inhibitory control on central 
nociceptive processing , and that this system can be modulated by injury (Kayser & 
Guilbaud, 1987; 1991; Kayser et ai., 1986; 1988; Lombard & Besson, 1989). The inherent 
plasticity of endogenous opioid systems is well documented; the spinal effects of opioids 
can be enhanced or reduced depending on pathology and activity in other segmental and 
non-segmental pathways (Dubner & Ruda 1992; Dickenson 1994; Cesselin 1995; Mao et 
ai., 1995; Stanfa & Dickenson 1995; Stanfa et ai., 1994; Dickenson 1997). 
It is worthy of note that plasticity of opioidergic inhibition subsequent to injury may reflect 
not only alterations in pro-opioid ligand mRNA expression and translation into active 
peptide within the spinal cord, but also recruitment of different levels of the neuroaxis; 
alterations in opioid receptor sensitivity; and modulation of opioid activity by 
complementary transmitter systems, including adrenergic, and glutamateINMDA 
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neurotransmitter systems (Dickenson, 1997; Mao, 1999) and anti-opioid peptides (Faris et 
al., 1983). 
Stanfa & Dickenson (1995), and Dickenson (1997) have reviewed the contribution of the 
opioid system to induction and maintenance of plasticity of central nociceptive 
transmission associated with inflammatory injury. Inflammation alters the dynamics of 
endogenous opioid transmission, both through modulating synthesis of endogenous 
transmitters and through altering the activity of both peripheral and central opioid 
receptors. In inflammatory states there is dramatic upregulation of dynorphin mRNA 
expression, and moderate upregulation of enkephalin mRNA (Nahin et al., 1989; Dubner 
& Ruda, 1992). While up regulation of enkephalin activity results in enhanced Il-opioid 
receptor mediated inhibition of excitatory nociceptive transmission, the functional 
consequences of enhanced dynorphin expression are considerably more complex; while 
dynorphin can emulate certain increases in central excitability which occur following 
inflammation (e.g. enhanced responses of nociceptive neurons), it inhibits others (Knox 
and Dickenson, 1987). Dynorphin and its 2-17 fragment may exert central analgesic 
action partly through non-opioid receptors (Hooke et al., 1995). Dynorphin (1-17) has 
been reported to act as an antagonist at the glutamate binding site of the NMDA receptor, 
while other dynorphin peptides have been reported to inhibit NMDA receptor channels of 
isolated trigeminal neurons (Dyn 2-17) (Chen et al., 1995) and AMPA and kainate 
responses in dorsal hom neurons (Dyn 1-17) (Kolaj et al., 1995). K-opioids also appear to 
antagonise the 11 receptor in the spinal cord (Stanfa et al., 1992). However, spinal 
dynorphin levels are also enhanced in neuropathic pain models, where opioid actions tend 
to be reduced, suggesting that upregulation of dynorphin in isolation does not play a key 
role in the induction or maintenance of plasticity of central nociceptive transmission. 
There is some evidence that inflammatory injury also alters the expression and/or activity 
of central opioid receptors; Goff et al. (1998) reported significant upregulation of 11-
receptor labelling in the lumbar dorsal hom associated with persistent intraplantar 
inflammation induced by CF A treatment. However, the majority of studies have failed to 
identify conclusive changes in the number or ligand affinity of any of the three opioid 
receptor types in response to inflammatory stimulation (Iadarola et al., 1988; Millan et al., 
1988; Delay-Goyet et al., 1989). 
Opioids have been shown to play a role in the mediation of certain types of long-term 
potentiation in the brain, notably in the lateral perforant and mossy fibre pathways of the 
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hippocampus, although the precise role of each receptor group remains undetermined. 
There is ample evidence that Il-and 8 receptors regulate LTP induction (Satoh et al., 1989; 
Derrick et al., 1991; Xie et al., 1991; Bramham et aI.,1991; 1992; Xie & Lewis, 1995a; 
Williams & Johnston, 1996), partially through interaction with the GABAergic inhibitory 
system (Bramham & Sarvey 1996). However, Xie & Lewis (1995b) reported that LTP of 
inhibitory neurotransmission in the dentate gyrus of the hippocampus required 8-receptor 
antagonism. K-receptor activation through dynorphin administration attenuates L TP in the 
hippocampus in a naloxone-reversible manner (Wagner et al., 1993; Drake et aI., 1994). 
Opioids have also been implicated in the induction of LTD in the hippocampus 
(Francesconi et al., 1997; Ikeda et al., 1999) and in the spinal cord (Pockett, 1995) where 
LTD induction has been both attenuated and inhibited by naloxone-mediated opioid 
receptor antagonism. 
Catecholamines 
Noradrenergic and adrenergic pathways, originating in the medulla and the pons (locus 
coerulus and subcoerulus) and projecting to the spinal dorsal hom, constitute a third key 
transmitter system which inhibits excitatory nociceptive transmission in the central 
nervous system. Adrenergic mediation of antinociception in the central nervous system 
has been thoroughly reviewed by Tasker et ai., (1992), Kingery et ai., (1997) and Millan, 
1998). 
Multiple types of 0,1' Uz and ~t '~2 and ~3 adrenergic receptors (AR's) have been 
described, the physiological significance of which is still under investigation (Millan, 
1998). at AR's are present at only low concentrations in the dorsal hom and have not 
been accorded a significant role in central nociceptive processing (Millan 1998). ~ AR's 
have been identified in the spinal cord (Nicholas et al., 1993) but there is presently no 
evidence to support a significant role for these receptors in nociceptive transmission. 0,2 
AR's are abundant in the superficial laminae of the DH and in the intermediate grey matter 
and are present at a somewhat lower density in deeper laminae of the dorsal hom as well 
as in the ventral hom (Dashwood et ai., 1985; reviewed by Millan, 1998). Investigation of 
central adrenergic mediation of antinociception has demonstrated a dominant role for the a 
2AR (Howe et ai., 1983; Osipov et al., 1984; Barbaro et ai., 1985; Jones & Gebhart, 1986). 
a 2AR-activated pathways inhibit central nociceptive transmission through various 
mechanisms (reviewed by Kingery et ai., 1997), including pre-synaptic inhibition of 
glutamate release from nociceptive fibres (Belcher et al., 1978; Fleetwood-Walker 1985) 
and post-synaptic inhibition of wide dynamic range spinal neurons (Belcher et al., 1978; 
Pertovaara et al., 1993). It is worthy of note that in addition to their abundance in the 
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central nervous system, ~ AR's are abundant in many other body systems including the 
vascular system and the sympathetic system, which may also modulate peripheral 
inflammation and pain transmission (reviewed by Millan, 1998). 
Purines 
Purines [adenosine, adenosine monophosphate (AMP), adenosine diphosphate (ADP) and 
adenosine triphosphate (ATP)] are present in all cells. There is mounting evidence 
adenosine may contribute to both physiological and pathophysiological central nociceptive 
transmission (reviewed by Sawnok & Sweeney (1989); Karlsten & Gordh, 2000). 
Adenosine is released from cells directly or via degradation of adenosine triphosphate 
(ATP) , and is involved in many regulatory mechanisms in both physiological and 
pathophysiological conditions (reviewed by Pelleg & Porter, 1990; Brundege & 
Dunwiddie, 1997; Abbrachio & Bumstock, 1998). Multiple adenosine (A) receptors have 
been cloned (AI, A2A , A2B and A3) (Fredholm et al., 1994). Al and A2 receptors occur 
in the spinal cord, with Al receptors predominating in lamina II (Choca et al., 1987; 1988) 
and in the brain (Goodman & Snyder, 1982; Braas et al., 1986). Adenosine receptors are 
widely distributed throughout the central nervous system, concentrated in lamina II of the 
dorsal hom. Adenosine is released from small-diameter nociceptive fibres in the dorsal 
hom and modulates spinal nociceptive transmission through presynaptic inhibition of 
sensory nerve terminals, and through hyperpolarisation of the post-synaptic membrane by 
increasing K+ conductance (Sawynok, 1998). 
There is now abundant evidence that adenosine modulates central nociceptive 
transmission, principally through Al receptors located in the superficial dorsal hom. 
Intrathecal administration of selective Al and A2 receptor analogues demonstrated an 
antinociceptive effect of spinal Al receptor activation (Karlsten, et al., 1990; Sawynok, 
1991). Activation of spinal Al receptors inhibits C-fibre evoked responses, wind-up and 
post-discharge of dorsal hom neurons (Reeve & Dickenson, 1995; Nakamura et al., 1997). 
In addition to its potential tonic inhibitory influence on physiological nociceptive 
transmission, there is mounting evidence to support a role of adenosine in the modulation 
of various manifestations of pathophysiological nociceptive transmission, including 
hyperalgesia associated with neuropathic injury (Yamamoto & Yaksh, 1991; Lee & Yaksh, 
1996; Cui et aI., 1998; Lavand'homme & Eisenach, 1999) and hyperalgesia induced by 
intrathecal prostaglandin F2 administration (Minami et al., 1992). 
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1.4 MOLECULAR PHARMACOLOGY OF PHymOLOGOCAL ~D 
PATHOPHYSIOLOGICAL NOCICEPTIVE TRANSMISSION 
The rapid response of nociceptive neurons in the central nervous system to peripheral 
noxious stimulation is mediated by transient processes, including receptor potentials in 
peripheral nociceptors, the conduction of action potentials, and rapid chemical 
transmission mediated by the opening of ligand-gated receptors coupled to ion channels 
(reviewed by Willis, 1996). However, noxious stimulation can also produce long-lasting 
modulation of central nociceptive neuronal activity. The intracellular signal transduction 
pathways activated by (for example) intracellular calcium influx or activation of receptors 
coupled to G-proteins or tyrosine kinase molecules, can produce intraneuronal metabolic 
changes which produce a prolonged alteration of neuronal excitability (Willis, 1996). 
Several types of signalling molecule have been implicated in the intracellular induction 
and/or maintenance of neuronal plasticity, including protein kinase enzymes, immediate 
early genes and their associated transcription factors and cytoskeletal proteins (reviewed 
by Morris, 1997). These are illustrated in Figure 1.5. Woolf & Costigan, (1999) and 
Woolf & Salter (2000) reviewed the molecular pathways which have been implicated in 
the induction and maintenance of central sensitisation of nociceptive transmission. Other 
signalling transduction pathways, such as those activated by opioidergic 
neurotransmission, reduce central nociceptive transmission (Willis, 1996). A greater 
understanding of the involvement of intracellular signal transduction mechanisms should 
lead to new targets for the therapy of persistent pain syndromes. 
Calcium calmodulin kinase (CaMKII) 
Many receptor-mediated events involve protein phosphorylation, which controls the 
functioning and binding properties of intracellular proteins. CaMKII is a protein kinase 
enzyme richly expressed in neurons, where it is a major constituent of post-synaptic 
density proteins (Kennedy et ai., 1983). It is a heteromultimer comprised of a and ~ 
subunits, 10 to 12 of which combine to form active CaMKII holoenzymes. Each subunit 
molecule contains an active site and a calmodulin binding site. The enzyme is calcium 
dependent, activated by the calcium-binding protein calmodulin which, when occupied by 
calcium, binds to a CaMKII subunit and elicits exposure of the catalytic domain of the 
enzyme. CaMKII phosphorylates numerous proteins involved in neurotransmitter 
synthesis and of dorsal root ganglia, presynaptic terminals (Ouimet et ai., 1984) and 
postsynaptic release, carbohydrate metabolism, and cytoskeleton 
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Figure 1.5: The pharmacology of central nociceptive transmission and central sensitisation. 
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assembly/dissociation, including GABAA receptors, phospholipase A2, microtubule-
associated protein 2 (MAP-2) and neurofilament proteins (reviewed by Hanson & 
Schulman, 1989). 
The distribution of the a and ~ isoforms of CaMKII has been described by Terashima et 
al. (1994), who reported that CaMKIla is strongly expressed in laminae I-IV of the dorsal 
hom (predominantly in presynaptic terminals and dendritic processes) but absent in 
laminae IV-X. CaMKII~ is distributed homogeneously throughout spinal cord grey 
matter located more densely in laminae IIII, and is also present in ventral hom 
motorneurons. 
CaMKII has intrinsic structural characteristics which make it a highly attractive candidate 
for the mediation of neuronal plasticity. The enzyme occupies a fixed position on the 
synaptic membrane which facilitates both its response to intracellular calcium influx and 
phosphorylation of ion channels (prerequisites for the induction of synaptic plasticity). 
CaMKII is the principal protein of the post-synaptic density (Kelly et al., 1984), a sub-
membrane structure physically linked to the post-synaptic membrane in a specific region 
in which both NMDA (notably the NR2B subunit) and non-NMDA receptors associated 
with modulation of synaptic activity are located (Carlin et al., 1980; Kennedy et al., 1983; 
Ocorr et al.,1991). CaMKII is transiently activated by phosphorylation but can also enter 
an autonomously activated state independent of calcium/calmodulin stimulation (reviewed 
by Lisman 1994; 1995). Following activation ofa group ofCaMKII molecules by calcium 
and calmodulin associated with significant neuronal stimulation, CAMKII 
autophosphorylates by an intersubunit intraholoenzyme reaction and becomes permanently 
'switched on', remaining active independent of the continued presence of calcium and 
calmodulin and earning CaMKII the label of 'molecular switch' (Saitoh & Schwartz, 
1985; Miller & Kennedy 1986). This is illustrated in Figure 1.6. 
Lisman (1985) speculated that autophosphorylation potential maintains the active state of 
the kinase molecular group even if individual molecules are dephosphorylated or replaced 
by newly synthesised unphosphorylated molecules. Self-perpetuating CaMKII activation 
can persist throughout the lifetime of the neuron and this mechanism potentially provides a 
molecular pathway through which 'memory storage' of a triggering synaptic event may be 
mediated, thus maintaining long-term changes in neuronal excitability in the absence of 
subsequent alterations in gene expression (Lisman, 1994). 
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Figure 1.6: CaMKII as a molecular switch 
A: In the absence of Ca2+/calmodulin (CaM), the active site of CaMKII is inhibited by binding 
of the inhibitory domain. 
B: Binding of CaM to its recognition site alters the enzyme's conformation, leading to 
phosphorylation of substrate proteins, including CaMKII itself. 
C: When the intracellular Ca2+ level falls, CaM dissociates itself from the enzyme; however, 
the phosphorylated threonine prevents reassociation of the inhibitory domain with the active 
site. Kinase activity is now partially independent of Ca2+ (the switch is "on"). 
D: Autophosphorylation may now occur at a site within the CaM binding domain, which 
causes the enzyme to be completely insensitive to CaM. Finally, CaMKII is dephosphorylated 
by phosphatases, returning it to its inactive state. 
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The role of CaMKIIa in the induction of neuronal plasticity has been extensively studied 
using a variety of molecular techniques, including enzyme antagonist studies (Wang & 
Feng, 1992) gene-knockout studies (Silva et al., 1992a, b; Stevens et aI., 1994) and direct 
assays of enzyme activity (Fukunaga et al., 1993). In the hippocampus, 
electrophysiological studies using CaMKIIa antagonists indicate that CaMKIIa is 
involved in the induction ofLTP (Malinow et aI., 1989; McGlade-McCulloch et al., 1993), 
while in-vitro assays of CAMKIIa activity indicate that CAMKIIa is rapidly and 
persistently activated in response to LTP-inducing stimuli (Fukunaga et al., 1993). Studies 
using CaMKIIa knockout mice (Stevens et al., 1994) have demonstrated the involvement 
of CaMKIIa in three distinct forms of synaptic plasticity; CaMKII-a knockout mice are 
severely impaired in their ability to learn certain spatial tasks despite intact synaptic 
transmission pathways and normal NMDA receptor function. STP, LTP and LTD are 
absent or dramatically attenuated in these mice in comparison with CaMKIIa intact 
control animals. CaMKIIa induces persistent enhancement of synaptic transmission by 
phosphorylating post-synaptic density ion channel proteins (including, most critically, 
NMDA receptors (Leonard et al., 1999; Shen & Meyer, 1999); AMPA receptors (Barria et 
al., 1997; Mammen et at., 1997); and other signalling proteins including immediate early 
genes (reviewed by Leonard et at., 1999; Shen & Meyer, 1999). CaMKIIa-mediated 
phosphorylation of AMP A receptors is an important step in the induction of L TP (Leonard 
et at., 1999). The calcium influx which activates CaMKIIa to produce LTP is commonly, 
but not exclusively, mediated by NMDA receptor activation (Leonard, 1999). 
There is ample evidence that CaMKIIa regulates key excitatory neurotransmitter systems 
involved in nociceptive processing. Intracellular application of CaMKIIa enhances 
glutaminergic transmission and excitatory synaptic potentials in acutely isolated rat spinal 
dorsal hom neurons (Kolaj et at., 1994; Pereda et al., 1998). It has been proposed that 
NMDA-mediated activation of kinase enzymes following intraneuronal calcium influx 
may be one mechanism through which central sensitisation of nociceptive transmission is 
maintained (reviewed by Coderre & Yashpal, 1994); however, other studies suggest that 
CaMKIIa regulates 'general' inter-neuronal communication, rather than mediating 
specific modalities of synaptic transmission involved in the induction and/or maintenance 
of synaptic plasticity (Pereda et al., 1998). 
CaMKIIa also regulates activity in key inhibitory neurotransmitter systems, including 
GABAA receptor activity and glycinergic transmission. The GABAA receptor has specific 
phosphorylation sites for CaMKII (McDonald & Moss, 1994) and CaMKIIa has been 
shown to enhance GABAA receptor activity and inhibitory synaptic responses in dorsal 
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hom neurons in-vitro (Wang et al., 1995a,b) suggesting that CaMKlIa may playa key role 
in the regulation of GABAA receptor activity and thus persistent enhancement of 
inhibitory synaptic responses. Basal kinase-mediated phosphorylation of either the 
GABAA receptor itself or a closely related protein is required to maintain GABAA receptor 
function in CAl hippocampal neurons (Chen et al., 1990). However, contradictory 
neuroanatomical data suggests that CaMKlIa is not involved in GABAergic neuronal 
responses or in presynaptic mechanisms within the axon terminals of dorsal hom neurons 
(Benson et al., 1992; Liu & Jones 1996) following inflammatory injury. CaMKlIa also 
enhances glycine currents in acutely isolated rat spinal neurons (Wang & Randic, 1996). 
Neurons in the superficial dorsal hom co-express NMDA and glycine receptors in the post-
synaptic membrane (Wang et al., 1998); NMDA-mediated intracellular calcium influx can 
modulate glycine receptor function in the superficial dorsal hom through CaMKlIa 
activation (Xu et al.,1999; 2000). When excitatory (NMDA) and glycinergic inhibitory 
synaptic transmission coincide, activation of post-synaptic transmission by glutamate 
released from sensory afferents may in tum inhibit post-synaptic neurons via augmentation 
of glycinergic input. This 'feedback' enhancement of the glycine response by NMDA 
activation represents a potential 'adaptive' spinal signalling pathway which could attenuate 
excitatory nociceptive transmission. CaMKlIa has also has been implicated in the 
regulation of prodynorphin gene expression in cultured spinal cord cells (Ha et al., 1997) 
and histamine (HI and H2) receptor-stimulated anti-nociception (Chung et al., 1998, 1999). 
The factors and mechanisms which regulate CaMKlIa gene expression in the CNS appear 
to be complex and remain poorly defined; indeed, regulation of CaMKlIa gene expression 
in the spinal cord has not been investigated to date. In the brain, regulation of CaMKIIa 
mRNA expression has been investigated predominantly using models of specific electrical 
stimulation such as L TP induction, tetanic stimulation or seizure induction. CamKlIa 
mRNA expression is increased following reduction of afferent input into hippocampal 
neurons, suggesting that CaMKII gene expression may be regulated by normal 
physiological neuronal activity. In models of neuronal plasticity in the brain, upregulation, 
downregulation and biphasic regulation of CaMKlIa mRNA expression have been induced 
using differing modalities of electrical stimulation. Mackler et al. (1992), Thomas et al. 
(1994) and Ouyang et al. (1999) reported enhanced CaMKlI mRNA expression in isolated 
hippocampal neurons following electrical stimulation, induction of L TP and tetanic 
stimulation respectively. Roberts et al. (1996) also reported upregu1ation of CaMKIIa 
mRNA expression in hippocampal neurons following the induction of LTP. In contrast, 
Liang et al. (1996) reported a reduction in CaMKlIa mRNA expression in neocortical 
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neurons for a short period (1-3 h) following tetanic stimulation, speculating that stimulus-
dependent mechanisms underlying neocortical plasticity involved reciprocal changes in 
CaMKIIa expression which regulated the balance of excitation and inhibition. Murray et 
al., (1995) reported reduced expression of CaMKIIa mRNA in hippocampal, neocortical 
and piriform cortical neurons following seizure activity. 
The intracellular mechanisms which drive alterations in CaMKIIa mRNA expression are 
equally poorly defined. Johnston & Morris (1995) reported that NMDA and nitric oxide 
(NO) stimulation of hippocampal neurons induced initial enhancement of CaMKIIa 
mRNA expression for 6 hours followed by dramatic downregulation of CaMKIIa mRNA 
expression observed 24 h post-stimulation, speculating that biphasic regulation of CaMKII 
a mRNA expression could modulate long-term responses of hippocampal neurons to 
NMDA receptor stimulation or NO release. Another study similarly reported that high-
dose NMDA stimulation of retinal neurons induced transient upregulation (for 2 h post-
stimulation) followed by downregulation (at 24 h) of CaMKIIa mRNA expression. 
(Laabich & Cooper, 2000). 
Evidently many questions regarding the involvement of CaMKIIa in nociceptive 
transmission and plasticity of central nociceptive processing remain unanswered. There is 
substantial evidence that other protein kinase enzymes, most notably protein kinase C 
(PKC) and protein kinase A (PKA) play pivotal roles in processes underlying neuronal 
sensitisation and enhancement of nociception (reviewed by Millan, 1999) and it would be 
of great interest to similarly identify and characterise a role for CaMKIIa in central 
nociceptive transmission and its modulation. 
Immediate early genes and transcription factors 
Immediate early genes (IEG's) are genes which are rapidly induced and/or expressed in 
neurons and other cells in response to an external stimulus. IEG's have been induced in 
cultured cells by growth factors, hormones, peptides and transmembranous ion fluxes. In 
neurons they can also be induced by after-discharges, electrical and chemical seizures, 
stimuli which share a 'common denominator', leading to or substituting for calcium influx 
through voltage-sensitive calcium channels (Greenberg et aI., 1985; Morgan et al., 1989). 
IEG's play an important role in the initiation of cell division, differentiation and neoplastic 
processes as well as mediating plasticity of cellular responses (reviewed by Angel & 
Karin, 1991). Over 100 IEG's have now been identified, most of which encode 
transcription factors (TF's). The functional properties of IEG's and their role in the 
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mediation of sustained plasticity of neuronal activity in the brain and spinal cord have been 
reviewed by Morris (1997) and Herdegen & Zimmerman (1995). 
Immediate early genes are characterised by certain key features: 
1. They are transcriptionally activated: lEG's are expressed de novo in response to an 
external stimulus by 'stimulation-transcription coupling' (Morgan & Curran, 
1991), activated by specific constitutively expressed trans-activating proteins 
through a mechanism which is independent of protein-synthesis; indeed, expression 
of these genes in the presence of protein-synthesis inhibitors is an important 
criterion for according lEG status to a particular gene (Curran & Morgan, 1987; 
Robertson, 1988). 
2. They are rapidly induced: mRNA for lEG's is often detected within 15 minutes of 
suitable cellular stimulation, protein becoming detectable within 30 minutes. 
Intracellular lEG mRNA levels are also rapidly attenuated subsequent to rapid 
inhibition of transcription degradation of mRNA (Greenberg et ai., 1984; Krujer et 
al., 1984; Lau et ai., 1987). 
3. They are often transiently expressed: The half-life ofmRNA is approximately 30 
minutes, while that of transcription factor protein is 2 hours, (Greenberg et ai., 
1984; Krujer et ai., 1984; Lau et ai., ·1987; reviewed by Dragunow et al., 1989). 
Rapidity of transcriptional activation implies that lEG promotors are poised for 
activation and transcription begins as soon as the second messenger is generated by 
the growth factor . 
lEG's encode for proteins; inducible transcription factors (ITF's), secretory proteins, 
enzymes and membrane receptors. ITF's are the protein products of lEG translation, a 
group of nuclear proteins that bind to regulatory DNA promotor and enhancer sites and 
control transcription of specific target or effector genes, either enhancing or repressing 
gene expression. It has been hypothesised that ITF's playa crucial role in mediating long-
lasting changes in CNS function and may be involved in establishing the neurological 
pathways responsible for learning, physiological adaptation to new environments, and 
certain persistent neurological diseases including forms of chronic pain (reviewed by 
Herdegen & Zimmermann, 1995; Morris 1997). ITF's activate or repress directly (on the 
promotor region) or indirectly the expression of other more durable genes which have been 
referred to as 'late effector genes' or LEG's, generally constitutively expressed in at higher 
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levels than IEG's (Curran & Morgan, 1987) which in tum are transcribed into proteins that 
mediate a prolonged change in cellular function. 
The precise role of IEG' s in the induction and maintenance of LTP, learning and memory 
in higher centres remains undetermined. In the hippocampus a close relationship has been 
identified between expression of certain lEG's and LTP (reviewed by Morris, 1997). 
Numerous 'families' ofIEG's have been associated with LTP, notably the fos genes, the 
jun genes, the 'zinc finger genes' including zif1268 (krox-20) and NGF1-A (krox-24) (Cole 
et aI.J 1989; Wisden et aI.J 1990), the growth factor ~-activin (Andreasson & Worley, 
1995), protease tissue plasminogen activator (tPA) (Qian et aI.J 1993), and cyclo-
oxygenase-II (Yamagata et al., 1993). The closest correlation between ITF expression and 
induction ofLTP has been observed for zif/268. This relationship is not however constant. 
While some workers have observed a dramatic increase in zif1268 mRNA in post-synaptic 
neurons in the hippocampus following high-frequency stimulation (Cole et al., 1989; 
Roberts et al., 1996), others have observed LTP induction in the absence of zif/268 
expression, and also zif/268 expression in the absence of LTP induction (Wisden et al., 
1990; Johnston & Morris, 1994). Recent evidence suggests that the principal role ofIEG's 
in neuronal plasticity is in the maintenance and stabilisation of persistent LTP (associated 
with phenotypic alteration of the neuron), rather than in the induction of LTP (reviewed by 
Walton et al., 1999). Strong induction of nerve growth factor 1A (NGF1-A) and zif/268 
occurs in association with long-lasting LTP in the hippocampus, but not in association with 
less stable forms of LTP (Abraham et aI. J 1993). Futhermore, increased expression of 
NGF1-A has been associated with some forms of long-term memory in primates and rats 
(Okuno & Miyashita, 1996; Richter-Levin et aI. J 1998). 
Herdegen & Zimmermann (1995) have reviewed evidence supporting the involvement of 
IEG's and ITF's in central sensitisation in the spinal cord. With the exception of zif1268 in 
lamina III of the lumbar spinal cord and constitutive expression ofjunD and COX-2, ITF's 
are absent in the dorsal hom under physiological conditions (Herdegen et aI.J 1991; Tolle 
et al., 1994). It has been proposed that a significant increase in levels of ITF's requires 
activation of both A-o and C-fibres (Hunt et al., 1987; Herdegen et al., 1991; Molander et 
al. J 1992) and consequently it has been speCUlated that enhanced expression of lEG's in 
dorsal hom neurons induces central sensitisation. Some groups have mapped constitutive 
and induced ITF expression in the dorsal hom following noxious thermal stimulation 
(Wisden et al., 1990), inflammatory injury (Lanteri-Minet et al.J 1993), and electrical 
nerve stimulation (Herdegen et al., 1991). 
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Persistent noxious stimulation triggers dramatic alterations in dorsal hom neuronal 
expression of immediate early genes involved in transcriptional control (c-Fos, c-jun, 
zif/268) and of genes encoding neuropeptides (dynorphin, enkephalin, Substance P, NPY) 
and their receptors (Iadarola & Caudle 1997). The upregulation of IEG expression has 
been shown in some cases to parallel the time course of hyperalgesia associated with 
inflammatory injury (Ji et at., 1994; Draisci et at., 1991). It would appear that a 
'transcriptional network' is activated in spinal pain-processing neurons, and if the stimulus 
is of a sufficient degree and duration, a network of target genes even further downstream 
can be activated resulting in long-term plasticity of the nociceptive response (Herdegen et 
at., 1991). 
A major challenge in our appreciation of the role of ITF's in synaptic plasticity remains 
identification of specific changes which they induce in neurotransmitter production or 
activity (reviewed by Sheng & Greenberg, 1990; Treisman, 1990; Herdegen & 
Zimmermann, 1995; Chaudhuri, 1997). Within the spinal cord, popular candidate targets 
for activation by ITF's include neuropeptides, glutamate, endogenous opioids and nitric 
oxide. Fos and Jun proteins have been linked with regulation of transcription of 
proenkephalin (Sonnenberg et at., 1989; Noguchi et at., 1992), prodynorphin (Naranjo et 
at., 1991; Noguchi et at., 1991) and nerve growth factor (Hengerer et at., 1991). SP and its 
NK-1 receptor (Duggan et at., 1988) have also been postulated as potential targets for ITF-
mediated upregulation. 
ZIFI268 
Constitutive expression of zif/268 throughout the grey matter of the spinal cord has been 
previously demonstrated using in-situ hybridisation techniques by Wisden et at., (1990). 
Upregulation of spinal zif/268 mRNA expression has been reported previously in 
association with numerous modalities of noxious stimulation. Wisden et at., (1990) 
demonstrated that noxious thermal stimulation of the hindpaw induced dramatic 
upregulation of zif/268 expression in laminae I, II, V and X (measured 15-30 minutes after 
stimulation), while non-noxious thermal stimulation at 42°C did not alter constitutive 
zif/268 expression. However Wisden et al., (1990) did not quantify zif/268 up-regulation, 
nor comment on the unilateral or bilateral nature of upregulation. Herdegen et at. (1991) 
studied zifl 268 mRNA expression following electrical stimulation of nociceptive fibres in 
the sciatic nerve, observing that selective stimulation of wide diameter A-fibres did not 
alter zif/268 mRNA expression beyond basal levels in the dorsal hom, while stimulation 
extended to include both Ao and C-fibres induced ipsilateral upregulation of zif/268 
mRNA expression in the dorsal hom. In this study, zif/268 protein expression was 
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detected 30-45 minutes after the onset of repetitive sciatic nerve stimulation and peaked 2-
3h post stimulation. There are few reports of regulation of zif/268 expression associated 
with inflammatory disease; while Buritova et al. (1995) investigated zif/268 protein 
regulation associated with high-dose carrageenan treatment, and Lanteri-Minet et ai. 
(1993) studied zif/268 protein expression (identified by immunocytochemistry techniques) 
associated with persistent CF A intrap1antar inflammation, regulation of zifl268 expression 
following mild or repeated inflammatory injury has not been investigated to date. 
Tissue piasminogen activator 
Plasminogen activators (PA's) are serine proteases which convert plasminogen into the 
active protease plasmin and thus provide a source of proteolytic activity in many biological 
systems (Collen, 1980; Dano et ai., 1985). Two types of PA have been identified; tissue-
type PA (tPA) (Astrup & Permin, 1947) and urokinase-type PA (uPA) (Williams, 1951). 
In the nervous system, PA's are involved in cell proliferation (Kalderon, 1984; Moonen et 
ai., 1985), migration (Moonen et ai., 1982) and differentiation in the developing brain tPA 
is secreted by neurons during neurite outgrowth and remodelling (Monard, 1988) and its 
substrates degrade many components of the extracellular matrix, enabling neurites to 
develop and sprout (Krystosek et ai., 1981; 1984). TPA has thus been proposed as an 
important regulatory molecule in neuron development, the modulation of neuronal 
architecture, and neuronal death (Tsirika et al., 1996). 
The role of tP A in the induction and maintenance of synaptic plasticity in the brain has 
been reviewed by Baranes et ai.(1998). Qian et ai. (1993) first reported that LTP induced 
an NMDA receptor-mediated increase in tP A gene expression in the dentate gyrus, 
suggesting that tP A played an important role in neuronal plasticity. TP A has since also 
been induced in cerebellar Purkinje neurons after cerebellar motor learning (Seeds et ai., 
1995), a process associated with activity-dependent synaptic plasticity. TP A-gene-
deficient mice show a selective defect in L TP (Frey et ai., 1996; Huang et ai., 1996) and 
spatial learning. Baranes et ai. (1998) reported that tP A was critically involved in the 
production of L TP and in synaptic growth. TP A has also been induced in association with 
cerebellar LTD (Seeds et ai., 1995). There are no reports of investigations into spinal 
regulation of tP A mRNA expression associated with inflammatory injury. 
JunD 
The involvement of jun D in plasticity of spinal nociceptive processing has been reviewed 
by Herdegen & Zimmermann (1995). Jun D protein is constitutively expressed at high 
levels in the brain (Lanterei-Minet et ai., 1993; Herdegen et ai., 1993; Herdegen et ai., 
1995) and in the spinal cord (Herdegen et al., 1991(a, b); 1994; Tolle, 1994). Numerous 
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studies have investigated the involvement of jun D in nociceptive transmission. Herdegen 
et al., (1991a) reported upregulation of jun D protein expression in spinal neurons 
following noxious stimulation of C and AD fibres from 4h post-stimulation, persisting for 
32 hours following stimulation. Lanteri-Minet et al., (1993) reported upregulation of jun 
D protein expression when measured 7-15 days following the induction of CF A 
intraplantar inflammation, but not in the initial stages of CF A-induced inflammation. 
Herdegen et al., (1994) reported upregulation of junD protein expression in the superficial 
dorsal hom in a formalin model of intraplantar inflammation, where jun D protein 
expression was maximal at 5h post-treatment, persisted at maximal levels for 10 hours 
post-injection (Pj). and remained significantly greater than constitutive levels at 24hours 
pj. Tolle et al. (1994) reported significant upregulation of jun D protein expression from 
4h following noxious thermal stimulation of the hindpaw. 
The involvement of jun D in the induction of L TP in the spinal cord has been investigated 
previously. Wisden et al. (1990) reported that constitutive expression of junD mRNA in 
the spinal cord was not upregulated when measured 30 minutes after induction ofLTP. 
1.5 CONCLUSIONS 
It is clear that the pain transmission system is subject to modulation at every level of the 
neuro axis. This system is inherently plastic, such that in any individual there is no 
constant clear relationship between the stimulus intensity and the conscious perception of 
pain. Pathophysiological pain transmission associated with inflammatory injury results 
from sensitisation of both peripheral and central nociceptive transmission, which may be 
attributed to alterations in excitatory and inhibitory systems involved in the induction and 
maintenance of central sensitisation. 
1.6 AIMS OF STUDY 
The purpose of the studies described in this thesis was to investigate plasticity of central 
nociceptive transmission associated with inflammatory injury. While ample experimental 
evidence suggests that the electrophysiological phenomenon of L TP is associated with 
central sensitisation of nociceptive transmission, to date there has been sparse 
experimental evidence to suggest that LTD of central nociceptive processing, the 
electrophysiological complement of L TP, may be related to hyposensitisation of central 
nociceptive processing. It was hypothesised that LTD-like phenomena may play an 
important role in the physiological response to mild inflammatory injury. On the basis that 
previous failures to observe a behavioural complement to central sensitisation might reflect 
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the high intensity of inflammatory challenge typically used in research into inflammatory 
pain (discussed in chapter 2), it was considered timely to study the pharmacological 
mechanisms associated with behavioural responses to low-intensity inflammatory 
challenge. Hypothesising that both the magnitude and the duration of inflammatory 
challenge critically influence central nociceptive transmission (discussed in chapter 2) the 
response to repeated inflammatory stimulation was studied, hypothesising that 
manipulation of the frequency of inflammatory challenge might provide further insights 
into mechanisms associated with physiological and pathophysiological responses to 
inflammatory injury. Clearly, mediators of depressed hyperalgesic responses would prove 
useful targets for the therapy of inflammatory hyperalgesia. Plasticity of nociceptive 
behaviour observed in-vivo was investigated further using in-situ hybridisation techniques 
to investigate regulation of key effector molecules in the spinal cord dorsal hom which 
have been implicated in the modulation of nociceptive transmission following 
inflammatory injury. In addition, an organotypic slice culture system for post-natal rat 
spinal cord was developed and characterised in order to provide a novel and useful 
technique for more detailed study of the molecular basis of central plasticity of nociceptive 
transmission. 
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CHAPTER 2: BEHAVIOURAL STUDIES 
That which is static and repetitive is boring. That which is dynamic and random is 
confusing. In between lies art 
John Locke 
2.1 INTRODUCTION 
2.1.1 Assessment of pain responses in animals 
Contemporary concern over the ethical justification for the use of live animals in scientific 
research is of particular relevance to pain research. While advances in in-vitro techniques 
provide alternatives to the 'whole animal model', evaluation of new analgesic drugs and 
basic research into the neural mechanisms involved in the development and maintenance 
of persistent and chronic pain conditions still rely heavily on in-vivo models. Ethical 
guidelines, which pertain specifically to pain research, have been reviewed by Loew 
(1987) and Dubner (1987). Beecher (1957) provided recommendations that provide the 
ethical benchmark used to assess the integrity of 'painful stimuli' applied to animals in 
behavioural studies. His recommendations, designed to guide the selection of stimuli used 
to test pain responses in laboratory animals but applicable to all in-vivo studies on pain 
behaviour, were: that the chosen stimulus should be applied to a region of the body where 
the responses measured would accurately indicate a pain response; that the stimulus should 
produce minimal damage at the pain threshold level; that the potential hazard to the test 
subject at the highest testing intensity should be small; that there should be a definable 
relationship between the intensity of the stimulus and the intensity of perceived pain; that 
repeated testing using the same stimulus should not affect the quantifiable response; that 
the stimulus should induce a clear end-point (response); that the stimulus should be 
sufficiently sensitive to allow small alterations in threshold to be detected and should 
permit detection of different doses of analgesic and that the stimulus should be applicable 
to both humans and animals. Wood (1984) provided a further definition of 5 essential 
criteria for tests used to measure pain responses in animal, namely validity (ability of the 
test to predict the clinical value of known analgesic agents); reliability (reproducibility); 
simplicity; sensitivity; and facility for quantitative analysis of collected data. 
A major hurdle in the use of animal models to investigate pain mechanisms is the 
recognition of alterations in stimulus-dependent pain behaviour in animals. Many studies 
use changes in nociceptive reflex behaviour as indicators of altered pain perception; 
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however such reflex behaviours often correlate poorly with stimulus-induced pain 
behaviour in humans. Certain behavioural parameters used as indicators of a 'pain 
response' in rodents - notably the tail flick response (also called the tail-immersion test) 
and limb withdrawal tests - are considered to be predominantly reflexive (Nolan et al., 
1987). Similar 'simple reflex' behavioural tests have been documented in other species, 
including skin flinch (Kamerling et al., 1985) and jaw opening reflexes (Mitchell, 1964). 
These reflex behaviours are, however, subject to modulation; for example, response 
thresholds or latency measurements can change in association with alterations in motor 
function, potentially induced by unilateral inflammation in the hind limb; or with learned 
avoidance strategies. By definition, simple reflex behaviours cannot indicate any affective 
component of pain sensation. For this reason some workers prefer to use organised 
unlearned behaviour, such as paw licking, face rubbing (Chapman et al., 1985) and 
vocalisation (Eddy, 1928; Kayser et al., 1998) as response indicators on the premise that 
these are specific 'pain responses' which include an 'affective' component. Experimental 
methods of evaluating pain responses to thermal or mechanical stimulation commonly 
measure a threshold response or response latency. Such methods assume that pain 
thresholds (the intensity of noxious stimulation which is first perceived as painful) are 
similar in humans and animals (Vierk, 1976). 
Mechanical stimulation 
Mechanical hypersensitivity in the form of tactile allodynia is a hallmark of certain types 
of neuropathic pain (Wahren & Torebjork, 1992) but also develops as a consequence of 
inflammatory injury. In recognition of this, great efforts have been made to develop an 
accurate means of assessing cutaneous responsiveness to applied mechanical force 
resulting in many different quantitative techniques for assessment of alterations in 
sensitivity to mechanical pressure. Paw withdrawal or vocalisation responses are most 
commonly chosen to 'quantify' mechanical sensitivity. Many techniques use a method 
similar to that originally described by Randall & Selitto (1957), where animals are fully or 
partially restrained and incrementally increasing mechanical force is applied to the paw via 
a blunt piston or similar device (e.g. Stein et al., 1988; Perrot et al., 1993.) Commercially 
produced automated pressure gauges are available for this purpose. Such models assess 
responses to deep pressure rather than light touch, such that reported experimentally 
induced 'withdrawal thresholds' are typically some 100-fold higher than the force of light 
tactile stimulation required to provoke a withdrawal response in the allodynic animal 
(Ahlgren & Levine, 1993). Kayser & Guilbaud (1987) suggested that the vocalisation 
threshold represents a more integrated nociceptive response than paw withdrawal and may 
provide a superior method of assessing changes in mechanical sensitivity. 
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In 1897, Von Frey described the use of horse hairs of various diameter and length to exert 
a controlled mechanical force on human skin. He connected horse hairs to a lever, which 
enabled him to measure the force, which each hair exerted on the skin, and thus quantify 
the force required to evoke a 'pain' response. While modem Von Frey hairs are plastic 
filaments rather than horse hairs, the Von Frey test remains one of the most common 
methods used on human or animal subjects to assess and quantify responses to a constant 
mechanical stimulus. 
Von Frey hairs are used in a variety of ways to assess sensitivity to mechanical pressure. 
Some measure a 'withdrawal response frequency' for the number of withdrawal responses 
evoked by repeated stimulation with hairs of different force (e.g. Gilchrist et al., 1996); 
while others use a 'withdrawal threshold', the lowest force of Von Frey hair which elicits a 
consistent withdrawal response (e.g. Brennan et al., 1996). Von Frey hairs are intrinsically 
limited in their capacity to assessing sensitivity to mechanical pressure. They provide a 
restricted categorical scale of measurement of applied force, and measure only one 
particular form of sensitivity to mechanical pressure, namely punctate hypersensitivity 
(reviewed by La Motte et al., 1991). Commercially produced devices are available which 
attempt to overcome the categorical nature of Von Frey testing: for example, the U go-
Basile analgesymeter (Ugo Basile, Comerio, Italy) generates a linearly increasing 
mechanical force applied by a small plastic tip. However such devices tend to produce a 
deep pressure stimulus rather than a light 'tactile' pressure stimulus. A distinct form of 
mechanical hypersensitivity to gentle swab stroking (in contrast to punctate stimulation) 
has been described which cannot be detected using Von Frey hairs, variously described as 
'stroking' hyperalgesia (Koltzenberg et al., 1992) and dynamic hyperalgesia (Ochoa et al., 
1993). There is substantial evidence to suggest that these two manifestations of 
mechanical hypersensitivity- punctate and stroking- are mediated through different 
mechanisms. The area of punctate hypersensitivity, which develops subsequent to 
cutaneous injury, is larger and develops more quickly than the zone of hypersensitivity to 
stroking stimuli (Cervero et al., 1993). Electrophysiological studies suggest that while 
punctate hypersensitivity is mediated by small diameter fibres, presumably nociceptors 
(Cervero et al., 1994), stroking hypersensitivity is conveyed by large diameter fibres, 
presumably mechanoreceptors (Torebjork et al., 1992). 
Thermal stimulation 
Reflexive foot withdrawal in response to noxious radiant heat is a widely used method for 
assessing nociceptive behaviour in rodents. Hardy et al. (1940) first described a method of 
application of a radiant heat source as a means of measurement of thresholds to noxious 
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thermal stimulation in human sUbjects. Hardy used a 500-1000 watt projection lamp to 
focus radiant heat onto a 'target' area of blackened skin, controlling the intensity of radiant 
heat using a rheostat, and the duration of exposure using an electrically timed shutter. 
Variations of Hardy's method have been adapted for use in many animal species. 
Hargeaves et al. (1988) developed a custom-built plastic cage with a glass floor, elevated 
so that a thermal source could be applied to the hind foot of rodents. Hargreaves' design 
incorporated a removable and exchangeable glass plate floor, which provided a 'minimally 
invasive' technique of assessing the behavioural response to application of heat stimulus to 
the plantar surface of the rodent foot. Hargreaves' heat stimulus was a 50 watt projector 
lamp placed in a case, which allowed it to be manoeuvred and accurately focused on its 
target. A digital timer and electronic photocell apparatus were used to automatically 
measure withdrawal latency to thermal stimulation. The Hargreaves model is now the 
standard method used to apply a radiant heat stimulus in experimental studies on rats; and 
thermal devices for use in this model are commercially available (e.g.Ugo-Basile, 
Comerio, Italy, plantar test 7370) delivers a ramping infrared stimulus. 
There are two commonly used alternatives to the radiant heat method described by Hardy 
which use conducted heat to stimulate nociceptive behaviour in rodents. These are the hot 
plate test, first described in 1944 by Woolf & Macdonald, and the tail immersion test, 
described in 1941 by D' Amour & Smith. Hot plates are commercially available and are 
typically set at a pre-determined temperature (commonly 50-55°C for behavioural tests 
conducted on rodents). Both of these methods of assessing nociceptive reflexes have 
numerous disadvantages in comparison to the radiant heat tests developed by Hardy and 
others. Neither method permits independent assessment of treatment effects in 
treated/untreated limbs, and the hot plate method does not permit immediate release from 
the noxious stimulus, unlike the Hargreaves' technique, in which the noxious stimulus 
stops at the instant when the test subject registers aversion. The tail-flick (TF) test, which 
measures response latency where the rodent's tail is submerged in water of pre-determined 
temperature, (believed to be a central spinal reflex) also has intrinsic limitations. The tail 
is a thermo-regulatory organ and tail skin temperature may vary considerably in response 
to environmental (Berge et al., 1988) and experimental (Tjolsen et al., 1988) conditions 
and also to drug treatment (Tjolsen et al., 1990). Such variations in cutaneous temperature 
affect nociceptive thresholds and compromise the validity of experimental data. The foot 
withdrawal response to noxious radiant heating of the skin (characterised and reviewed by 
Yeomans & Proudfit, 1994) thus offers numerous advantages over alternative thermal 
methods of nociceptive testing, although there is evidence to suggest that the plantar 
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surface of the rodent foot may also playa role in thermo-regulation (Duggan et al., 1978; 
Gordon, 1990). 
Electrical stimulation 
Noxious electrical stimulation has been used in both human (reviewed by Kattims, 1998) 
and animal (reviewed by Raffe, 1992) studies to assess nociceptive behaviour. Electrical 
tooth-pulp stimulation has been used in humans (Olausson & Sagvik, 2000), laboratory 
animals (Han et al., 1999), companion animals and horses (Steffey et ai., 1977) to evaluate 
cranial nerve nociception and indicate the efficacy of analgesic agents administered during 
dental treatment. Electrical stimulation of the tail, footpad, cutaneous zones of the forearm, 
muscles and nerves have also been described in various species as a means of assessing 
nociceptive behaviour and evaluating analgesic agents (reviewed by Raffe, 1992). 
2.1.2. Animal models of inflammatory pain 
The ultimate test for an animal model is its value for leading to pain treatments in human 
and veterinary clinical practice (Koltzenberg, 1999). Pain models are broadly separated 
into three functional divisions based on current understanding of the underlying 
mechanisms and pharmacology of pain sensation (reviewed by Dickenson, 1999; Yaksh, 
1999), namely: models of acute high-intensity pain- such as the hot plate test, the tail-flick 
test and paw pressure tests; models of pain resulting from inflammation and tissue damage 
of variable intensity and duration and models of pain associated with nerve damage- such 
as sciatic nerve ligation or compression. 
The mechanisms of inflammatory and neuropathic pain differ markedly from those of 
acute pain and there is considerable plasticity in both the transmission and modulation of 
these prolonged pain states (Dickenson, 1999). 
Inflammatory pain has been experimentally induced in animal models by numerous 
stimulus modalities, including thermal injury, mechanical injury, surgical incision and 
administration of endogenous or exogenous inflammatory agents (reviewed by Jasmin et 
ai., 1998). Administration of an exogenous inflammatory agent remains the most 
commonly used means of investigating mechanisms involved in inflammatory pam. 
Randall & Selitto (1957) first described a model where peripheral inflammation was 
induced by local injection of a chemical irritant. Many different agents have since been 
used in this model, most commonly carrageenan, complete Freund's adjuvant (CFA) , 
capsaicin and formalin, but also kaolin, turpentine, elastase, trypsin, capsaicin, dextran, 
hyaluronidase, mustard oil and acid phosphatase (reviewed by Vinegar et al., 1976; 
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Otterness & Bliven, 1985) and recently bee venom (Chen et al., 1999). Each of these 
irritants induces an inflammatory response of characteristic nature and duration. 
The carrageenan-oedema model was introduced by Winter et al. in 1962 as an alternative 
to the irritants originally described by Randall & Selitto (1957). Following the 
characterisation of indomethacin analgesia using this model (Winter et al., 1963), 
carrageenan-induced footpad oedema became established as a dominant model for the 
evaluation of potential anti-inflammatory agents and research into inflammatory pain. The 
carrageenans (kappa, lambda and iota) are a family of polysulphated polysaccharides 
isolated from marine algae. The inflammatory response to an isolated high-dose 
intraplantar carrageenan injection has been well characterised. ",-carrageenan produces a 
characteristic biphasic inflammatory response when injected into the rat footpad (Vinegar 
et al., 1968), with an 'eady' phase of approximately 1 hour duration, and a 'late' phase 
from 2 hours post-injection (p.i.). Maximum hyperalgesia after carrageenan injection 
occurs 2-3 hours pj. (Yamamoto et al., 1993). The inflammatory response and 
hyperalgesia associated with carrageenan injection (2 -4 mg) subsides to control values 
within seven days of injection [Castro-Lopez et al., 1994; Fletcher et al., 1997; Kayser et 
al., 1998), while vascular permeability and leucocyte accumulation following carrageenan 
injection into an air pouch return to control values by 7 days post-treatment (Hambleton & 
Miller, 1989). Carrageenan induces inflammation by activating pro-inflammatory cells 
and induces hyperalgesia by promoting the release of potent inflammatory mediators, 
including nitric oxide, histamine and 5-hydroxytryptamine (5-HT) (predominant mediators 
of the eady phase response), kinins and cytokines (which maintain increased vascular 
permeability for up to 2.5 hours post-injection), and prostaglandins (predominant 
mediators of the late phase response) from 2.5 until at least 6 hours post-injection, closely 
associated with the migration of leucocytes into the inflamed site) (reviewed by Di Rosa et 
ai, 1971). All of these mediators activate or sensitise nociceptive sensory neurons (Lang et 
al., 1990). High doses of carrageenan have been shown to induce both peripheral 
sensitisation (Seibert et al., 1994; Salvemini et al., 1995) and central sensitisation (Kayser 
et al., 1998; Perrot et al., 1999) in behavioural and electrophysiological studies of 
nociceptive processing. In their characterisation of the 'carrageenan oedema assay', 
Winter et al. (1962; 1963) and Vinegar et al. (1968) administered doses of 1mg 
carrageenan in an injection volume of 50 Ill. However, for reasons that are unexplained, 
contemporary models of inflammatory injury typically administer substantially higher 
doses of carrageenan [typically 100 - 200111 of 2 - 4%, equivalent to 2 - 8mg carrageenan] 
(e.g. Dirig et al., 1998; Kayser et al.,1998; Pertovaara et aI., 1998; Perrot et al., 1999) 
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with doses of 6mg or more commonly used (Castro-Lopez et al., 1994; Ichitani et al., 
1997; Buritova & Besson, 1998; Honore et al., 1998; Tsuruoka et al., 1998). 
Complete Freund's adjuvant (CF A) induces a chronic inflammatory focus and is employed 
in the investigation of mechanisms of persistent inflammatory pain. It is typically 
administered by intra-plantar or intra-articular injection (reviewed by Colpaert, 1987), 
producing a prolonged inflammatory response which peaks 8-24 hours after injection and 
is maintained at peak levels for at least 14 days following intraplantar injection (Hay et al., 
1997; Goff et al., 1998; Stein et al., 1988) and for up to 8 weeks following intra-articular 
injection (Colpaert, 1987). 
Capsaicin, the pungent constituent of chilli peppers, produces acute pain and 
inflammation through selective excitation of C-polymodal nociceptors accompanied by 
depletion of substance P from the afferent terminals of these receptors (Kenins, 1982; 
LaMotte et al., 1992). Capsaicin acts by binding to vanilloid receptors, non-selective 
cation channels which permit the influx of calcium and other ions into neurons to result in 
action potential generation leading to pain sensation, and release of substance P and other 
neuropeptides. In the rat, high doses of capsaicin desensitise neurons to subsequent 
capsaicin administration or other nociceptive stimulation (Lynn, 1992; Szallasi, 1994). 
Intradermal administration of capsaicin is commonly used in human as well as animal 
subjects (e.g. Gilchrist et al., 1996) as an inflammatory stimulant, produCing characteristic 
dose-dependent pain sensation of short duration accompanied by primary and secondary 
hyperalgesia (reviewed by Willis, 1997b). The capacity of topical or intradermal 
application of capsaicin to induce desensitisation of nociceptors has led to the development 
of capsaicin-derived products as anti-inflammatory and topical analgesic agents (reviewed 
by Wilcox, 1999). 
Formalin, characterised by Dubuisson & Dennis (1977), induces a characteristic biphasic 
inflammatory and nociceptive response consisting of an early, brief painful response of 5-
10 minutes duration and declining to a low level, produced by direct nociceptor 
stimulation, followed by a tonic (prolonged) period of persistent pain starting at 20 
minutes following formalin administration and lasting for approximately 40 minutes. This 
second phase is a consequence of the release of endogenous inflammatory mediators 
(Dickenson & Sullivan, 1987b). In the 'formalin test', a standard method used to induce 
pain behaviour in rat models, 2.5-5% formalin is typically administered by intraplantar 
injection to produce dose-dependent pain responses for approximately 1 hour pj. 
(reviewed by Carstens, 1992). 
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2.1.3 Plasticity of nociceptive transmission associated with inflammatory injury 
Inflammatory injury induces peripheral and central sensitisation of nociceptive 
transmission. Ample evidence from diverse sources, including behavioural studies (e.g. 
Kaneko & Hammond, 1997), and electrophysiological studies (e.g. Aertsen et al., 1989; 
Eblen-Zajjur & Sandkuhler, 1997) indicates that plasticity of nociceptive transmission 
associated with inflammatory injury is critically dependent upon the intensity of the 
inflammatory insult, and at least part of this plasticity is centrally mediated (reviewed by 
Treede et al., 1992; Levine & Yaksh, 1994; Woolf, 1995 and in Chapter 1). 
To date, few behavioural studies have investigated dose-dependent responses to mild 
inflammatory injury using standard inflammatory agents. The dose of 3-5mg formalin 
standardly used in the formalin test (e.g. Dirig & Yaksh, 1995) produces a 'ceiling effect' 
which has the potential to hinder investigations into molecular mechanisms of central 
plasticity. Kaneko & Hammond (1997) used a range of concentrations of formalin (0.25% 
to 2.5%) to report a significant dose-dependent change in pain responses to formalin 
treatment, proposing that an alteration in the intensity of formalin-induced peripheral 
inflammation could induce an alteration in the balance of central and peripheral 
nociceptive transmission to result in markedly different neuronal and behavioural 
responses to noxious challenge. With the exception of a study by Tabo & Eisele (1998) 
describing intraplantar doses of 1mg and 0.1mg carrageenan, few studies have investigated 
behavioural responses to low doses of carrageenan. The mild inflammatory response 
induced by low-dose carrageenan offers significant advantages to the behaviourist over the 
higher doses of carrageenan standardly used, over and above distinct animal welfare 
advantages. Low-dose carrageenan reduces the degree of inflammation-induced warming 
of the plantar skin towards a critical threshold at which artefactual facilitation of heat-
evoked responses occurs (Hole & Tjolsen, 1993), and reduces the marked alterations in 
weightbearing and posture observed using higher doses of carrageenan (Tabo et al., 1998). 
The Hargreaves model has been shown to be a highly sensitive means of measuring 
nociceptive behaviour relative to alternative methods of assessing pain in laboratory 
animals, including the hot-plate, tail-flick, weight-bearing and Randall-Selitto assays 
(reviewed by Tabo et al., 1998; Pertovaara et al., 1998). 
Repetitive inflammatory stimulation 
There have been similarly few studies of repeated acute inflammatory stimulation and its 
effects on nociceptive responses. Repeated carrageenan treatment has been reported to 
induce both hypersensitisation (Kayser et al., 1998; Perrot et al., 1999) and tachyphylaxis 
(Welsh & Nolan, 1994) of hyperalgesic responses. These differences may be related to the 
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dose of carrageenan used. It is worth noting that repeated intraplantar administration of 
150 III saline for 4 days has been reported to induce a progressive increase in post-injection 
swelling and transient hyperalgesic behaviour (Levine et al., 1985). 
2.1.4. Aims and objectives 
The principal aim of the studies described in this chapter was to develop a behavioural 
model which could accurately detect plasticity of nociceptive transmission (potentially up 
regulation or down regulation) associated with mild repetitive inflammatory injury. Since 
the intensity and duration of inflammatory injury critically influence nociceptive 
transmission, it was hypothesised that this model could facilitate evaluation of both 
physiological and pathophysiological nociceptive responses and possibly assess the 
'adaptive' nociceptive response to injury. 
2.2 MATERIALS AND METHODS 
Adult male Wi star rats [ Harlan, U.K.](n=72) weighing 200-280g were used in all studies. 
Rats were acclimatised to behavioural apparatus for two weeks before behavioural testing 
began. 
2.2.1 Intraplantar drug administration 
All treatments were administered by intraplantar injection in a volume of 50 III into the 
right (ipsilateral) hindpaw, by 27g, O.Sml syringe. 'A- carrageenan solutions (C3889, 
SIGMA, UK) were prepared and aliquoted 7 days prior to use and stored at 4°C. 
Emulsions (50% and 12.5% ) of CFA(F5881, SIGMA, UK) used in pilot study 1 were 
prepared 2 hours before use. All solutions were warmed to room temperature prior to 
administration. 
2.2.2. Behavioural testing 
All measurements were made on ipsilateral ( ipsi) and contralateral (contra) hindpaws. 
Paw circumference 
Paw circumference (PC) was recorded in mm using fine silk filament and was used as a 
measure of post-injection oedema. 
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Thermal withdrawal latency 
The tail flick test was used to assess thermal withdrawal latency (TWL) in pilot study 1. 
Each animal was restrained on the recorder's forearm and its tail submerged in a water 
bath set at a constant water temperature of 48°C. The latency to aversion response 
(removing tail from water, in seconds) was measured (to O.ls) using a hand-held 
stopwatch. In all subsequent studies, TWL was assessed using an adaptation of the 
behavioural model described by Hargreaves et al., (1988). Animals were placed on an 
elevated glass plate in a clear plastic box of dimensions 28 cm by 18cm by 11.5cm. The 
thermal stimulus was a focused beam of light (50W projector bulb, OSRAM 5008-V) 
accurately directed onto the plantar surface of the footpad. Time to aversion was measured 
in seconds (to O.ls) using a hand-held stopwatch. 
Mechanical withdrawal threshold 
Mechanical withdrawal threshold was assessed using an adaptation of the behavioural 
model described by Hargreaves et al., (1988). The glass floor of the chamber described 
above was replaced with a wide wire mesh floor through which filaments could be passed. 
A staircase method (Chaplan et at., 1994; Tabo et al., 1998) was used to measure 
mechanical withdrawal threshold. (Table 2.1). In study 2.1, a ranked score (from 1-9) was 
assigned to Semmes-Weinstein Von-Frey filaments of force 1.17 g to 75.85 g [Table 2.1 
(A)]. Filaments were presented in increasing order of stiffness, with an interval of 5 
seconds between successive applications. Each filament was pushed to bending at various 
locations on the plantar surface of the paw. A positive response was noted if the paw was 
sharply withdrawn. In the absence of a positive response, a stronger stimulus was 
presented; following a stronger response, filaments of lower bending force were applied to 
confirm the minimum force which elicited a withdrawal response. This process was 
repeated 4 times. The mechanical withdrawal threshold (MWT) was defined as the 'score' 
which elicited a response. In study 2.2, no MWT responses were recorded at the 1.17 g. 
The scoring system was consequently revised such that a ranked score (from 1-8) was 
applied Semmes-Weinstein Von-Frey filaments of force 1.17 g to 75.85 g [Table 2.1 (B)]. 
Thermal and mechanical responses were assessed once daily for 3 days before test 
recording began. At each time point, TWL was measured twice in each subject, while the 
staircase method of assessing MWT was repeated three times. 
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2.2.3 STUDIES 
PILOT STUDY 1: Selection of an inflammatory agent 
Objective of study: To compare the inflammatory effects of low doses of carrageenan (Cx) 
and complete Freund's Adjuvant (CFA), administered by intraplantar injection. 
Animals ( n = 3/group) received an intraplantar injection of 50 III of 0.9% saline (Group 
1), 0.0625% carrageenan (Group 2), 0.6% Cx (Group 3), 50% CF A (Group 4), and 12.5% 
CF A (Group 5). Tail flick (TF) and paw circumference (PC) measurements were recorded 
prior to intraplantar treatments, at 0.5 hpj., at hourly intervals for 7 hpj., and again at 24 
hpj .. 
PILOT STUDY 2: Determination of peak inflammatory and hyperalgesic effect of 
intraplantar carrageenan treatment 
Objective of study: To characterise the duration of the inflammatory response and 
associated hyperalgesia following low-dose intraplantar carrageenan treatment. 
Animals (n = 3/treatment group) received an intraplantar injection of 50 III of 0.6% Cx 
(Group 1) or 0.1 % Cx (Group 2). Paw circumference (PC), thermal withdrawal latency 
(TWL) and mechanical withdrawal threshold (MWT) were measured pre-injection, at 
hourly intervals for 11 hours pj. and at 24 hours pj. 
PILOT STUDY 3: Preliminary investigation of low-dose carrageenan intraplantar 
inflammation 
Objective of study: To characterise further behavioural responses to intra-plantar injection 
of low-dose carrageenan. 
Animals (n = 4/treatment group) received an intraplantar injection of 50 III of saline 
(Group 1), 0.5% Cx (Group 2) or 0.1 % Cx (Group 3). PC, TWL and MWT measurements 
were performed on ipsilateral (injected) and contralateral (non-injected) paws pre-injection 
and at 2 and 6 hours pj.. Rats were euthanased 6 hours pj. Photographs were taken of 
ipsilateral and contralateral paws at each time point. 
Table 2.1 
A: Conversion table of ranked scoring system applied to gramme force specification of 
Semmes-Weinstein Von-Frey filaments in study 2.1 
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Force 1.17 2.04 3.63 5.50 8.51 11.54 15.14 23.83 75.86 
(g) 
Score 1 2 3 4 5 6 7 8 9 
B: Conversion table of ranked scoring system applied to gramme force specification of 
Semmes-Weinstein Von-Frey filaments in studies 2.2 and 2.3 
Force 2.04 3.63 5.50 8.51 11.54 15.14 23.83 75.86 
(g) 
Score 1 2 3 4 5 6 7 8 
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STUDY 2.1: Weekly repeated carrageenan treatment 
Objective of study: To study behavioural responses to weekly repeated intra-plantar 
injection of low-dose carrageenan. 
Animals (72 in total) were randomly assigned to 3 treatment groups and received the 
following treatments (n=24/group): 0.5% Cx (Group 1); 0.1% Cx (Group 2); 0.9% saline 
(Group 3). Behavioural testing and assessment of inflammation were performed pre-
injection and at 6 hours post-injection on each day. Six animals from each group were 
euthanased each week (by intraperitoneal injection of barbiturate (Euthatal, Intervet, UK) 
following completion of behavioural testing, such that within each treatment group there 
were 24 animals which received one carrageenan treatment, 18 animals which received 2 
treatments, 12 animals which received three treatments and 6 animals which received 4 
treatments. 
STUDY 2.2: Daily repeated carrageenan injection 
Objective of study: To study behavioural responses to daily repeated intra-plantar 
injection of low-dose carrageenan. 
Animals (n = 121 treatment group) received an intraplantar injection of 50 III of 0.1% "A-
carrageenan (Group 1), or 0.9% saline (Group 2) at 24 hour intervals for 5 days. On each 
day, behavioural testing and assessment of inflammation were performed pre-treatment 
and at 2 h, 4 hand 6 hpj. 
STUDY 2.3: Preliminary investigations into receptor systems involved in 
tachyphylaxis of hyperalgesia 
Objective of study: To investigate the involvement of three pharmacological systems in 
the tachyphylaxis of hyperalgesia reported in study 2.2. It was hypothesised that the 
plasticity of nociceptive responses observed in study 2.2 could reflect modulation of 
NMDA-induced enhanced excitatory transmission; enhancement of opioid-mediated 
central inhibition of excitatory nociceptive transmission; or enhancement of u 2 
adrenoceptor-mediated central inhibition of excitatory nociceptive transmission. 
Experimental design: In study 2.2, tachyphylaxis of hyperalgesic behaviour occurred on 
days 3 and 4, followed by restoration of marked hyperalgesia on day 5. It was assumed, 
therefore, that specific events on days 1 and 2 induced attenuation of hyperalgesic 
responses on days 3 and 4. Specific receptor modulating agents were administered on days 
3,4 and 5. 
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STUDY 2.3(A) 
Animals (n = 61 treatment group) received an intraplantar injection of 50 ~l of 0.1 % 'A-
carrageenan (Group 1), or 0.9% saline (Group 2) at 24 hour intervals for 5 days. The 
NMDA receptor antagonist memantine hydrochloride (MEM) [ TOCRlS, UK] was 
prepared in 0.9% normal saline and administered by sic injection on days 3,4 and 5, at time 
o (immediately following carrageenan or saline treatment) at a dose of 20mg/kg (in a 
volume of 0.75ml), and again at 2h post-carrageenan/saline treatment at a dose of 5mg/kg 
(in a volume of 0.19 ml). 
Study 2.3(B) 
Animals received an intraplantar injection of 50 ~l of 0.1 % 'A-carrageenan (Groups 1 and 
2, n = 61 treatmenr group), or 0.9% saline (Groups 3 and 4, n = 31 treatment group) at 24 
h intervals for 5 days. The opioid receptor antagonist naltrexone hydrochloride (NTX) 
[Research Biochemicals International, UK] was administered by sic injection immediately 
following carrageenan or saline treatment on days 3, 4 and 5. Animals in groups 1 and 3 
received a dose of 0.5mg/kg NTX, while animals in groups 2 and 4 received a dose of 
0.05mg/kg NTX. 
Study 2.3(C) 
Animals (n = 61 treatment group) received an intraplantar injection of 50 ~l of 0.1 % 'A-
carrageenan (Group 1), or 0.9% saline (Group 2) at 24 hour intervals for 5 days. The a2 
receptor antagonist atipamezole hydrochloride (AT!) [ Smithkline Beecham, UK] was 
prepared in 0.9% nOlmal saline and administered by sic injection on days 3,4 and 5, at time 
o (600~g/kg in a volume ofO.56ml) and at 2h post-carrageenan/saline treatment (400~g/kg 
in a volume of 0.37ml). 
2.3.3. Behavioural testing 
On each day, behavioural testing and assessment of inflammation were performed pre-
treatment and at 2 h, 4 hand 6 hpj. PCmax (the maximum PC, [mm]) , TWLmin (the 
minimum TWL, [s]) and MWTmin, (the lowest MWT score) were noted in each subject on 
days 1-5. The maximal increase in PC, L1PCmax (mm) induced by treatment was 
calculated on each day: L1PCmax (mm) = PCmax - pre-treatment PC. 
2.2.4 STATISTICAL ANALYSIS 
Pilot studies 1,2,3 
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After confirmation of normality of distribution using Anderson-Darling normal probability 
plots, PC and TWL data were investigated using analysis of variance (ANOY A) 
techniques (general linear model analysis (GLM) , one way ANOYA and balanced 
ANOYA analysis). Treatment and time were considered to be fixed factors, while 
individual animal variation was considered to be a random factor. Tukey's post-hoc test 
for multiple comparisons was used to assess time-related effects of treatment within each 
treatment group. In pilot studies 1, PC and TFL values in carrageenan-treated animals 
were compared to those of saline-treated animals at each time point. In pilot studies 2 and 
3, PC and TWL values in carrageenan-treated animals were compared to those of saline-
treated animals at each time point and the effect of time on ipsilateral and contralateral PC 
and TWL was investigated within each treatment group using GLM analysis. In pilot 
studies 2 and 3, median MWT scores provided an overview of the distribution of MWT 
responses associated with low dose carrageenan treatment. 
Study 2.1 
The number of animals included in each treatment group declined with each successive 
week, as 6 animals in each group were euthanased at the end of each test period on each 
week of the study. Thus 72 animals received a single treatment (n = 24/ treatment group); 
54 animals received 2 treatments (n = 18/treatment group); 36 animals received 3 
treatments (n = 12/ treatment group) and 18 animals received 4 treatments (n = 6/ 
treatment group). 
PC and TWL data 
The increase in PC (L\PC, mm) induced by treatment was determined by subtracting pre-
injection PC from post-injection PC (measured at 6 h p.i.) in ipsilateral and contralateral 
paws. The decrease in TWL (L\TWL, s) associated with treatment was determined by 
subtracting post-injection TWL from pre-injection TWL in ipsilateral and contralateral 
paws. General linear model (GLM) analyses and Tukey-Kramer multiple comparison 
tests were performed on ipsilateral and contralateral L\PC and L\ TWL. Treatment and time 
were considered as fixed factors. Animals were considered as a random factor. The effect 
of treatment (0.5% and 0.1% carrageenan compared with saline) on ipsilateral and 
contralateral L\PC and L\TWL was investigated. Within each treatment group, the effect of 
treatment was investigated by comparing ipsilateral and contralateral L\PC and L\ TWL on 
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each week of the study. The effect of repeated treatment on ipsilateral/contralateral MC 
and ~ TWL was also investigated. 
MWTdata 
The change in MWT (~MWT) associated with treatment was determined by subtracting 
the post-treatment MWT score from the pre-injection MWT score in ipsilateral and 
contralateral paws. Kruskal-Wallis and Mann-Whitney tests were used to compare ~MWT 
between treatment groups. Within each group, the Wilcoxon signed-rank test 
(hypothesising that the median ~MWT= 0) was used to compare pre- and post-injection 
MWT, while Friedman analysis was used to investigate the effect of weekly repeated 
treatment on ~MWT. 
Study 2.2 
PC and TWL data 
The maximal increase in PC, ~PCmax (mm) induced by treatment was calculated on each 
day: ~PCmax (mm) = PCmax - pre-treatment PC. Data analysis was performed on 
baseline (pre-treatment) TWL (s), baseline (pre-treatment) PC (mm), TWLmin (s) and on 
TWL (s) at 2 h, 4 hand 6 hpj. Data analysis was also performed on ~PCmax and on 
median MWTmin scores. 
General linear model (GLM) analyses and Tukey-Kramer multiple comparison tests were 
performed on ipsilateral and contralateral PCmax, TWLmin and TWL at 2 h, 4 hand 6 h 
pj.. Treatment (carrageenan and saline) and repeated treatment (1, 2, 3, 4 and 5 daily 
repeated treatments) were considered as fixed factors. Animals were considered as a 
random factor. 
The effect of treatment on ipsilateral and contralateral PC, TWL and TWLmin was 
investigated at each time point on each day of the study. Within each treatment group, the 
effect of treatment was investigated by comparing ipsilateral and contralateral PC, TWL 
and TWLmin at each time point on each day of the study. The effect of repeated treatment 
on ipsilateral/contralateral ~PC and ~TWL was also investigated using ANOYA 
techniques combined with Tukey's post-hoc test for multiple comparisons. 
MWTdata 
Non-parametric tests were used to investigate changes in MWTmin., The effect of 
treatment on ipsilateral and contralateral MWT min was studied using Friedman analysis. 
Within each treatment group, the Wilcoxon signed-rank test was used to compare MWT min 
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in ipsilateral and contralateral paws on each day of the study. Friedman analysis was used 
to investigate the effect of daily repeated treatment on ipsilateral and contralateral MWT 
min in each treatment group. 
Studies 2.3 (A,B,C) 
Data analysis was performed on baseline TWL (s), baseline PC (mm), TWLmin (s), !J. 
PCmax and on median MWTmin scores. 
PC and TWL data 
The effect of repeated treatment on ipsilateral/contralateral !J.PC and !J. TWL was 
investigated using general linear model analysis combined with Tukey's post-hoc test for 
multiple comparisons. Within each treatment group, the effect of treatment was 
investigated using ANOV A techniques to compare ipsilateral and contralateral baseline 
PC, !J.PCmax and TWLmin at each time point on each day of the study. 
General linear model (GLM) analyses and Tukey-Kramer multiple comparison tests were 
performed on ipsilateral (and contralateral) PC, TWL and TWLmin. Treatment and 
repeated treatment (1, 2, 3, 4 and 5 daily repeated treatments) were considered as fixed 
factors. Animals were considered as a random factor. 
MWTdata 
Non-parametric tests were used to investigate changes in MWTmin .. Friedman analysis 
was performed on ipsilateral and contralateral MWT min to compare saline and carrageenan 
treatment. Within each treatment group, the Wilcoxon signed-rank test was used to 
compare MWTmin in ipsilateral and contralateral paws on each day of the study. Friedman 
analysis was used to investigate the effect of repeated treatment on ipsilateral and 
contralateral MWT min in each treatment group. 
TWLmin and MWT data in study 2.3 were compared with TWLmin and MWT data from 
study 2.2. The same protocol for behavioural testing was used in studies 2.2 and 2.3. Due 
to slight differences in the intensity of the thermal stimulus, TWL measurements in study 
2.3 (A) and 2.3 (B) were greater than those recorded in study 2.2 on days 1 and 2 (in the 
absence of receptor antagonist administration. Consistent differences in TWL were 
observed in both carrageenan and saline-treated animals. It was therefore considered 
inappropriate to compare TWL data from study 2.2 and studies 2.3 (A) and 2.3 (B) 
statistically. TWLmin data in study 2.3 (C) were compared with TWLmin data in study 
2.2 
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MWTmin measurements in studies 2.3 (A), 2.3 (B) and 2.3 (C) did not differ significantly 
from those recorded in study 2.2, therefore MWTmin data from all studies were compared 
with those of study 2.2 
2.3 RESULTS 
2.3.1 Pilot study 1 
Paw circumference 
Baseline PC was 28.5 mm ± 0.5 mm in ipsilateral and contralateral paws (Figure 2.1 A,B). 
In 0.6% Cx-treated animals, ipsilateral PC was maximal 2 hours p.i. (33.2± 0.2 nun); in 
0.0625% Cx-treated animals, ipsilateral PC was maximal at 7 hours p.i. (33.0 ± 1.5 mm). 
In 50% CFA-treated animals, ipsilateral PC was maximal 24 hours p.i. (34.7± 0.3 nun); in 
12.5% CFA-treated animals, ipsilateral PC was maximal at 7 hours p.i. (32.3 ± 0.6 nun). 
GLM analysis indicated a significant treatment effect on ~PC [F(4, 134) =15.53, p< 0.01]. 
Post-hoc analysis indicated that the change in PC measured in Cx-treated animals (groups 
2 and 3) and 50 % CF A-treated animals (group 4), but not 12.5% CF A-treated animals 
(group 5) was significantly greater than group 1 (saline-treated) animals (p < 0.05). 
In 0.6% Cx and 0.0625% Cx-treated animals, ipsilateral PC was significantly greater than 
that of group 1 (saline-treated) animals over time (p < 0.001). Ipsilateral PC in Cx-treated 
animals was significantly greater than that of saline-treated animals at 24 h p.i. (by 2.9 
mm, p < 0.01 for group 2 and by 1.5mm, p < 0.01 for group 3). 
In CF A-treated animals, ipsilateral PC increased over the duration of the test period and 
was maximal when measured 24 hours p.i. (34 ± 0.4 mm in 50% CF A-treated animals, 
30.0 ±1.5 mm in 12.5% CFA-treated animals). Ipsilateral PC in 50 % CFA-treated 
animals was significantly greater than that of saline-treated animals over time (p<0.01). 
Ipsilateral PC in 12.5% CF A-treated animals did not differ significantly over time from 
saline-treated animals. 
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Figure 2.1 
Change in mean ± S.E.M paw circumference (PC) measured over 24h (A) (and over 8 h 
p.i., B), following intra-plantar injection with 50 III of saline (Group 1), 0.6% carrageenan 
[Cx] (Group 2), 0.06% carrageenan (Group 3), 50% complete Freunds Adjuvant [CFA] 
(Group 4) and 12.5% CFA (Group 5) (n=3/group). Pre-injection value = time O. 
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Figure 2.2 
Change in mean ± S.E.M tail-flick latency (TF, s) measured over 24h (A) (and over 8h, B), 
following intra-plantar injection with 50 fll of saline (Group 1), 0.6% carrageenan [Cx] 
(Group 2), 0.0625% carrageenan (Group 3), 50% complete Freunds Adjuvant [CFA] 
(Group 4) and 12.5% CFA (Group 5) (n = 3/group). Pre-injection value = time O. 
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Tail flick latency 
There was considerable variation between treatment groups in baseline TFL (Figure 2.2). 
Pre-treatment TFL was 7.15 ± 1.30 s in group 1; 7.80 ± 1.40 s in group 2; 8.07 ± 1.48 sin 
group 3; 5.37 ± 0.13 s in group 4 and 4.49 ± 0.31 s in group 5. 
GLM analysis indicated a significant difference between treatment groups in tail flick 
latency (TFL) measurements (F(4,134) = 9.03, P < 0.01); however, post-hoc analysis 
indicated that only TFL measurements in Group 5 (12.5% CFA-treated animals) were 
significantly shorter than those of all other groups. There was no treatment effect on TFL 
over time and no significant effect of time on TFL within any group. 
2.3.2 Pilot study 2 
Paw circumference 
Paw circumference measurements recorded in pilot study 2 are shown in figure 2.3 (A). 
Baseline ipsilateral PC was 27.0± 0.58 mm in 0.6% Cx-treated animals and 27.0 ± 0.01 
mm in 0.1 % Cx-treated animals. In 0.6% Cx -treated animals, ipsilateral PC was maximal 
at 4 hpj. (34.8 ± 1.2 mm). In 0.1 % Cx-treated animals, ipsilateral PC was maximal at 5 h 
pj. (29.5 ±1.3 mm) was measured at 5 hours pj. 
Ipsilateral PC in 0.6% Cx-treated animals was significantly greater than that of 0.1 % Cx-
treated animals over time (F [2,62] = 104.62, P < 0.001). Ipsilateral PC changed 
significantly over time in 0.6% Cx-treated animals (F[12, 24] = 10.5, P < 0.001) but not in 
0.1% Cx-treated animals (F[12, 24] =1.58, p = 0.16). In 0.5% Cx-treated animals at 24h 
pj., ipsilateral PC (29.3 ± 0.3) was significantly greater (p < 0.05) than baseline ipsilateral 
Pc. In 0.1% Cx-treated animals at 24h pj., ipsilateral PC (27.5 ± 0.5) was not 
significantly different from baseline ipsilateral PC. Ipsilateral PC was significantly 
greater than contralateral PC over the duration of the study in both 0.6% Cx-treated 
animals (F [1, 62] = 165.4, p < 0.001) and 0.1% Cx- treated animals (F [1, 62] = 28.34, P 
< 0.001). 
Thermal withdrawal latency (TWL) 
Baseline ipsilateral TWL was 20.69 ± 3.00 s in 0.6% Cx-treated animals and 20.26 ± 3.09 
s in 0.1 % Cx-treated animals [Figure 2.3 (B)]. In 0.6% Cx -treated animals, the lowest 
ipsilateral TWL (TWLmin) occurred 3 hpj. (8.75 ± 3.95s). In 0.1 % Cx-treated animals, 
the lowest ipsilateral TWL (TWLmin) occurred 11 hpj. (13.95 ± 0.53 s) [Figure 2.3 (B)]. 
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Ipsilateral TWL in 0.6% Cx-treated animals was significantly lower than that of 0.1 % Cx-
treated animals over time (F [2, 62] = 18.54, P < 0.001). Ipsilateral TWL changed 
significantly over time in 0.6% Cx-treated animals (F[12, 24] = 2.15, p < 0.05) but not in 
0.1 % Cx-treated animals (F[12, 24] =1.32 , P = 0.27). In 0.6% Cx-treated animals at 24h 
pj., ipsilateral TWL (14.6 ± 1.4 s) was significantly greater (p < 0.01) than baseline 
ipsilateral Pc. In 0.1 % Cx-treated animals at 24h pj., ipsilateral TWL (23.2 ± 3.7 s) was 
not significantly different from baseline ipsilateral TWL. Ipsilateral TWL was significantly 
lower than contralateral TWL over time in 0.6% Cx-treated animals (F [1, 62] =19.49, p < 
0.001) but not in 0.1 % Cx- treated animals 
Mechanical withdrawal threshold (MWT) 
Baseline ipsilateral MWT was 6 (6,7) in 0.6% Cx-treated animals and 7(3,7) in 0.1 % Cx-
treated animals [Figure 2.3(C)J. In 0.6% Cx-treated animals, the lowest ipsilateral 
MWT(MWTmin) was 2.33 (1,3), recorded 5 hpj. and was also 2.33 (2,3) at 11 hpj. In 
0.1 % Cx-treated animals, the lowest ipsilateral MWT(MWTmin) was 2.33 (1,3) occurred 
11 hpj. Ipsilateral MWT in 0.6% Cx-treated animals did not differ significantly from that 
recorded in 0.1 % Cx-treated animals. 
2.3.3. PILOT STUDY 3 
Paw circumference 
Baseline ipsilateral PC did not differ between treatment groups (28.0 ± 0.5 mm in 0.5% 
Cx-treated animals, 27.75 ± 0.5 mm in 0.1 % Cx-treated animals and 26.25 ± 0 .. 25 rom in 
saline-treated animals) [Figure 2.4 (A)]. There was no effect of treatment on contralateral 
PC. In 0.5%-Cx-treated animals, ipsilateral PC at 6 hpj. was 32.8 ± 0.5mm. In 0.1 % Cx-
treated animals. Ipsilateral PC at 6 h p.i. was 31.4 ± 0.9mm. In saline-treated animals, 
ipsilateral PC at 6 hpj was 26.75 mm ± 0.25 mm. 
There was a significant treatment effect on ipsilateral PC (F[2, 26]=18.07, p < 0.001). 
Ipsilateral PC in Cx-treated animals (both 0.5% and 0.1 %) was significantly greater than 
saline-treated animals at 6 hours pj.(p< 0.001 for both 0.5% and 0.1 % Cx). There was no 
significant difference in ipsilateral PC between 0.5% and 0.1 % Cx- treated animals at 6h 
p.i. (p=0.14). 
In 0.5% Cx-treated animals, ipsilateral PC was significantly greater than contralateral PC 
treated animals at 2 hpj. (p < 0.01) and 6 hpj. (p < 0.001). In 0.1% Cx-treated animals, 
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ipsilateral PC was significantly greater than contralateral PC at 2 h p.i. (p < O.OS) and 6 h 
p.i. (p < 0.01). In saline-treated animals, ipsilateral PC was not significantly different from 
contralateral PC at 2 hpj. or 6 h p.i. 
In O.S% Cx -treated animals, ipsilateral PC was significantly greater than pre-treatment 
PC at 2h and at 6 h p.i. (p < 0.001 for both). In 0.1 % Cx -treated animals, ipsilateral PC 
was significantly greater than pre-treatment PC at 2h p.i. (p < 0.01) and at 6 h p.i. (p < 
0.001). 
Thermal withdrawal latency 
Baseline ipsilateral TWL was 13.67 ± 0.5 s in O.S% Cx-treated animals, 12.S0 ± 0.3 s in 
0.1% Cx-treated animals and 14.10 ± 0.9 s in saline-treated animals (Figure 2.4 (B)J. 
There was no effect of treatment on contralateral TWL in any treatment group. 
There was a significant treatment effect on ipsilateral TWL (F [2,26] = 6.3, p < 0.01). 
Ipsilateral TWL in O.S% Cx-treated animals was significantly lower than that of saline-
treated animals at both 2h p.i. (p < 0.01) and at 6h p.i. (p < O.OS) [Figure 2.4 (B)]. 
Ipsilateral TWL in 0.1 % Cx-treated animals was significantly lower than that of saline-
treated animals at both 2h p.i. (p < 0.01) and at 6h p.i. (p < O.OS). 
In saline-treated animals, ipsilateral TWL was not significantly different from contralateral 
TWL at 2h or 6 hpj. However in O.S% Cx and 0.1 % Cx-treated animals, ipsilateral TWL 
was significantly lower than contralateral TWL at both 2 h p.i. (p < 0.01 for both) and 6 h 
p.i. (p < 0.01 and p < O.OS respectively). 
In saline-treated animals, ipsilateral post-treatment TWL(at 2 hand 6 h p.i.) was not 
different from pre-treatment TWL. In O.S% Cx-treated animals, post-treatment ipsilateral 
TWL was significantly lower than pre-treatment TWL at 2h pj. (8.23 ± 2.43 s, p < 0.01), 
and was close to significance at 6h pj. (9.08 ± 1.16 s, p = 0.OS2). In 0.1% Cx-treated 
animals, ipsilateral TWL was significantly lower than pre-treatment TWL at 2h p.i. (8.8S 
± 0.76s, p < 0.01) and was close to significance at 6h p.i. (10.2S ± 1.33 s, P = 0.07). 
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Mechanical withdrawal threshold 
MWT data are shown in figure 2.4 (C). Baseline ipsilateral MWT was 8 (8,8) in 0.5% Cx-
treated animals, 6.75 (5.25, 8) in 0.1 % Cx-treated animals and 7.25 (7,7.75) in saline-
treated animals. There was no effect of treatment on contralateral MWT in any treatment 
group. Saline treatment induced no change in ipsilateral MWT. There was a significant 
treatment effect on ipsilateral MWT at 2 hand 6 hpj. (p< 0.01 for both). Ipsilateral 
MWT in calTageenan-treated animals (0.1 % and 0.5) was significantly lower than that of 
saline-treated animals at both 2 and 6 hours pj. (p < 0.05 for all). In saline-treated animals, 
ipsilateral MWT was not significantly different from contralateral MWT at any time. In 
0.5% Cx-treated animals, ipsilateral MWT was significantly lower than contralateral 
MWT at both 2 h (p < 0.05) and 6 hpj. (p < 0.05). In 0.1% Cx-treated animals, 
ipsilateral MWT was significantly lower than contralateral MWT at 6 h p.i. (p < 0.05) but 
not at 2 hpj. 
Ipsilateral MWT in calTageenan-treated animals (0.1% and 0.5) at 2 hand 6 hpj. was 
significantly lower than pre-injection MWT (p < 0.05 for all). 
2.3.4 STUDY 2.1: Inflammatory and nociceptive responses to weekly repeated 
carrageenan treatment 
Baseline pre-injection PC, TWL and MWT in ipsilateral and contralateral paws did not 
differ between saline and carrageenan-treated animals on any week of the study. 
Carrageenan and saline treatment did not alter contralateral PC, TWL and MWT relative to 
baseline values on any week of the study. Ipsilateral baseline PC did not change 
significantly over the course of the study in any treatment group. Single and repeated 
saline treatment induced no change in ipsilateral PC, TWL or MWT. 
Paw circumference 
Changes in paw circumference measurements recorded in study 2.1 are shown in figure 
2.5. Baseline PC pre-treatment on week 1 was 27.8 ± 0.1 mm for saline, 27.8 ± O.lmm 
for 0.5% Cx and 28.8 ± 0.1 mm for 0.1 % Cx-treated animals. At 6 hpj. on week 1, 
ipsilateral PC was 28.04 ± 0.1 mm in saline-treated animals, 33.0 ± 0.2 mm in 0.5% Cx-
treated animals and 31.0 ± 0.2 mm in 0.1 % Cx-treated animals. 
Treatment effect 
Statistical analysis of the effects of carrageenan treatment on ipsilateral ~PC is 
summarised in Table 2.2 
·<::. 
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• Following a single treatment, there was a significant effect of treatment on ipsilateral 
L\PC (F [2,46] = 125.9, P < 0.001). Carrageenan treatment (0.5% and 0.1%) 
significantly increased L\PC relative to saline treatment (p<0.001 in both groups). 
Post-hoc analysis indicated 0.5% Cx treatment also induced a significantly greate~ 
increase in that ipsilateral L\PC than 0.1 % Cx treatment (p < 0.001). 
• In the course of 2 treatments, a significant treatment effect was observed on both week 
1(F[2,34]=102.23, p<O.OOl) and week 2 (F[2,34]=17.79, p<O.OOl); 0.5% and 0.1% 
carrageenan induced a significantly greater .6-PC relative to saline control animals on 
both weeks 1 and 2 (p<0.001). 0.5% carrageenan also induced a significantly greater.6-
PC relative to 0.1 % carrageenan-treated animals on week 1 (p < O.OOI)'but not week 2 
of the study]. 
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Table 2.2 
Study 2.1: Summary of statistical analysis of the effects of the effects of intraplantar 
injection of 50 Ill, 0.5% carrageenan (Cx), 0.1% Cx and saline on ipsilateral paw 
circumference (PC, mm). PC was measured in ipsilateral (ipsi) paws pre-injection and at 
6h post-injection. The effect of treatment on ipsilateral ~PC (post-inection PC- pre-
injection PC, mm) was investigated using ANOV A techniques combined with Tukey-
Kramer multiple comparison tests. ~PC in 0.5% and 0.1 % carrageenan-treated animals 
was compared with ~PC in saline-treated animals on each week of the study. ~PC in 
0.5% and 0.1 % animals were also compared on each week of the study (n = 24 following 1 
treatment, n = 18 following 2 treatments, n = 12 following 3 treatments and n = 6 
following 4 treatments) . 
••• = p<O.OOI, •• = p<O.OI, • = P < 0.05, NS = no significant difference between 
treatment groups. 
Treatment 0.5% ex/ 0.1% ex/ 0.5% ex/ 
saline saline 0.1% ex 
1 treatment (n = 24) ••• • •• • •• 
2 treatments (n = 18) week 1 ••• • •• • •• 
week 2 ••• • •• NS 1 
I 
3 treatments (n = 12) week 1 ••• ••• • •• 
week 2 ••• • •• NS 
week 3 ••• ••• • • 
4 treatments (n = 6) week 1 ••• • •• NS 
, 
week 2 • • NS 
week 3 ••• • •• NS 
week 4 ••• • •• NS 
• 
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• In the course of 3 treatments, a significant treatment effect was observed on week 
1 (F[2,22]=81.1, p < 0.001), week 2 (F[2,22]=19.S7, P < 0.001) and week 3 
(F[2,22]=37.6S, P < 0.001). M>C in O.S% Cx-treated animals was significantly 
greater than that of saline-treated animals on all 3 weeks (p < 0.001); and was 
significantly greater than 0.1 % Cx treatment on weeks 1 (p < 0.001) and week 3 ( P < 
0.01) but not on week 2. LlPC in 0.1 % Cx-treated animals was significantly greater 
than that of saline-treated animals on all 3 weeks (p < 0.001 on all three weeks). 
• In the course of 4 treatments, a significant treatment effect was observed on all 4 
weeks: week I(F[2,10]=18.SS, p < 0.001), week 2 (F[2,10]=4.S, P < O.OS) week 3 
(F[2,10]=27.S3, P < 0.001) and week 4 F[2,10]=19.41, P < 0.001). LlPC induced by 
O.S% Cx was significantly greater than saline treatment on all 4 weeks (p < 0.001 on 
weeks 1, 2 and 4, p < O.OS on week 2). LlPC induced by 0.1% Cx was also 
significantly greater than saline treatment on each week (p < 0.001 on weeks 1, 2 and 
4, p< O.OS on week 3). There was no significant difference in LlPC measured in O.S% 
and 0.1 % Cx-treated animals on any week of the study. 
Ipsilateral/contralateral effect 
Statistical analysis of the effects of carrageenan and saline treatment on ipsilateral (relative 
to contralateral) LlPC is summarised in Table 2.3. 
• Following a single treatment (n = 24/ group), a significant treatment effect on 
ipsilateral (relative to contralateral) LlPC was observed in carrageenan-treated 
animals. Ipsilateral LlPC was significantly greater than contralateral LlPC in both O.S% 
and 0.1 % Cx-treated animals (F[I,23]=447.7, p <0.001) and (F[1,23]=302.3, p<O.OOl) 
respectively. 
• In the course of 2 treatments (n = 18/group), in O.S% Cx-treated animals, ipsilateral Ll 
PC was significantly greater than contralateral LlPC on both week 1 (F[1,17] = 224.S, P 
< 0.001) and week 2 (F[1,17] = 12.2, P < 0.01). Similarly, in 0.1 % Cx-treated animals, 
ipsilateral LlPC was significantly greater than contralateral LlPC on both week 1 
(F[1,17] = 148.S, P < 0.001) and week 2 (F[l, 17] = S2.06, P < 0.001). 
r 
76 
Table 2.3 
Study 2.1: Summary of statistical analysis of the effects of intraplantar injection of 50 ~l, 
0.5% carrageenan (Cx), 0.1 % Cx and saline on ipsilateral (relative to contralateral) paw 
circumference (PC, mm). PC was measured in ipsilateral and contralateral paws pre-
injection and at 6h post-injection. Within each treatment group, on each week of the study, 
the effect of treatment on ipsilateral (relative to contralateral) ~PC (post-inection PC- pre-
injection PC, mm) was analysed using AN OVA techniques (n = 24 following 1 treatment, 
n = 18 following 2 treatments, n = 12 following 3 treatments and n = 6 following 4 
treatments) . 
••• = p<O.OOI, •• = p<O.OI, • = P < 0.05, NS = no significant difference between 
ipsilateral and contralateral ~PC. 
Treatment 0.5% Cx 0.1% ex saline 
1 treatment (n = 24) ••• • •• NS 
2 treatments (n = 18) week 1 ••• • •• NS 
week 2 •• • •• NS 
3 treatments (n = 12) week 1 ••• • •• NS 
week 2 ••• • •• NS 
week 3 ••• • •• NS 
4 treatments (n = 6) week 1 ••• •• NS 
week 2 • •• NS 
week 3 ••• •• NS 
week 4 ••• • NS 
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• In the course of 3 treatments (n = 12/group), a significant treatment effect on ipsilateral 
(relative to contralateral) ~PC was observed in O.S% and 0.1% carrageenan-treated 
animals PC (F[1,S7] = 324.S, p < 0.001 and F[1,S7] = 206.4, p < 0.001 respectively). 
Further analysis showed that in O.S% Cx-treated animals, ipsilateral ~PC was 
significantly greater than contralateral ~PC on week 1 (F[l,ll] = 168.6, P < 0.001), 
week 2 (F[l,ll] = 64.0, p < 0.001) and week 3 (F[l,ll] = 90.8, p < 0.001). In O.l % 
Cx-treated animals, ipsilateral ~PC was significantly greater than contralateral ~PC on 
week 1 (F[l,ll] = 67.4, p < 0.001) and week 2 (F[1,11] = 40.8, p < 0.001) and week 3 
(F[l,ll] =S9.7, p < 0.001). 
• In the course of 4 treatments (n = 6/group), a significant treatment effect on ipsilateral 
(relative to contralateral) ~PC was observed in O.S% and 0.1% carrageenan-treated 
animals (F[1,38] = 119.27, p < 0.001 and F[1,37] = 88.7, p < 0.001 respectively). 
Further analysis showed that in O.S% Cx-treated animals, ipsilateral ~PC was 
significantly greater than contralateral ~PC on week 1 (F[l,S] = S4.9, p < 0.001), week 
2 (F[l,S] = 8.03, p < O.OS), week 3 (F[l,S] = 49.7, p < 0.001) and week 4 (F[l,S] = 
236.1, P < 0.001. In 0.1 % Cx-treated animals, ipsilateral ~PC was significantly greater 
than contralateral ~PC on week 1 (F[l,S] = 20.3, P < 0.01), week 2 (F[l,S] = 19.7, P < 
0.01), week 3 (F[l,S] = 33.8, P < 0.01) and week 4 (F [l,S] = 13.0, p < O.OS). 
Effect of repeated treatment 
Statistical analysis of the effects of repeated carrageenan or saline treatment on ipsilateral 
~PC are summarised in Table 2.4. 
• In animals which received 2 treatments, there was a significant effect of repeated 
treatment on ipsilateral ~PC induced by O.S% Cx (F[1,17]=17.86, p<O.OOl); ~PC was 
significantly less on week 2 (2.8 ± 1.7 mm) than week 1 ( 4.9 ± 1.2 mm). Similarly, 
there was a significant effect of repeated treatment on ipsilateral ~PC induced by 0.1 % 
Cx treatment (F[1,17] = 6.89, p<O.OS); ~PC was significantly less on week 2 (2.3 ± 
1.4 mm) than week 1 (3.4 ± 0.9 mm). Ipsilateral ~PC did not change following single 
or repeated saline treatment. 
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Table 2.4 
Study 2.1: Summary of statistical analysis of the effects of repeated intraplantar injection 
of 50 ~l, 0.5% carrageenan (Cx), 0.1 % Cx and saline on ipsilateral paw circumference 
(PC, mm). PC was measured in ipsilateral paws pre-injection and at 6h post-injection. 
Within each treatment group, on each week of the study, the effect of repeated treatment 
on ipsilateral MC (post-inection PC- pre-injection PC, mm) was investigated using 
general linear model analysis combined with Tukey-Kramer multiple comparison tests (n = 
18 following 2 treatments, n = 12 following 3 treatments and n = 6 following 4 
treatments) . 
••• = p<O.OOl, •• = p<O.Ol, • = P < 0.05, NS = no significant effect of repeated treatment 
on ipsilateral ~pc. 
Treatment 0.5% Cx 0.1% Cx saline 
2 treatments (n = 18) ••• • NS 
3 treatments (n = 12) •• NS NS 
4 treatments (n = 6) • NS NS 
79 
• In animals which received 3 treatments, there was a significant effect of repeated 
treatment on ipsilateral i1PC induced by treatment with O.S% carrageenan (F[2,22] = 
7.1, p < 0.01); i1PC was significantly less on week 2 (2.96 mm) than on weeks 1 (S.04 
mm) and 3 (4.33 mm) ( p < O.OS). In 0.1 % Cx and saline-treated animals, there was 
no effect of repeated injection on the increase in change in ipsilateral PC induced by 
treatment. 
• In animals which received 4 treatments, there was a significant effect of repeated 
treatment on ipsilateral i1PC induced by treatment with O.S% carrageenan (F[3,IS] = 
4.26, p<O.OS); i1PC was 4.3 ± 0.6 mm on week 1, 2.1 ± 0.7 mm on week 2 
(significantly lower than week 3, p<O.OS), 4.S ± 0.7 mm on week 3 and 3.1 ± 0.2 mm 
on week 4. In 0.1 % Cx (i1PC of 2.2 ± 0.6 mm-3.2 ± O.S mm) and in saline-treated 
animals, there was no effect of repeated injection on i1PC. 
Thermal withdrawal latency 
The change in TWL induced by carrageenan and saline treatment (i1TWL) is shown in 
figure 2.6. Baseline ipsilateral TWL recorded pre-treatment on week 1 was 11.4 ± 0.4 s in 
saline-treated animals, Il.S4 ± 0.42 s in O.S% Cx-treated animals and 11.2 ± 0.38 s in 
0.1 % Cx-treated animals. Post- treatment (6 h p.i.) ipsilateral TWL on week 1 was 10.2 ± 
O.S s in saline, 6.26 ± 0.38 s in O.S% Cx and 8.S1 s ± 0.60 s in 0.1 % Cx-treated animals. 
Ipsilateral baseline TWL did not change significantly over the course of the study in any 
treatment group. There was no significant difference between ipsilateral and contralateral 
baseline PC on any week of the study. 
Treatment effect 
Statistical analysis of the effects of carrageenan treatment on ipsilateral i1TWL IS 
summarised in Table 2.S 
• Single treatment: i1TWL induced by O.S% Cx treatment was significantly greater than 
that induced by both saline treatment (p < 0.001) and 0.1% Cx treatment (p < 0.001). 
i1 TWL induced by 0.1 % Cx treatment was significantly greater than that induced by 
saline treatment (p < O.OS). 
.. .., ... '-~ 
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TableZS 
~ 
Study 2.1: Summary of statistical analysis of the effects of intraplantar injection of 50 )..1.1, 
0.5% carrageenan (Cx), 0.1% Cx and saline on ipsilateral thermal withdrawal latency 
(TWL, s). TWL was measured in ipsilateral (ipsi) paws pre-injection and at 6h post-:. 
injection. The effect of treatment on ipsilateral L\TWL (pre-inection TWL- post-injection,: 
TWL, s) was investigated using ANOVA techniques combined with Tukey-Kramer 
multiple comparison tests. L\TWL in 0.5% and 0.1 % carrageenan-treated animals were 
compared with L\TWL in saline-treated animals on each week of the study. L\TWL in 
0.5% and 0.1 % animals were also compared on each week of the study (n = 24 following 1 
treatment, n = 18 following 2 treatments, n = 12 following 3 treatments and n = 6 
following 4 treatments) . 
••• = p<O.OOI, •• = p<O.OI, • = P < 0.05, NS = no significant difference between 
treatment groups. 
Treatment 0.5% ex! 0.1% ex! 0.5% ex! 
saline saline 0.1% ex 
1 treatment (n = 24) ••• • ••• 
2 treatments (n = 18) week 1 •••• • •• •• 
week 2 ••• •• ••• 
3 treatments.(n = 12) week 1 ••• •• •• 
week 2 •••• NS •• 
week 3 ••• NS • •• 
4 treatments (n = 6) week 1 • NS NS I 
week 2 ••• NS •• 
week 3 •• NS NS 
week 4 •• NS ... 
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• In animals which received 2 treatments, a significant treatment effect on ipsilateral /j, 
TWL was observed on both week 1 (F[2, 34] = S2.0, P < 0.001) and week 2 (F[2,34] 
= 34.1, P < 0.001). O.S% ex treatment induced a significantly greater /j,TWL than 
saline treatment on both weeks 1 and 2 (p < 0.001). 0.1 % ex treatment also induced a 
significantly greater /j,TWL than saline treatment on both weeks 1 (p < 0.001) and 
week 2 (p < 0.01). O.S% ex treatment induced a significantly greater /j,TWL relative to 
0.1 % ex treatment both week 1 (p < 0.01) and week 2 (p < 0.001). 
• In animals which received 3 treatments, a significant treatment effect on ipsilateral /j, 
TWL was observed on both week 1 (F[2,22] = 20.7, P < 0.001), week 2 (F[2,22] = 
14.4, P < 0.001) and week 3 (F[2,22] = 20.7, P < 0.001). O.S% ex treatment induced a 
significantly greater /j,TWL than saline treatment on weeks 1, 2 and 3 (p < 0.001). 
0.1 % ex treatment induced a significantly greater /j,TWL than saline treatment on 
week 1 (p < 0.01), but not on week 2 (p = 0.06) or week 3 ( P = 0.30). O.S% ex 
treatment induced a significantly greater /j,TWL relative to 0.1% ex treatment on 
weeks 1,2 and 3 (p<0.01). 
• In animals which received 4 treatments, a significant treatment effect on ipsilateral /j, 
TWL was observed on both week 1 (F[2,10] = 3.8, P < O.OS), week 2 (F [2,10] = 9.86, 
P < 0.01), week 3 (F[2,10] = 6.6, P < O.OS) and week 4 (F[2,10] = 16.1, P < 0.01). 
While O.S% ex induced a consistent reduction of 41 -46% in ipsilateral TWL on all 4 
weeks of the study, 0.1% ex induced a reduction of 29% on week 1, 1% on week 2, 
lS% on week 3 and 7% on week 4. Further analysis showed that O.S% ex treatment 
induced a significantly greater /j,TWL than saline treatment on all 4 weeks (p < O.OS on 
week 1, p < 0.01 on weeks 2, 3 and 4); more detailed analysis did not indicate a 
significant difference in /j,TWL in 0.1 % ex-treated animals relative to saline-treated 
animals on any particular week of the study. O.S% ex treatment induced a 
significantly greater /j,TWL relative to 0.1 % ex treatment on weeks 2 and 4 (p < 0.01) 
but not on weeks 1 and 3. 
Ipsilateral/contralateral effect 
Statistical analysis of the effect of carrageenan and saline treatment on ipsilateral (relative 
to contralateral) /j,TWL is summarised in Table 2.6 
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Table 2.6 
Study 2.1: Summary of statistical analysis of the effects of intraplantar injection of 50 ~l, 
0.5% carrageenan (Cx) , 0.1 % Cx and saline on ipsilateral (relative to contralateral) 
thermal withdrawal latency (TWL,s. TWL was measured in ipsilateral and contralateral 
paws pre-injection and at 6h post-injection. Within each treatment group, on each week of 
the study, the effect oftreatment on ipsilateral (relative to contralateral) L).TWL (pre-
inection TWL- post-injection TWL, s) was investigated using ANOVA techniques en = 24 
following 1 treatment, n = 18 following 2 treatments, n = 12 following 3 treatments and n 
= 6 following 4 treatments) . 
••• = p<O.OOl, •• = p<O.OI, • = p < 0.05, NS = no significant difference between 
ipsilateral and contralateral L). TWL. 
Treatment 0.5% Cx 0.1% Cx saline 
1 treatment (n = 24) ••• •• NS 
2 treatments (n = 18) week 1 ••• • •• NS 
••• week 2 • •• • •• NS 
3 treatments (n = 12) week 1 ••• NS NS I I 
week 2 ••• • •• NS 
week 3 ••• • •• NS 
4 treatments (n = 6) week 1 •• • NS 
week 2 • NS NS 
week 3 • NS NS 
week 4 • NS NS 
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• Following a single treatment, O.S% Cx and 0.1 % Cx treatment induced a significant 
reduction in ipsilateral TWL (relative to contralateral) TWL, from 11.S4 ± 0.42 s to 
6.26 ± 0.38 s (F[1,23] = 86.3, P < 0.001), a 4S.7% reduction, and from 11.2 ± 0.38 s to 
8.Sl ± 0.6 s (F[1,23) = 14.29, P < 0.01), a 24% reduction, respectively. 
• In the course of 2 treatments (n = 18/group), a significant treatment effect on ipsilateral 
(relative to contralateral) ~TWL was observed in carrageenan, but not saline, treated 
animals TWL (F[1,S2] =110.7, P <0.001 and F[1,S2] = 23.93, P < 0.001 respectively). 
In O.S% Cx-treated animals, ipsilateral ~TWL was significantly greater than 
contralateral ~TWL on both week 1 (F[l,17] = 98.3, P < 0.001) and week 2 (F[l,17] = 
20.0, P < 0.001). In 0.1% Cx-treated animals, ipsilateral ~TWL was significantly 
greater than contralateral ~PC on both week 1 (F[1,17] = 41.0, P < 0.001) and week 2 
(F[1,17] = 6.0, P < O.OS). 
• In the course of 3 treatments, both O.S% and 0.1 % Cx, but not saline, treatment induced 
a significant reduction in ipsilateral (relative to contralateral)TWL (F[1,S7] = 144.S9, P 
< 0.001 and F[1,S7] = 14.79, P < 0.001 respectively). Further analysis showed that in 
O.S% Cx-treated animals, ipsilateral ~TWL was significantly greater than contralateral 
~TWL on week 1 (F [1,11] = 8S.S, P < 0.001), week 2 (F [1,11] = 26.2, P < 0.001) and 
week 3 (F[l,ll] = 33.S, P < 0.001). In 0.1% Cx-treated animals, ipsilateral ~TWL 
was significantly greater than contralateral ~TWL on week 1 (F[l,ll] = 26.3, P < 
0.001), and week 3 (F[l,ll] = 12.8, P < 0.001), but not on week 2 (F[l,ll] = 2.6, P < 
0.13). 
• In the course of 4 treatments, both O.S% and 0.1% carrageenan, but not saline, 
treatment induced a significant reduction in ipsilateral (relative to contralateral)TWL 
(F [1,38] = 66.S8, p < 0.001 and F[1,38] = S.63, P < O.OS respectively). Further 
analysis showed that in O.S% Cx-treated animals, ipsilateral ~TWL was significantly 
greater than contralateral ~ TWL on week 1 (F[ 1 ,S] = 21.1, P < O. a 1), week 2 (F[ 1 ,S] 
= 9.1, P < O.OS), week 3 (F[l,S] = 12.9, P < O.OS) and week 4 (F[l,S] = 16.1, P < 0.01). 
In 0.1% Cx-treated animals, ipsilateral ~TWL was significantly greater than 
contralateral ~TWL on week 1 (F[l,S] = 12.8, P < O.OS), and close to significance on 
week 4 (F[1,11] = S.03, P < 0.06) but not on week 2 or 3. 
. 'I'¥:' : 
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Effect of repeated treatment 
In animals which received 2, 3 or 4- treatments, repeated treatment did not alter Ll TWL 
associatedwith intraplantar injection of saline or carrageenan (0.5% and 0.1 %). 
Mechanical withdrawal threshold ........ -.~. 
" 
Mechanical withdrawal threshold measurements recorded in study 2.1 are shown in figure 
2.7. Baseline ipsilateral MWT recorded pre-treatment on week 1 was 8 (8,9) in saline-
treated animals, 8 (8,9) in 0.5% ex-treated animals and 8 (7.25,9) in 0.1% ex-treated 
animals. Ipsilateral baseline MWT did not change significantly over the course of the 
study in any treatment group. At 6 h p.i. on week 1, ipsilateral MWT was 8 (7,9) in saline-
treated animals, 4- (3,5) in 0.5% ex-treated animals and 6 (4,7) in 0.1 % ex-treated animals. 
Treatment effect 
Statistical analysis of the effects of carrageenan treatment on ipsilateral MWT is 
summarised in Table 2.7. 
• Following a single treatment, a significant treatment effect on ipsilateral .1MWT was 
observed. LlMWT induced by 0.5% ex was significantly greater than that induced by 
saline (p < 0.001) and 0.1 % carrageenan (p < 0.001). LlMWT induced by 0.1 % ex was 
significantly greater than that induced by saline (p < 0.001). A binary logistic 
regression model, applied to the distribution pattern of ipsilateral and contralateral 
MWT scores recorded on week 1, indicated that the distribution of ipsilateral MWT 
scores in 0.5% ex-treated animals deviated strongly from the model fitted and that of 
ipsilateral MWT in 0.1 % ex-treated animals showed a small deviation from the model 
fitted. Ipsilateral MWT in saline-treated animals and contralateral MWT in all 
treatment groups fitted the binary logistic regression model closely. 
•. In animals which received 2 treatments, LlMWT induced by 0.5% ex was 
significantly greater than that induced by saline and 0.1 % ex on weeks 1 and 2 ( P < 
0.001 relative to saline on both week 1 and week 2, p < 0.05 relative to 0.1 % ex on 
both week 1 and week 2). LlMWT induced by 0.1 % ex was significantly greater than 
that induced by saline on both weeks of the study (p < 0.01 on week 1, p < 0.05 on 
week 2). LlMWT induced by 0.5% ex Was also significantly greater than that induced 
by 0.1% carrageenan (p < 0.05) on both weeks of the study ( p < 0.01 on week 1 and p 
<0.001on.week2) . 
'.:':;' l~j)', --'.:_" 
6 4 
I- ~ :2 <l
 
2 0 6
 
I-
4 ~ ~ 2
 o
 
•
•
•
 
0.
5%
 C
x 
•
•
•
 
1 
•
•
•
 
0.
1%
 C
x 
1 
tr
ea
tm
en
t 
•
•
•
 
2 
w
e
e
k 
_
O.
5%
CX
 
_
O.
1%
CX
 
_
sa
lin
e 
sa
lin
e 
_
O.
5%
CX
 
_
O.
1%
CX
 
_
sa
lin
e 
3 
6 
_
O.
5%
CX
 
_
O.
1%
CX
 
••
• 
_
sa
lin
e 
4 ~ 
•
•
•
 
:E
 
<
l 
••
 
2 
•
 
0 
1 
2 
2 
tr
ea
tm
en
ts
 
6 
_
0.
5%
Cx
 
_
0.
1%
C
x 
•
 
•
 
_
sa
lin
e 
4 
I- ~ 
•
 
:E
 
<
l 
•
 
2 
•
 
•
 
o
 
1 
2 
3 
4 
4 
tr
ea
tm
en
ts
 
86
 
87 
• In animals which received 3 treatments, L1MWT induced by O.S% ex was significantly 
greater than that induced by saline (p < 0.001) and 0.1 % carrageenan (p < O.OS) on all 
three weeks of the study (p < 0.001 relative to saline on weeks 1, 2 and 3; p < O.OS 
relative to 0.1% ex on weeks 1,2 and 3). L1MWT induced by 0.1% ex was 
significantly greater than that induced by saline on weeks 1 and 2 of the study (p < 
0.01 and p < O.OS respectively), but not on week 3 . 
• In animals which received 4 treatments, the L1MWT associated with carrageenan 
treatment was significantly greater than that induced by saline on weeks land 4 
(p<O.OS on both weeks following O.S% ex treatment, and p<O.OS on both weeks 
following 0.1 % ex treatment). L1MWT associated with O.S% ex was not significantly 
different from that induced by 0.1 % ex on week 1 or week 4. 
Ipsilateral! contralateral effect 
Statistical analysis of the effects of carrageenan treatment on ipsilateral MWT IS 
summarised in Table 2.7 
• Single treatment: both O.S% and 0.1 % ex induced a significant increase in ipsilateral 
(relative to contralateral) L1MWT on (p < 0.001 and p < 0.01 respectively). Saline 
injection did not alter ipsilateral (relative to contralateral) L1MWT. 
• In animals which received 2 treatments, both O.S% and 0.1 % ex induced a significant 
increase in ipsilateral (relative to contralateral) L1MWT on both week 1 (p < 0.001 and 
p < 0.01 respectively) and week 2 (p < 0.001 and p < 0.01 respectively). Saline 
injection induced a significant increase in ipsilateral (relative to contralateral) L1MWT 
on week 1 (p < O.OS) (median change of O.S), but no significant change in MWT on 
week 2. 
4.-
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Table 2.7 
Study 2.1: Summary of statistical analysis of the effects of intraplantar injection of 50 fll, 
0.5% carrageenan (ex) and 0.1% ex on ipsilateral mechanical withdrawal threshold 
(MWT). MWT was measured in ipsilateral (ipsi) paws pre-injection and at 6h post-
injection. On each week of the study, the effect of treatment on ipsilateral i1MWT (pre-
inection MWT - post-injection MWT) was investigated using Friedman analysis. i1MWT 
in 0.5% and 0.1% carrageenan-treated animals were compared with i1MWT in saline-
treated animals on each week of the study. i1MWT in 0.5% and 0.1 % animals were also 
compared on each week of the study (n = 24 following 1 treatment, n = 18 following 2 
treatments, n = 12 following 3 treatments and n = 6 following 4 treatments) . 
••• = p<O.OOl, •• = p<O.Ol, • = p < 0.05, NS = no significant difference between 
treatment groups. 
Treatment 0.5% ex/ 0.1 % ex/ 0.5% Cx/ 
saline saline 0.1% Cx 
1 treatment (n = 24) ••• • •• • •• 
2 treatments (n = 18) week 1 ••• •• • • 
week 2 ••• • ••• 
3 treatments (n = 12) week 1 ••• •• • 
week 2 ••• • • 
week 3 ••• NS • 
4 treatments (n = 6) week 1 • • NS 
week 2 • • NS 
week 3 • • NS 
week 4 • • NS 
- -- - ... - - .. - -- .. _-- - -- .. - - -- -- -
- -_._- ---_ ... __ .. _- ---_ .._-_ .. -
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• In animals which received 3 treatments, both 0.5% and 0.1% ex, but not saline, 
treatment induced a significant increase in ipsilateral (relative to contralateral) ~WT 
on all three weeks (p < 0.01 on weeks 1,2 and 3 following 0.5% ex treatment, p < 0.01 
on week 1 and p < 0.05 on weeks 2 and 3 following 0.1 % ex treatment). 
• In animals which received 4 treatments, 0.5% ex induced a significant reduction in 
ipsilateral ~T on weeks 1, 2, 3 and 4 (p < 0.01). 0.1% carrageenan injection also 
induced a significant reduction in ipsilateral MWT (compared to pre-injection MWT) 
on weeks 1, 2, 3 and 4 (p < 0.05). Single or repeated saline injection induced no 
change in ipsilateral MWT. In all 3 treatment groups, the median change in ipsilateral 
and contralateral MWT did not alter with repeated injection. 
Effect of repeated treatment 
There was no effect of repeated treatment on ipsilateral or contralateral ~WT m 
carrageenan or saline-treated animals. 
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Table 2.8 
Study 2.1: Summary of statistical analysis of the effects of intraplantar injection of 50 Ill, 
0.5% carrageenan (Cx) and 0.1 % Cx and on ipsilateral (relative to contralateral) 
mechanical withdrawal threshold (MWT). MWT was measured in ipsilateral and 
contralateral paws pre-injection and at 6h post-injection. Within each treatment group, on 
each week of the study, the effect of treatment on ipsilateral (relative to contralateral) 6 
MWT (pre-injection MWT - post-injection MWT) was investigated using the Wilcoxon 
Signed-Rank test (n = 24 following 1 treatment, n = 18 following 2 treatments, n = 12 
following 3 treatments and n = 6 following 4 treatments) . 
••• = p<O.OOl, •• = p<O.Ol, • = P < 0.05, NS = no significant difference between 
ipsilateral and contralateral .0.. TWL. 
Treatment 0.5% Cx 0.1% Cx saline 
1 treatment (n = 24) ••• •• NS 
2 treatments (n = 18) week 1 ••• •• • 
••• week 2 ••• • • NS 
3 treatments (n = 12) week 1 •• •• NS 
week 2 •• • NS 
week 3 •• • NS 
4 treatments (n = 6) week 1 NS I •• • 
week 2 •• • NS 
week 3 •• • NS 
week 4 •• • NS 
-
-_ .... _----_._-
-
-.!" 
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2~3S STUDY Z~Z:: Beha.vioural responses~ to daily repeated carrageenan treatment 
Paw circumference 
Paw circumference measurements recorded in study 2.2 are shown in figure 2.8. PCmax 
recorded on each day is shown in Table 2.9."-":' 
,~- i: 
Treatment effect 
Ipsilateral PCmax in Cx-treated animals was significantly greater than that of saline-
treated animals on-each day of the study (F[l,ll] = 50.0, p < 0.001 on day 1; F[I,Il] = 
96.8, p < 0.001 on day 2; F[I,ll] =317.3, P < 0.001 on day 3; F[1,1l] = 451.0, p < 0.001 
on day 4 and F[I,11] = 498.3, p < 0.001 on day 5). 
Effect of repeated treatment 
Baseline PC 
In saline-treated animals, baseline ipsilateral did not change over the duration of the study. 
In carrageenan-treated animals, baseline PC increased significantly over the study period 
(F [4,44] = 48.8, p < 0.001). Further analysis indicated that PC on day 1 was significantly 
lower than on all other days (p< 0.001); PC on day 2 was significantly lower than on days 
3,4 and 5 ( P < 0.01), while there was no significant difference in baseline ipsilateral PC 
recorded on days 3, 4 and 5. 
PC max 
There was no effect of repeated injection on ipsilateral pre-treatment PCmax or MCmax 
in saline-treated animals. 
In carrageenan-treated animals, ipsilateral PCmax increased significantly over the course 
of the study (F[4,44] = 17.6, p < 0.001). Further analysis showed that PCmax recorded on 
day 1 was significantly lower than that recorded on day 4 (p < 0.05) and day 5 (p < 0.001); 
PCmax recorded on day 2 was significantly lower than that recorded on days 3,4 and 5 (all 
p < 0.001). PCmax recorded on day 5 was significantly greater than that recorded on all 
other days (p < 0.001). 
MC (PCmax - baseline PC) did not alter significantly over the course of the study. 
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Figure 2.9 
Study 2.2: Mean ± S.E.M. ipsilateral PCmax (mm) measured on 5 consecutive days 
following daily repeated intaplantar injection of 50 !-L1, 0.1 % carrageenan (n=12 in each 
group). 
PCmax (mm) 
Day carrageenan saline 
1 30.8 ± 0.3 28.3 ± 0.1 
2 30.5 ± 0.2 28.4 ± 0.1 
3 31.3 ± 0.1 28.2 ± 0.1 
4 31.5±0.2 28.1 ± 0.1 I 
5 32.3 ± 0.2 28.1±0.1 
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Thermal withdrawal latency 
Thennal withdrawal latency measurements recorded in study 2.2 are shown in figure 2~9; 
TWLmin recorded on each day is shown in Table 2.10. 
Treatment effect 
Baseline TWL .~ .. 
There was no treatment effect on contralateral baseline TWL on any day of the study. 
Ipsilateral baseline TWL was significantly lower on day 2 in carrageenan-treated animals 
(F[l,ll] = 7.1, p < 0.05), but not on any other day. 
Post-treatment TWL 
Contralateral TWL was significantly lower in carrageenan-treated animals (relative to 
saline-treated animals) at 4h pj. on days 1 and 4 (p < 0.05 on both days). There was no 
significant difference between treatment groups in contralateral TWL at 2h pj. or at 6 h 
pj. on any day of the study. 
Ipsilateral TWL was significantly lower in carrageenan-treated animals (relative to saline-
treated animals) at 2h pj. on all days of the study, and at 4h pj. and 6 hpj. on days 1,2 
and 5. On days 3 and 4, carrageenan treatment did not induce a significant reduction in 
ipsilateral TWL (relative to saline-treated animals) at 4h and 6h p.i. 
TWLmin 
GLM analysis indicated a significant effect of carrageenan treatment (relative to saline 
treatment) on ipsilateral TWLmin on days 1,2 and 5 but not on days 3 and 4.( (F[l,lO] = 
13.5, p < 0.01 on day 1; (F[1,10] = 18.9, P < 0.001 on day 2; (F[l,ll] = 0.8, P = 0.4 on day 
3; (F[1,10] =2.8, P = 0.1 on day 4 and (F[I,lO] =37.7, p < 0.001 on day 5. No treatment 
effect was observed on contralateral TWLmin on any day of the study. 
Ipsilateral/contralateral effect 
In saline-treated animals, there was no difference between ipsilateral and contralateral 
baseline TWL values on any day of the study and no difference between ipsilateral and 
contralateral post-treatment TWL values on any day of the study. 
In carrageenan-treated animals, ipsilateral baseline TWL was significantly lower than 
contralateral baseline TWL on day 3 (F[l,Il] = 5.1, P < 0.05) and day 5 (F[I,llJ = 7.8, P 
< 0.05), but not on days 1, 2 and 4. Ipsilateral TWL was significantly lower than 
contralateral TWL at 2h, 4h and 6h p.i. on ail 5 days ofthe. study. 
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Table 2.10 
Mean ± SEM baseline TWL (s) and TWLmin(s) measured in ipsilateral (ipsi) and 
contralateral (contra) paws measured on 5 consecutive days following daily repeated 
intaplantar injection of 50 !-Ll, 0.1 % carrageenan (n= 12 in each group). 
Treatment carrageenan baseline TWL (s) saline baseline TWL (s) 
Day contralateral ipsilateral contralateral ipsilateral 
1 10.8 ± 0.2 10.6 ± 0.3 10.7 ± 0.2 10.7 ± 0.3 
2 10.6 ± 0.2 10.0 ± 0.2 10.6 ± 0.1 10.7 ± 0.1 
3 10.8 ± 0.2 10.2 ± 0.2 10.7 ±0.3 10.4 ± 0.2 
4 10.1 ± 0.2 10.0 ± 0.3 10.1 ±0.2 10.3 ± O.l 
5 10.5 ±0.2 10.0 ± 0.2 10.6 ± 0.2 10.6 ± O.l 
Day carra~eenan TWLmin (s) saline TWLmin (s) 
contralateral ipsilateral contralateral ipsilateral 
1 10.0 ± 0.0 8.5 ± O.l 10.1 ± 0.0 10.0 ± 0.0 
2 9.84 ± 0.0 8.2 ± 0.1 10.0 ± 0.0 10.0 ± 0.0 
3 10.2 ± 0.2 9.4 ± 0.2 10.0 ± 0.2 9.8 ± 0.2 
4 9.6 ± O.l 9.0 ± 0.2 9.2 ± 0.1 9.6± 0.1 
5 9.8 ± 0.1 7.8 ± 0.2 10.0 ± O.l 9.9 ± 0.2 
J 
I 
I 
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TWLmin 
In carrageenan-treated animals, ipsilateral TWLmin was significantly lower than 
contralateral TWLmin on all 5 days of the study (F[1,10] =18.3, P < 0.01 on day 1; 
(F[1,10] = 11.4, p < 0.01 on day 2; (F[1,10] 11.4, p < 0.01 on day 3; (F[1,10] =5.8, p < 
0.05 on day 4 and (F[1,10] = 32.0, p < 0.001 on day 5. 
Effect of repeated treatment 
There was no effect of repeated treatment on ips lateral or contralateral baseline TWL in 
saline or carrageenan-treated animals. 
In saline-treated animals, a significant effect of repeated treatment on contralateral (but not 
ipsilateral) TWL was observed at 4h p.i. and 6h p.i. TWL recorded at 4h p.i. on day 4 (9.73 
± O.ls) was significantly shorter than on all other days (p<0.05). TWL recorded at 6h p.i. 
on day 4 (9.86 ± 0.2) was significantly shorter than on days 1 and 2 (p<0.03 and p<O.Ol 
respectively). 
In Cx-treated animals a significant effect of repeated treatment on ipsilateral TWL was 
observed. Responses measured on days 3 and 4 were significantly longer than those 
measured on days 1,2 and 5 at various time points. This was most marked at 4h p.i., when 
TWL on day 3 was 10.16 ± 0.2s, compared to 8.69 ±O.2s on day 1, 8.73 ± 0.2s on day 2 
and 8.2 ±O.2s on day 5. On day 4, ipsilateral TWL at 4 h was 9.67 ±0.3 s, significantly 
longer than days 1 (p < 0.04) and 5(p < 0.001). 
In Cx-treated animals, a significant effect of repeated treatment on contralateral TWL at 
4h p.i. was also observed, where TWL recorded on day 3 (10.96 ± 0.2)s was significantly 
longer than on all other days (p < 0.05) [ 10.25 ± O.1s on day 1; 10.3 ± O.ls on day 2; 
10.33 ± 0.2 s on day 4 and 10.32 ± 0.2 s on day 5]. There was no significant effect of 
repeated treatment on contralateral TWL at 2 h p.i. or 6 h p.i. 
TWLmin 
In saline-treated animals, a significant effect of repeated treatment on contralateral ( but 
not ipsilateral) TWLmin was observed F (4,44)=7.92, p<O.OOl]. Contralateral TWLmin 
measured on day 4 was significantly lower than that recorded on all other days (p<O.OOl). 
In carrageenan-treated animals, a significant effect of repeated treatment on ipsilateral ( 
but not contralateral) TWLmin was observed (F[4,44] = 27.5, p<O.OOl). Further analysis 
showed that ipsilateral TWLmin on day 3 was significantly higher than that observed on 
days 1 (p < 0.01), 2 and 5 (p < 0.001). Ipsilateral TWLmin on day 4 was significantly 
higher than that observed on days 2 (p < 0.05) and 5 (p < 0.001). 
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Mechanical withdrawal threshold 
Mechanical withdrawal threshold scores recorded in study 2.2 are shown in figure 2.10. 
Baseline MWT and MWTmin recorded on each day are shown in Table 2.11. 
Treatment effect 
Baseline MWT 
There was no significant difference between carrageenan and saline-treated animals in 
ipsilateral or contralateral baseline MWT on any day of the study. 
MWTmin 
Carrageenan treatment produced a significant treatment effect on ipsilateral MWTmin 
(relative to saline treatment) on all 5 days of the study [day 1, p < 0.001; day 2, p < 0.001; 
day 3, p < 0.05; day 4, p < 0.05; day 5, p < O.OOlJ. 
Ipsilateral/contralateral effect 
In saline-treated animals, there was no significant difference between ipsilateral and 
contralateral MWTmin on any day of the study. 
In carrageenan-treated animals, ipsilateral MWTmin was significantly lower than 
contralateral MWTmin on days 1,2 and 5 (p < 0.01), but not on days 3 and 4 (p < 0.06). 
Effect of repeated treatment 
In carrageenan-treated animals, Kruskal-Wallis analysis indicated a significant effect of 
repeated treatment on ipsilateral (but not contralateral) MWTmin. Further analysis using 
Mann-Whitney tests indicated that MWTmin on day 3 was significantly greater than on 
days 1,2 and 5 ( P < 0.001), while MWTmin on day 4 was also significantly greater than 
MWTmin on days 1,2 and 5 (p < 0.002 on days 1,2 and 5). 
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Table 2.11 
Median (and interquartile ranges, QI and Q3) lowest MWT score (MWTmin) measured in 
ipsilateral and contralateral paws on each day of repeated inj ection of 0.1 % carrageenan or 
0.9% saline (50 /-LI) (n = 121 group). 
Treatment carrageenan baseline MWT saline baseline MWT 
Day contralateral ipsilateral contralateral ipsilateral 
1 8 (7.75, 8) 8 (8,8) 8 (7.75, 8) 8 (7.75, 8) 
2 8 (8, 8) 8 (7.75, 8) 8 (8, 8) 8 (8,8) 
3 8 (8, 8) 8 (7.5, 8) 8 (8, 8) 8 (7.75, 8) 
4 8 (7.75, 8) 8 (7.5, 8) 8 (8, 8) 8 (8, 8) 
5 7 (7.75, 8) 8 (7.5, 8) 8 (8, 8) 8 (7.75, 8) 
Treatment carrageenan MWTmin saline MWTmin 
Day contralateral ipsilateral contralateral ipsilateral 
I 
1 7.5 (7,8) 6 (4.25,6) 8 (8,8) 7.5(7,8) 
2 8 (7,8) 6 (5,6) 8(8,8) 7.92(7.5,8) 
3 8 (7,8) 7 (7,7) 8(8,8) 7.67(7,8) 
4 8 (8,8) 7.67 (7,8) 8 (8,8) 7.67(7,8) 
5 8 (7.25,8) 4 (3,6) 8 (8,8) 7.92(7,5,8) 
-_ ...._-_ ..... -
--
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Figure 2.10 
The effects of daily intraplantar injection of 50 ).!l 0.1 % carrageenan and 50 ).!l 0.9% saline 
on median MWTmin. Median MWTmin (the lowest recorded MWT score) was recorded 
in the ipsilateral (A) and contralateral (B) paw on 5 consecutive days (n = 121 group). 
c 
A 
8 
7 
6 
'E 5 
l-S 4 
~ 3 
2 
1 
o 
8 
6 
c: 
E 
I-~ 4 
:E 
2 
o 
8 
-r-
1 2 
r- r-
2 
r-
3 
Day 
-
3 
Day 
-
4 
r-
4 
r-
'--
5 
-
'-
5 
- carrageenan 
c=:J saline 
- carrageenan 
C=::J saline 
101 
2.3.6 STUDY 2.3 (A): Preliminary investigations into the effects of the NMDA 
receptor antagonist, memantine, on inflammatory and nociceptive responses to daily 
repeated carrageenan treatment 
Paw circumference 
Baseline (pre-treatment) ipsilateral PC was 29.2 ± 0.2 mm in Cx-treated animals and 29.0 
± 0.1 mm in saline-treated animals. PCmax recorded in study 2.3 (A) is shown in Figure 
2.11 (A) 
Treatment effect 
Ipsilateral PCmax in Cx-treated animals was significantly greater than that of saline-
treated animals on each day of the study (F[l,S] = 106.2, P < 0.001 on day 1; F[l,S] = 62.S, 
p < 0.001 on day 2; F[l,S] = 24S.0, P < 0.001 on day 3; F[l,S] = 282.0, P < 0.001 on day 4 
and F[l,S] = 60S.0, p < 0.001 on day S). 
Effect of repeated treatment 
There was no effect of repeated injection on ipsilateral PCmax in saline-treated animals. 
In carrageenan-treated animals, PCmax increased significantly over the course of the study 
(F[4,20] = 20.6, P < 0.001). Further analysis showed that PCmax recorded on day 1 was 
significantly lower than that recorded on day 3 (p < O.OS), 4 (p < 0.001) and day S (p < 
0.001); PCmax recorded on day 2 was significantly lower than that recorded on days 4 (p 
< 0.001) and S (p < 0.001). PCmax recorded on day S was significantly greater than that 
recorded on days 1,2 and 3 (p < 0.001). i1PC (Pcmax - baseline PC) did not alter 
significantly over the course of the study. 
Thermal withdrawal latency 
Baseline (pre-treatment) ipsilateral TWL was 10.4S ± 0.3 s in Cx-treated animals and 
10.62 ± O.S s in saline-treated animals. TWLmin recorded in study 2.3 (A) is shown in 
Figure 2.11 (B) and Table 2.12. 
Treatment effect 
TWLmin 
GLM analysis indicated a significant effect of carrageenan treatment (relative to saline 
treatment) on ipsilateral TWLmin on days 1,2 and S but not on days 3 and 4 (F[l,S] = 69.4, 
P < 0.001 on day 1; F[l,S] = 22.6, p < 0.01 on day 2; F[l,S] = 4.4, P = 0.09 on day 3; 
F[1,S] =0.2, P = 0.8 on day 4 and F[1,S] =S.3, P < O.OS on day S). No treatment effect 
was observed on contralateral TWLmin on any day of the study. 
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Table 2.12 
Mean ± SEM minimal thermal withdrawal latency (TWLmin, s) and median (first and 
third interquartile) minimal mechanical withdrawal threshold (MWTmin) measured in 
ipsilateral and contralateral paws following repeated intraplantar injection of 0.1% 
carrageenan or 0.9% saline (50 Ill) in combination with systemic treatment with 
memantine (n = 6/group). 
MEMANTINE 
Treatment carrageenan TWLmin (s) saline TWLmin (s) 
Day contralateral ipsilateral contralateral ipsilateral 
1 10.59 ± 0.05 9.38 ± 0.15 10.12 ± 0.07 10.24 ± 0.09 
2 10.03 ± 0.07 9.27 ± 0.20 10.22 ± 0.04 10.39 ± 0.08 
3 10.16 ± 0.09 9.71 ± 0.08 10.02 ± 0.06 9.93 ± 0.12 
4 10.51 ± 0.07 9.94 ± 0.20 10.15 ±0.10 9.97 ± 0.07 
5 10.42 ± 0.06 9.2 ± 0.30 10.13 ± 0.09 10.00 ± 0.12 
Treatment carrageenan MWTmin saline MWTmin 
Day contralateral ipsilateral contralateral ipsilateral 
1 8(8,8) 6.5(5.75,7) 8(7.75,8) 8(7,8) 
2 8(8,8) 6(5.75,7) 8(7.75,8) 7.5(7,8) 
3 8(8,8) 8(8,8) 8(8,8) 7.5(8,8) 
I 
4 8(8,8) 8(8,8) 8(8,8) 8(8,8) 
5 8(8,8) 6(6,7.25) 8(7.75,8) 8(8,8) 
Ipsilateral/contralateral effect 
TWLmin 
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In saline-treated animals, ipsilateral TWLmin was not significantly different from 
contralateral TWLmin on any day of the study. 
In carrageenan-treated animals, ipsilateral TWLmin was significantly lower than 
contralateral TWLmin on days 1,2 and 5 of the study (F[I,5] =32.6, P < 0.01 on day 1; 
(F[1,5] = 21.2, P < 0.01 on day 2; and (F[1,5] = 8.9, p < 0.05 on day 5. Ipsilateral 
TWLmin was not significantly different from contralateral TWLmin on day 3 (F[ 1 ,5] 
=0.l4, P = 0.7 or on day 4 (F[I,5] =1.07, p = 0.35). 
Effect of repeated treatment 
TWLmin 
In carrageenan-treated animals, there was no significant effect of repeated treatment on 
ipsilateral TWLmin (F [4,29]=2.37, P = 0.09). 
In saline-treated animals, there was a significant effect of repeated treatment on ipsilateral 
TWLmin [F[4,29] = 3.15, P = 0.04]; however post-hoc analysis did not identify particular 
days on which this effect occurred. 
Mechanical withdrawal threshold (MWT) 
Baseline (pre-treatment) ipsilateral MWT was 8 (7,8) in Cx-treated animals and 8 (8,8) in 
saline-treated animals. MWTmin recorded in study 2.3 (A) is shown in Figure 2.11 (C) 
and Table 2.12. 
Treatment effect 
Ipsilateral MWTmin in carrageenan-treated animals was significantly lower than that of 
saline-treated animals on days 1,2 and 5 (p<0.05 on days 1 and 2, p<O.OI on day 5), but 
not on days 3 and 4. 
Ipsilateral/contralateral effect 
In carrageenan-treated animals, ipsilateral MWTmin was significantly lower than 
contralateral MWTmin on days 1 and 2 (p < 0.05) and lay close to significance on day 5 
(p < 0.06), but was not significantly lower than contralateral MWTmin on days 3 and 4. 
Effect of repeated treatment 
In carrageenan-treated animals there was a significant effect of repeated treatment on 
ipsilateral MWTmin (Friedman test, p < 0.001, adjusted for ties). MWTmin on day 3 was 
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significantly higher than that measured on days 1,2 and 5 (p < 0.05). MWTmin on day 4 
was significantly higher than that measured on days 1,2 and 5 (p < 0.05). 
In saline-treated animals, Friedman analysis indicated a significant effect of repeated 
treatment on ipsilateral MWTmin (p < 0.02, adjusted for ties), however more detailed 
analysis did not identify any day on which MWTmin differed significantly from other 
days. 
2.3.7. STUDY 2.3(B): Preliminary investigations into the effects of the opioid receptor 
antagonist, naltrexone, on inflammatory and nociceptive responses to daily repeated 
carrageenan treatment 
Paw circumference 
Baseline (pre-treatment) ipsilateral PC was 29.0 ± 0.2 mm in group 1 (Cx-treated) animals, 
29.8 ± 0.8 mm in group 3 (Cx-treated) animals, 29.0 ± 0.2 mm in group 2 (saline-treated) 
animals and 29.4 ± 0.5 mm in group 4 (saline-treated) animals. PCmax recorded in study 
2.3 (B) is shown in Figure 2.12 (A). 
Treatment effect 
O.5mg/kg NTX (Groups 1 and 3): Ipsilateral PCmax in group 1 (carrageenan-treated) 
animals was significantly greater than that of group 3 (saline-treated) animals on each day 
of the study (F[1,2] = 121.00, P < 0.01 on day 1; (F[1,2] = 100.0, P < 0.01 on day 2; 
(F[I,2] =169.0, P < 0.01 on day 3; (F[1,2] = 51.6, p < 0.01 on day 4 and (F[1,2] = 243.0, P 
< 0.001 on day 5). 
O.05mg/kg NTX (Groups 2 and 4): Ipsilateral PCmax in group 1 (carrageenan-treated) 
animals was significantly greater than that of group 3 (saline-treated) animals on each day 
of the study (F[1,2] =27.0, P < 0.01 on day 1; (F[1,2] = 102.0, P < 0.01 on day 2; (F[1,2] 
=196.0, P < 0.01 on day 3; (F[I,2] = 192.0, P < 0.01 on day 4 and (F[1,2] = 680.0, p < 
0.001 on day 5). 
Repeated treatment 
pemax 
In saline-treated animals (Groups 3 and 4), PCmax did not change over the course of the 
study. 
In group 1 animals PCmax increased significantly over the course of the study ( F[ 4,20] = 
104.9, P < 0.001). Further analysis showed that PCmax recorded on day 1 was 
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significantly lower than that recorded on day 3 (p < 0.001), 4 (p < 0.001) and day 5 (p < 
0.001); PCmax recorded on day 2 was significantly lower than that recorded on days3 (p < 
0.01),4 (p < 0.001) and 5 (p < 0.001). PCmax recorded on day 5 was significantly greater 
than that recorded on all other days 3 (p < 0.001). MC (Pcmax - baseline PC) did not alter 
significantly over the course of the study. 
In group 2 animals (0.05mglkg NTX), PCmax increased significantly over the course of 
the study ( F[4,20] = 166.0, P < 0.001). Further analysis showed that PCmax recorded on 
day 1 was significantly lower than that recorded on day 3 (p < 0.01), 4 (p < 0.001) and day 
5 (p < 0.001); PCmax recorded on day 2 was significantly lower than that recorded on 
days3 (p < 0.05), 4 (p < 0.001) and 5 (p < 0.001). PCmax recorded on day 5 was 
significantly greater than that recorded on all other days 3 (p < 0.001). MC (PCmax-
baseline PC) did not alter significantly over the course of the study. 
Thermal withdrawal latency (TWL) 
Baseline (pre-treatment) ipsilateral TWL was 10.3 ± 0.1 s in group 1 (Cx-treated) animals, 
10.7 ± OJ s in group 3 (Cx-treated) animals, 10.6 ± 0.4 mm in group 2 (saline-treated) 
animals and 10.8 ± 0.1 s in group 4 (saline-treated) animals. TWLmin recorded in study 
2.3 (B) is shown in Figure 2.12 (B) and Table 2.13 
Treatment effect 
Baseline TWL 
There was no difference in ipsilateral or contralateral baseline TWL measurements 
recorded in carrageenan and saline-treated animals on any day of the study. 
TWLmin 
0.5 mg/kg NTX' Group 1 and group 3 
GLM analysis indicated a significant effect of carrageenan treatment (relative to saline 
treatment) on ipsilateral TWLmin on days 1,2 and 5 but not on days 3 and 4.( (F[1,2] = 
99.8, P < 0.001 on day 1; (F[1,2] = 228.9, P < 0.01 on day 2; (F[1,2] =5.1, P = 0.15 on day 
3; (F[1,2] = 1.8, P = 0.31 on day 4 and (F[1,2] =111.5, P < 0.01 on day 5. No treatment 
effect was observed on contralateral TWLmin on any day of the study. 
0.05 mg/kg NTX' Group 2 and group 4 
GLM analysis indicated a significant effect of carrageenan treatment (relative to saline 
treatment) on ipsilateral TWLmin on days 1,2,4 and 5 but not on days 3 and 4.( (F[1,2] = 
81.8, P < 0.05 on day 1; (F[1,2] = 39.0, P < 0.05 on day 2; (F[1,2] = 0.4, P = 0.60 on day 3; 
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Table 2.13 
Mean ± SEM minimal thennal withdrawal latency (TWLmin) recorded following daily 
intraplantar injection of 50 Ill, 0.1 % carrageenan (n = 6/group) or 50 Ill, 0.9% saline(n = 
3/group) accompanied by systemic naltrexone (NTX) treatment on days 3,4 and 5. 
0.1% Group 1 Group 2 
carrageenan O.Smg/kg NTX O.OSmg/kg NTX 
Day 
contralateral ipsilateral contralateral ipsilateral 
1 10.1 ± 0.08 8.3 ± 0.20 10.2 ± 0.12 8.7 ± 0.27 
2 10.3 ± 0.06 7.9 ±0.29 10.1 ± 0.10 804 ±0.14 I 
3 10.1 ±0.08 9.9 ± 0.14 10.1±0.17 9.6 ± 0.10 ! 
4 10.0±0 11 9.5±0.10 10.0 ± 0.03 9.8 ± 0.16 
5 10.2 ± 0.07 6.8 ± 0040 10.0 ± 0.07 6.8 ± 0.26 
saline Group 3 Group 4 
Day O.Smg/kg NTX O.OSmg/kg NTX 
contralateral ipsilateral contralateral ipsilateral 
1 10.2 ± 0.13 10.3 ± 0.03 10.2 ± 0.16 10.2 ± 0.16 
2 9.9 ± 0.27 10.1±0.08 10.3 ±0.13 10.1 ±0.07 
3 10.1 ± 0.13 10.2 ± 0.12 10.1 ±0.11 9.9 ± 0.24 
4 10.2 ± 0.17 10.1 ± 0.06 10.2 ±0.09 10.1±0.19 
5 10.0 ± 0.02 9.9 ± 0.04 10.2 ±0.08 9.7±0.15 
-- -
--_ ... _ .. __ .._- ... _--- . __ ..... - ..... _-_ ....... - '--- _ ...... _-
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(F[1,2] = 39.8, p < 0.01 on day 4 and (F[1,2] =31.3, p < 0.05 on day 5. No treatment 
effect was observed on contralateral TWLmin on any day of the study. 
Ipsilateral/contralateral effect 
Baseline TWL 
In all treatment groups, there was no difference between ipsilateral and contralateral 
baseline TWL values on any day of the study. 
TWLmin 
In saline-treated animals (Groups 3 and 4), ipsilateral TWLmin was not significantly 
different from contralateral TWLmin on any day of the study. 
In group 1 (carrageenan! 0.5 mg/kg NTX-treated) animals, ipsilateral TWLmin was 
significantly lower than contralateral TWLmin on days 1,2 and 5 of the study (F[1,5] 
=46.6, p < 0.001 on day 1; (F[1,5] = 127.0, p < 0.001 on day 2; and (F[1,5] = 155.9, p < 
0.001 on day 5. Ipsilateral TWLmin was not significantly different from contralateral 
TWLmin on day 3 (F[1,5] =4.6, p = 0.08 or on day 4 (F[1,5] =1.7, p = 0.25). 
In group 2 (carrageenan! 0.05 mg/kg NTX-treated) animals, ipsilateral TWLmin was 
significantly lower than contralateral TWLmin on days 1,2, 4 and 5 of the study (F[1,5] 
=150.9, P < 0.001 on day 1; (F[1,5] = 79.4, p < 0.001 on day 2; (F[1,5] = 18.3, p < 0.01 on 
day 4 and (F[1,5] = 67.8, p < 0.001 on day 5. Ipsilateral TWLmin was not significantly 
different from contralateral TWLmin on day 3 (F[1,5] = 3.3, p = 0.13). 
Effect of repeated treatment 
In group 1 animals, there was a significant effect of repeated treatment on ipsilateral 
TWLmin [F(4,25)=24.23, p < 0.001]; more detailed analysis indicated that TWLmin on 
day 5 was significantly lower than all on other days of the study (p < 0.001); ipsilateral 
TWLmin on day 3 was significantly greater than that recorded on days 1 (p < 0.01),2 and 
5 (both p<O.OOl). Ipsilateral TWLmin on day 4 was also significantly greater than that 
recorded on days 1 (p < 0.05), 2 (p <0.01) and 5 (p <0.001). 
In group 2 animals, there was also a significant effect of repeated daily treatment on 
ipsilateral TWLmin [F(4,29) = 35.07 p < 0.001]; more detailed analysis indicated that 
TWLmin on day 5 was significantly lower than all other days of the study (p < 0.001). 
Ipsilateral TWLmin on day 3 was significantly greater than that recorded on days 1 (p < 
0.05), 2(p < 0.001) and 5 (p < 0.001). Ipsilateral TWLmin on day 4 was also significantly 
greater than that recorded on days 1 (p < 0.01),2 (p < 0.001) and 5 (p < 0.001). 
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Mechanical withdrawal threshold (MWTmin) 
Baseline (pre-treatment) ipsilateral MWT was 8 (8,8) in group 1 (ex-treated) animals, 8 
(7,8) in group 3 (ex-treated) animals, 8 (8,8) in group 2 (saline-treated) animals and 8 
(7,8) in saline-treated animals. MWTmin recorded in study 2.3(B) is shown in Figure 2.12 
(e) and Table 2.14. 
Treatment effect 
0.5 mg/kg NTX treatment (Groups 1 and 3): In group 1 animals, ipsilateral MWTmin was 
significantly lower than that of saline-treated animals on all 5 days of the study, (p < 0.01 
on all days relative to both group 3 and group 4). 
0.05 mg/kg NTX treatment (Groups 2 and 4): In group 2 animals, ipsilateral MWTmin 
was significantly lower than that of saline-treated animals on all 5 days of the study [day 
1, p < 0.001; day 2, p < 0.001; day 3, p < 0.05; day 4, p < 0.01; day 5, p < 0.001]. 
Ipsilateral MWTmin in group 1 animals was not significantly different from group 2 
animals on any day of the study. 
Ipsilateral MWTmin in group 2 animals was not significantly different from group 4 
animals on any day of the study. 
Ipsilateral! contralateral effect 
In saline-treated animals (groups 3 and 4), there was no significant difference between 
ipsilateral and contralateral MWT min on any day of the study. 
In group 1 animals, ipsilateral MWTmin was significantly lower than contralateral 
MWTmin on days 2 (p<0.05) and 5 (p < 0.05), while on days 1 (p < 0.06) and day 4 (p < 
0.06), the score difference lay just outside accepted significance levels. On day 3 there 
was no significant difference between ipsilateral and contralateral MWTmin (p=0.18). 
In group 2 animals, ipsilateral MWTmin was significantly lower than contralateral 
MWTmin on days 1 (p < 0.05), day 2 (p < 0.05), day 4 ( P < 0.05) and day 5 (p < 0.05) but 
not on day 3 (p = 0.10). 
III 
Table 2.14 
Median (with semi-interquartile ranges) minimum mechanical withdrawal threshold 
(MWTmin) recorded following daily intraplantar injection of 50 ).1.1, 0.1 % carrageenan 
(n=6/group) or 50 ).1.1, 0.9% saline(n = 3/group) accompanied by systemic naltrexone 
(NTX) treatment on days 3, 4 and 5. 
0.1% Group 1 Group 2 
carrageenan O.Smg/kg NTX O.OSmg/kg NTX 
Day 
cOlltralateral ipsilateral contralateral ipsilateral 
1 8 (7.75,8) 6.5 (5,7.25) 8(8,8) 6.5 (5.5, 7) 
2 8 (7.75,8) 6 (5,7) 8(8,8) 7 (5.65, 7) 
3 8 (7.75,8) 7 (5.75, 8) 8(7.75,8) 7 (6,8) 
4 8 (7.75,8) 6 (5, 6.5) 8(8,8) 6 (4.75, 6.25) 
5 8 (7.75,8) 2.5 (1,3) 8(8,8) 3(2.75,3.25) 
saline Group 3 Group 4 
Day O.Smg/kg NTX O.OSmg/kg NTX 
contralateral ipsilateral contralateral ipsilateral 
1 7.67 (7,8) 7.67 (7,8) 8 (8,8) 8 (8,8) 
2 8 (8,8) 8 (8,8) 8 (8,8) 8 (8,8) 
3 8 (8,8) 8 (8,8) 8 (8,8) 8 (8,8) 
4 8 (8,8) 8 (8,8) 8 (8,8) 8 (8,8) 
5 8 (8,8) 8 (8,8) 8 (8,8) 8 (8,8) 
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2.3.8. STUDY 2.3(C): Preliminary investigations into the effects of the a-2 
adrenoreceptor antagonist, atipamezole, on inflammatory and nociceptive responses 
to daily repeated carrageenan treatment 
Paw circumference 
Baseline (pre-treatment) ipsilateral PC was 29.0 ± 0.3 rom in Cx-treated animals and 29.2 
± 0.4 mm in saline-treated animals. PCmax recorded in study 2.3 (C) is shown in Figure 
2.13 (A) 
Treatment effect 
Ipsilateral PCmax in Cx-treated animals was significantly greater than that of saline-
treated animals on each day of the study (F[I,S] = 20.9, P < 0.01 on day 1; (F[l)] = 122.S, 
p < 0.001 on day 2; (F[I,S] = 48.1, P < 0.01 on day 3; (F[I,S] = 3S.1, P < 0.01 on day 4 and 
(F[I,S] = 33.6, P < 0.01 on day S). 
Effect of repeated treatment 
There was no effect of repeated injection on ipsilateral pre-treatment PC or PCmax in 
saline-treated animals. 
In carrageenan-treated animals, there was no effect of repeated treatment on baseline pre-
treatment PC. However, PCmax increased significantly over the course of the study 
(F[4,20] = 20.6, P < 0.001). Further analysis showed that PCmax on day 1 was 
significantly lower than that on days 3 (p < O.OS), 4 (p < 0.01) and S (p < 0.001); PCmax 
on day 2 was significantly lower than that on days 4 (p < 0.01) and S (p < 0.001). PCmax 
on day S was significantly greater than that on days 1,2 and 3 (p < 0.001). ~PC (PCmax-
baseline PC) did not alter significantly over the course of the study. 
Thermal withdrawal latency (TWLmin) 
Baseline (pre-treatment) ipsilateral TWL was 10.S ± 0.6 s in Cx-treated animals and 10.6 ± 
O.S s in saline-treated animals. TWLmin recorded in study 2.3 (C) is shown in Figure 2.13 
(B) and Table 2.1S. 
Treatment effect 
GLM analysis indicated a significant effect of carrageenan treatment (relative to saline 
treatment) on ipsilateral TWLmin on days 1, 2 and S but not on days 3 and 4 [(F[I,S] = 
41.9, P < 0.001 on day 1; (F[l,S] = 20.2, P < 0.01 on day 2; (F[l,S] = 0.2, P = 0.67 on day 
3; (F[I,S] =S.29, P = 0.07 on day 4 and (F[l,S] =14.3, P < 0.01 on day S]. Contralateral 
TWLmin did not change in response to carrageenan treatment (relative to saline treatment) 
on any day of the study. 
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Ipsilateral/ contralateral effect 
In saline-treated animals, ipsilateral TWLmin was not significantly different from 
contralateral TWLmin on any day of the study. 
In carrageenan-treated animals, ipsilateral TWLmin was significantly lower than 
contralateral TWLmin on days 1, 2 and 5 of the study (F[I,5] =56.3, P < 0.001 on day 1; 
(F[I,5] = 26.4 P < 0.01 on day 2; and (F[1,5] = 14.9, p < 0.01 on day 5. Ipsilateral 
TWLmin was not significantly different from contralateral TWLmin on day 3 (F[ 1 ,5] = 
3.2, p = 0.14 or on day 4 (F[1,5] = 3.3, P = 0.13). 
Effect of repeated treatment 
In saline-treated animals there was a significant effect of repeated treatment on ipsilateral 
TWLmin (F [4,29]=10.35, p < 0.001). TWLmin on day 5 was significantly lower than on 
all other treatment days (p < 0.04 compared with day 1, p < 0.01 compared with day 2, p < 
0.001 compared with days 3 and 4). There was no effect of repeated treatment on 
ipsilateral TWLmin in carrageenan-treated animals. 
Mechanical withdrawal threshold (MWT) 
Baseline (pre-treatment) ipsilateral MWT was 8 (7,8) in Cx-treated animals and 8 (7,8) in 
saline-treated animals. MWTmin recorded in study 2.3 (C) is shown in Figure 2.13 (C) 
and Table 2.7 
Treatment effect 
Ipsilateral MWTmin in carrageenan-treated animals was significantly lower than that of 
saline-treated animals on days 1 (p<0.05), 2 (p < 0.01) and 5( p <0.01), but not on days 3 
and 4. 
Ipsilateral/contralateral effect 
In carrageenan-treated animals, ipsilateral MWTmin was significantly lower than 
contralateral MWTmin on days 1,2 and 5 ( p < 0.05). In saline-treated animals, ipsilateral 
MWTmin did not differ significantly from contralateral MWTmin on any day of the study. 
Effect of repeated treatment 
In carrageenan-treated animals there was a significant effect of repeated treatment on 
ipsilateral MWTmin (Friedman test, p < 0.001, adjusted for ties). MWTmin on day 3 was 
significantly higher than that measured on days 1, 2 and 5 (p < 0.05). MWTmin on day 4 
was significantly higher than that measured on days 1,2 and 5 (p < 0.05). 
115 
Table 2.15 
Mean ± SEM minimal thermal withdrawal latency (TWLmin) and median (first and third 
interquartile) minimal mechanical withdrawal threshold (MWTmin) measured in 
ipsilateral and contralateral paws following repeated intraplantar injection of 0.1% 
carrageenan or 0.9% saline (50 !J.l) in combination with systemic treatment with 
atipamezole (n = 6/group). 
ATIP AMEZOLE 
Treatment carrageenan TWLmin saline TWLmin 
Day contralateral ipsilateral contralateral ipsilateral 
1 10.18 ± 0.07 9.18 ± 0.14 10.29 ±0.04 10.29 ± 0.06 
2 10.22 ± 0.08 9.56 ± 0.18 10.09 ±0.06 10.3 ±0.09 
3 9.93 ± 0.13 10.21 ± 0.05 10.29 ±0.09 10.17 ± 0.09 
4 10.21 ± 0.13 9.89 ± 0.12 10.12 ±0.08 10.18 ± 0.05 
5 10.06 ± 0.02 8.00 ± 0.54 10.21 ±0.04 10.1 ±0.06 
Treatment carrageenan MWTmin saline MWTmin 
Day contralateral ipsilateral contralateral ipsilateral 
1 8(8,8) 7(6.75,7) 8(8,8) 8(7,8) I 
2 8(8,8) 6(6,6.25) 8(8,8) 8(7,8) ! 
3 8(8,8) 8(7.75,8) 8(8,8) 8(8,8) 
4 8(8,8) 8(7,8) 8(8,8) 8(8,8) 
5 8(8,8) 5.5(4.75,6) 8(8,8) 8(8,8) 
- .... _- - --_ .... _- ... _--
- -
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2.3.9: Comparison of nociceptive responses in study 2.3 with those of study 2.2 
Thermal withdrawal latency 
Study 2.3(A): Comparison of the effect of me man tine treatment on TWLmin responses on 
days 3,4 and 5 with those responses observed in study 2.2 
Ipsilateral TWLmin recorded in memantine/carrageenan-treated animals in study 2.3 (A) 
was significantly higher than that recorded in carrageenan-treated animals in study 2.2 on 
all 5 days (p < 0.001 on days 1,2,4 and 5; p < 0.05 on day 3). Contralateral TWLmin 
recorded memantine/carrageenan-treated animals in study 2.3(A) was also significantly 
higher than that recorded in carrageenan-treated animals in study 2.2 on days 1-4 ( P < 
0.01 on days 1 and 4; p < 0.05 on days 2 and 3), but not on day 5. 
Study 2.3(B): Comparison of the effect of 0.5 mg/kg NTXtreatment on TWLmin responses 
on days 3,4 and 5 with those responses observed in study 2.2 
Ipsilateral TWLmin recorded in group 1 animals in study 2.3(B) did not differ significantly 
from that recorded in carrageenan-treated animals in study 2.2 on days 1, 2, 3 or 5. 
However, TWLmin recorded in carrageenan/0.5 mg/kg NTX animals on day 4 was 
significantly lower than that recorded in animals in study 2.2 which received carrageenan 
treatment alone. Contralateral TWLmin in group 1 animals in study 2.3(B) was also 
significantly lower than that recorded in animals in study 2.2 on day 4, but not on any 
other day. 
Study 2.3 (B): Comparison of the effect of 0.05 mg/kg NTX treatment on TWLmin 
responses on days 3,4 and 5 in comparison with those responses observed in study 2.2 
Ipsilateral TWLmin recorded in group 2 animals in study 2.3(B) did not differ significantly 
from that recorded in carrageenan-treated animals in study 2.2 on days 1 or 2, but was 
significantly lower than that recorded in animals in study 2.2 which received carrageenan 
treatment alone on days 3,4 and 5. Contralateral TWLmin in group 2 animals in study 
2.3(B) was also significantly lower than that recorded in animals in study 2.2 on days 2 
and 4 . 
Study 2.3 (C): Comparison of the effect of atipamezole treatment on TWLmin responses on 
days 3,4 and 5 in comparison with study 2.2 
Ipsilateral TWLmin recorded in atipamezolee/carrageenan-treated animals in study 2.3(A) 
was significantly higher than that recorded in carrageenan-treated animals in study 2.2 on 
days 1-4 (p < 0.001 on each day), but not on day 5. Contralateral TWLmin recorded 
117 
atipamezole/carrageenan-treated animals in study 2.3 (A) was also significantly higher 
than that recorded in carrageenan-treated animals in study 2.2 on day 2 (p < 0.05) and day 
4 (p < 0.01), but not on days 1,3 and 5. 
Mechanical withdrawal threshold 
Study 2.3(A): Comparison of the effect of me man tine treatment on MWTmin responses on 
days 3, 4 and 5 with those responses observed in study 2.2 
Mann-Whitney analysis indicated no significant difference between MWTmin recorded in 
carrageenan-treated animals in study 2.3(A) and study 2.2 on days 1-4 of repeated 
carrageenan treatment. On day 5, MWTmin in memantine/carrageenan treatment animals 
[6 (6, 7.25)] was significantly different (p < 0.05) from that recorded in animals which 
received carrageenan treatment alone [4.5 (4.25,6)]. 
Study 2. 3(B): Comparison of the effect of O. 5 mg/kg NTX treatment on MWTmin responses 
on days 3,4 and 5 with those responses observed in study 2.2 
Mann-Whitney analysis indicated no significant difference between MWTmin recorded in 
carrageenan-treated animals in study 2.3(B) and study 2.2 on days 1-3 of repeated 
carrageenan treatment. On day 4, MWTmin in 0.5 mg/kg NTX-treated animals [6 (5,6.5)] 
was significantly different (p < 0.05) from that recorded in animals which received 
carrageenan treatment alone [7 (7,8)]. On day 5, MWTmin in 0.5 mg/kg NTX-treated 
animals [2.5 (1,3)] was significantly different (p < 0.05) from that recorded in animals 
which received carrageenan treatment alone [4.5 (4.25, 6)]. 
Study 2.3(B): Comparison of the effect of 0.05 mg/kg NTX treatment on MWTmin 
responses on days 3,4 and 5 with those responses observed in study 2.2 
Mann-Whitney analysis indicated no significant difference between MWTmin recorded in 
carrageenan-treated animals in study 2.3 (B) and study 2.2 on days 1-3 of repeated 
carrageenan treatment. On day 4, MWTmin in 0.05 mg/kg NTX-treated animals [6(4.75, 
6.25)] was significantly different (p < 0.05) from that recorded in animals which received 
carrageenan treatment alone [7 (7,8)]. On day 5, MWTmin in 0.05 mg/kg NTX-treated 
animals [3 (2.75, 3.25)] was significantly different (p < 0.05) from that recorded in animals 
which received carrageenan treatment alone [4.5 (4.25, 6)]. 
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Study 2.3(C): Comparison of the effect of atipamezole treatment on MWTmin responses on 
days 3,4 and 5 in comparison with study 2.2 
Mann-Whitney analysis indicated that MWTmin scores recorded in carrageenan-treated 
animals in study 2.3(A) were significantly different from those recorded in study 2.2 on 
days 1-4 but not on day 5. MWT scores were consistently higher in study 2.3(C) than in 
study 2.2, although by a very small factor. 
2.4 DISCUSSION 
2.4.1 Selection and characterisation of a suitable inflammatory agent 
Pilot studies were used to select and characterise an appropriate inflammatory agent, which 
would permit investigation of behavioural responses to repeated mild acute inflammatory 
lllJUry. Behavioural responses to low doses of carrageenan and complete Freund's 
adjuvant were assessed since these are the most common agents used in the investigation 
of pain responses associated with intraplantar inflammatory injury. Pilot studies indicated 
that carrageenan was a more suitable inflammatory agent than CF A for use in the 
investigation of nociceptive behavioural plasticity associated with mild inflammatory 
injury. In pilot study 1, while the inflammatory response (Ll PC) to low-dose (12.5%) CFA 
was not significantly different from that induced by saline treatment, 50% CF A induced an 
inflammatory response which persisted for at least 24 h p.i. suggesting that 50% CF A 
treatment was likely to produce an inflammatory response of similar persistence to that 
induced by treatment with 100% CFA (Colpaeli, 1987). Pilot studies 1,2 and 3 indicated 
that 0.6%, 0.5% and 0.1 % carrageenan induced a significant inflammatory response (Ll PC) 
and hyperalgesic behaviour (Ll TWL, LlMWT) relative to saline treatment, which was 
maximal between 2h p.i. and 6 hpj. Following 0.6% carrageenan treatment, intraplantar 
inflammation and hyperalgesia was still present, but diminished, at 24 hpj. Following 
0.1 % Cx treatment, residual intraplantar inflammation and hyperalgesia were no longer 
present at 24 h p.i. These observations thus showed that 0.5% and 0.1 % carrageenan 
provided an inflammatory stimulus which was mild in nature relative to the chemical 
inflammatory stimuli standardly used to induce intraplantar inflammation for the purpose 
of investigations into inflammatory pain. Responses to 0.5% and 0.1 % carrageenan were 
nonetheless significant, of predictable relatively short duration, and thus suitable for use in 
subsequent investigations into nociceptive responses induced by mild repetitive 
inflammatory injury. For subsequent studies, inflammatory and behavioural responses 
were recorded at 6h pj. since the maximal inflammatory response (Ll PC) occurred at this 
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time point, and this was consistently accompanied by thennal and mechanical 
hyperalgesia. 
Considerable variation in the time course of thennal and mechanical hyperalgesia 
associated with carrageenan treatment was observed in pilot studies. Tail flick latency was 
rejected as a method for assessing nociceptive thresholds due to the wide variation in 
response thresholds observed in pilot study 1. Baseline thennal withdrawal latency in pilot 
study 2, using a modified Hargreaves' method, was approximately 20 s. Hargreaves et at. 
(1988) reported a baseline TWL of 9.7-10.0 s following exposure to radiant heat, and 
baseline TWL of approximately 10 s is standardly reported by other studies which have 
used the Hargeaves model (e.g. Tabo & Eisele, 1998; Dirig et at., 1998). Subsequently, 
the intensity of the radiant heat source was adjusted to produce a baseline TWL of 
approximately 10 s so that!::' TWL observed in these studies could be compared in a 
quantitative manner with previous studies that employed the method of Hargreaves et at. 
(1988). 
2.4.2. Characterisation of hyperalgesia associated with low-dose carrageenan 
treatment 
Behavioural responses to high-dose intraplantar carrageenan treatment (2-6 mg) in the rat 
have been characterised in detail (Vinegar et al., 1962; Winter et al., 1962; 1963; Castro-
Lopez et at., 1994; Ichitani et at., 1997; Buritova & Besson 1998; Dirig et at., 1998; 
Honore et at., 1998; Kayser et at., 1998; Pertovaara et at. 1998; Tsuruoka et at., 1998; 
Perrot et at., 1999a,b). Few studies, however, have investigated behavioural responses to 
low dose carrageenan stimulation. 
Single administrations of 0.5% (0.25 mg) and 0.1 % (0.05 mg) Cx produced a consistent 
inflammatory reaction accompanied by consistent mechanical and thennal hyperalgesia. 
The thennal hyperalgesia induced by a single administration of 0.25 mg Cx was similar 
quantitatively to that previously reported following higher doses of carrageenan (Dirig et 
at., 1998; Tabo et at., 1998). Administration of 0.25 mg Cx induced a mean reduction of 
46% (relative to control values) in TWL, while treatment with 0.05 mg Cx induced a mean 
reduction of 24%. Tabo et at. (1998) reported a reduction of 48-54% in TWL following 
treatment with Img Cx, while Dirig et at. (1998) reported a reduction of 61 % in TWL 
following injection of 4mg Cx. Tabo et al. (1998) also reported a significant reduction in 
TWL of 16% (relative to control values) following a single dose of 0.1 mg (1001ll of 0.1 %) 
carrageenan, observing that this dose did not induce any alteration in posture or weight-
bearing in the ipsilateral limb. 
i 
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While methods used to analyse MWT data in study 2.1 indicated a significant reduction in 
MWT induced by both 0.25 mg and 0.05 mg ex administered on a single occasion, the 
categorical nature of these data (which thus required non-parametric statistical analysis) 
does not permit direct quantitative comparison with data analysed using parametric 
methods of statistical analysis. A reduction in MWT to 18-34% of baseline values 
following injection of 1mg carrageenan, and to 41.8% of baseline values following 
injection of O.lmg carrageenan, was reported previously by Tabo et al. (1998). In study 
2.1, 0.25 mg ex induced a dramatic reduction in MWT from a score of 8 (8,9) to 4 (3,5) 
while 0.05mg ex induced a less intense but consistent reduction in MWT from 8 (8,9) to 6 
(4, 7). Thus strong and 'sub-maximal' thermal and mechanical hyperalgesic responses to 
intraplantar carrageenan treatment were determined in study 2.1 
Plasticity of nociceptive transmission associated with inflammatory injury is well 
recognised, and it has been established that the intensity of injury critically influences the 
ultimate conscious sensation of pain. Nociceptive reponses ultimately result from an 
interaction between ascending 'excitatory' nociceptive transmission and descending or 
locally mediated 'anti-nociceptive' inhibitory transmission; inflammatory injury activates 
both 'pro' nociceptive/hyperalgesic and 'anti' nociceptive/hyperalgesic mechanisms at 
every level of the nociceptive transmission system. Identification of the mechanisms 
responsible for the transformation of nociceptive transmission pathways from 
'physiological' to 'pathophysiological' requires proper appreciation of the interaction 
between pro-nociceptivelhyperalgesic and anti-nociceptive/hyperalgesic pathways. 
However, research into plasticity of nociceptive processing associated with inflammatory 
injury has tended to focus on peripheral and central sensitisation associated with high-
intensity models of inflammatory injury. Such models provide the means to investigate 
excitatory pathways associated with the induction of central sensitisation of nociceptive 
processing, but may not permit investigation of complementary compensatory 'anti-
hyperalgesic' (inhibitory) pathways induced as an adaptive response to injury, since any 
adaptive 'anti-hyperalgesic' response is likely to be over-ridden by the intensity of the 
inflammatory stimulus. 
While few studies have investigated the effects of differing intensities of carrageenan-
induced inflammatory injury, studies using the formalin model have highlighted the 
intrinsic limitations of high-intensity models of inflammatory injury in investigations into 
central plasticity of nociceptive processing (Kaneko & Hammond, 1997, 1998; John et al., 
1998; Kaneko et al., 2000). In a series of studies into the role of GABAA receptors in 
formalin-induced nociception in the rat using a range of doses of formalin from 0.25-2.5%, 
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Kaneko & Hammond (1997a; b; 1998) and John et al., 1998) identified marked differences 
in GABAA receptor-mediated responses associated with incremental doses of formalin, 
administered by intraplantar injection. They observed that the effect of GABAA receptor 
blockade on pain responses (recorded as flinching behaviour) changed in direct association 
with the dose of formalin, speculating that the change in effect was associated with dose-
dependent antagonism of tonic GABA-mediated inhibition of excitatory nociceptive 
transmission by inflammatory stimulation. There have been conflicting reports on the 
ability of high-dose formalin treatment to induce central sensitisation; while Xu et al. 
(1995) reported that a single injection of 5% formalin did not induce prolonged 
sensitisation to nociceptive input in spinalised rats, other reports have demonstrated the 
induction of central sensitisation by 2.5-5% formalin (Dickenson & Sullivan, 1987 (b); 
1987 (c); Ji et al., 1997; 1999). Kaneko & Hammond (1997) speculated that the inability 
to detect central sensitisation after high-dose formalin treatment under certain 
experimental conditions could reflect extensive release of inhibitory neurotransmitters 
(such as GABA) into the spinal cord leading to dominance of inhibition over excitation of 
dorsal horn neuronal responses. 
It is highly likely that the central response to carrageenan treatment varies in a similar 
fashion to the central response to formalin treatment, highlighting the need for 
investigations into central plasticity of nociceptive processing following inflammatory 
injury to be performed over a range of stimulus intensities, if the interaction of excitatory 
and inhibitory pathways in the induction of central nociceptive plasticity is to be 
elucidated. In his review of the induction of pain, Millan (1999) suggested that the 
dominance of research into mechanisms underlying the induction of pain rather than the 
inhibition of pain reflected frustration with the development of novel analgesics based on 
the principle of reproducing endogenous mechanisms of antinociception. An improved 
understanding of endogenous anti-nociceptive and anti-hyperalgesic mechanisms may 
become possible through the exploitation oflow-intensity models of inflammatory pain. 
2.4.3. Characterisation of nociceptive plasticity associated with repeated low-dose 
carrageenan treatment 
Few studies have investigated the consequences of repeated mild acute inflammatory 
stimulation, although repetitive stimulation with high doses of carrageenan has been 
reported previously (Kayser & Guilbaud 1987; Kayser et al., 1998; Perrot et al., 1999). In 
study 2.1, baseline (pre-treatment) nociceptive responses and hyperalgesic responses 
induced by carrageenan treatment (0.25 mg and 0.05 mg) were not clearly altered by 
weekly repeated treatment. In contrast, in study 2.2, while baseline nociceptive responses 
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were not altered by daily repeated treatment with low-dose carrageenan (0.05 mg), daily 
repeated treatment (0.05 mg Cx) induced tachyphylaxis of thermal and mechanical 
hyperalgesia. Significant attenuation of the maximal thermal hyperalgesic response 
(TWLmin) and of the maximal mechanical hyperalgesic response (MWTmin) to 
carrageenan treatment was observed on days 3 and 4, an effect which was abolished when 
the stimulus was repeated on day 5. TWL responses were significantly longer at various 
time points post-treatment (for up to 6 hpj.) on days 3 and 4 relative to days 1, 2 and 5. 
This effect was limited to the ipsilateral foot and was absent in control animals that 
received daily repeated doses of saline, where no change in the magnitude of transient 
paw swelling or nociceptive behaviour occurred. 
Tachyphylaxis of nociceptive processing associated with repeated low-dose carrageenan 
treatment has been reported previously in sheep (Welsh & Nolan, 1994) observed at a 
distant site (the ipsilateral ear) following repeated intradermal injection of 0.0625% 
carrageenan in the forelimb at a 14-day inter-treatment interval. However, in contrast to 
the tachyphylaxis of hyperalgesic responses observed in study 2.2 and reported by Welsh 
& Nolan (1994), there have been numerous reports of enhanced nociceptive transmission 
following repeated carrageenan treatment. Ferreira et al. (1978) reported that while 
unilateral hyperalgesia developed following an isolated carrageenan treatment, a 
subsequent carrageenan treatment into the contralateral paw after a 2 hour interval reduced 
the time to maximal mechanical hyperalgesia in both the ipsilateral and contralateral paws, 
suggesting that this change was centrally mediated. Repeated intraplantar administration of 
2mg carrageenan at a 7 day interval induced sensitisation of nociceptive processing 
characterized by an enhanced inflammatory response and an enhanced bilateral 
behavioural response following the second treatment (Kayser et al., 1998; Perrot et al., 
1999). Kayser et al. (1998) assessed pain behaviour at 15, 30, 60, 120 minutes and 7 days 
following carrageenan treatment, observing that repeated unilateral carrageenan injection 
induced bilateral enhancement of pain-related behaviour at all time points following the 
second treatment, while Perrot et al. (1999) reported bilateral enhancement of pain 
behaviour assessed at 3h following repeated carrageenan treatment. Moreover, while 
tachyphylaxis of nociceptive transmission was observed following daily administration of 
0.05 mg Cx in study 2.2, daily repeated administration of saline (150 fll) over 4 days has 
been previously reported to induce a progressive increase in post-injection swelling, 
transient hyperalgesic behaviour (maximal at 3 hours and absent by 7 h p.i., nociceptive 
thresholds reduced by 18-22% using the Randall-Selitto test) which was bilateral (Levine 
et al., 1985). Similarly, previous studies which investigated plasticity of nociceptive 
behaviour associated with repeated high dose carrageenan treatment reported enhanced 
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nociceptive processing following repeated treatment, which may extend beyond the site of 
mJury. 
These contrasting reports of both enhanced and attenuated nociceptive processing 
associated with differing frequency and intensity of inflammatory stimulation demonstrate 
the enormous inherent capacity for plasticity- both enhancement and attenuation - of 
central nociceptive transmission, critically dependent upon the nature, the magnitude and 
the frequency of inflammatory challenge. 
The tachyphylaxis of nociceptive processing observed in study 2.2 may have been 
mediated through modulation of activity at any or all levels of the pain transmission 
system, from the periphery to the cerebral cortex. Melzack & Wall (1965), in their 
exposition of the theory of 'gate control' , demonstrated that spinal nociceptive 
transmission is subject to modulation both segmentally (within the cord itself), and by 
supraspinal influences. 
Modulation of peripheral nociceptive transmission 
As was discussed in chapter 1, hyperalgesic behaviour is classically subdivided into a 
'primary' component, associated with peripheral sensitisation of nociceptors (Meyer & 
Campbell, 1981), and a 'secondary' component, associated with modulation of central 
nociceptive transmission. Thus the tachyphylaxis observed in study 2.2 may have been 
mediated, at least in part, through modulation of peripheral nociceptor sensitivity. 
Peripheral sensitisation is mediated through multiple mechanisms (reviewed by Millan, 
1999). These include: 
Modulation of receptor activity: primary afferent nociceptors normally express a 
combination of excitatory and inhibitory receptors, including opioid receptors, GABA, 
vanilloid, histamine, bradykinin, neurokinin and excitatory amino acid receptors (reviewed 
by Dray, 1994). Injury modulates the activity of many of these receptors: for example, 
opioid receptors, normally ineffective in modulating normal activity in articular 
nociceptors, become effective following intense inflammatory stimulation (reviewed by 
Stein, 1994 and in chapter 1). 
Modulation of receptor expression: for example, adrenoreceptors are expressed de novo 
following peripheral nerve injury (Sato & Perl, 1991, Bossut & Perl, 1995). 
Modulation of neurotransmitter release and synergistic interaction of sensitising agents: 
In addition to modulation of receptor activity and expression, peripheral injury modulates 
the synthesis of a multitude of excitatory and inhibitory agents. Many of the sensitising 
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agents that excite nociceptor terminals following tissue injury synergise to enhance 
peripheral terminal sensitivity to other pro-nociceptive agents for example, prostaglandins 
sensitise peripheral nociceptor terminals to the actions of bradykinin, as well as other 
stimuli (reviewed by Dray & Urban, 1997 and Millan, 1999). Moreover, these agents 
subsequently alter the activity of key ion channels such as the TTX-resistant sodium 
channel, altering the intrinsic excitability of the nociceptor or activate intracellular 
mediators such as protein kinase enzymes (Gold et al., 1996, Dray & Urban, 1996). 
It is worthy of note that numerous endogenous peripheral anti-nociceptive mechanisms 
exist, the enhancement of which could attenuate hyperalgesia associated with 
inflammatory injury. Opioid peptides are synthesised in peripheral tissues [for example, ~ 
-endorphin is synthesised by immune cells (Lyons & Blalock, 1997)] and can inhibit 
nociceptive transmission through activation of receptors located on nociceptors and 
sympathetic terminals (Catheline et al., 1997; Stein & Yassouridis, 1997). Disruption of 
the perineurial blood-nerve barrier in inflamed tissue, a potential consequence of repetitive 
inflammatory stimulation, could also improve access of circulating pools of opioids (and 
other agents) to peripheral nociceptor terminals (Antonijevic et al., 1997; Coggeshall et 
al., 1997). 
While intense inflammatory injury modulates both excitatory and inhibitory receptors and 
systems to ultimately produce excitatory dominance resulting in hyperalgesic behaviour, it 
is possible that a less intense inflammatory stimulus could alter the balance of excitatory 
and inhibitory transmission to ultimately produce downregulation of hyperalgesia, through 
attenuation of excitatory dominance or enhancement of inhibition. It would be of great 
interest to evaluate all of the mechanisms through which peripheral nociceptor behaviour 
is modulated in a model of mild repetitive inflammatory injury. An understanding of 
physiological 'adaptation' of peripheral nociceptive responses to mild injury, could 
provide a strategy that could be exploited clinically to prevent the development of 
persistent pathophysiological hyperalgesia. 
Modulation of central (spinal) nociceptive transmission 
Changes in spinal nociceptive transmission following intense inflammatory injury that 
result in central sensitisation - reflecting enhanced dorsal hom neuronal excitability and 
leading to behavioural hyperalgesia were discussed in chapter 1. Pronociceptive and 
antinociceptive mechanisms induced in the spinal cord by inflammatory injury have been 
extensively investigated and reported (reviewed by Basbaum & Fields, 1984). However a 
fundamental deficiency persists in our understanding of the factors that transform the 
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nociceptive system from a 'physiological' state, in which pronociceptive and 
antinociceptive mechanisms are balanced, to a 'pathophysiological' state in which pro-
nociceptive mechanisms become dominant, potentially for a prolonged period or even 
permanently. 
Many parallels have been drawn between afferent stimulation-induced central sensitisation 
of dorsal hom neurons following inflammatory injury, and the electrophysiological 
phenomenon of long-term potentiation of dorsal hom neuronal responses [reviewed by 
Pockett, 1995 (b)]. Afferent stimulation-induced central sensitisation of dorsal hom 
neurons has been recognised since 1965, when Melzack and Wall demonstrated that 
peripheral afferent stimulation could also induce spinally mediated antinociception. They 
demonstrated that conditioning stimulation of large-diameter A~ and Aa fibres could 
excite small intemeurons in the superficial dorsal hom to exert inhibitory effects on 
presynaptic terminals of A8 and C fibres, or could produce post-synaptic inhibition of 
spinal nociceptive projection neurons. On the basis of the gate control theory, 
transcutaneous electrical nerve stimulation (TENS) techniques were developed for the 
relief of acute and chronic pain. Electrical stimulation at an intensity and frequency which 
is selective for A~ and Aa fibres (100 Hz, low intensity) produces analgesia or 
hypo algesia that does not persist beyond the duration of stimulation (Johnson et al., 1991). 
Conditioning stimulation at low-frequency, moderately painful intensity which is selective 
for A8 fibres (1-10 Hz), administered repetitively, can produce a long-lasting or even 
permanent analgesic effect which is not explained by the gate-control theory (Thorsen & 
Lumsden, 1997). It has been proposed that this form of afferent-induced antinociception 
may represent long-term depression of excitatory nociceptive transmission in the spinal 
dorsal hom (reviewed by Sandkuhler, 2000). 
LTD of spinal excitatory nociceptive transmission has been thoroughly characterised 
(Ceme et al., 1991; Randic et al., 1993; Pockett & Figurov, 1993; Pockett, 1995). 
However, while the efficacy of specific techniques of electrical stimulation for the 
treatment of acute or persistent pain (including painful TENS, electroacupuncture and 
certain forms of needle acupuncture) have been attributed to the induction of spinal LTD 
(reviewed by Sandkuhler), the factors which induce LTD, as opposed to LTP, of central 
spinal nociceptive transmission, have not been identified and no 'physiological' or 
adaptive role for spinal LTD has been proposed to date. The development of 
tachyphylaxis of central nociceptive transmission in response to repeated 0.1% 
carrageenan treatment could represent LTD of spinal nociceptive transmission in the dorsal 
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hom as an 'anti-hyperalgesic' adaptive response to mild repetitive injury. This hypothesis 
correlates well with observations of LTD in the hippocampus, which is similarly induced 
by milder patterns of stimulation than those which produce L TP of synaptic transmission 
(Malenka, 1993; Malenka & Nicoll, 1993; Pockett, 1995), and with indirect evidence of 
LTD of synaptic transmission induced by specific patterns of electrical stimulation which 
produce analgesia through the use of TENS techniques (Sandkuhler, 2000). 
Existing knowledge about the molecular basis of plasticity of nociceptive transmission 
induced by inflammatory injury supports the potential for LTD-like attenuation of spinal 
nociception as a mechanisms for the tachyphylaxis of hyperalgesia observed in study 2.2. 
In addition to the enhancement of excitatory nociceptive transmission (via EAA's, 
tachykinins and prostaglandin systems amongst others), multiple 'antinociceptive' 
systems, including GABAergic, adrenergic and opioidergic transmission, are enhanced in 
the spinal cord in response to injury (reviewed by Millan, 1999 and in chapter 1). 
Analgesia induced by electrical conditioning stimuli (including electro acupuncture ) is 
associated with enhanced release of endogenous opioids (Sjolund et al., 1977, 1979). 
Recognising that spinal nociceptive transmission represents a complex balance of 
excitatory and inhibitory nociceptive transmission, each of which may be enhanced in 
response to inflammatory injury, it is clearly possible that, depending upon the nature and 
intensity of injury, inhibitory rather than excitatory neurotransmission may dominate. 
These complementary transmitter systems are interdependent and interconnected. For 
example, tonic NMDA receptor-mediated modulation of central opioid antinociceptive 
systems- or vice versa- has been reported previously (Dickenson, 1997; Mao, 1999). A 
more complete appreciation of the molecular basis of the transformation from excitatory 
towards inhibitory dominance, which developed in study 2.2 between days 2 and 3 and 
was maintained on day 4, but abolished on day 5, may help identify key molecular targets 
for therapeutic agents designed to combat or prevent post-injury hyperalgesia. 
2.4.3.3. Modulation of supraspinal nociceptive transmission - modulation of 
descending facilitation and inhibition 
Enhanced descending inhibition, or indeed, attenuated descending facilitation, may have 
contributed to the tachyphylaxis of hyperalgesic behaviour observed in study 2.2. 
Descending inhibitory pathways arise in a number of structures, including the 
periaqueductal grey matter, the loci coerulus and subcoerulus, the nucleus raphe magnus 
and several nuclei of the bulbar reticular formation. The cerebral cortex and various 
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limbic structures, including the hypothalamus, contribute to descending modulation 
(reviewed by Willis & Westlund, 1997, and in chapter 1). Many studies have suggested 
that inflammation induces transient or sustained activation of descending inhibitory 
pathways, which dampen down the activity of sensitised projection neurons in the dorsal 
horn (Basbaum & Fields, 1984; Cervero & Laird, 1996a,b; Ren & Dubner, 1996; 
Sandkuhler, 1996; Traub, 1997). It is believed that descending inhibitory pathways 
operate through direct inhibition of peripheral neurons, suppression of neurotransmitter 
release from nociceptor terminals, and engagement of inhibitory interneurons (Reviewed 
by Millan, 1999). Descending inhibitory pathways use several different neurotransmitter 
systems, including opioids (Millan, 1993), catecholamines (Millan, 1997), serotonin 
(Millan, 1997) and GABA (Hammond, 1997). Plasticity in all of these pathways has been 
demonstrated following intense inflammatory stimulation (reviewed in chapter 1). Certain 
of these pathways (notably adrenergic but not opioidergic) exert tonic inhibitory influence 
on nociception; for example, via activation of (12 adrenoreceptors located in the dorsal horn 
(Schaible et al., 1991). 
Attenuation of descending facilitatory pathways could also have contributed to the 
attenuation of hyperalgesia. It has been suggested that descending facilitation originates in 
the rostro-medial medulla (Wiertelak, 1994 (a), (b), (c), (d); Watkins et al., 1994) and in 
the anterior pretectal area of the brainstem (Rees & Roberts, 1993; Rees et al., 1995). 
Descending facilitatory mechanisms contribute to the induction of dorsal horn sensitisation 
and hyperalgesia (Pertovaara et al., 1996; Mansikkka & Pertovaara, 1997), through the 
recruitment of nitric oxide and NMDA receptors in the dorsal horn (Watkins et al., 1994; 
1995; Wiertelak et al., 1994 (a), (b), (c), (d)). While agents associated with engagement of 
these facilitatory pathways have been identified, the mechanisms which control their 
activation are not well appreciated. Several agents, including the 'anti-opioidergic' agents 
neuropeptide FF and cholecystokinin, have been implicated in the engagement of 
descending facilitation (reviewed by Millan, 1999). It has been proposed that GABA 
mediates tonic inhibition of descending facilitatory pathways (Hammond, 1997). 
In higher centres as elsewhere in the nociceptive system, the ultimate dominance of pro-
nociceptive, or anti-nociceptive, transmission depends upon the balance of interacting 
excitatory and inhibitory pathways. Enhancement of descending inhibitory dominance 
induced by mild repetitive inflammatory injury may represent a physiological adaptive 
mechanism which prevents the development of maladaptive hyperalgesia. 
'Stress-induced analgesia' represents a manifestation of supraspinal descending 
modulation of spinal nociceptive transmission mediated through opioidergic and non-
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opioidergic mechanisms (reviewed in chapter 1)- essentially an 'adaptive response'of the 
nociceptive transmission system to potential continuous or repetitive insult. Since 'stress' 
has been defined as anything related to an alteration in psychological homeostatic 
processes (Burchfield, 1979), the repetitive nature of inflammatory stimulation employed 
in study 2.2 provided ample potential for stimulation of conditioned psychological or fear-
induced endogenous hypoalgesic behaviour. However, while 'stress-induced' analgesic 
responses could account for the tachyphylaxis of hyperalgesia observed on days 3 and 4 of 
study 2.2, they do not explain the return of marked hyperalgesia on day 5 in association 
with repetitive inflammatory stimulation of constant magnitude. 
2.4.4. Preliminary investigations into the pharmacology of nociceptive plasticity 
induced by repetitive mild inflammatory stimulation 
2.4.4.1. Study Design 
Since a host of peripheral and central mechanisms, mediated through the modulation or 
excitatory andlor inhibitory neurotransmission, may have been implicated in tachyphylaxis 
of hyperalgesic behaviour, preliminary studies were undertaken to identify candidate 
mechanisms likely to contribute to the observed nociceptive plasticity. It was considered 
of interest in the first instance to identify the existence and relative importance of 
'excitatory' and 'inhibitory' modulation to the observed nociceptive plasticity. Excitatory 
nociceptive transmission in the central nervous system is driven predominantly by 
neuropeptides (including substance P, NKA, CGRP and NPY); excitatory amino acids 
(EAA's), and prostaglandins. The role of the NMDA receptor was of particular interest 
due to the key role of this receptor in both the induction of synaptic plasticity in the central 
nervous system and the induction of post-inflammatory central sensitisation of nociceptive 
processing in the dorsal hom (reviewed by Dickenson, 1990; Coderre & Yaksh, 1996; and 
in Chapter 1). Many inhibitory transmitter systems contribute to spinal and supraspinal 
modulation of nociceptive transmission, including GABA, endogenous opioids and 
adrenergic pathways. The roles of opioid and U 2 adrenoreceptor-mediated plasticity of 
nociceptive processing were of particular interest in study 2.3, since these are key 
transmitter systems implicated in both segmental spinal and supraspinal descending 
inhibition, and their activity is modulated by inflammatory injury. Moreover, the NMDA 
receptor, opioid and U 2 adrenoreceptors are clinically effective anti-hyperalgesic and 
analgesic therapeutic agents (reviewed by Millan, 1999). 
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NMDA receptors, opioid receptors and 0.2 adrenoreceptors are expressed throughout the 
peripheral and nervous system and in non-neuronal sites (discussed in chapter 1). Specific 
evaluation of the central effects of NMDA, opioid and 0.2 adrenoreceptor antagonism can 
thus only be achieved through local (intrathecal) administration of appropriate antagonists. 
While providing an invaluable means of assessing spinal activity of specific agents, 
intrathecal drug delivery was not considered to be appropriate for the purpose of a 
preliminary screening study. Intrathecal drug delivery may fundamentally alter central 
mechanisms of nociceptive plasticity through the necessity for spinal surgery in small 
rodents to enable insertion of intrathecal catheters. 
Receptor antagonists were selected which would achieve effective active concentrations 
within the central nervous system following subcutaneous administration. Specific 
antagonists were not administered on days 1 and 2 in order to allow the induction of 
behavioural plasticity, since tachyphylaxis of hyperalgesia developed only on days 3 and 4 
of repetitive low-dose carrageenan administration. Antagonists were also administered on 
day 5 in order to evaluate the role of each receptor system in the restoration of 
hyperalgesia. 
2.4.4.2. Study 2.3(A) 
Selection of an NMDA receptor antagonist 
Since glutamate is the principal and ubiquitous excitatory neurotransmitter in the central 
nervous system, NMDA receptor antagonism is likely to produce depression or modulation 
of general sensory transmission (reviewed by Eide, 1999). However, the role ofNMDA in 
nociceptive plasticity is primarily due to its induction of plasticity of central excitatory 
nociceptive transmission (reviewed in chapter 1). The psychomimetic and psychomotor 
side-effects of NMDA receptor antagonists in humans are well documented (reviewed by 
Olney & Farber, 1995). Thus, in order to study the role of NMDA receptors in the 
behavioural plasticity observed in study 2.2, an agent was required which would 
effectively achieve central spinal NMDA blockade while avoiding side-effects which 
would distort accurate assessment of hyperalgesic behaviour. 
Memantine is a non-competitive NMDA antagonist with a half-life of 4.6h following 
subcutaneous administration in the rat (Parsons et al., 1993). Due to its moderate potency, 
rapid channel blocking/unblocking kinetics and strong voltage dependency, memantine 
effectively blocks NMDA receptors with minimal adverse psychomimetic and 
psychomotor effects (reviewed by Parsons et al., 1999). Reports of memantine 
antagonism of 'physiological' nociceptive transmission, as opposed to hyperalgesia, 
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remain somewhat inconclusive. Memantine has been reported to attenuate spinal neuronal 
responses to noxious (but not innocuous) peripheral stimulation (Neugebauer et al., 1993). 
Olivar & Laird (1999) reported that memantine (ID50 = 17± 12 mg/kg) inhibits responses 
to pinch stimuli in anaesthetised rats. However, a study on human subjects reported that 
memantine administration (30 mg p.o.) did not alter flexor reflex thresholds or magnitude, 
pain and tolerance thresholds (Schepelmann, et al., 1998). 
Systemic memantine administration attenuates hyperalgesic behaviour associated with 
inflammatory injury. Neugebauer et al.(1993) and Eisenberg et al.(1994) reported that 
memantine (10-15 mg/kg) attenuated hyperalgesic behaviour in high-dose carrageenan 
models of peripheral inflammatory injury in rats. Eisenberg et al.(1993) reported that 
memantine (2.5-10 mg/kg delivered by intraperitoneal injection) attenuated pain behaviour 
induced by high-dose intraplantar formalin treatment. Systemic memantine administration 
also attenuates hyperalgesic behaviour associated with neuropathic injury; Carlton & 
Hargett (1995) and Eisenberg et at. (1995) reported that memantine blocked and reversed 
thermal hyperalgesia and mechanical allodynia without obvious effects on motor reflexes 
at doses of 10-20mg/kg in models of neuropathic pain. Side-effects in animals 
characteristic for NMDA receptor antagonists (including ataxia, myorelaxation and 
amnesia) only develop at higher doses of 20-30 mg/kg (Danysz et al., 1994), reflecting the 
relatively low affinity of memantine for NMDA receptors relative to more potent NMDA 
antagonists such as MK-801, dextromethorphan and dextromethorphan (Chaplan et aI., 
1997). Memantine thus fulfilled the specifications of an NMDA receptor antagonist which 
could be used to investigate the effect of NMDA receptor blockade on tachyphylaxis of 
hyperalgesic behaviour. Two doses of memantine were administered (20 mg/ kg at 0 hand 
5 mg/ kg at 2 hpj. ) in order to maintain serum memantine at or above 10 mg/kg for the 
duration of behavioural testing, a dose which was chosen in order to achieve antagonism of 
central NMDA receptors without induction of adverse side-effects. 
It is worthy of note that NMDA receptor activation has also been implicated in peripheral 
mechanisms of hyperalgesia. Intraplantar memantine administration has been shown to 
attenuate formalin-induced lifting and licking behaviour, without affecting central pain 
responses (Davidson & Carlton, 1998), suggesting that part of the antihyperalgesic effect 
of memantine may be achieved through blockade of NMDA receptors on peripheral 
cutaneous nociceptors. 
Inflammatory and hyperalgesic responses associated with carrageenan/memantine 
treatment 
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Memantine administration did not alter baseline PC, TWL or MWT responses in saline-
treated control animals on days 3, 4 and 5. Memantine administration did not alter 
contralateral TWL or MWT responses. Memantine administration did not alter the 
magnitude of the inflammatory response to repeated carrageenan treatment on days 3,4 and 
5 relative to that observed in study 2.2 (Figure 2.11). In animals which were treated with 
carrageenan alone, PCmax was 32.3 ± 0.3 mm on day 3, 30.6 ± 0.2 mm on day 4 and 32.3 
± 0.2 mm on day 5. In memantine-carrageenan-treated animals, PCmax was 32.3 ± 0.3 
mm on day 3,30.6 ± 0.2 mm on day 4 and 32.3 ± 0.2 mm. 
While the inflammatory response to daily repeated carrageenan treatment in study 2.3 (A) 
was not significantly different from that observed in study 2.2, significant thermal and 
mechanical hyperalgesia were not observed on days 1 and 2 in study 2.3 (A), so that the 
effect of memantine treatment on plasticity of nociceptive behaviour could not be assessed. 
2.4.4.3. Study 2.3(B) 
Selection of an opioid receptor antagonist 
A host of highly selective agents have now been described which have been of great use in 
defining the pharmacology of the three major opioid receptor classes (reviewed by 
Pasternak, 1993). For example, ~-funaltrexamine selectively antagonises Il-opioid 
receptors (Ward et al., 1982), while naltrindole selectively blocks 8-opioid receptors 
(Abdelhamid et al., 1991) and nor-binaltorphinimine acts against K receptors (Portoghese et 
al., 1991). Other agents have been described that can further differentiate receptor 
subtypes (reviewed by Pasternak, 2000). 
Study 2.3(B) was a preliminary study, which aimed to investigate the potential 
involvement of opioidergic pathways in the mediation of nociceptive plasticity observed 
following repeated carrageenan treatment. It was recognised that thorough 
characterisation of the role of the separate opioid receptors would require systematic 
administration of subtype-specific receptor antagonists, which was beyond the intended 
scope of a preliminary study. The three major opioid receptor types, Il, 8 and K, differ in 
their pharmacological effects on nociceptive transmission (reviewed by Dickenson, 1997a; 
Pasternak, 2000, and in chapter 1). It is well established that the opioidergic response to 
inflammatory injury depends critically upon the intensity and duration of injury, but the 
factors which regulate this plasticity remain undetermined and may differ between the 
different opioid receptor types (reviewed by Dickenson, 1997). Il- opioid receptor 
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activation consistently inhibits excitatory nociceptive transmission at peripheral, spinal and 
supraspinal sites (Pasternak, 2000). Similarly, 0 receptor activation produces strong 
analgesic and anti-hyperalgesic effects through actions at both spinal (Heyman et ai., 
1987; Stewart & Hammond, 1993; 1994) and supraspinal sites (Ossipov et al., 1995; 
Thosipov & Hammond, 1997; 1991). The effects of K opioid receptor activation are less 
well defined, with both pro-and antinociceptive effects attributed to K opioid receptor 
activation (reviewed in chapter 1). Moreover, K opioid agonists have been shown to 
functionally antagonise the ~-receptor in the spinal cord (Stanfa et al., 1992). It was 
therefore of interest to differentiate between the potentially antagonistic effects of ~- and 
K receptor activation. 
Naltrexone is a non-selective opioid receptor antagonist with a lO-fold preference for ~­
receptors (Yoshimura et al., 1982; Millan et al., 1989), which has been characterised as a 
'long-acting' opioid antagonist in the rat (Ragavan et a!., 1983; Zukin et al., 1982), 
reaching peak serum levels at 1h pj. following subcutaneous administration with an 
elimination half-life of 4.6h. (Yoburn et al., 1986). Millan (1989) reported that naltrexone 
attenuated ~-receptor (morphine)-mediated antinociception by 50% at doses of 0.016 
[0.009-0.029Jmg/kg, while higher doses of 0.16 [0.062-0.422J mg/kg) attenuate K receptor 
(U50488H) mediated responses by 50%. Naltrexone administration (1-3 mg/kg) has no 
effect on physiological nociceptive thresholds (Bienkowski et ai., 1999). NTX thus 
fulfilled the specifications of an opioid receptor antagonist suitable for investigation of 
potential opioidergic mediation of tachyphylaxis of hyperalgesic behaviour. NTX was 
suitable for administration by subcutaneous injection, while the relatively prolonged half-
life of NTX in the rat ensured effective opioid receptor blockade for the duration of 
behavioural testing on each day of the study. 
In the absence of data relating to specific NTX dose rates required for o-opioid receptor 
blockade, it was considered that high dose NTX administration would produce general 
opioid receptor blockade. Two doses of NTX were thus administered to differentiate ~­
selective antagonism (0.05 mg/kg NTX) from general (~, 0 and K) receptor antagonism 
(0.5 mg/kg NTX). 
Naltrexone administration did not alter the magnitude of the inflammatory response to 
repeated carrageenan treatment on days 3,4 and 5 relative to that observed in study 
2.2.(Figure 2.12(A). It is worthy of note that baseline PC in both carrageenan and saline-
treated animals was slightly higher in study 2.3(B) than in study 2.2., but the difference 
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between PCmax in carrageenan-treated animals in study 2.3 and study 2.2 remained 
constant. 
Naltrexone administration did not alter thermal or mechanical response thresholds in 
saline-treated control animals [Figure 2.12(B)], consistent with previous evidence that 
opioid receptors do not affect 'physiological' nociceptive transmission (Bienkowski et al., 
1999). Naltrexone administration (0.5 mg/kg and 0.05 mg/kg) did not alter the pattern of 
nociceptive responses to thermal stimulation associated with repeated carrageenan 
administration and did not affect TWLmin on days 3 and 4. This suggests that suggesting 
that opioidergic mechanisms did not play a dominant role in the mediation of 
tachyphylaxis of thermal hyperalgesia observed in study 2.2. However, TWLmin on day 5 
was significantly lower in NTX-treated animals (6.8 ± 0.4 s following 0.5 mg/kg NTX and 
to 6.8 ± 0.3 s following 0.05 mg/kg NTX ) than in animals which received carrageenan 
treatment alone (7.8 ± 0.2 s). 
Naltrexone administration (0.5 mg/kg and 0.05 mg/kg) did not alter the pattern of 
nociceptive responses to mechanical stimulation associated with repeated carrageenan 
administration and did not affect MWTmin on days 3 and 4. This suggests that opioidergic 
mechanisms did not playa dominant role in the mediation of tachyphylaxis of mechanical 
hyperalgesia observed in study 2.2. However, MWTmin was significantly lower in NTX-
treated animals on day 5 (2.5 (1, 3) in 0.5 mg/kg NTX-treated animals, and 3 (2.75, 3.25) 
in 0.05 mg/kg NTX animals) than in animals which received carrageenan treatment alone 
[4.5 (3, 6)]. 
The enhancement of both thermal and mechanical hyperalgesic responses on day 5 by 
opioid antagonism suggests that tonic engagement of opioid inhibitory pathways was 
present on day 5 of repeated mild inflammatory stimulation. The lack of dramatic change 
in tachyphylaxis of thermal hyperalgesia on days 3 and 4 associated with naltrexone 
treatment suggest that opioid mechanisms were not prime mediators of this tachyphylaxis. 
The partial restoration of mechanical hyperalgesia on day 4 (but notably not day 3) 
associated with naltrexone treatment suggests that opioidergic mechanisms may have 
played some role in the tachyphylaxis of mechanical hyperalgesia induced by repeated 
carrageenan treatment. 
Differential modulation of thermal and mechanical nociceptive responses associated with 
selective opioid receptor antagonism has been reported previously. Millan (1989) 
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investigated behavioural responses to non-noxious and noxious thermal and mechanical 
stimulation following administration of selective opioid receptor agonists. He reported 
that at moderate matched intensities, both ~- receptor agonists and K-receptor agonists 
were equipotent against thermal and mechanical stimuli, while at noxious intensities of 
thermal and mechanical stimulation, and in distinction to ~- receptor activation, the 
potency of K-receptor agonists against noxious thermal (but not mechanical) stimulation 
was intensity dependent. While the objectives of Millan's study were quite distinct to 
those of the present study, these data indicate a precedent for differential modulation of 
thermal and mechanical nociceptive responses, potentially mediated through K-receptor 
activity. 
In study 2.3(B), no significant difference was observed in the pattern of thermal and 
mechanical nociceptive responses recorded in low-dose NTX (relative ~-selective opioid 
antagonism) and high-dose NTX (general opioid receptor antagonism). This would 
suggest that at least a component of the endogenous opioidergic attenuation of 
hyperalgesia on day 5 of repeated carrageenan treatment is mediated by 8 and/or K 
receptors, rather than exclusively by ~ opioid receptors. More precise definition of the 
roles of 8 and K receptors in the attenuation of hyperalgesic responses associated with 
repeated mild inflammatory stimulation will require systematic administration of more 
selective 8 and K receptor antagonists. Furthermore, it was not possible to distinguish 
between antagonism of spinal and supraspinal opioid receptors and it is therefore possible 
that the observed effects were due to blockade of opioid receptors located peripherally, 
spinally or in higher centres. Intrathecal and intracerebroventricular administration of 
selective agonists and antagonists should permit identification of the precise location of 
opioidergic modulation of nociceptive transmission. 
2.4.4.4. Study 2.3(C) 
Selection of an a2 adrenoreceptor antagonist 
Atipamezole is a potent and highly selective a 2 adrenoreceptor (AR) antagonist (Scheinin 
et al., 1989; Virtanen et al., 1989; Winter & Rabin 1992; Haapalina et al., 1997) which 
penetrates rapidly into the eNS following subcutaneous injection (Biegon et al., 1992) 
with an elimination half-life of 2 h in the rat (Haapalina et al., 1998). A dose of 300 ~ 
g/kg administered by subcutaneous injection induces complete central a 2AR blockade and 
stimulates central noradrenaline release in the rat (Haapalinna et al., 1997). At this dose, 
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atipamezole has been reported to have no adverse effects on general central sensory 
transmission in rats (Jakala et al., 1992; Sirvio et aI., 1993). 
Atipamezole has been reported to produce variable and conflicting effects on pain 
responses in rats, associated with habituation of the subject to test conditions, the nature 
and intensity of noxious stimulation, the dose of atipamezole administered and the 
response parameter measured (Mansikka & Pertovaara, 1995; Mansikka et aI., 1996; 
Kaupilla et al., 1999). Mansikka & Pertovaara (1995) reported that systemic administration 
of 10 Ilg /kg and 1 mg/kg atipamezole did not alter mechanical hyperalgesia (assessed 
using Von Frey hairs) following unilateral topical application of mustard oil to the hind 
paw, while a dose of 100 Ilg Ikg atipamezole significantly attenuated mustard-oil induced 
hyperalgesia. Mansikka et al. (1996) reported that intrathecal administration of 
atipamezole (2.5 Ilg) to the lumbar spinal cord, or intracerebral administration into the 
nucleus raphe magnus did not attenuate hyperalgesia associated with intraplantar 
application of mustard oil, although the same dose applied directly to the lateral reticular 
nucleus of the medulla completely reversed hyperalgesia. Kaupilla et al.(1999) similarly 
reported variation in pain responses associated with differing doses of systemic 
atipamezole, administered in combination with noxious mechanical stimulation or 
intraplantar formalin administration. They observed that doses of 30Ilg/kg and 1.5 mg/kg 
atipamezole (administered by intraperitoneal injection) did not significantly alter paw 
withdrawal latency to noxious mechanical stimulation or pain behavior in the formalin test, 
but did increase licking latency in the hot-plate test and reduce response latencies in the 
tail-flick test. Our study shows that a dose of 400-600llg/kg atipamezole administered by 
subcutaneous injection, which produces complete central u2- adrenoreceptor blockade 
(Haapalina et al., 1998) permits investigation of u 2-adrenergic regulation of nociceptive 
transmission without producing motor dysfunction which would obscure behavioural 
responses. 
Atipamezole was selected in preference to other u 2- adrenoreceptor antagonists due to the 
pharmacological characteristics of the drug discussed above, which proposed to provide a 
good level of central u 2- adrenoreceptor antagonism for the duration of behavioural 
testing. The two doses of atipamezole administered, 600 Ilg/kg at 0 hand 400 Ilg/kg at 2 h 
p.i., were used in order to achieve serum levels of close to 300 Ilg/kg for as long as 
possible over the period of behavioural testing. 
Atipamezole administration did not alter the magnitude of the inflammatory response to 
repeated carrageenan treatment on days 3,4 and 5 relative to that observed in study 
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2.2.(Figure 2.13). It is worthy of note that baseline PC in both carrageenan and saline-
treated animals was slightly higher in study 2.3(C) than in study 2.2. 
Atipamezole administration did not alter nociceptive behaviour associated with repeated 
carrageenan administration, suggesting that u 2-adrenergic mechanisms did not play a 
dominant role in the mediation of plasticity of nociceptive responses which occurred in 
study 2.2. 
The modulation of central nociceptive transmission by central u 2-adrenergic pathways 
following inflammatory injury remains a contentious issue (reviewed by Kingery et al., 
1997). Some behavioural (Hylden et al., 1991) and electrophysiological (Stanfa & 
Dickenson, 1994) studies using high-dose intraplantar carrageenan inflammation have 
reported that intense inflammatory injury enhances the analgesic effects of u 2-adrenergic 
agonists, thus suggesting that endogenous ~-adrenergic (antinociceptive) 
neurotransmission may be enhanced in response to injury. However, a study by Idanpaan-
Heikkila et al.(1994) did not identify any enhancement of u 2-adrenergic responses 
following high-dose carrageenan treatment. It is possible that engagement or enhancement 
of endogenous u 2-adrenergic antinociceptive transmission is critically influenced by the 
nature and severity of inflammatory injury. 
In study 2.3(C), systemic administration of atipamezole administration meant that the 
potentially conflicting peripheral, spinal and supraspinal effects of u2-adrenenoreceptor 
antagonism could not be distinguished. Mansikka et al. (1996) reported that intrathecal 
administration of atipamezole (2.5 Ilg) to the lumbar spinal cord, or intracerebral 
administration into the nucleus raphe magnus did not attenuate hyperalgesia associated 
with intraplantar application of mustard oil, although the same dose applied directly to the 
lateral reticular nucleus of the medulla completely reversed hyperalgesia. In the same 
study it was reported that medetomidine (an u 2-adrenoceptor agonist) administration to the 
lumbar cord, reversed ipsilateral mechanical hyperalgesia without altering contralateral 
mechanical withdrawal thresholds, and attenuated nociceptive responses in control rats 
following application, while medetomidine administration into the nucleus raphe magnus 
or into the lateral reticular nucleus of the medulla did not affect nociceptive or 
hyperalgesic responses. Mansikka et al. (1996) thus elegantly demonstrated that u 2-
adrenergic blockade antagonises mechanical hyperalgesia through action on the medulla, 
whereas u2-adrenoceptor stimulation antagonises mechanical hyperalgesia through direct 
action on the spinal cord. Study 2.3.2 demonstrates the complexity of u 2-adrenergic 
modulation of central nociceptive transmission following acute injury and highlights the 
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need for reappraisal of the involvement of ctz-adrenergic mechanisms in the central 
response to moderate, as opposed to intense, inflammatory injury. 
2.5 CONCLUSIONS 
Mild inflammatory injury induced by 0.5% and 0.1% carrageenan treatment induced 
consistent hyperalgesic behaviour which was not altered by weekly repetitive stimulation. 
Temporary attenuation of hyperalgesia developed following daily repeated mild 
inflammatory injury induced by 0.1 % carrageenan treatment, but hyperalgesia returned 
when this repetitive inflammatory stimulation was maintained. These studies demonstrate 
that the intensity and the frequency of mild inflammatory challenge critically regulate 
nociceptive transmission and the development of hyperalgesic behaviour. Identification of 
differences in the expression of pro- nociceptive and anti-nociceptive agents induced in 
association with 'maximal' ('ceiling') and 'sub-maximal' thermal and mechanical 
hyperalgesic responses, may lead to greater understanding of the mechanisms which 
transform nociceptive transmission from 'physiological' to 'pathophysiological'. LTP of 
neuronal transmission in the dorsal horn has been reported following high-intensity 
inflammatory injury (Liu & Sandkuhler 1995, 1996; Sandkuhler & Liu, 1998) and 
associated with central sensitisation of nociceptive transmission. In contrast, LTD of 
neuronal transmission in the spinal dorsal horn has been reported as a purely 
electrophysiological phenomenon induced through specific patterns of electrical 
stimulation and while it has been speculated that LTD of synaptic transmission in the 
dorsal horn may provide an alternative mechanism for suppression of excitatory 
nociceptive transmission, this speCUlation is not supported by evidence produced in studies 
using natural noxious stimulation or injury. It is possible that the tachyphylaxis of 
hyperalgesia observed in study 2.2 may represent LTD of dorsal horn nociceptive 
responses. 
The tachyphylaxis observed in study 2.2 may represent a 'physiological' pathway, directed 
towards restoration of functional 'homeostasis' of nociceptive processing, which functions 
until a critical level of inflammatory challenge is surpassed, whereupon adaptive 
mechanisms are overridden and persistent hyperalgesia develops. Manipulation of the 
intensity and frequency of inflammatory challenge in standard models of inflammatory 
pain may provide further insights into mechanisms associated with physiological and 
pathophysiological responses to inflammatory injury. Clearly, improved understanding of 
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physiological mechanisms which prevent the onset of persistent hyperalgesia offers huge 
potential for the development of new therapeutic strategies to pre-empt the development of 
persistent post-injury hyperalgesia, and to provide novel targets for the treatment of 
hyperalgesia associated with inflammatory injury. 
Preliminary study 2.3 (A), investigating the role of NMDA receptors, gave inconclusive 
results. Repetition of this study in a population of test subjects with demonstrable thermal 
and mechanical hyperalgesia is indicated. Preliminary studies on the role of opioid 
receptors and a 2A adrenoreceptors in the mediation of tachyphylaxis of hyperalgesic 
behaviour induced by daily repeated low-dose carrageenan treatment suggest that these 
receptor systems did not playa major role in the observed tachyphylaxis. However opioid 
receptors and a 2A adrenoreceptors appeared to influence, to a degree, the development of 
pronounced thermal and mechanical hyperalgesic behaviour on day 5 of repeated 
carrageenan treatment. These observations demonstrate once again the constant interplay 
between excitatory (hyperalgesic) and inhibitory (antihyperalgesic) nociceptive 
transmission following inflammatory injury. In study 2.3 it was not possible to identify 
the location -peripheral, spinal or supraspinal- at which receptor antagonists induced their 
effects on day 5. FUliher studies using intrathecal and supraspinal administration of the 
same antagonists will identify specific sites at which the observed modulation of 
nociceptive behaviour occurred. For example, it remains possible that tachyphylaxis of 
hyperalgesia was mediated by descending inhibitory mechanisms originating in higher 
centres; in order to investigate this, it shall be necessary to perform more specific studies 
which can target those key regions associated with descending inhibition of nociceptive 
transmission, including the periaqueductal grey matter (P AG) and the ventromedial 
medulla. The mechanisms underlying the observed tachyphylaxis of hyperalgesia 
associated with mild repetitive inflammatory injury remain unresolved, but are likely to 
involve a combination of spinal and supraspinal mechanisms and multiple molecular 
mediators. Clearly, greater appreciation of endogenous mechanisms which attenuate 
hyperalgesia following inflammatory injury should lead to improved management of 
persistent pain associated with inflammatory injury. 
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CHAPTER 3: AN IN-SITU HYBRIDISATION STUDY OF POTENTIAL 
MOLECULAR MEDIATORS OF PLASTICITY OF NOCICEPTIVE 
PROCESSING IN THE SPINAL CORD FOLLOWING INFLAMMATORY 
INJURY 
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Not everything that counts can be counted, and not everything that can be counted 
counts 
Albert Einstein 
3.1 INTRODUCTION 
Pathophysiological pain sensation is an expression of plasticity of nociceptive 
transmission, potentiated at multiple sites and mediated by diverse mechanisms, located 
both peripherally and centrally. Central sensitisation of nociceptive transmission, a 
common denominator of numerous pathological pain states, is a manifestation of transient 
or persistent enhancement of dorsal horn neuronal responses to noxious stimulation 
(reviewed by Millan, 1999). Persistent enhancement of dorsal horn nociceptive 
transmission may be an expression of long-term potentiation or long term depression of 
synaptic transmission in the spinal cord, associated with phenotypic changes in dorsal horn 
nocisponsive neurones (reviewed in Chapter 1). Mechanisms of dorsal horn sensitisation 
share many common characteristics with long-term potentiation, but are not invariably 
comparable, as was discussed in chapter 1. Rapid and reversible sensitisation of dorsal 
horn neuronal responses can occur in the absence of morphological changes, and may 
require peripheral input for its maintenance (Millan, 199). In contrast, LTP or LTD in 
higher centres can persist for prolonged periods in the absence of stimulation , and are 
associated with phenotypic changes in sensitised neurons (reviewed in Chapter 1). The 
association of synaptic plasticity in the dorsal horn with central sensitisation and 
pathophysiological pain states remains poorly defined. 
The molecular basis of stimulus-dependent neuronal plasticity has been extensively 
studied in higher centres, where L TP and LTD of synaptic transmission are believed to 
express the synaptic basis of memory. Stimulus-induced intraneuronal calcium influx 
through excitatory amino acid receptors, transduced by protein kinase enzymes to activate 
immediate early genes has been strongly implicated in the induction and/or maintenance of 
LTP in higher centres (reviewed by Roberson et al., 1996, and in chapter 1). Many other 
signalling molecules and neurotransmitter molecules have been implicated in the induction 
and/or maintenance of synaptic plasticity in higher centres, including GABA (Kanter & 
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Haberly, 1993; Yasui et at., 1993; Tomasulu et al., 1993; Watanebe et at., 1995), and 
endogenous opioids (Satoh et at., 1989; Bramham et at., 1992; Xie & Lewis, 1995a; 
Williams & Johnston 1996; Ishihara et at., 1990; Bramham et at., 1991; Derrick et at., 
1991; 1992; Xie et at., 1991; Francesconi et al., 1997; Ikeda et al., 1999). The molecular 
basis of L TP and LTD in the spinal cord remains poorly defined, although it has been 
postulated that similar mechanisms mediate synaptic plasticity in the spinal cord and in 
higher centres. Excitatory amino acid receptors (Sandkuhler et al., 1996), immediate early 
genes (Wisden et al., 1990), CaMKII a (Kolaj et al., 1994) and endogenous opioids 
(Pockett, 1995), amongst other agents, have been implicated in the induction of persistent 
synaptic plasticity in the spinal cord dorsal hom. 
In studies 3.1 and 3.2, in-situ hybridisation techniques were used to investigate the 
expression of key neurotransmitters and intracellular signalling pathways implicated in 
nociceptive transmission, many of which have also been implicated in the induction and 
maintenance of L TP and LTD in higher centres (discussed in chapter 1). Since it has been 
speculated that persistent changes in central nociceptive transmission may represent L TP 
and LTD of dorsal hom neurotransmission, leading to the development of a 'memory of 
pain' in the dorsal hom as a mechanism for persistent pain sensation, it was of interest to 
correlate expression of genes known to mediate synaptic plasticity in higher centres, with 
the plasticity of nociceptive behaviour observed in studies 2.1 and 2.2. 
The agents investigated were: the kinase enzyme CaMKIIa, an intracellular mediator 
activated by intraneuronal calcium ion influx which phosphorylates (and thus covalently 
modifies) key proteins involved in neurotransmitter production and release; the immediate 
early genes zif/268, tPA and jun D, which are rapidly and independently activated by 
neuronal stimulation; the cyclo-oxygenase enzymes COX-I, and COX-2, which catalyse 
prostaglandin synthesis, and the precursor genes for key 'inhibitory' neurotransmitters, 
proenkephalin, prodynorphin and glutamic acid decarboxylase [GAD, which catalyses 
synthesis of y-amino-butyric acid (GABA) and is entirely restricted to GABAergic 
neurons]. Gene expression was investigated in the superficial laminae (IIII) and in lamina 
V of the lumbar spinal dorsal hom, key laminae involved in central processing of 
nociceptive information and the major targets of investigations into plasticity of central 
nociceptive transmission (reviewed in chapter 1 ). 
Identification of specific regional and cellular sites of gene expression within nervous 
tissue using in-situ hybridisation (ISH) techniques was first described by Gee et al.(1983), 
and subsequently characterised and developed in greater detail by Lewis et al.(1985; 1988) 
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and Young et al.(1986 a;b). ISH provides a highly sensitive method of identification of 
mRNA expression. A nucleic acid probe tagged with radiolabelled nucleotides (or other 
molecules which permit colorimetric or light detection) is hybridised directly onto a tissue 
section where it recognises its cognate mRNA to form a stable probe-RNA duplex 
(reviewed by Wisden & Morris, 1992). After removing surplus probe, tissue sections are 
either exposed for autoradiography or processed histochemically to reveal specific sites of 
gene expression. Synthetic deoxyribonucleotides are now the predominant form of nucleic 
acid probe used in ISH studies, having been proven to be generally more specific, more 
reliable and more resilient to repeated use than alternative forms of complementary DNA 
and RNA nucleic acid probes (Wisden & Morris, 1992). 
3.2 MATERIALS AND METHODS 
In-situ hybridisation was performed according to the method described by Morris et al. 
(1986) and reviewed by Wisden & Morris (1994). 
3.2.1. Probe design 
Base sequences for probes were obtained from the U.S. National Centre for Biotechnology 
(USA). Synthetically produced probes were commercially synthesised on an Applied 
Biosystems DNA synthesiseI' by Genosys Biotechnologies (Europe) Ltd.. Probes were 
stored at -200 C and used at a working concentration of 5ngl Ill. The following sequences 
were used in in-situ hybridisation studies (5' -3 '): 
Tubulin T26 (45-mer) complementary to a section of the 3' non-coding region: (Miller et 
al., 1987) 
Preproenkephalin (45mer) complementary to bases 388-432 of the predicted gene 
sequence (Howells et al., 1984; Yoshikawa et aI., 1984) 
Prodynorphin (45-mer) complementary to base sequences 862-906 of the predicted gene 
sequence (Civelli et al., 1985) 
Cyclo-oxygenase-1 (COX-1) (45mer), complementary to nucleotides spanning amino 
acids 13-28 (Feng et al., 1993; Yamagata et al., 1993) 
Cyclo-oxygenase-2 (COX-2) (45mer) (Feng et al., 1993; Yamagata et al., 1993) 
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Calcium calmodulin kinase II, a-subunit (45mer) complementary to nucleotides spanning 
amino acids 408-422 (Lin et al., 1987) 
Zif/268 (45-mer), complementary to nucleotides spanning amino acids 2-16 (Millbrand, 
1987) 
Tissue plasminogen activator (TP A) (45mer) complementary to nucleotides spanning 
amino acids 265-280 (Ny et al., 1988) 
GAD 67 (45mer) complementary to base sequence published by Julien et al.(1990) 
CCTGCACACATCGGTTGCATCCTTGGAGTATACCCTTTCCTTG 
Jun-D (45mer) complementary to nucleotides corresponding to the last 20 amino acids of 
the predicted protein (Ryder et al., 1989) 
3.2.2. Probe labelling protocol 
0.9 Ill. diethylpyrocarbonate (DEPC)-treated water 
1.25 Ill. lOx terminal deoxynucleotidyl transferase( TdT) tailing buffer (Pharmacia) 
1.5 Ill. oligonucleotide probe (5 11g/ fll) 
2.0 Ill. 35S d-ATP 
0.6 Ill. terminal deoxynucleotidyl transferase (TdT) [Pharmacia] 
Reagents were dispensed in the order listed above into a 1.5ml eppendorf tube, pipette-
mixed and incubated at 35-37 °C for approximately 2 hours. Following incubation, 60 Ill. 
of sterile DEPC-treated water was added to the incubation mixture to arrest TdT enzyme 
activity. 
3.2.3. Purification of labelled oligonucleotide probes 
The radiolabelled oligonucleotide solutions were transferred into biospin-6 
chromatography spin columns (Biorad Ltd., U.K.) in order to remove non-incorporated 
nucleotides from the reaction mixture. The columns were inverted several times to 
resuspend settled gel. The tip was removed from the 1.5ml gel tube and excess buffer 
drained into an eppendorf tube positioned below it. Spin columns were centrifuged for 2 
minutes at 1000rpm in a swinging bucket centrifuge until all buffer had drained from the 
gel. The reaction mixture was carefully applied drop-wise to the centre of the column and 
the column re-centrifuged for 4 minutes at 1000 r.p.m. 
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3.2.4. Analysis of purified probes 
2 Ill. of purified eluate was mixed into 4ml of scintillation fluid and specific radioactivity 
measured using a liquid scintillation counter. The oligonucleotide probe was considered 
'labelled' and suitable for use if a count of between 100,000 and 300,000 counts per III 
was obtained. Having confirmed the success of the labelling reaction, 2 III of 1 molar 
dithiothreitol (DTT, Sigma) was added to the probe to provide protection against oxidative 
damage during storage. Labelled probes were stored at -20°C and freeze-thawed for 
repeated use for up to a month. 
3.2.5. Tissue preparation 
Preparation of poly-I-lysine coated slides 
Slides were coated in a O.lmg/ml solution of poly-L-lysine hydrobromide (P-1524, 
SIGMA, u.K.) in DEPC-treated water to optimise adhesion of tissue sections. Slides were 
wrapped in aluminium foil and baked for 4-6 hours at 180°C then immersed in poly-L-
lysine solution, air-dried and stored in aluminium foil at 4°C. 
Spinal cord ejection 
Fresh spinal cord tissue was prepared using a method described by Meikle et al.(1981). 
Following euthanasia, the vertebral column was dissected and the vertebral canal exposed. 
A pipette tip was inserted into the caudal end of the canal and sterile 0.9% saline injected 
at constant pressure to expel the spinal cord from the cervical extremity of the canal. The 
lumbar enlargement of the cord was excised, snap-frozen in liquid nitrogen then stored at -
70° C. 20 Ilm sections of lumbar spinal cord were cryostat-cut (Reichert-Jung) and thaw-
mounted onto poly-L-lysine coated slides. Slides were air dried for 20 minutes, fixed in 
ice-cold 4% depolymerised paraformaldehyde (PF A) dissolved in IX PBS buffer solution 
for 5 minutes; rinsed in Ix phosphate-buffered saline (PBS) for 10 minutes and dehydrated 
in serial dilutions of ANALAR ethanol. Slides were stored in 100% ANALAR ethanol at 
4°C prior to use. 
3.2.6. Hybridisation of radio nucleotide probes onto tissue sections 
Labelled probes were diluted in hybridisation buffer for application onto slides. The 
buffer was prepared according to the protocol described below: 
10ml of 20x stock sodium citrate (SSC) and 25ml of 100% de-ionised formamide, de-
ionised using 'Amberlite' MB-l mixed resin beads, were gently mixed in a sterile 
graduated polypropylene (Falcon) tube. To this mixture was added: 
2.5ml 0.5M sodium phosphate 
0.5ml sodium pyrophosphate 
1ml 5mglml polyadenylic acid 
5g dextran sulphate 
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DEPC-treated water was added to give a total volume of 50 ml. The buffer mix was gently 
mixed on a rocking platform overnight and stored at 4°C. 
Radiolabelled probe was diluted in hybridisation buffer in a ratio of 200)ll of 
probelhybridisation buffer. I)ll of probe and 4)l1 of I M DTT were added to each 100)ll of 
hybridisation buffer and mixed thoroughly to overcome the tendency of the high-viscosity 
hybridisation buffer to displace the low-density probe. 200)l1 of labelled hybridisation 
mixture was applied to each slide. Slides were covered with a parafilm coverslip and air 
bubbles removed by gentle pressure, then placed on an elevated 'platform' in a petri dish. 
4X SSC-saturated tissue was placed beside the slides to prevent dehydration during 
incubation. Petri dishes were then sealed and incubated overnight at 42° C. Fifty-times 
excess concentration of unlabelled probe was added to hybridisation buffer and applied to 
selected sections to assess non-specific binding of probe to tissue. 
mRNA present in tissue sections strongly hybridised to the probe during incubation to 
form a region of double stranded nucleic acid, which was resistant to single-stranded 
RNA'ase attack. Deionised water was used for all washing procedures. Coverslips were 
removed in a solution of I X stock sodium citrate (SSC) and sections were washed in pre-
warmed SSC at 55-60° C for 30 minutes. Sections were finally passed through a series of 
room temperature rinses, spending a few seconds in each, of IXSSC, O.IX SSC, 70% 
analytical grade (AR) ethanol, 95% (AR) ethanol and air dried before exposure to 
radiographic film. 
3.2.7. Exposure of hybridised tissue to radiographic film 
Sections were stabilised on blank paper using double-sided adhesive tape and exposed to 
radiographic film (Kodak Bio-Max MR 20.3 x 25.4cm) for 3-20 days depending on the 
labelling-intensity of the probe and the predicted abundance of specific mRNA in tissue 
sections. Exposed film was developed in D-19 (Kodak) developer for 3 minutes, rinsed in 
water for 1 minute and fixed in UNIFIX solution for 3 minutes. 
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3.2.8. Photographic emulsion coating of slides 
Emulsion coating was performed under safelight in a water bath set at 45° C. Ilford K5 
photographic emulsion was dissolved in 0.5% Glycerol at 45° C, in a ratio of 1: 1. Each 
slide was dipped into emulsion and then allowed to air dry for 6 hours. Dry slides were 
placed in a light-resistant box containing a few grains of silica gel to protect against 
oxidation and stored at 4 °C for 5 times as long as the length of exposure time required to 
produce a visible signal on radiographic film. 
3.2.9. Development and counterstaining of emulsion-dipped slides 
Exposed slides were developed in D-19 Kodak developer for 2 minutes, rinsed in water for 
30 seconds, fixed in freshly-prepared 30% sodium thiosulphate solution for 2 minutes and 
rinsed in distilled water for 20 minutes. Slides were then immersed in neutral red solution 
for 45 minutes, rinsed, and dehydrated in serial dilutions of ethanol. Counterstained slides 
were transferred to histoclear solution (National Diagnostics) overnight and mounted using 
'Histomount' solution and glass coverslips. 
3.2.10 Quantitative analysis of labelled tissue sections 
Study 3.1: Weekly repeated carrageenan treatment 
Semi-quantitative densitometry was performed on the counterstained cells under bright-
field microscopy using a Macintosh image analysis system (Image v.I.52 software, 
[NIH]). Following tissue processing, 4-6 tissue sections from each treatment group at each 
time point were analysed. For each tissue section, measurements were made bilaterally in 
laminae Illl and lamina V of the spinal dorsal hom. The method of analysis used 
depended on the abundance of labelled cells in the tissue section. There was strong 
expression of CamKIla and proenkephalin mRNA in the superficial laminae of the dorsal 
hom such that labelling of individual cells could not be measured. Thus CaMKIla and 
proenkephalin mRNA expression in laminae IIll were quantified by measuring the mean 
relative optical density (M.R.O.D.) of two regions of fixed size within the superficial 
laminae in each lumbar section (n = 4-6 in each group). 
mRNA expression of all other oligonucleotide probes in laminae IIll and lamina V, with 
the exception of COX-I and COX-2, was performed by analysing six regions 
corresponding to counterstained cells within each lamina on each side, measuring the mean 
relative optical density of silver-grain clustering (M.R.O.D.), indicating labeling intensity, 
and the major axis of each cell, indicating cell size. COX-l and COX-2 mRNA expression 
in study 1 were analysed using the method used for all oligonucleotide probes in study 2. 
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Study 3.2: Daily repeated carrageenan treatment 
Spinal cord was harvested from saline-treated animals euthanased at 1h p.i. and 6 h p.i. on 
days 1 and 5 (n = 4 at each time point on each day). In each section, the density of silver 
grains clustered over individual counterstained cells was measured under bright-field 
microscopy using a KS400 image analysis system (USA). Measurements were made 
bilaterally in the superficial laminae (I-II) and lamina V of the dorsal horn. Six counter-
stained cells were measured in both ipsilateral and contralateral laminae IIII and V, 
producing a total silver-grain count and diameter (in ).lm) for 6 positively labelled cells. 
The mean silver-grain count/cell, mean cell diameter and mean silver-grain count/unit area 
were thus calculated in ipsilateral and contralateral laminae IIII and V. 
3.2.11 Statistical analysis 
In studies 3.1 and 3.2, analysis of variance techniques supplemented by the Tukey-Kramer 
test for multiple comparisons were used to investigate the effects of repeated carrageenan 
treatment on mRNA expression of labelled probes in the laminae IIII and in lamina V. 
GLM analysis and Tukey-Kramer multiple comparison tests were used to compare mRNA 
expression (quantified as M.R.O.D). in study 3.1, and total silver-grain count/cell in study 
3.2) and cell diameter between treatment groups at each time point. Within each treatment 
group, GLM analysis was used to compare ipsilateral and contralateral mRNA expression 
and cell diameter at each time point. GLM analysis and Tukey-Kramer multiple 
comparison tests were used to investigate the effect of weekly (study 3.1) or daily (study 
3.2) repeated treatment on ipsilateral and contralateral mRNA expression. 
3.3 RESULTS 
3.3.1. CALCIUM CALMODULIN KINASE IIa 
Basal CaMKIIa rnRNA expression 
Preliminary studies of CaMKIIa mRNA expression in spinal cord tissue taken from 
untreated control animals demonstrated constitutive expression of CaMKIIa mRNA in 
spinal cord grey matter. In studies 3.1 and 3.2, CaMKIIa positive cells were observed 
throughout the grey matter of the lumbar spinal cord and in the hippocampus. The absence 
of CaMKIIa mRNA expression in tissue sections labelled with fifty-times excess 
unlabelled probe confirmed probe specificity. Cells in the superficial laminae (II II) 
expressing CaMKIIa mRNA were of uniform 8-15 ).lm diameter. CaMKIla positive cells 
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in huninae V varied in diameter from 8- 32 )..Lm, although the majority of cells, counted 
were 25-32 )..LID., There'was no significant difference between treatment groups in the 
diameterofCaMKIIa. positive cells. CaMKIIa. labelled cells in the lumbar spinal cord of 
carrageenan and saline-treated animals are shown in Figure 3.1. 
Study J.1: Weekly repeated carrageenan treatment 
Laminae IIll 
CaMKIIa. mRNA expression in laminae IIll in study 3.1 is shown in Figure 3.2. 
Treatment effect 
-, . 
.. ,,,,, 
.. ~. 
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GLM analysis indicated a significant treatment effect on ipsilateral, but not contralateral, 
CaMKIIa. mRNA expression in laminae IIII (F[2,58] = 3.42, P < 0.05) and'F[2,58] = 1.36, 
P = 0.26 respectively). Further analysis indicated that ipsilateral CaMKIIa. mRNA 
expression was significantly upregulated in 0.5% carrageenan-treated animals relative to 
saline-treated animals (p < 0.01) and relative to 0.1% carrageenan-treated animals (p < 
0.05). CaMKIIa. mRNA expression in 0.1% carrageenan animals was not significantly 
different from that of saline-treated animals. More detailed analysis did not indicate a 
significant treatment effect on ipsilateral mRNA expression on any particular week of the 
study. 
Ipsilaterallcontralateral effect 
Saline treatment did not alter ipsilateral CaMKIIa. mRNA expression (relative to 
contralateral expression) on any week of the study. In 0.5% carrageenan-treated animals, 
CaMKIIa. mRNA was up-regulated ipsilaterally on all 4 weeks of the study but only 
significantly so on weeks 2 (F[ 1,11] = 7.59, P < 0.05) and week 3 (F[l,ll] = 6.27, P < 
0.05); considerable variation in ipsilateral CamKIIa. mRNA expression was observed on 
week 1. In 0.1 % carrageenan-treated animals, CaIvlKIIa. mRNA was up-regulated 
ipsilaterally on week 2 (F[1,1l] = 6.88, P < 0.05) and week 4 (F[l,ll] = 8.1, p < 0.05). 
Figure 3.1 CaMKIIa mRNA expression 
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Figure 3.2: Study 3.1: CaMKIla mRNA expression in laminae 1111 
Expression of CaMKIIa mRNA, expressed as the mean ± SEM mean relative optical 
density (M.R.O.D.) of silver-grain expression in ipsilateral (A) and contralateral (B) 
laminae IIII of lumbar spinal cord, measured in animals euthanased 6 hours following 
intraplantar injection of 50 III of 0.5% carrageenan (0.5% Cx), 0.1 % carrageenan (0.1 % 
Cx) or 0.9% saline (n=4-6/group). 
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Effect of repeated treatment 
Weekly repeated treatment did not alter the magnitude of ipsilateral or contralateral 
CaMKIIa mRNA expression in any treatment group. 
Lamina V 
In lamina V there was no significant treatment effect, no significant ipsilateral/ 
contralateral effect and no effect of repeated treatment on CaMKIIa mRNA expression. 
Study 3.2: Daily repeated carrageenan treatment 
Laminae 1111 
CaMKIIa mRNA expression in laminae IIII in study 3.2 is shown in Figure 3.3 
Treatment effect 
No significant treatment effect was observed in ipsilateral or contralateral laminae IIII at 1 
h p.i. or at 6 h p.i. on day 1 or day 5. 
Ipsilateral!contralateral effect 
In carrageenan-treated animals, CaMKIIa mRNA expression was not upregulated 
ipsilaterally (relative to contralateral expression) at 1h p.i. on any day of the study. At 6h 
p.i., CaMKIIa mRNA expression was upregulated ipsilaterally on each day of the study: 
day 1 (F[1,3] = 11.58, p < 0.05), day 2 (F [1,3] = 48.25, p < 0.01, day 3 (F[1,3] = 119.86, 
p < 0.01) and day 5 (F[1,3] = 80.43, p < 0.01). 
In saline-treated animals, CaMKIIa mRNA expression was upregulated ipsilaterally at 1h 
p.i. on day 1 (F [1,3] =12.99, p < 0.05), but not day 5 (F [1,3]= 0.47, p = 0.54). At 6 hpj., 
CaMKIIa mRNA expression was not upregulated ipsilaterally (relative to contralateral 
expression) on day 1 (F [1,3] =7.41, p = 0.07) or day 5 (F [1,3]=3.51, P = 0.16). 
Effect of repeated treatment 
In carrageenan-treated animals at 1 h p.i., daily repeated treatment did not alter ipsilateral 
(F [3,9] =1.31, P = 0.33) or contralateral (F [3,9] =0.98, p = 0.45) CaMKIIa rnRNA 
expressIOn. At 6h pj. there was a significant effect of repeated treatment on both 
ipsilateral (F [3,9] = 13.83, p < 0.001) and contralateral (F[3,9] = 7.88, p < 0.01) CaMKIIa 
mRNA expression. Ipsilateral expression was significantly lower on day 3 than on days 1 
(p < 0.01), 2 (p < 0.01) and day 5(p < 0.01). Contralateral mRNA expression was 
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Figure 3.3: Study 3.2: CaMKIIa mRNA expression in laminae 1111 
Expression of CaMKIIa mRNA, expressed as the mean ± SEM mean silvergrain count/cell 
of silver-grain expression in ipsilateral (A) and contralateral (B) laminae lIII of lumbar 
spinal cord, measured in animals euthanased Ih or 6h following intraplantar injection of 50 
III of 0.1 % carrageenan or 0.9% saline (n=4/group). 
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significantly higher on day 1 than on day 3 (p < 0.02) and day 5 (p < 0.05). Contralateral 
expression was significantly higher on day 2 than on day 3 (p < 0.05). 
In saline-treated animals at 1 hpj. there was a significant effect of repeated treatment on 
contralateral (F [1,3] = 32.46, P < 0.05) but not ipsilateral (F[1,3] = l.16, P = 0.36) 
CaMKIIa mRNA expression. At 6h pj., repeated saline treatment did not alter ipsilateral 
or contralateral CaMKIIa mRNA expression (F[1,6] = 6.63, p = 0.08) and F[1,6]=l.16, p = 
0.36 respectively). 
Lamina V 
CaMKIIa mRNA expression in lamina V in study 3.2 is shown in Figure 3.4. 
Treatment/time effect 
On day 2, ipsilateral CaMKIIa mRNA expression was significantly higher at 1h pj. than 
at 6h pj. in carrageenan-treated animals (p < 0.05). There was no other significant 
treatment! time effect on ipsilateral or contralateral CamKIIa mRNA expression on days 1, 
3 or 5. 
Ipsilateral/contralateral effect 
Ipsilateral CaMKIIa mRNA expression was not upregulated (relative to contralateral 
expression) at lh or 6h pj. following carrageenan or saline treatment on any day of the 
study. 
Effect of repeated treatment 
In carrageenan-treated animals at 1 hpj., there was a significant effect of repeated 
treatment on contralateral, (F[3,9] = 3.87, P < 0.05) but not ipsilateral, CaMKIIa mRNA 
expression. Contralateral CaMKIIa mRNA expression was significantly higher on day 5 
than day 1 (p < 0.05). At 6h pj., there was a significant effect of repeated treatment on 
ipsilateral CaMKIIa mRNA expression (F[3,9] = 3.75, P < 0.05). Ipsilateral expression 
was significantly higher on day 3 than day 1 (p < 0.05). There was no effect of repeated 
saline treatment on ipsilateral or contralateral CaMKIIa mRNA expression. 
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Figure 3.4: Study 3.2: CaMKIla mRNA expression in lamina V 
Expression of CaMKIIa mRNA, expressed as the mean ± SEM mean silvergrain count/cell 
of silver-grain expression in ipsilateral (A) and contralateral (B) lamina V of lumbar spinal 
cord, measured in animals euthanased 1 h or 6 h following intraplantar injection of 50 JlI of 
0.1 % carrageenan or 0.9% saline (n = 4/group). 
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3".3'.2' ZIF /Z68, 
Basal Zif/268' mRNA expressiorr 
There was no significant difference between groups in the· diameter of cells expressing zifl 
268 mRNA ,nor in the number of zifl268 mRNA positive cells. There was considerable 
inter-individual variation in the intensity of zifl268· mRNA expression. Zifl268 labell~~ 
cells in the lumbar spinal cord of carrageenan and saline-treated animals are shown ill 
Figure 3.5. 
Study 3.1: Weekly repeated carrageenan treatment 
Laminae IIII 
Zifl268 mRNA expression in laminae IIII in study 3.1 is shown in Figure 3.6 
Treatment effect 
GLM analysis indicated no significant treatment effect on ipsilateral or contralateral 
zifl268 mRNA expression in laminae IIII. 
Ipsilaterallcontralateral effect 
Zifl268 mRNA expression was upregulated in the ipsilateral cord (relative to the 
contralateral cord) in animals treated with 0.5% Cx (F[I,19] = 5.12, P <0.05); further 
analysis indicated that this effect occurred on week 1 (p < 0.05) and week 3 (p < 0.05) and 
was close to significance on week 2 (p = 0.07). Zifl268 mRNA expression was 
upregulated in the ipsilateral cord (relative to the contralateral cord) in animals treated.with 
0.1 % Cx on week 1 (p < 0.05) and was close to significance on week 2 (p = 0.067). 
Zifl268 mRNA expression was upregulated in the ipsilateral cord (relative to the 
contralateral cord) in saline-treated animals (F[I,27]=4.29, p <0.05), although post-hoc 
analysis did not indicate a particular week on which this effect was observed. 
Effect of repeated treatment 
Weekly repeated treatment did not alter the intensity of zifl268 mRNA expression in 
ipsilateral or contralateral laminae IIII in carrageenan or saline-treated animals. 
Lamina V 
Zifl268 mRNA expression in lamina V in stUdy 3.1 is shown in Figure 3.7. 
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Figure 3.5: zif/268 mRNA expression 
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Figure 3.6: Study 3.1: Zif/268 mRNA expression in laminae 1111 
Expression of zifl268 mRNA, expressed as the mean ± SEM mean relative optical 
density (M.R.O.D.! cell in ipsilateral (A) and contralateral (B) laminae lIII of lumbar 
spinal cord, measured in animals euthanased 6 hours following intraplantar injection 
of 50 ~l of 0.5% carrageenan (0.5% Cx), 0.1 % carrageenan (0.1 % Cx) or 0.9% saline 
(n=4-6/ group). 
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Figure 3.7: Study 3.1: Zifl268 mRNA expression in lamina V 
Expression of zif/268 mRNA, expressed as the mean ± SEM mean relative optical density 
(M.R.O.D.! cell in ipsilateral (A) and contralateral (B) lamina V of lumbar spinal cord, 
measured in animals euthanased 6 hours following intraplantar injection of 50 III of 0.5% 
carrageenan (0.5% ex), 0.1% CalTageenan (0.1% ex) or 0.9% saline (n=4-6/group). 
following intraplantar injection of 50 III of 0.5% canageenan (ex), 0.1 % ex or 0.9% 
saline. 
150 
d 1001 
n:: 
:E 
50 
o 
100 
75 
c 
d 
n:: 50 
:E 
25 
o 
A: ipsilateral zif 268 mRNA expression in 
lamina V 
- 0.5% ex 
II - 0.1% ex T - saline 
2 3 4 
Week 
B: contralateral zif 268 mRNA expression 
in lamina V 
- 0.5% ex 
- 0.1% ex 
- saline 
1 2 3 4 
Week 
160 
Treatment effect 
There was no treatment effect on the intensity of ipsilateral or contralateral zif/268 mRNA 
expression on any week of the study. 
Ipsilateral/contralateral effect 
Zif1268 mRNA expression was upregulated in the ipsilateral cord (relative to the 
contralateral cord) in animals treated with 0.1% carrageenan (F[I,27] = 7.23, P < 0.01), 
although more detailed analysis did not indicate any particular week on which this effect 
was observed. Zif1268 mRNA expression was not upregulated in the ipsilateral cord 
(relative to the contralateral cord) observed in 0.5% carrageenan or saline-treated animals. 
Effect of repeated treatment 
Weekly repeated treatment did not alter ipsilateral or contralateral Zif268 mRNA 
expression in lamina V in any treatment group. 
Study 3.2: Daily repeated carrageenan treatment 
Laminae 1111 
Zif/268 mRNA expression in laminae IIII in study3.2 is shown in Figure 3.8. 
Treatment effect 
There was no significant effect of treatment on ipsilateral or contralateral zif/268 mRNA 
expression at 1 hpj. or 6 hpj. on day 1 or day 5. In carrageenan-treated animals, 
contralateral zif/268 mRNA expression was significantly enhanced at 1 hpj. relative to 6 
hpj. on day 2 (F[3,7] = 17.39 , P < 0.05) but this effect was not observed on any other 
day. 
Ipsilaterallcontralateral effect 
In carrageenan-treated animals, ipsilateral zif/268 mRNA expression was upregulated 
(relative to contralateral expression) at Ih pj. on day 1 (F[I,3] = 32.17, P <0.01) and day 
3 (F [1,3] = 14.27, P < 0.05), and was close to significance on day 2 (F [1,3] = 8.67, P = 
0.06) but not on day 5 (F[I,3] = 3.79, p= 0.15. Ipsilateral zif/268 mRNA expression was 
upregulated (relative to contralateral expression) at 6 hpj. expression on day 2 (F[I,3] = 
8.42, P <0.05), day 3 (F[I,3] =34.28, P < 0.001) and day 5 (F[I,3] = 29.34, P < 0.01), and 
was close to significance on day I(F [1,3] = 5.37, P = 0.06). 
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Figure 3.8: Study 3.2: Zif 268 mRNA expression in laminae 1111 
Expression of zif/268 mRNA, expressed as the mean ± SEM mean silvergrain count/cell of 
silver-grain expression in ipsilateral (A) and contralateral (B) laminae IIII of lumbar spinal 
cord, measured in animals euthanased 1 h or 6 h following intraplantar injection of 50 )..ll of 
0.1 % carrageenan or 0.9% saline (n = 4/group). 
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Figure 3.9: Study 3.2: zif/268 mRNA expression in lamina V 
Expression of zif/268 mRNA, expressed as the mean ± SEM mean silvergrain count/cell of 
silver-grain expression in ipsilateral(A) and contralateral(B) lamina V of lumbar spinal 
cord, measured in animals euthanased 1 h or 6 h following intraplantar injection of 50 I ..d of 
0.1 % carrageenan or 0,9% saline (n = 4/group), 
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In saline treated animals, ipsilateral zifl268 mRNA expression was upregulated (relative 
to contralateral expression) at 1h pj. on day 1 (F[1,3] = 16.87, P < 0.05) and day 5 (F [1,3] 
= 15.75, P < 0.05). Ipsilateral zifl268 mRNA expression was also up regulated (relative to 
contralateral expression) at 6h pj. on day 1 (F[1,3] = 108.38, P < 0.01 and day 5 (F 
[1,3]=39.12, P < 0.01). 
Effect ofrepeated treatment 
In carrageenan treated animals, there was a significant effect of daily repeated treatment on 
contralateral (but not ipsilateral) zifl268 mRNA expression at 1 h p.i. (F[3,9] = 5.03, P < 
0.05); post-hoc analysis did not indicate a particular day on which this effect occurred 
although the difference was close to significance on day 1 (p = 0.07) and day 3 (p = 0.07). 
At 6h p.i. there was no effect of repeated carrageenan treatment on ipsilateral or 
contralateral zifl268 mRNA expression. In saline treated animals there was no effect of 
daily repeated treatment on contralateral zifl268 mRNA expression at 1h p.i. or 6 h p.i. 
Ipsilateral zifl268 mRNA expression at 1h p.i. was significantly higher on day 5 than day 1 
(F[1,3] = 12.63, P < 0.05). Daily repeated treatment did not alter the intensity of ipsilateral 
zif/268 mRNA expression at 6h pj. 
Lamina V 
Zifl268 mRNA expression in lamina V in study 3.2 is shown in Figure 3.9. 
Treatment effect 
There was no significant treatment effect on ipsilateral or contralateral zif/268 mRNA 
expression at 1 h p.i. or 6h p.i. on day 1 or day 5. 
Ipsilaterallcontralateral effect 
In carrageenan treated animals, the intensity of ipsilateral zifl268 mRNA expression did 
not differ from contralateral expression at 1h p.i. or 6 h p.i. on any day of the study. In 
saline treated animals, ipsilateral zifl268 mRNA was upregulated (relative to contralateral 
expression) at 1 h p.i. and 6 h p.i. on day 5 (F [1,3]=21.08 and p < 0.05 and F[1,3]=24.09, 
p < 0.05 respectively) but not on day 1. 
Effect of repeated treatment 
There was no effect of repeated carrageenan or saline treatment on ipsilateral or 
contralateral zif/268 mRNA expression at 1h or 6h p.i. 
3.3.3".. TISSUE. PLASMINOGEN ACTIVATOR 
Basal tP A mRNA expression 
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tP A mRNA expression was detected in a very small number of cells in laminae IIII and 
lamina V. Small numbers of tP A positively labelled cells were observed throughout the 
grey matter of the lumbar spinal cord and in the hippocampus. The absence of tP A mRNA:· 
expression in tissue sections labelled with fifty-times excess unlabelled probe confirmed 
probe specificity. Cells in laminae IIII expressing tP A rnRNA were of uniform 8-15 J.lm 
diameter. tP A positive cells in laminae V varied in diameter from 8-32J.lm. There was no 
significant difference between treatment groups in the diameter of tP A positive cells. TP A 
labelled cells in the lumbar spinal cord of carrageenan and saline-treated animals are 
shown in Figure 3.10. 
Study 3.1: Weekly repeated carrageenan treatment 
Laminae IIII 
TP A rnRNA expression in laminae IIn in study 3.1 is shown in Figure 3.11. 
Treatment effect 
Carrageenan treatment (relative to saline treatment) did not alter the number of tP A mRNA 
positively labelled cells in ipsilateral or contralateral laminae IIn on any week of the study. 
Ipsilaterallcontralateral effect 
In 0.5% carrageenan-treated animals, more tP A positive cells were identified in ipsilateral 
(relative to contralateral) laminae IIn on week 1 (F[I,6]=6.76, p<0.05) but not on weeks 2, 
3 or 4. 
Effect of repeated treatment 
Weekly repeated carrageenan or saline treatment did not alter the number of tP A mRNA 
positively labelled cells in ipsilateral or contralaterallaminae IIn. 
Lamina V 
Treatment effect 
Carrageenan treatment did not alter the tPA mRNA positive cell count (relative to saline 
treatment) in ipsilateral or contralateral lamina Von any week of the study. 
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Figure 3.11: Study 3.1: Expression of tP A mRNA expression in laminae 1111 
Expression of tissue plasminogen activator (tPA) mRNA, expressed as the mean ± SEM 
number of cells expressing tPA in ipsilateral (Graph A) and contralateral (Graph B) 
laminae 11II of lumbar spinal cord, measured in animals euthanased 6 hours following 
intraplantar injection of 50 /-tl of 0.5% carrageenan (0.5% Cx), 0.1 % carrageenan (0.1 % 
Cx) or 0.9% saline (n = 4-6/group). 
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Ipsilateral/contralateral effect 
Carrageenan and salfue treatment did not alter the ipsilateral" (relative' to contralateral) tP A 
positive cell count in lamma Von any week of the study. 
....~ 
Effect of repeated treatment 
There was no effect of weekly repeated carrageenan or saline treatment on the ipsilateral 
or contralateral tP A positive cell count. 
3.3.4. JUND 
Basal Jun D mRNA expression 
Jun D mRNA positive cells were observed throughout the grey matter of the lumbar spinal 
cord and in the hippocampus. The absence of Jun D mRNA expression in tissue sections 
labelled with fifty-times excess unlabelled probe confirmed probe specificity. Cells in the 
superficial laminae (II II) expressing Jun D mRNA were of uniform 8-ISllm diameter. Jun 
D positive cells in laminae V varied in diameter from 8-32Ilm. There was no significant 
difference between treatment groups in the diameter of Jun D positive cells. JunD 268 
labelled cells in the lumbar spinal cord of carrageenan and saline-treated animals are 
shown in Figure 3.12. 
Study 3.2: Daily repeated carrageenan treatment 
Laminae IJll 
Jun D mRNA expression in laminae IIII in study 3.2 is shown in Figure 3.13. 
Treatment effect 
There was no significant treatment effect on the intensity of ipsilateral or contralateral Jun 
D mRNA expression at Ih pj. or 6h pj. on day 1 or day S. 
Ipsilaterallcontralateral effect 
In carrageenan-treated animals, Jun D mRNA was significantly upregulated in ipsilateral 
(relative to contralateral) laminae fJII at lh pj. on day 1 (F[I,3] = 24.82, P < O.OS), and 
was close to significance on day 2 (F[I,3] = 9.28,p=0.06), day 3 (F[1,3] = 9.S8, p =0.06) 
and day 5 (F[1,31 = 8.75, P = 0.06). At 6h pj., ipsilateral Jun D mRNA expression was 
upregulated (relative: to contralateral" expression) on day 1 (F[1,3] = 12.48, p< 0.05) and 
day 5 (FCI,3] = 11.2r~p-<0.05) ~d was close to significance on days 2 (F[I,3] = 8.88, P = 
:;:r.. 
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Figure 3.13: Study 3.2: Jun D mRNA expression in laminae IIII 
Expression of Jun D mRNA, expressed as the mean ± SEM mean silvergrain count/cell of 
silver-grain expression in ipsilateral(A) and contralateral(B) laminae IIII of lumbar spinal 
cord, measured in animals euthanased 1h or 6 h following intraplantar injection of 50 f-LI of 
0.1 % carrageenan or 0.9% saline (n = 4/group). 
= 
Q) 
o 
40 
40 
;:; 30 
c: 
::::s 
o 
o 
.= 20 cv 
~ 
Cl 
~ 
Q) 
~ 10 
t/) 
A: ipsilateral junO mRNA expression in 
laminae 1/11 
5 
B: contralateral junO mRNA expression in 
laminae 1/11 
~Cx1h 
_ Cx6h 
~Cx1h 
_ Cx6h 
~saline 1h 
_ saline6h 
w.· .... 1 saline 1 h 
IZ5Zl saline 6h 
2 3 5 
Day 
., . 
170 
Figure 3.14: Study 3.2: Jun D mRNA expression in lamina V 
Expression of jun D mRNA, expressed as the mean ± SEM mean silvergrain count/cell of 
silver-grain expression in ipsilateral(A) and contralateral(B) lamina V of lumbar spinal 
cord, measured in animals euthanased Ih or 6 h following intraplantar injection of 50 f!l of 
0.1 % carrageenan or 0.9% saline (n = 4/group). 
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0.06) and day 3 (F[1,3J =7.98, p = 0.07). In saline-treated animals, Jun D mRNA was 
significantly upregulated in ipsilateral (relative to contralateral) laminae IIII at 1 hpj. on 
day 1 (F[1,3J = 2l.2, P < 0.02) and day 5 (F[1,3J = 42.01, P < 0.01) and also at 6h pj. on 
day 1 (F[1,3J = 26.31, P < 0.01) and day 5 (F [1,3J = 40.67, P < 0.01). 
Lamina V 
Jun D mRNA expression in laminae V in study 3.2 is shown in Figure 3.14. 
Treatment effect 
There was no significant treatment effect on ipsilateral or contralateral Jun D mRNA 
expression at 1 hpj. or 6 h p.i. on day 1 or day 5. 
Ipsilaterallcontralateral effect 
Significant downregulation of ipsilateral (relative to contralateral) Jun D mRNA 
expression was observed in carrageenan-treated animals at 6h pj. on day 2 (p < 0.05) and 
day 3 (p < 0.05). In carrageenan-treated animals at 1h pj. and in saline-treated animals at 
1h pj. and 6 hpj., treatment did not alter the intensity of ipsilateral (relative to 
contralateral) Jun D mRNA expression on any day of the study. 
Effect of repeated treatment 
There was no effect of repeated treatment on ipsilateral or contralateral Jun D mRNA 
expression in carrageenan or saline-treated animals at 1h or 6h . 
3.3.5. CYCLO-OXYGENASE ENZYMES 
Basal COX mRNA expression 
Both COX-1 and COX-2 positive cells were observed throughout the grey matter of the 
lumbar spinal cord and in the hippocampus but not in other brain regions, including 
thalamus and hypothalamus. COX-1 labelled cells in the lumbar spinal cord are shown in 
fugure 3.15. COX-2 labelled cells in the lumbar spinal cord are shown in figure 3.19. 
The absence of COX-lor COX-2 mRNA expression in tissue sections labelled with fifty-
times excess unlabelled probe further confirmed probe specificity for COX-1 and COX-2 
mRNA. Cells in the superficial laminae (laminae I and II) expressing COX isoenzyme 
mRNA were of uniform diameter, range 8-l5~m. There was greater variation in the 
diameter of cells expressing COX-l and COX-2 mRNA in laminae V, from 8- 32~m 
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diameter. There was no significant difference between treatment groups in the diameter of 
the cell population expressing mRNA for either enzyme. 
3.3.5.1. COX-l 
Laminae IIII 
COX-1 mRNA expression in laminae IJII in study 3.1 is shown in Figure 3.16. 
Treatment effect 
Carrageenan treatment did not alter the intensity of ipsilateral COX-1 mRNA expression 
relative to saline treatment. There was a significant treatment effect on contralateral COX-
1 mRNA expression (F[2,43] = 3.6, P < 0.05), where 0.5% Cx induced significantly greater 
expression than saline treatment (p < 0.05), however this was not associated with any 
individual week of the study. 
Ipsilaterai!contraiaterai effect 
There was significant ipsilateral (relative to contralateral) upregulation of COX-1 mRNA 
in all treatment groups: 0.5% Cx (F[1,29] = 5.22, P < 0.05, 0.1 % Cx (F[1,27] = 13.74, P < 
0.001 and saline (F[1,29] = 77.00, P < 0.01), however this was not associated with any 
individual week of the study. 
Effect of weekly repeated treatment 
Weekly repeated treatment did not alter COX-l mRNA expression. 
Lamina V 
In lamina V, there was no significant treatment effect, no significant ipsilateral/ 
contralateral effect and no effect of repeated treatment on COX-1 mRNA expression. 
Study 3.2: Daily repeated carrageenan treatment 
Laminae 1111 
COX-l mRNA expression in lamina IIII in study 3.2 is shown in Figure 3.17. 
Treatment effect 
There was no significant treatment effect on ipsilateral or contralateral COX-l mRNA 
expression on day 1 or day 5. 
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Figure 3.16: Study 3.1: COX-l mRNA expression in laminae 1111 
Expression of COX-1 mRNA, expressed as the mean ± SEM silver-grain count/ cell in 
ipsilateral (ipsi) and contralateral (contra) laminae IIII of lumbar spinal cord, measured in 
animals euthanased 6 hours following intraplantar injection of 50 III of 0.5% carrageenan 
(0.5% Cx), 0.1 % CalTageenan (0.1 % Cx) or 0.9% saline (n=4-6/group). COX-1 mRNA 
expression in ipsilateral laminae IIII was significantly greater in 0.5% carrageenan-treated 
animals (relative to saline-treated animals) on week 2 of the study (p < 0.05). 
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Figure 3.17: Study 3.2: COX-l mRNA expression in laminae 1111 
Expression of COX-l mRNA, expressed as the mean ± SEM silver-grain count! cell In 
ipsilateral (A) and contralateral (B) laminae IIII of lumbar spinal cord, measured In 
animals euthanased Ih and 6h following injection of 50 III of 0,1 % carrageenan or 0,9% 
saline (n=4/ group), 
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Figure 3.18: Study 3.2: COX-l mRNA expression in lamina V 
Expression of COX-1 mRNA, expressed as the mean ± SEM silver-grain count! cell m 
ipsilateral (A) and contralateral (B) lamina V of lumbar spinal cord, measured in animals 
euthanased 1h and 6h following injection of 50 )..LI of 0.1 % carrageenan or 0.9% saline 
(n=4! group). 
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Ipsilaterallcontralateral effict 
Carrageenan treatment di<i not alter the intensity of ipsilateral (relative to contralateral) 
COX-1 mRNA expression at L hpj. or 6 h p-j. on any day of the study, although close to 
significance at 6h pj. on day 2 (F [1,3] = 9.71 p = 0.053). Saline treatment did. not alter 
the intensity of ipsilateral (relative to contralateral) COX-l mRNA expression at 1 hpj. of 
6h pj. on any day of the study. ~~: 
Effect of repeated treatment 
Daily repeated treatment did not alter the intensity of ipsilateral or contralateral COX-1 
mRNA expression in carrageenan or saline-treated animals. 
Lamina V " 
COX-1 mRNA expression in lamina V in study 3.2 is shown in Figure 3.18. 
Treatment effect 
On day 1 and day 5, carrageenan treatment did not alter the intensity of ipsilateral or 
contralateral COX-l mRNA expression relative to saline treatment. In both carrageenan 
and saline-treated animals, ipsilateral and contralateral COX-1 mRNA expression at 6h pj. 
were not significantly different from that observed at 1 h p.i. 
In carrageenan-treated animals, contralateral (but not ipsilateral) COX-1 mRNA 
expression was significantly higher at 1h pj. than at 6h p.i. on day 2 (F[l, 3J = 18.00, p< 
0.05) and day 3 (F[1,3J = 26.2, P < 0.01). 
Ipsilaterallcontralateral effect 
Carrageenan treatment did not alter the intensity of ipsilateral (relative to contralateral) 
COX-1 mRNA expression at 1h pj. or 6h p.i. on any day of the study. Saline treatment 
did not alter the intensity of ipsilateral (relative to contralateral) COX-1 mRNA 
expression at 1 h p.i. or 6 h p.i. on day 1 or day 5 of the study. 
Effect of repeated treatment 
Daily repeated treatment did not alter the intensity of ipsilateral or contralateral COX-1 
mRNA expression in carrageenan or saline-treated animals. 
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Figure 3.20: Study 3.1: COX-2 mRNA expression in laminae 1111 
Expression of COX-2 mRNA, expressed as the mean ± SEM silver-grain count/ cell III 
ipsilateral (ipsi) and contralateral (contra) laminae IIII of lumbar spinal cord, measured in 
animals euthanased 6 hours following intraplantar injection of 50 III of 0.5% carrageenan 
(0.5% Cx), 0.1 % carrageenan (0.1 % Cx) or 0.9% saline (n=4-6/group). Both ipsilateral 
and contralateral COX-2 mRNA expression were significantly greater in carrageenan-
treated animals (relative to saline-treated animals) on all three weeks of the study. 
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Treatment effect 
A significant treatment effect on COX-2 mRNA expression was observed in both 
ipsilateral and contralateral laminae lIII (F[2,43] = 43.9, P < 0.001) and F[2,43] = 36.4, p < 
0.001 respectively). Ipsilateral COX-2 mRNA expression was significantly higher in 
carrageenan-treated animals (both 0.5% and 0.1 %) than saline-treated animals (p < 0.001 
for both groups), but there was no significant difference in COX-2 mRNA expression in 
0.5% and 0.1% carrageenan-treated animals. Detailed week-by-week analysis indicated 
carrageenan treatment induced significantly greater ipsilateral COX-2 mRNA expression 
than saline treatment on all 3 weeks of the study [p < 0.05 on week 1, p < 0.001 on weeks 
2 and 3 in 0.5% Cx-treated animals, p < 0.05 on week 1, p < 0.01 on week 2 and p < 0.001 
on week 3 in 0.1 % Cx-treated animals). Contralateral COX-2 mRNA expression was also 
significantly higher in carrageenan-treated animals (both 0.5% and 0.1%) than saline-
treated animals (p < 0.001 for both groups), while there was no significant difference in the 
level of COX-2 mRNA expression in 0.5% Cx and 0.1 % Cx-treated animals. 
Ipsilateral!contralateral effect 
GLM analysis indicated significant ipsilateral (relative to the contralateral) upregulation of 
COX-2 mRNA expression in all treatment groups (0.5% Cx, F[1,29] = 8.19, P < 0.01); 
0.1 % Cx, F[1,27] = 35.4, p < 0.001); saline, F[1,27] = 14.72, P < 0.001). More detailed 
analysis did not indicate significant ipsilateral upregulation of ipsilateral (relative to 
contralateral) COX-2 mRNA expression in saline-treated animals on any particular week 
of the study, while in both 0.5% Cx and 0.1 % Cx-treated animals, significant ipsilateral 
upregulation of ipsilateral (relative to contralateral) COX-2 mRNA was observed on weeks 
1,2 and 3 (p < 0.05 on each week). 
Effect of weekly repeated treatment 
Weekly repeated treatment did not alter ipsilateral or contralateral COX-2 mRNA 
expressIOn. 
Lamina V 
In lamina V, there was no significant treatment effect, no significant ipsilateral! 
contralateral effect and no effect of repeated treatment on COX-2 mRNA expression. 
Study 3.2: Daily repeated carrageenan treatment 
Laminae 1111 
COX-II mRNA expression in laminae lIII in study 3.2 is shown in Figure 3.21. 
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Figure 3.21: Study 3.2: COX-2 mRNA expression in laminae 1111 
Expression of COX-2 mRNA, expressed as the mean ± SEM silver-grain count/ cell III 
ipsilateral (A) and contralateral (B) laminae IIII of lumbar spinal cord measured III 
animals euthanased 1h and 6h following injection of 50 j.ll of 0.1 % canageenan or 0.9% 
saline (n=4/ group). 
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Figure 3,22: Study 3,2: COX-2 mRNA expression in lamina V 
Expression of COX-2 mRNA, expressed as the mean ± SEM silver-grain count/ cell in 
ipsilateral(A) and contralateral(B) lamina V of lumbar spinal cord measured in animals 
euthanased 1h and 6h following injection of 50 Jll of 0.1 % carrageenan or 0.9% saline (n = 
4/ group). 
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Treatment effect 
On day 1, ipsilateral COX-2 mRNA expression was significantly upregulated in 
carrageenan-treated animals (relative to saline-treated animals) at 1 h p.i. (p < 0.01) and at 
6 hpj. (p < 0.01). Ipsilateral COX-2 mRNA expression was significantly higher at 6h pj. 
than at Ihp.i. on day 1 (p< 0.05). On day 5, ipsilateral COX-2 mRNA expression was not 
significantly upregulated in carrageenan-treated animals (relative to saline-treated animals) 
at 1 h p.i. or 6 h p.i. 
On days 2 and 3, the intensity of ipsilateral and contralateral COX-2 mRNA expression at 
6h pj. was not significantly different from that observed at Ih pj. 
Ipsilateral/contralateral effect 
In carrageenan-treated animals, ipsilateral COX-2 mRNA expression was upregulated 
(relative to contralateral mRNA expression) at 1 h p.i. on day 2 (F [1,3] = 26.94, P < 0.02) 
and was close to significance on day 1 and day 3. At 6h pj., ipsilateral COX-2 mRNA 
expression was upregulated (relative to contralateral mRNA expression) on day 1 F[I,3] = 
45.05, P < 0.01, but not on any other day, although close to significance on day 3 (F[I,3] = 
8.92, P = 0.058) and day 5 (F[I,3] = 7.9, P = 0.067). In saline-treated animals ipsilateral 
COX-2 mRNA expression was upregulated (relative to contralateral mRNA expression )at 
Ih pj. on day I(F [1,3] =30.3 , p <0.01) but not on day 5. At 6h p.i., ipsilateral COX-2 
mRNA expression was upregulated (relative to contralateral) on day 1 (F [1,3] = 10.64, P < 
0.05) but not on day 5. 
Effect of repeated treatment 
There was no effect of daily repeated treatment on ipsilateral or contralateral COX-2 
mRNA expression in any treatment group. 
Lamina V 
COX-2 mRNA expression in lamina V in study 3.2 is shown in Figure 3.22. 
Treatment effect 
There was no effect of treatment on ipsilateral or contralateral COX-2 mRNA expression 
on day 1 or day 5. 
Ipsilateral/contralateral effect 
In carrageenan-treated animals, COX-2 mRNA was significantly upregulated in ipsilateral 
(relative to contralateral) lamina Vat Ih pj. on day 2 (F[I,3] = 14.74, p < 0.05) but not on 
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any other day. COX-2 mRNA was not significantly upregulated in ipsilateral (relative to 
contralateral) lamina Vat 6 h p.i. on any day of the study. 
In saline-treated animals, COX-2 mRNA was not significantly upregulated in ipsilateral 
(relative to contralateral) lamina Vat 1 h p.i. or 6 h p.i. on any day ofthe study. 
Effect of repeated treatment 
There was no effect of daily repeated carrageenan or saline treatment on ipsilateral or 
contralateral COX-2 mRNA expression at lh or 6h p.i. on any day of the study. 
3.3.6. PROENKEPHALIN 
Basal proenkephalin mRNA expression 
Preliminary studies of proenkephalin mRNA expression in spinal cord tissue taken from 
untreated control animals demonstrated constitutive expression of proenkephalin mRNA in 
spinal cord grey matter. Proenkephalin mRNA positive cells were observed in superficial 
laminae and elsewhere in the dorsal hom of the lumbar spinal cord, and in the 
hippocampus. The absence of proenkephalin mRNA expression in tissue sections labelled 
with fifty-times excess unlabelled probe confirmed probe specificity. Cells in the 
superficial laminae (IIII) expressing proenkephalin mRNA were of uniform 8-15!J.m 
diameter, while positively-labelled cells in laminae V varied in diameter from 8- 32!J.m. 
There was no significant difference between treatment groups in the diameter of 
proenkephalin positive cells. Proenkephalin labelled cells in the lumbar spinal cord are 
shown in figure 3.23. 
Study 3.1: Weekly repeated carrageenan treatment 
Laminae 1111 
Proenkephalin mRNA expression in laminae IIII in study 3.1 is shown in Figure 3.24. 
Treatment effect 
There was a significant treatment effect on proenkephalin mRNA expression in ipsilateral 
superficial laminae (F [2,51] = 5.44, P < 0.01). Proenkephalin mRNA expression was 
significantly upregulated in 0.5% carrageenan-treated animals relative to saline-treated 
animals, (p < 0.01), but not relative to 0.1% carrageenan-treated animals (p < 0.14). 
Proenkephalin mRNA expression in 0.1 % carrageenan-treated animals was not 
significantly different from that of saline-treated animals (p < 0.06). Post-hoc analysis did 
not indicate a significant treatment effect on any individual week of the study. There was 
no significant treatment effect on contralateral proenkephalin mRNA expression. 
Figure 3.23: proenkepbalin mRNA expression 
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Figure 3.24 Study 3.1: Proenkephalin mRNA expression in laminae 1111 
Expression of proenkephalin mRNA, expressed as the mean ± SEM mean relative optical 
density (M.R.O.D.)/ cell in ipsilateral (A) and contralateral (B) laminae IIII of lumbar 
spinal cord, measured in animals euthanased 6 hours following intraplantar injection of 50 
)..\,1 of 0.5% carrageenan (0.5% Cx), 0.1% canageenan (0.1 % Cx) or 0.9% saline (n = 4-
6/group). 
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Ipsilaterallcontralateral effect 
Proenkephalin mRNA expression was significantly upregulated in ipsilateral (relative to 
contralateral) superficial laminae in all three treatment groups. In O.S% carrageenan -
treated animals (F[1,32] = 17.47, P < 0.001), post-hoc analysis indicated significant 
upregulation of ipsilateral (relative to contralateral) proenkephalin mRNA expression only 
on week 3 (F[l,S] = 30.02, P < 0.01), although close to significance on week 2 (F[l,S] = 
S.4S, P < 0.08). In 0.1% carrageenan -treated animals (F[1,32] = 8.S3, P < 0.01), post-hoc 
analysis indicated significant upregulation of ipsilateral (relative to contralateral) 
proenkephalin mRNA expression on week 2 (F[1,9] = 12.14, P < 0.03) and week 4 (F[1,9] 
= lS.04, P < 0.02). In saline-treated animals (F[l,32]= 7.68, p<O.Ol), post-hoc analysis 
indicated significant upregulation of ipsilateral (relative to contralateral) proenkephalin 
mRNA on week 2 (F[1,S] = 26.86, P < 0.01) and week 4 (F[1,S] = 6.84, P < O.OS). 
Effect of repeated treatment 
There was no significant effect of weekly repeated treatment on proenkephalin mRNA 
expression in ipsilateral or contralateral laminae VII in carrageenan or saline-treated 
animals. 
Lamina V 
Proenkephalin mRNA expression in lamina V in study 3.1 is shown in Figure 3.2S. 
Treatment effect 
There was no effect of carrageenan treatment on ipsilateral or contralateral proenkephalin 
mRNA expression in lamina V (relative to that observed following saline treatment). 
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Figure 3.25 Study 3.1: Proenkepltalin mRNA expression in lamina V 
Expression of proenkephalin mRNA, expressed as the mean ± SEM mean relative optical 
density (M.R.O.D.)/ cell in ipsilateral (A) and contralateral (B) lamina V of lumbar spinal 
cord, measured in animals euthanased 6 hours following intraplantar injection of 50 III of 
0.5% carrageenan (0.5% Cx), 0.1 % Cx or 0.9% saline. 
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Ipsilateral/contralateral effect 
Proenkephalin mRNA expression was significantly upregulated in ipsilateral (relative to 
contralateral) lamina V in all three treatment groups. In 0.5% carrageenan -treated animals 
(F[1,32] = 13.92, p < 0.001), post-hoc analysis indicated significant upregulation of 
ipsilateral (relative to contralateral) proenkephalin expression on week 1 F[1,9] = 6.25, p < 
0.05) and week 3 (F[1,9] = 28.53, p < 0.01). In 0.1% carrageenan-treated animals (F[1,32] 
= 8.53, p < 0.01), post-hoc analysis indicated significant upregulation of ipsilateral 
(relative to contralateral) proenkephalin expression on week 3 F[1,9] = 6.60, p < 0.05) and 
week 4 (F[1,9] = 7.1, p < 0.05). In saline-treated animals (F[1,32] = 7.68, p < 0.01)], post-
hoc analysis did not indicate any particular week on which significant upregulation of 
ipsilateral (relative to contralateral) proenkephalin expression occurred. 
Effect of repeated treatment 
Weekly repeated treatment did not alter the intensity of ipsilateral or contralateral 
proenkephalin mRNA expression in carrageenan or saline-treated animals. 
Study 3.2: Daily repeated carrageenan treatment 
Laminae IIII 
Proenkephalin mRNA expression in laminae IIII in study 3.2 is shown in Figure 3.26. 
Treatment effect 
Carrageenan treatment did not alter the intensity of ipsilateral proenkephalin mRNA 
expression (relative to saline treatment) at 1 h p.i. or 6 h p.i. on day 1 or day 5. However, 
on day 5 at 6 hpj., contralateral proenkephalin mRNA expression in carrageenan-treated 
animals was significantly upregulated relative to saline-treated animals (F [1,6]] = 5.36, p 
< 0.05). 
Ipsilateral!contralateral effect 
In carrageenan-treated animals, ipsilateral proenkephalin mRNA expression was 
upregulated (relative to contralateral) at 1 hpj. on day 3 (F [1,3] = 28.32, p < 0.01) and 
day 5 ( F[1,3] = 95.82, p < 0.01). At 6h p.i., ipsilateral proenkephalin mRNA expression 
was upregulated (relative to contralateral) on day 2 (F[1,3] = 38.74, P < 0.01), day 3 
(F[1,3] = 29.85, p < 0.02) and day 5 (F[1,3] = 1l.17, P < 0.05). In saline-treated animals, 
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Figure 3.26 Study 3.2: Proenkephalin mRNA expression in laminae 1111 
Expression of enkephalin mRNA, expressed as the mean ± SEM silver-grain count/ cell 
in ipsilateral (A) and contralateral (B) laminae IIII of lumbar spinal cord, measured in 
animals euthanased 1 h or 6h following intraplantar injection of 50 III of 0.1 % carrageenan 
or 0.9% saline (n=4/group). 
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Figure 3.27 Study 3.2: Proenkephalin mRNA expression in lamina V 
Expression of enkephalin mRNA, expressed as the mean ± SEM silver-grain count/ cell 
in ipsilateral (A) and contralateral (B) lamina V of lumbar spinal cord , measured in 
animals euthanased lh or 6h following intraplantar injection of 50 ~l of 0.1 % carrageenan 
or 0.9% saline (n=4/group). 
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ipsilateral proenkephalin mRNA expression was upregulated (relative to contralateral) at 1 
hpj. on day 5 (F [1,3] = 37.24, P < 0.01) but not on day 1 (F[1,3] = 6.59, p = 0.08). At 6h 
p.i., ipsilateral proenkephalin mRNA expression was upregulated (relative to contralateral 
expression) on day 1 (F[1,3] = 24.49, P < 0.05) but not on day 5 (F [1,3] = 4.02, P = 0.14). 
Effect of repeated treatment 
In carrageenan-treated animals there was a significant effect of daily repeated treatment on 
contralateral (but not ipsilateral) proenkephalin mRNA expression at 1h pj. (F[1,6] = 
10.97, P < 0.01); contralateral mRNA expression was significantly higher on day 3 than on 
day 5 (p < 0.05). There was no effect of repeated treatment on ipsilateral or contralateral 
proenkephalin mRNA expression in carrageenan-treated animals at 6h p.i. or in saline-
treated animals at 1 hand 6h pj. 
Lamina V 
Proenkephalin mRNA expression in lamina V in study 3.2 is shown in Figure 3.27. 
Treatment effect 
Carrageenan treatment did not alter the intensity of ipsilateral proenkephalin mRNA 
expression (relative to saline treatment) at 1 h p.i. or 6 hpj. on day 1 or day 5. In 
carrageenan-treated animals on day 5, ipsilateral proenkephalin mRNA expression was 
significantly higher in carrageenan-treated animals at 6h pj. than at 1h pj. (F[1,6] = 25.0, 
P < 0.05). 
Ipsilateral!contralateral effect 
Proenkephalin mRNA expression was not significantly upregulated in ipsilateral (relative 
to contralateral) lamina V in carrageenan or saline-treated animals at 1 hpj. or 6 hpj. on 
any day of the study. 
Effect of repeated treatment 
Daily repeated carrageenan or saline treatment did not alter the intensity of ipsilateral or 
contralateral proenkephalin mRNA expression at 1 hpj. or 6 h p.i. 
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1.3'.1.. DYNORPHIN 
Basal prodynorphin mRNA expression. 
Small numbers of prodynorphin mRNA positive cells were observed in laminae IIII and V 
of the lumbar spinal dorsal hom and in the hippocampus, but not in other brain regions .. 
The absence ofprodynorphin mRNA expression in tissue sections labelled with fifty-tim~; 
excess unlabelled probe confinned probe specificity. Positively labelled cells in laminae if· 
II were of unifonn 8-15 ).lm diameter, while positively-labelled cells in laminae V varied 
in diameter from 8- 32).lm. There was no significant difference between treatment groups 
in the diameter ofprodynorphin positive cells. Prodynorprun labeled cells in the lumbar 
spinal cord are shown in Figure 3.28. 
Study 3.1: Weekly repeated carrageenan treatment 
Laminae IIll 
Treatment effect 
Carrageenan treatment did not alter the intensity of ipsilateral . or contralateral 
prodynorphin mRNA expression on any week of the study. 
Ipsilaterallcontralateral effect 
Prodynorphin mRNA expression was not upregulated in ipsilateral (compared to 
contralateral) superficial laminae in carrageenan or saline-treated animals on any week of 
the study. 
Effect of repeated treatment 
There was no significant effect of weekly repeated treatment on ipsilateral or contralateral 
prodynorphin mRNA expression in carrageenan or saline-treated animals. 
Lamina V 
Prodynorphin mRNA expression in lamina V in study 3.1 is shown in Figure 3.29. 
Treatment effect 
There was no significant difference between treatment groups in mRN A expression in 
either ipsilateral or contralateral lamina V on any week of the study. 
Figure 3.28 prodynorphin mRNA expression 
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Figure 3.29: Study 3.1: Prodynorphin mRNA expression in lamina V 
Expression of prodynorphin mRNA, expressed as the mean ± SEM mean relative optical 
density (M.R.O.D.)/ cell in ipsilateral (A) and contralateral (B) lamina V of lumbar spinal 
cord, measured in animals euthanased 6 hours following intraplantar injection of 50 ~l of 
0.5% carrageenan (0.5% Cx), 0.1 % Cx or 9.9% saline. 
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Ipsilateral/contralateral effect 
Prodynorphin mRNA expression was upregulated in ipsilateral (compared to contralateral) 
lamina V in O.S% ex-treated animals (F[1,38J=S.4, p<O.OS) but not in other treatment 
groups. More detailed week-by-week analysis using Turkey's post-hoc test indicated a 
significant difference in ipsilateral/contralateral mRNA expression on week 3 (F[l,SJ = 
8.37, p < 0.01) and week 4 (F[l,SJ = 2.2S, p < O.OS) 
Effect of repeated treatment 
There was no significant effect of weekly repeated treatment on prodynorphin mRNA 
expression in any treatment group. 
Study 3.2: Daily repeated carrageenan treatment 
Laminae IIII 
Prodynorphin mRNA expression in laminae IIll in study 3.2 is shown in Figure 3.30. 
Treatment effect 
There was no significant difference between treatment groups in mRNA expression in 
either ipsilateral or contralateral laminae I/ll on day 1 or day S. 
Ipsilaterallcontralateral effect 
Prodynorphin mRNA expression was not upregulated in ipsilateral (compared to 
contralateral) superficial laminae in carrageenan or saline-treated animals at 1 h p.i. or 6 h 
p.i. on any day of the study. However, near-significant upregulation of ipsilateral mRNA 
expression occurred in both carrageenan and saline-treated animals. 
In carrageenan-treated animals at 6 hpj., ipsilateral prodynorphin mRNA expression was 
upregulated (relative to contralateral) on day 1 (F[1,3J = 7.S1, p < 0.07) and day 2 (F[1,3J 
= 9.33, p < 0.06). In saline-treated animals, ipsilateral prodynorphin mRNA expression 
was upregulated (relative to contralateral) at 1 h p.i. on day 1 (F [1,3J = 7.S8, p < 0.07) and 
day S (F[1,3J = 9.39, p < 0.06) and at 6 h p.i. (F[1,3J = 8.S7, p < 0.06). 
Effect of repeated treatment 
In carrageenan-treated animals, the intensity of ipsilateral prodynorphin mRNA expression 
at 1 h p.i. and 6 h p.i. was not altered by daily repeated treatment. In saline-treated 
I __ _ 
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Figure 3.30: Study 3.2: Prodynorphin mRNA expression in laminae 1111 
Expression of prodynorphin mRNA, expressed as the mean ± SEM silver-grain count/ cell 
in ipsilateral (A) and contralateral (B) laminae IIII of lumbar spinal cord , measured in 
animals euthanased 1 h or 6h following intraplantar injection of 50 ~l of 0.1 % carrageenan 
or 0.9% saline (n = 4/group). 
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animals, ipsilateral prodynorphin expression was significantly higher on day 1 than on day 
5 at 6h p.i. (F [1,3] =14.55, P < 0.05). There was no significant effect of daily repeated 
treatment on contralateral prodynorphin mRNA expression at 6h in carrageenan or saline-
treated animals. There was a significant effect of daily repeated treatment on contralateral 
prodynorphin expression at 1 h p.i. in carrageenan-treated animals (F[3,9] = 6.15, p < 0.05; 
mRNA expression on day 1 was significantly higher than on day 2 (p < 0.02) and day 3 (p 
< 0.02). 
Lamina V 
Treatment effect 
Carrageenan treatment did not alter the intensity of ipsilateral or contralateral 
prodynorphin mRNA expression (relative to saline treatment) at 1 h p.i. or 6 hpj. on day 1 
or day 5. 
Ipsilaterall co ntralateral effect 
Carrageenan or saline treatment did not alter the intensity of ipsilateral (relative to 
contralateral) prodynorphin mRNA expression at 1 hpj. or 6 hpj. on any day of the 
study. 
Effect of repeated treatment 
Daily repeated carrageenan or saline treatment did not alter the intensity of ipsilateral or 
contralateral prodynorphin mRNA expression at 1 hpj. or 6 hpj. 
3.3.8. GAD 67 
Basal GAD 67 mRNA expression 
GAD 67 mRNA positive cells were observed throughout the grey matter of the lumbar 
spinal cord and in the hippocampus. The absence of GAD 67 mRNA expression in tissue 
sections labelled with fifty-times excess unlabelled probe confirmed probe specificity. 
Cells in the superficial laminae (I1II) expressing GAD 67 mRNA were of uniform 8-151lm 
diameter. GAD 67 positive cells in laminae V varied in diameter from 8-32Ilm. There 
was no significant difference between treatment groups in the diameter of GAD 67 
positive cells. 
GAD 67 labelled cells in the lumbar spinal cord are shown in Figure 3.31. 
Figure 3.31 GAD 67 mRNA expression 
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Study 3.2: Daily repeated carrageenan treatment 
Laminae IIII 
GAD 67 mRNA expression in laminae IIII in study 3.2 is shown in Figure 3.32. 
Treatment effect 
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Carrageenan treatment did not alter the intensity of ipsilateral or contralateral GAD 67 
rnRNA expression (relative to saline treatment) at 1 hpj. or 6 h p.i. on day 1 or day 5. 
In carrageenan-treated animals, ipsilateral GAD rnRNA expression was significantly 
higher at 1h than at 6h p.i. on day 3 (F[1,6] = 34.17, P < 0.01), but not on any other day. 
Ipsilaterallcontralateral effect 
In carrageenan-treated animals, ipsilateral GAD 67 rnRNA expression was upregulated 
(relative to contralateral) at 1 hpj on day 1 (F[1,3] = 20.44, P < 0.05), day 2 (F[1,3] = 
18.78, P < 0.05) and day 3 (F [1,3] = 28.91, P < 0.01), but not on day 5. There was no 
difference in the intensity of ipsilateral and contralateral GAD 67 mRNA expression at 6 h 
poi. on any day of the study. In saline-treated animals, ipsilateral GAD 67 mRNA 
expression was upregulated (relative to contralateral) at 1 h p.i on day 1 (F[1,3] = 42.41, P 
< 0.01) and day 5 (F[l,7]=37.27, P < 0.01, and at 6 hpj. on day 1 (F [1,3] = 36.46, 
p<O.Ol) and day 5 (F[1,3] = 16.98 , P < 0.05). 
Effect of repeated treatment 
In carrageenan-treated animals there was a significant effect of daily repeated treatment on 
ipsilateral GAD mRNA expression at 1h poi. (F[3,9] = 8.44, P < 0.01); GAD mRNA 
expression was significantly greater on day 3 than day 5 (p < 0.01). There was no effect of 
repeated daily injection on ipsilateral or contralateral GAD 67 mRNA expression at 6 h p.i. 
in carrageenan-treated animals, nor in saline-treated animals at 1 hpj. or 6 hpj. 
Lamina V 
GAD 67 rnRNA expression in lamina V in study 3.2 is shown in Figure 3.33. 
Treatment effect 
Carrageenan treatment did not alter the intensity of ipsilateral or contralateral GAD 67 
mRNA expression (relative to saline treatment) at 1 hpj. or 6 h p.i. on day 1 or day 5. 
201 
Figure 3,32: Study 3,2: GAD 67 mRNA expression in laminae 1111 
Expression of GAD 67 mRNA, expressed as the mean ± SEM silver-grain count! cell In 
ipsilateral (A) and contralateral (B) laminae IIII of lumbar spinal cord measured in animals 
euthanased 1h and 6h following injection of 50 III of 0.1 % carrageenan or 0.9% saline 
(n=4/ group). 
A: ipsilateral GAD 67 mRNA expression in 
laminae 1111 
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Figure 3.33 Study 3.2:GAD 67 mRNA expression in lamina V 
Expression of GAD 67 mRNA, expressed as the mean ± SEM silver-grain count/ cell III 
ipsilateral (A) and contralateral (B) lamina V of lumbar spinal cord measured in animals 
euthanased 1h and 6h following injection of 50 /-tl of 0.1 % carrageenan or 0.9% saline 
(n=4/ group). 
A: ipsilateral GAD 67 mRNA expression in 
lamina V 
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Ipsilaterallcontralateral effect 
In carrageenan-treated animals, ipsilateral GAD mRNA expression was not significantly 
upregulated (relative to contralateral expression) at 1 h or 6 hpj. on any day of the study. 
In saline-treated animals ipsilateral GAD mRNA expression was significantly upregulated 
(relative to contralateral expression) at 1 hpj. on day 1(F[1,3] = 13.6, P < 0.05) but not on 
day 5. Ipsilateral GAD mRNA expression was not significantly upregulated (relative to 
contralateral expression) at 6 hpj. on day 1 or day 5 . 
Effect of repeated treatment 
Daily repeated carrageenan or saline treatment did not alter the intensity of GAD 67 
mRNA expression at 1h or 6h pj. 
3.4. DISCUSSION 
3.4.1. CaMKIIa 
Lamina V 
Minimal changes in the intensity of CaMKIla mRNA expression in lamina V were 
observed in carrageenan-treated animals (relative to saline-treated animals) in studies 3.1 
and 3.2, suggesting that CaMKIla in lamina V does not contribute to the mediation of 
alterations in nociceptive behaviour following repeated mild inflammatory injury. 
Laminae 1111 
Study 3.1 
0.5% (but not 0.1 %) carrageenan treatment induced significant upregulation of ipsilateral 
CaMKIla mRNA expression relative to saline treatment in laminae I1II. Both 0.5% and 
0.1 % carrageenan (but not saline) treatment induced significant ipsilateral (relative to 
contralateral) upregulation of CaMKIla mRNA expression in laminae IIII. These results 
demonstrate that inflammatory injury (accompanied by hyperalgesia) stimulates unilateral 
upregulation of CaMKIla mRNA expression in laminae IIII of the spinal dorsal hom. 
While 0.1 % carrageenan-treated animals displayed hyperalgesic behaviour and significant 
upregulation of ipsilateral (relative to contralateral) CaMKIla mRNA expression, the 
intensity of ipsilateral CaMKIla expression in 0.1 % carrageenan -treated animals did not 
differ significantly from CaMKIla mRNA expression in saline-treated animals. Study 3.1 
therefore suggests that the magnitude of upregulation of CaMKIla mRNA expression is 
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directly related to the intensity of inflammatory injury and may contribute to the induction 
of enhanced nociceptive transmission through a centrally mediated mechanism. 
Study 3.2 
A similar pattern of CaMKlla mRNA expression was observed in study 3.2, where daily 
repeated 0.1% carrageenan treatment induced significant ipsilateral (relative to 
contralateral) upregulation of CaMKlla mRNA expression in laminae IIII at 6h p.i. on 
each day of the study but did not induce significant upregulation of ipsilateral CaMKlla 
mRNA expression (relative to saline) on day 1 or day 5 [although contralateral CaMKIla 
mRNA expression was significantly up regulated relative to saline treatment at 6 h p.i. on 
days 1 and 5. A significant reduction in the magnitude of ipsilateral CaMKIla mRNA 
expression coincided with tachyphylaxis of hyperalgesic responses on day 3. This 
observation further supports the hypothesis that upregulation of spinal CaMKIla mRNA 
expression may contribute to enhanced nociceptive transmission. It must be noted, 
however, that significant changes in contralateral CaMKIla mRNA expression were also 
observed in the absence of alterations in nociceptive behaviour; contralateral CaMKIla 
mRN A expression was significantly higher on day 2 than on days 3 and 5. 
Involvement of CaMKII a in the mediation of central plasticity of nociceptive transmission 
As was discussed in chapter 1, CaMKIla can modulate the activity of a multitude of 
intracellular agents and neurotransmitters implicated in the mediation of central 
nociceptive plasticity. The intensity-dependent unilateral upregulation of CaMKIIa mRNA 
expression in laminae IIII of the spinal dorsal hom following inflammatory injury 
(presumably, but not definitively accompanied by increased CaMKlla enzyme) could thus 
contribute to the induction and maintenance of enhanced nociceptive processing through a 
modulating many different neurotransmitter pathways. 
Over a rapid timescale, increased CaMKIla activity in the superficial dorsal hom could 
enhance nociceptive responses through enhancing central excitatory (glutaminergic) 
transmission (Kolaj et al., 1994; Soderling et al., 1994; Pereda et ai., 1998). It must be 
noted, however, that CaMKIla can also enhance inhibitory ('anti-nociceptive') 
neurotransmission in dorsal hom neurons in-vitro. It is possible that the intensity of 
neuronal stimulation and intraneuronal calcium influx determine the targets of CaMKlla 
activation to subsequently drive predominantly excitatory or inhibitory transmission. 
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Increased CaMKlIa activity could also lead to persistent enhancement of nociceptive 
behaviour by increasing receptor activity (NMDA, AMP A) and activating signalling 
proteins (including immediate early genes) leading to the induction and maintenance of 
L TP of synaptic transmission in the superficial dorsal hom. As was previously discussed 
(chapter 1), CaMKlIa contributes to the induction and maintenance of L TP in the 
hippocampus (Malinow et al., 1989; Fukunaga et aI,. 1993; McGlade-McCulloch et al., 
1993; Miyamoto & Fukunaga, 1996) through mechanisms which have not yet been 
completely defined, but which include phosphorylation of NMDA and AMP A receptors 
and modulation of the activity of nuclear transcription factors, IEG expression and gene 
transcription (Lisman et al., 1997). Modulation of intracellular signalling factors by 
protein kinase enzymes other than CaMKlIa is well recognised (Hughes & Dragunow, 
1995; Bito et al., 1997; Carafoli et al., 1997; Lisman et al., 1997; Deisseroth et aI., 1998). 
Studies 3.1 and 3.2 investigated regulation of CaMKlIa gene expression rather than 
enzyme activity. Regulation of CaMKlIa mRNA expression in brain or spinal cord 
following natural noxious stimulation has not been reported previously; in the brain, 
regulation of CaMKlIa mRNA expression in the brain has been investigated 
predominantly using highly specific and essentially 'artificial' models of electrical 
stimulation (Chapter 1). It has been speculated that changes in expression and subsequent 
translation of CaMKlIa mRNA may critically regulate the balance of excitatory and 
inhibitory neurotransmission in higher centres (Liang et al., 1996). It is therefore possible 
that modulation of CaMKlIa mRNA transcription (and its subsequent translation into the 
potentially active kinase enzyme) provides an additional mechanism through which 
CaMKlIa could regulate plasticity of nociceptive transmission in the spinal dorsal hom. 
The intracellular mechanisms which regulate CaMKlIa gene transcription have not yet 
been defined, although NMDA and NO have been shown to modulate CaMKlIa mRNA 
expression in hippocampal neurons (Johnston & Morris, 1995, Laabich & Cooper, 2000). 
NMDA and NO play key roles in central nociceptive transmission (reviewed by Milan, 
1999 and in chapter 1), and therefore it is highly possible that NMDA and NO also 
regulate the modulation of CaMKlI gene expression in response to inflammatory injury in 
the superficial dorsal hom 
In conclusion, this study provides new insights into CaMKlIa mRNA expression activity 
in the spinal cord following mild inflammatory injury. CaMKlI has received relatively 
scant attention in relation to its potentially important role in central nociceptive plasticity 
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in comparison with the related protein kinase enzymes PKC and PKA, which have been 
extensively characterised (reviewed by Millan, 1999). While upregulation of CaMKlI 
expression was identified in the ipsilateral superficial dorsal hom in association with mild 
inflammatory injury in studies 4.1 and 4.2, it was not possible to localise this upregulation 
more precisely to excitatory or inhibitory neuronal populations. Such localisation would 
help to more precisely identify the role of CaMKlI in the mediation of central nociceptive 
plasticity. 
In studies 3.1 and 3.2, upregulation of CaMKlIa appeared to drive excitatory (pro) 
nociceptive transmission. Since CaMKlI can enhance both excitatory and inhibitory 
central nociceptive transmission, it is possible that the degree of CaMKII upregulation and 
the consequences of its upregulation- potentially predominantly excitation or inhibition-
are critically regulated by the intensity of inflammatory injury. For example, 'feedback' 
enhancement of post-synaptic glycinergic transmission by NMDA receptor activation, 
mediated by CaMKlIa, has been reported previously and represents an potential 'adaptive' 
signalling pathway which could attenuate excitatory nociceptive transmission (Xu et al., 
1999; 2000). Martin et al. (1999) recently characterised the regulation of protein kinase C 
expression in the spinal dorsal hom in a model of CF A inflammation, using double-
labelling immunocytochemistry techniques to distinguish excitatory and inhibitory neurons 
in superficial laminae. In this study, upregulation of PKC immunoreactivity in the 
ipsilateral dorsal hom following CF A inflammation was localised to excitatory neurons, 
leading to the conclusion that PKC-mediated enhancement of excitatory central 
nociceptive transmission contributes to central sensitisation during persistent 
inflammation. Studies 3.1 and 3.2 clearly identify a potential role for CamKlIa in the 
mediation of central nociceptive plasticity following mild repetitive inflammatory 
stimulation, and it would be of great value to characterise the expression of CaMKlIa over 
a range of inflammatory stimulus intensities using techniques similar to those employed by 
Martin et al.(1999). 
3.4.2. Zif/268 
While previous studies (Wisden et al., 1990; Herdegen et al., 1991; Lanteri-Minet et al., 
1993; Buritova et ai.,1995) have investigated regulation of zif/268 gene expression 
associated with intense inflammatory injury or noxious stimulation, current understanding 
of the role of zif/258 mRNA in physiological and pathophysiological central nociceptive 
processing leaves many impOliant questions unanswered. Previous studies have not 
conclusively demonstrated a role for zif/268 mRNA upregulation in the mediation of 
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central sensitisation of nociceptive transmission in the spinal cord; it remains feasible that 
zif/268 mRNA up regulation observed in previous studies reflects a non-specific zif/268 
response to intense noxious stimulation which does not directly mediate alterations in 
central nociceptive transmission. Several studies have reported upregulation of spinal 
zif/268 mRNA expression in the absence of noxious stimulation; for example, Beckman et 
al (1995) reported upregu1ation of zif/268 mRNA expression in brain and spinal cord 20 
and 60 minutes following morphine withdrawal in morphine-dependent animals. Studies 
of zif/268 protein expression in the brain following noxious stimulation (Herdegen et al., 
1990; Lanteret-Minet et al., 1993, 1994) have similarly noted that zif/268 expression is 
not specifically localised or upregulated in 'nociceptive' regions of the forebrain or 
hindbrain. 
Lamina V 
Minimal changes in the intensity of zi£'268 mRNA expression in lamina V were observed 
in carrageenan-treated animals (relative to saline-treated animals) in studies 3.1 and 3.2, 
suggesting that zif/268 gene expression in lamina V does not contribute to the mediation of 
altered nociceptive behaviour following repeated mild inflammatory injury. 
Laminae 1111 
In study 3.2, the intensity of zif/268 mRNA expression at 1 hpj. was not significantly 
different from that observed at 6h pj. in both carrageenan and saline-treated animals, 
suggesting that zifJ268 mRNA up regulation was either maximal at Ih p.i. and persisted for 
at least 6 hpj., or that upregulation was transient and occurred between 1 hpj. and 6 h p.i. 
Wisden et ai., (1990) reported very rapid upregulation of zif/268 expression in laminae 
VII, within 15-30 minutes of noxious thermal stimulation. Lanteri-Minet et al.(1993) 
reported maximal upregulation of zif/268 mRNA within 4 hours of intraplantar CF A 
treatment, which was subsequently maintained for 15 days post treatment. Thus, while the 
time-course of zif/268 mRNA induction following inflammatory injury remains 
incompletely characterised, these studies suggest that zif/mRNA upregulation is rapid and 
maximal within 1 h of inflammatory injury. 
In studies 3.1 and 3.2, no treatment effect was observed in ipsilateral or contralateral 
laminae VII. No significant difference in the level of gene expression at 1 h p.i. and 6 h 
pj. was observed in carrageenan or saline-treated animals. However consistent ipsilateral 
(relative to contralateral) upregulation of zif/68 mRNA expression was observed in both 
carrageenan and saline-treated animals. Weekly or daily repeated carrageenan treatment 
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did not alter the intensity of zifl68 mRNA expression. (although ipsilateral expression was 
significantly higher on day 5 than day 1 in saline-treated animals at 1 p.i.). These studies 
thus suggest that zif/68 mRNA upregulation in the spinal cord reflects a general neuronal 
response to stimulation and may contribute to the induction of central plasticity of 
nociceptive transmission depending on the severity of noxious stimulation. 
Studies 3.1 and 3.2 used inflammatory stimuli of dramatically lower intensity than those 
previously employed to investigate changes in zifl268 gene and protein expression 
following inflammatory injury. Using immunocytochemistry techniques, Buritova et al. 
(1995) counted the number of zif/268 positively labelled cells in the lumbar superficial 
dorsal hom at 3 h following administration of 1-6 mg carrageenan in 150 III saline, 
reporting that carrageenan induced a dose-dependent increase in the number of zif/268 
mRNA positively labelled neurons in the superficial dorsal hom (at 3 hpj.), while 
attenuation of inflammation by indomethacin pre-administration dose-dependently reduced 
the total number of zif/268 positive neurons in the superficial dorsal hom. Buritova et 
al.(1995) reported no change in the number of zif/268 positively labelled cells in the 
superficial dorsal hom following intraplantar saline treatment. Lanteri-Minet et al.(1993) 
reported rapid upregulation of zif/268 protein expression in the superficial dorsal hom 
following intraplantar CF A administration, which peaked at 4 hours pj. (preceding 
maximal paw oedema by several hours). In the same study, Lanteri-Minet et al.(1993) 
observed that zif/268 expression was maintained at peak levels for 15 days following CFA 
treatment and was maintained at elevated levels (relative to constitutive zif/268 protein 
expression) for 4 weeks post treatment. It was observed that intra-articular injection of 
CF A induced significantly stronger and more prolonged zif/268 expression in laminae I-IV 
than intraplantar injection. Neither Buritova et al.(1993) or Lanteri-Minet et al.(1993) 
investigated the regulation of zif/268 protein expression in individual cells. While 
plasticity of central nociceptive processing may result from both modulation of activity in 
individual neurons and from recruitment or activation of additional neurons in the dorsal 
hom (discussed in chapter one), studies 3.1 and 3.2 focused exclusively on modulation of 
activity in individual neurons. The insights into the role of zif/268 in the mediation of 
plasticity of spinal nociceptive processing provided by these studies highlight the critical 
dependence of the intraneuronal molecular response to injury upon the severity of that 
injury. 
In contrast to previous reports, in studies 3.1 and 3.2, carrageenan treatment induced 
hyperalgesic behaviour but did not induce significant upregulation of zif/268 gene 
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expression relative to saline treatment. Moreover, in both studies, upregulation of 
ipsilateral (relative to contralateral) zif1268 gene expression in the superficial laminae was 
observed in both 0.1 % carrageenan and saline-treated animals. This suggests that zif/268 
was upregulated in response to general neuronal stimulation, but that this upregulation was 
not associated with the induction of hyperalgesia, or with the plasticity of nociceptive 
responses observed in study 3.2. These results suggest that any potential involvement of 
zif/268 in the mediation of both 'physiological' central nociceptive transmission, and in 
plasticity of nociceptive transmission following less intense injury should be reappraised. 
3.4.3. Tissue Plasminogen Activator 
In study 3.1 tPA mRNA expression was identified in a very small number of cells in 
laminae IIII and V. A small increase in the number of tPA mRNA positive cells in 
laminae IIII was identified in 0.5% carrageenan-treated animals (relative to saline-treated 
animals), but this increase was significant only on week 1. No change in the number of 
tPA positive cells was observed in lamina V. It is worthy of note that the time course of 
tP A mRNA induction in association with inflammatory injury has not yet been 
characterised. It is possible that tP A is rapidly and transiently induced following 
inflammatory stimulation,; such transient induction would not have been detectable in 
study 3.2, where tPA mRNA was measured only at 6 h post-treatment. However, previous 
studies of tP A mRNA induction in brain tissue suggest that upregulation of tP A mRNA 
expression following specific stimulation is maintained for a considerable period following 
stimulation (Qian et ai.,1993; Baranes et ai., 1998). Since strong upregulation of 
expression is predicted for IEG's involved in the induction central neuronal plasticity 
(reviewed by Morris (1997) and Herdegen & Zimmerman (1995 ), study 3.1 suggests that 
tP A expression in the dorsal horn does not contribute to the induction of central changes in 
nociceptive transmission following inflammatory injury. 
3.4.4. Jun D 
Lamina V 
Minimal alteration in the intensity of jun D mRNA expression in lamina V was observed 
in carrageenan-treated animals (relative to saline-treated animals) in study 3.2, suggesting 
that jun D in lamina V does not contribute to the mediation of plasticity of nociceptive 
transmission associated with repeated mild inflammatory injury. 
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Laminae IIII 
No significant alteration in the intensity of expression of ipsilateral or contralateral jun D 
mRNA expression in carrageenan-treated animals (relative to saline-treated animals) was 
observed) at 1 h or 6h p.i. on day 1 or day 5. However, significant ipsilateral (relative to 
contralateral) upregulation of junD mRNA was observed in both carrageenan and saline-
treated animals at 1 hpj. Daily repeated carrageenan treatment did not alter the 
magnitude of jun D mRNA expression in the superficial dorsal hom. 
This study provides the first reported investigation of jun D gene regulation associated 
with mild repeated inflammatory stimulation. While the time course of jun D mRNA 
upregulation and subsequent protein expression in the spinal cord has not been thoroughly 
characterised, jun D appears to be rapidly upregulated and translated into active protein 
following intense noxious stimulation (Herdegen et at., 1991a; 1994; Tolle et at., 1994). 
Previous studies have shown that enhanced expression of jun D protein persists for a 
prolonged period following intense inflammatory injury or noxious stimulation. Herdegen 
et at.(1994) reported that ipsilateral upregulation of junD protein expression in the 
superficial dorsal hom persisted at maximal levels for 10 hpj. and remained significantly 
greater than constitutive levels at 24 h p.i. following formalin treatment, while Lanteri-
Minet et at., (1993) observed elevated jun D protein expression for 7-15 days following 
intraplantar CF A treatment. In study 3.2, jun D mRNA expression was consistently higher 
at Ih pj. than at 6h pj. in carrageenan-treated animals, although significantly so only on 
day 2, suggesting that jun D mRNA upregulation was transient. 
Study 3.2 provides useful new insights into the involvement of jun D in spinal nociceptive 
transmission. In laminae VII, a similar magnitude of ipsilateral upregulation of jun D 
mRNA expression was observed in carrageenan and saline-treated animals, suggesting that 
the observed upregulation reflected a 'general' neuronal response to stimulation and did 
not contribute to alterations in nociceptive behaviour. The pattern of expression of jun D 
following repeated mild inflammatory stimulation is notably similar to the pattern of 
zif/268 discussed previously (section 3.4.2). 
In conclusion, these studies highlight the necessity for thorough evaluation of IEG 
expression and regulation associated with different modalities and intensities of 
inflammatory stimulation, in order to ascertain a definitive role for these agents in both 
physiological nociceptive transmission and plasticity of central nociceptive transmission. 
While previous studies have suggested that zif1268 and jun D contribute to plasticity of 
central nociceptive transmission following intense injury, studies 3.1 and 3.2 suggest that 
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these immediate early genes are not involved in the induction of hyperalgesic behaviour or 
the induction of plasticity of nociceptive transmission induced by mild inflammatory 
stimulation. 
3.4.6. CYCLO-OXYGENASE ENZYMES 
3.4.6.1. COX-l 
Lamina V 
No significant treatment effect and no effect of repeated treatment on expression of COX-l 
mRNA in lamina V were observed in studies 3.1 and 3.2, suggesting that COX-l mediated 
prostaglandin synthesis in lamina V is not involved in the induction or maintenance of 
hyperalgesic responses following mild inflammatory injury. 
Laminae IIII 
In studies 3.1 and 3.2, carrageenan treatment did not alter the intensity of COX -1 mRNA 
expression in ipsilateral laminae IIII relative to saline treatment. A significant effect of 
treatment on contralateral COX-1 expression in laminae IIII was observed in study 3.1, 
where 0.5% carrageenan treatment induced significant upregulation of contralateral COX-
1 mRNA expression relative to saline treatment. However, more detailed analysis did not 
identify a particular week on which this significant effect occurred. 0.1 % carrageenan 
treatment did not alter the intensity of COX-1 gene expression relative to saline treatment 
in study 3.1 or study 3.2. 
In study 3.1, significant ipsilateral (relative to contralateral) upregulation of COX-1 
mRNA expression occurred in all treatment groups, although more detailed statistical 
analysis indicated no significant ipsilateral/contralateral effect on any individual week of 
the study. No significant ipsilateral upregulation of COX-l mRNA expression was 
observed in carrageenan or saline-treated animals in study 3.2. 
The ipsilateral upregulation of COX-1 gene expression observed in study 3.1 suggests that 
there is a central COX-1 mRNA response to peripheral stimulation. The lack of treatment 
effect on ipsilateral COX-l gene expression observed in studies 3.1 and 3.2 suggests that 
spinal expression of COX-1 does not play an important role in the modulation of 
nociceptive behaviour associated with mild inflammatory injury. 
These conclusions are in agreement with previous investigations of COX-l gene regulation 
associated with high intensity inflammatory injury. Beiche et al.(1996; 1998) and 
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Goppelt-Struebe & Beiche(1997) assessed COX-1 mRNA induction in the rat spinal cord 
over 22 days following intraplantar inoculation of CFA (100 Ill,) using RT-PCR 
techniques, and observed no change from constitutive levels of COX-1 mRNA expression 
over the duration of the study. A parallel study by Beiche et aZ.(1998) using western 
blotting techniques identified no change in COX-1 protein expression during the course of 
CF A-induced peripheral inflammation. In contrast to these results and of studies 3.1 and 
3.2, in-situ hybridisation analysis of COX-1 mRNA expression in rat lumbar spinal cord 
by Ichitani et aZ.(J997) reported a complete absence of COX-1 mRNA expression in 
lumbar spinal cord grey matter, either constitutively or subsequent to peripheral 
inflammation (induced by 6mg carrageenan) or axotomy. Identification of cellular COX-
1 mRNA expression cells by in-situ hybridisation in the present study reflects the higher 
sensitivity of the hybridisation method described by Wisden & Morris (1997). 
COX-1 has been classically described as the 'constitutive' cyclo-oxygenase isoform, 
expressed in many different cell types and responsible for the production of prostanoids 
involved in homeostatic functions such as the regulation of vascular responses, gastric 
mucosal protection, and co-ordination of the actions of circulating hormones (reviewed by 
Rang et al., 1999a). The roles of the different classes of prostaglandin molecule in central 
neurotransmission have not yet been characterised. While a pro-nociceptive role of 
prostaglandin mediated neurotransmission in the central nervous system is well established 
(reviewed by Dirig & Yaksh, 1998), prostaglandins may also act more generally as 
neuromodulatory agents within the central nervous system, having the potential to activate 
several different second messenger pathways through interaction with several G-protein 
coupled receptors (reviewed by Coleman et al., 1994; Pierce et al., 1995), and to activate 
multiple different prostanoid receptor targets (reviewed by Smith et al., 1998; Rang et al., 
1999a). A potential 'homeostatic' role for COX-1 mediated prostaglandin synthesis in the 
central nervous system warrants further investigation. 
3.4.6.2. COX-2 
Lamina V 
No significant treatment effect and no effect of repeated treatment on expression of COX-2 
mRNA in lamina V were observed in studies 3.1 and 3.2, suggesting that COX-2 mediated 
prostaglandin synthesis in lamina V is not involved in the induction or maintenance of 
hyperalgesic responses following mild inflammatory injury. 
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Laminae IIII 
Time course of COX-2 mRNA induction 
Ipsilateral upregulation of COX-2 in carrageenan-treated animals was consistently 
recorded at 6h pj. but not consistently at 1 h p.i., suggesting a lag period preceding COX-2 
mRNA induction following inflammatory injury. This is in agreement with previous 
reports on the time-scale of COX enzyme induction following intense inflammatory 
stimulation. Hay & De Belleroche(1997) reported a two-fold increase in COX-2 mRNA 
expression (quantified by northern-blot analysis) at 4 hpj. following intraplantar treatment 
with 2mg carrageenan. Hay et al.(1997) similarly reported that upregulation of COX-2 
mRNA expression was maximal at 2-4h pj. following high-dose CF A treatment. In an in-
situ hybridisation study, Itchitani et al.(1997) reported that induction of COX-2 mRNA 
following high-dose carrageenan treatment was transient and had returned to baseline 
levels at 24h pj. Using RT-PCR techniques, Beiche et al.(1998) reported a two-fold 
increase in COX-2 mRNA expression at 6 h following CF A inoculation, which had 
subsided at 3 days post-inoculation but was again present during the chronic phase of CF A 
inflammation 22 days post inoculation. Beiche et al.(1998) also identified COX-2 mRNA 
up-regulation in cervical sections of spinal cord over this period, suggestive of COX-2 
mRNA beyond the region of stimulation. 
Involvement of COX-2 in the mediation of central plasticity of nociceptive transmission 
In study 3.1, carrageenan treatment induced significant bilateral dose-dependent 
upregulation of COX-2 mRNA expression (relative to saline treatment) in laminae I1II. 
Significant ipsilateral (relative to contralateral) upregulation of COX-2 gene expression 
was observed in both carrageenan and saline-treated animals. Thus there appeared to be a 
clear dose-dependent relationship between COX-2 gene expression in laminae IIII and 
hyperalgesic behaviour associated with inflammatory injury. 
In study 3.2, however, no clear relationship was observed between COX-2 gene expression 
and the observed plasticity of nociceptive responses. Hyperalgesic behaviour observed in 
carrageenan-treated animals on day 5 in study 3.2 (Chapter 2, study 2.2) was not 
associated with upregulation of COX-2 gene expression. No consistent pattern of COX-2 
mRNA upregulation occurred in study 3.2. Carrageenan treatment induced significant 
ipsilateral upregulation of COX-2 mRNA expression (relative to saline treatment) in 
laminae IIII on at 1 hpj. and at 6h pj. on day 1, but not on day 5. In contrast to study 3.1, 
no significant treatment effect on contralateral COX-2 mRNA expression was observed on 
day 1 or day 5. In carrageenan-treated animals, significant ipsilateral (relative to 
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contralateral) COX-2 mRNA upregulation was observed at 6h p.i. only on day 1, although 
the near-significance of upregulation observed on days 3 and 5 was likely to be a 
consequence of the small sample size of the study. In saline-treated animals, significant 
ipsilateral (relative to contralateral) COX-2 mRNA upregulation was observed at 6h p.i. on 
day 5 but not on day 1. In carrageenan-treated animals, significant ipsilateral (relative to 
contralateral) COX-2 mRNA upregulation was observed at 1h p.i. only on day 2, although 
the near-significance of upregulation observed on days 1 and 3 was likely to be a 
consequence of the small sample size of the study. In saline-treated animals, significant 
ipsilateral (relative to contralateral) COX-2 mRNA upregulation was observed at 1 h p.i. 
on day 1 but not on day 5. The intensity of COX-2 expression in carrageenan-treated 
animals was not significantly altered by daily repeated carrageenan treatment. 
The contrasting results of studies 3.1 and 3.2 suggest that spinal COX-2 contributes to the 
induction of hyperalgesia associated with inflammatory injury, but its regulation in 
response to inflammatory stimulation is critically determined by the intensity and the 
frequency of that stimulation. Prostaglandins, the products of COX activity, are known to 
play an important role in central sensitisation. These studies suggest that induction of 
spinal COX-2 may play an important role in the rapid central synthesis of prostaglandins, 
which activate and sensitise central nociceptive neurons, contributing to the development 
of hyperalgesia following peripheral injury. However, COX-2 induction does not appear 
to playa significant role in the maintenance of enhanced nociceptive transmission, or in 
the induction of subsequent plasticity of nociceptive processing associated with mild 
repetitive inflammatory injury. It is possible that an endogenous regulatory mechanism 
may exist which inhibits central COX-2 induction in response to mild persistent or 
repeated injury. This hypothesis is supported by evidence gained from studies of the role 
of prostaglandins in persistent hyperalgesia induced by intraplantar CF A treatment. Hay et 
at. (1996) reported that prostaglandin levels in lumbar spinal cord measured over 7 days 
following CF A treatment remained elevated for the duration of the study, while COX-2 
mRNA levels were only transiently increased. It must be noted that prolonged elevation of 
central spinal PO levels may be maintained through synthesis by non-neuronal cells, 
including astrocytes (Marriot et al., 1990) and non-neuronal cells such as endoneurial mast 
cells, macrophages, neutrophils and Schwann cells (Tracy & Walker, 1995). 
In non-neuronal tissues, inhibition of COX activity using non-steroidal anti-inflammatory 
drugs (NSAID's) induces COX-1 and COX-2 mRNA expression (Lu et al., 1995). Hay 
and De Bellroche(1997) reported that systemic administration of a COX-2 selective 
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NSAID resulted in upregulation of spinal COX-2 mRNA expression. This evidence 
supports the existence of an feedback mechanism in which COX-2 mRNA expression is 
induced in response to enzyme antagonism or reduced enzyme activity. It is possible, 
conversely, that high spinal prostaglandin levels may provide the endogenous central 
regulatory mechanism which inhibits central induction of COX-2 following inflammatory 
injury, or central COX-2 mRNA expression may be regulated by any of the many other 
neurotransmitter pathways activated by inflammatory injury. 
Bilateral upregulation ofCOX-2following inflammatory injury 
In study 3.1, significant upregulation of COX-2 mRNA was observed in both ipsilateral 
and contralateral laminae IIII following carrageenan treatment, although hyperalgesic 
behaviour was absent in the contralateral limb. There is now substantial evidence 
(reviewed by Koltzenburg et al., 1999), to suggest that unilateral stimulation can produce 
bilateral effects in the somatosensory system. In addition to contralateral hyperalgesic 
behaviour following repeated unilateral inflammatory stimulation (Kayser et aI., 1998; 
Levine et al., 1986), contralateral modulation of expression of numerous genes involved in 
nociceptive processing has been reported following unilateral stimulation, including 
substance P, CGRP, neuropeptide Y, galanin and ~-endorphin ( Hughes & Smith 1989; 
Piehl et al., 1991, Zhang et al., 1996). Ichitani et al. (1997) similarly reported strong 
bilateral up-regulation of COX-2 mRNA following high-dose carrageenan inflammation. 
The disparity between COX-2 mRNA upregulation and hyperalgesic behaviour suggests 
that a critical level of COX-2 and consequently prostaglandin induction is required to 
induce hyperalgesic behaviour; it must be noted that prostaglandins are only one of many 
neurotransmitters involved in the central response to peripheral inflammation. 
3.4.6.3. Conclusions 
These studies indicate that COX-2, but not COX-I, gene expression in laminae If II, plays a 
significant role in the induction of hyperalgesia associated with inflammatory injury. 
Expression of cyclo-oxygenase enzymes in lamina V does not appear to contribute to the 
induction of hyperalgesic behaviour following inflammatory injury. Induction of COX-2 
mRNA following inflammatory injury is dependent on the intensity and the frequency of 
inflammatory stimulation, and may be subject to endogenous inhibitory regulation. 
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3.4.7. ENDOGENOUS OPIOIDS-PROENKEPHALIN AND PRODYNORPHIN 
3.4.7.1. Proenkephalin 
Lamina V 
Carrageenan treatment did not alter the magnitude of proenkephalin mRNA expression 
(relative to saline treatment) in lamina V, and repeated carrageenan treatment did not alter 
the magnitude of proenkephalin mRNA expression. In study 3.1, 0.5% carrageenan 
treatment induced significant ipsilateral upregulation of proenkephalin mRNA expression 
(relative to contralateral expression) in lamina 5, although further analysis did not indicate 
a particular week on which this effect occurred. This suggests no role for enkephalin-
mediated mechanisms located in lamina V in the induction or maintenance of hyperalgesia 
associated with mild inflammatory injury. 
Laminae IIII 
Previous studies have identified enhanced proenkephalin expression in the superficial 
dorsal hom following intense inflammatory stimulation using high-dose carrageenan or 
CFA treatment (Iadarola et at., 1988a; Draisci et at., 1989; 1991; Noguchi et al., 1992; 
Przewlocka et at., 1992). Using in-situ hybridisation techniques, Noguchi et at.(l992) 
reported that carrageenan inflammation (4.5-6 mg in 200 III solution) induced a two-fold 
increase in ipsilateral proenkephalin mRNA expression in laminae IIII. Iadarola et 
at.(1988a) reported a 50-80% increase in proenkephalin mRNA (quantified using cDNA 
hybridisation techniques) following intraplantar CFA treatment, which was not however 
followed by a significant enhancement of met-enkephalin peptide expression. Przewlocka 
et at.(1992) reported persistently enhanced ipsilateral proenkephalin mRNA expression in 
laminae IIII for 14 days following intraplantar CF A treatment. 
The results of studies 3.1 and 3.2 are consistent with previous reports of proenkephalin 
gene upregulation following intense inflammatory stimulation and demonstrate, moreover, 
that proenkephalin mRNA is also consistently and unilaterally upregulated in response to 
mild inflammatory injury in an intensity-dependent fashion. In study 3.1, 0.5% (but not 
0.1 %) carrageenan treatment induced significant upregulation of ipsilateral proenkephalin 
mRNA expression (relative to saline treatment) in laminae IIII, the intensity of which was 
not altered by weekly repeated treatment. Ipsilateral proenkephalin mRNA expression 
was significantly upregulated (relative to contralateral) in carrageenan and saline-treated 
animals. 
A similar pattern of proenkephalin mRNA expression was observed in study 3.2. Daily 
repeated carrageenan treatment did not induce significant upregulation of ipsilateral 
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proenkephalin mRNA expression (relative to saline treatment) at 1 h p.i. or 6h p.i. 
Ipsilateral proenkephalin mRNA expression was significantly upregulated (relative to 
contralateral expression) in carrageenan-treated animals at 6 h p.i. on days 2, 3 and 5 
(although not on day 1) [and also at 1 hpj. on days 3 and 5]. Ipsilateral proenkephalin 
mRNA expression was significantly upregulated (relative to contralateral expression) in 
saline-treated animals at 6 hpj. on day 1 but not on day 5 [and also at Ih pj. on day I). 
The induction of ipsilateral upregulation of proenkephalin mRNA expression by saline 
treatment in the absence of altered in nociceptive responses suggests that tonic opioid 
inhibition of excitatory nociceptive transmission may be enhanced in response to even 
mild peripheral stimulation, presumably directed towards the maintenance of nociceptive 
sensitivity at 'physiological baseline' up to a critical level of inflammatory insult. Due to a 
high constitutive level of expression of proenkephalin mRNA and met-enkephalin peptide 
(Majane et al., 1983; Iadarola et a!., 1985; 1986), subtle changes in proenkephalin mRNA 
expression are not easily identified. The limited sensitivity of the semi-quantitative 
analytical employed in the present study may explain the lack of significant up regulation 
of ipsilateral proenkephalin mRNA expression in 0.1% carrageenan-treated animals 
relative to saline-treated animals in studies 3.l and 3.2, although ipsilateral (relative to 
contralateral) proenkephalin mRNA upregulation was observed in both 0.1 % and saline-
treated animals. 
While regulation of proenkephalin mRNA expression in a carrageenan model of repeated 
inflammatory stimulation has not been reported previously, Przewlocka et al.(1992) 
reported no change in the magnitude of ipsilateral proenkephalin mRNA upregulation over 
14 days following induction of CF A-induced arthritis, a stimulus that is dramatically more 
intense and prolonged than that employed in the present studies. In studies 3.1 and 3.2, the 
magnitude of carrageenan and or saline-induced ipsilateral proenkephalin mRNA 
induction observed at 6 h p.i. was not significantly altered by weekly or daily repeated 
treatment. This suggests that the tachyphylaxis of hyperalgesic behaviour observed in 
study 3.2 was not mediated predominantly by a significant upregulation of opioidergic 
inhibitory transmission in the spinal cord. 
It is worthy of note that the opioid system, while predominantly active in the spinal cord 
(Meagher et al. 1993), also enhances descending inhibition through opioid receptor 
stimulation in higher centers including the peri-aqueductal grey matter (Budai & Fields, 
1998) and the forebrain (Grau, 1987; Meagher et a!., 1989; 1990). Plasticity of 
nociceptive behaviour following repeated inflammatory stimulation could also potentially 
reflect enhanced opioidergic transmission in higher centres. 
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3.4.7.2. Prodynorphin 
Carrageenan treatment did not significantly alter the intensity of prodynorphin mRNA 
expression (relative to saline treatment) in laminae IIII or lamina V. The results of studies 
3.1 and 3.2 contrast with previous reports of dramatic induction of prodynorphin mRNA 
and peptide expression following high-dose carrageenan or CF A treatment. Iadarola et al. 
(1988b) reported rapid unilateral and segmentally specific enhancement of prodynorphin 
mRNA expression in the dorsal hom (within 8h of treatment), followed by enhanced 
dynorphin A(1-8) peptide expression (from 2 days post-treatment to peak at 4 days post-
treatment) associated with intense peripheral inflammation and thermal hyperalgesic 
behaviour induced by a variety of inflammatory agents including carrageenan and CF A. 
Ruda et al.(1988) reported enhanced expression ofpreprodynorphin mRNA and dynorphin 
peptide in laminae IIII and V NI of the lumbar spinal dorsal hom following intraplantar 
CFA treatment. Nahin et al.(1989) reported that CFA intraplantar inflammation produced 
a significant increase in the actual number of neurons that expressed dynorphin in laminae 
I1II. Previous studies typically reported a delay of at least 24 h between the induction of 
prodynorphin mRNA transcription and subsequent expression of the active peptide and 
also typically reported that the observed expression of active peptide appeared to fall short 
of the magnitude of mRNA upregulation. Iadarola et al.(1988b) reported that dynorphin 
peptide levels typically began to rise 24 h after carrageenan treatment, and peaked some 
72 h following CF A treatment. Two potential explanations for this disparity have been 
proposed (Iadarola et al., 1988a,b); translation of active peptide may require substantial 
prior accumulation of mRNA, or diffusion of dynorphin peptide products into the 
extracellular environment may prevent accumulation of the active peptide at the site of 
production. 
Controversy persists over the consequences of increased spinal dynorphin expreSSIOn 
following inflammatory injury, with both pro- and anti-nociceptive actions attributed to the 
peptide. Dynorphin induces expansion of the receptive fields of lamina I projection 
neurons following intense inflammatory stimulation (Hylden et al., 1989; 1991), and it has 
been speculated that dynorphin may contribute to the development of contralateral 
hyperalgesic behaviour following intense inflammatory injury (Millan & Colpaert 
1990;1991). However, K receptor activation has also been shown to attenuate hyperalgesia 
associated with inflammation (Millan et al., 1985; 1988; Kayser & Guilbaud, 1991; Millan 
& Colpaert, 1990; 1991), while dynorphin application has been reported to produce 
hypo algesia in normalgesic animals (Han & Xie, 1982; Piercey et al., 1982; Przewlocki et 
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at., 1983; Spampinato & Candelletti, 1985). It is worthy of note that dynorphin 
administration often produces profound motor dysfunction and neurotoxicity (Hermann & 
Goldstein, 1985; Faden & Jacobs, 1984), so that reports of altered nociceptive behaviour 
following dynorphin administration should be interpreted with a degree of caution. 
Studies 3.1 and 3.2 identified no significant change in dynorphin gene expression 
following mild repetitive inflammatory injury and thus no key role for the peptide in the 
induction of plasticity of nociceptive behaviour associated with mild repetitive 
inflammatory injury. 
3.7.3. Conclusions 
The pattern of endogenous opioid gene expression induced by mild repetitive 
inflammatory stimulation in studies 3.1 and 3.2 differed in several respects from that 
which has been previously reported in association with severe acute or persistent 
inflammatory stimulation. Studies 3.1 and 3.2 indicate that enkephalin gene expression is 
consistently and dose-dependently upregulated following mild stimulation, and that the 
magnitude of this upregulation is not altered by repetitive stimulation. This confirms a 
tonic role of endogenous enkephalinergic inhibition of ascending nociceptive transmission, 
presumably directed towards maintenance of 'physiological' baseline central nociceptive 
sensitivity. In contrast, studies 3.1 and 3.2 indicate that while dynorphin may contribute to 
the induction and/or maintenance of central nociceptive plasticity associated with intense 
inflammatory injury, it does not contribute to tonic opioidergic regulation of nociceptive 
transmission and has no physiological antinociceptive role. 
3.4.8. GAD 67 
Lamina V 
Carrageenan treatment did not alter the magnitude of GAD 67 gene expression (relative to 
saline treatment) in lamina V. Repeated carrageenan treatment did not alter the magnitude 
of GAD 67 gene expression in lamina V. This suggests no key role for GAB A-mediated 
mechanisms located in lamina V in the induction or maintenance of hyperalgesia 
associated with mild inflammatory injury. 
Laminae IIII 
Previous studies have reported enhanced GABA gene expression in the superficial dorsal 
hom following intense inflammatory stimulation using high-dose carrageenan or CF A 
treatment. Castro-Lopes et at. (1994b) reported an ipsilateral increase in spinal GABA 
protein expression and in the total number of GABA-immunoreactive cells in the 
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superficial dorsal hom following intraplantar treatment with 6 mg carrageenan in an 
injection volume of 150 ~l (some 120 fold greater than the dose administered in the 
present study). In study 3.2, carrageenan treatment did not significantly alter the intensity 
of GAD 67 mRNA expression (relative to saline treatment) in laminae IIII. In both 
carrageenan and saline-treated animals, GAD 67 mRNA expression was ipsilaterally 
upregulated in laminae IIII neurons at Ih p.i. (although not on day 5 in carrageenan-treated 
animals) but not at 6h p.i. Repeated treatment did not alter the magnitude of gene 
expression. There was no significant difference in the level of GAD 67 gene expression at 
Ih and 6h p.i., suggesting that enhancement of GAD 67 gene expression was rapid and 
maximal at 1 h p.i. 
Saline treatment also induced ipsilateral upregulation of GAD 67 mRNA expression, in the 
absence of inflammation or altered nociceptive responses. This suggests that tonic 
GABAergic inhibitory transmission in the superficial dorsal hom is enhanced by mild 
peripheral stimulation. 
In conclusion, study 3.2 demonstrates that even mild inflammatory stimulation induces 
rapid upregulation of GABA. Plasticity of nociceptive behaviour associated with daily 
repeated mild inflammatory injury does not appear to be mediated by upregulation of 
GABAergic transmission. 
3.5. GENERAL CONCLUSIONS 
As was discussed in chapter 1, spinally-mediated plasticity of nociceptive responses may 
represent both transitory, reversible, stimulus-dependent potentiation of dorsal hom 
neuronal responses, or persistent, phenotypic modification of dorsal hom sensory neurons 
such that they persistently respond in an amplified manner to a given stimulus. 
Consistency of baseline nociceptive responses observed in studies 3.1 and 3.2 would 
suggest that a fundamental phenotypic alteration in dorsal hom nociceptive neuronal 
responsiveness was not induced in either study. It must be recognised, however, that 
baseline responses were measured on each day prior to carrageenan treatment. 
Recognising that inflammatory injury immediately and fundamentally alters peripheral and 
central nociceptive transmission, it is possible, if unlikely, that long-lasting (phenotypic) 
alteration of inflammatory nociceptive transmission could have occurred, without 
simultaneous without long-lasting modulation of 'physiological' nociceptive transmission. 
In-situ hybridisation analysis of gene expression was performed at 6 h p.i., since the 
maximal inflammatory response, accompanied by thermal and mechanical hyperalgesia 
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was present at this time point (Chapter 2). In-situ hybridisation analysis of gene 
expression was also performed at 1 hpj. in study 3.2, since it was recognised that 
expression of several genes under investigation- most notably the immediate early genes 
jun D, tPA and zif/268- was transient in nature, so that analysis performed only at 6 hpj. 
could fail to detect any change in the intensity of their expression. Failure to detect 
upregulation of immediate early gene expression in studies 3.1 and 3.2 thus does not rule 
out the possibility that their expression was modulated in response to inflammatory injury. 
Dramatic upregulation of immediate early gene expression is a hallmark of synaptic 
plasticity in higher centres (Morgan & Curran, 1991, reviewed by Morris, 1997), and the 
absence of intensity-dependent upregulation of these lEG's would therefore suggest that 
LTP mediated through upregulation of zif/268, jun D or tPA did not contribute to the 
development of hyperalgesia in study 3.1 or 3.2. However, the transient nature of 
stimulus-induced lEG upregulation means that their involvement in the induction of 
nociceptive plasticity observed in studies 2.1 and 2.2, while unlikely, cannot be ruled out 
definitively. 
Studies 3.1 and 3.2 investigated expression of genes which are upregulated and 
subsequently translated into active peptides or proteins over a wide time-scale; while 
immediate early genes can be upregulated in less than one hour following specific 
stimulation, and rapidly translated into transcription factors (Morgan & Curran, 1991), 
late-stage effector genes such as proenkephalin and prodynorphin, are not upregulated 
immediately following specific stimulation, requiring activation by up-stream intracellular 
mediators, and are not translated into active peptides until at least several hours following 
inflammatory stimulation. 
The pattern of gene expression identified following mild repetitive inflammatory 
stimulation differed in several respects from that which has been reported previously 
following intense inflammatory stimulation (Herdegen & Zimmermann, 1995; Stanfa and 
Dickenson, 1995). It is possible that previous reports of dramatic upregulation of key 
genes (immediate early genes, GABA and prodynorphin) following intense inflammatory 
stimulation may in fact represent an 'extreme' or 'end-stage' molecular response and do 
not accurately represent the physiological response of the spinal cord to those levels of 
injury which have clear clinical relevance. 
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In lamina V, there was no strong evidence of altered gene expression induced by repetitive 
mild inflammatory injury. The role of lamina V in nociceptive processing appears to be a 
predominantly modulatory one in which ascending excitatory information and descending 
inhibitory information are integrated (reviewed in chapter 1). It is possible that the 
modulatory role of primary afferent fibres located in lamina V was not engaged in 
response the mild intensity inflammatory stimulus used in studies 3.1 and 3.2, and may 
require more intense or persistent noxious stimulation for its engagement in central 
modulation of nociceptive transmission. 
In laminae IIII, both carrageenan and saline treatment induced enhanced ipsilateral 
(relative to contralateral) expression of all of the markers that were investigated (with the 
exception of prodynorphin), suggesting that those markers which were not activated 
specifically by noxious stimulation, nonetheless contributed to the spinal sensory response 
to general peripheral stimulation. 
In study 3.1, hyperalgesia associated with carrageenan treatment correlated closely with 
significantly enhanced transcription of CaMKIla mRNA in laminae l/ll; moreover, 
tachyphylaxis of hyperalgesic behaviour in study 2.2 correlated with attenuation of 
CaMKII a upregulation in study 3.2. Since increased expression of CaMKIIa, leading to 
regulation of expression of a range of kinase-dependent receptors and intracellular 
mediators, is a hallmark of LTP induction in higher centres (reviewed by Morris, 1997), 
this evidence suggests that LTP-like central plasticity of nociceptive transmission in the 
dorsal hom could have contributed to the development of hyperalgesia observed in studies 
3.1 and 3.2. As an intracellular signalling molecule that is instantaneously activated by 
neuronal stimulation, alterations in CaMKlIa expression could induce rapid nociceptive 
plasticity through modulation of the activity of many nociceptive mediators. It is worthy 
of note that, while predominantly associated with enhancement of glutaminergic 
transmission, CaMKIIa also has the potential to enhance inhibitory transmission and the 
factors which control the targets of CaMKIIa upregulation in dorsal hom neurons 
following inflammatory injury have not yet been determined. 
In study 3.1, mild inflammatory injury induced consistent significant upregulation of both 
agents implicated in the induction of enhanced nociceptive transmission/central 
sensitisation (COX-2), and agents associated with the attenuation of nociceptive 
transmission (proenkephalin), in the superficial dorsal hom, demonstrating once again that 
ultimate modulation of pain sensation following inflammatory injury is determined by the 
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interaction of excitatory and inhibitory transmitter pathways. Evidently, the hyperalgesia 
observed in study 2.1 was the result of ultimate excitatory dominance, while the 
tachyphylaxis observed in study 2.2 reflected attenuation of excitatory dominance. 
Notably, enkephalin has been implicated in the induction of both LTP and LTD in higher 
centres, and thus could have contributed to the induction of LTD of nociceptive 
transmission in study 2.2. 
Expression of COX-I, prodynorphin or GAD 67 mRNA did not appear to be modulated in 
relation to the intensity of inflammatory injury or in relation to changes in nociceptive 
responses. This would suggest that these mediators did not play a key role in the 
modulation of spinal nociceptive transmission associated with mild inflammatory injury, 
neither in the development of hyperalgesia (study 2.1), nor in the subsequent adaptive 
tachyphylaxis of hyperalgesia induced by mild repetitive inflammatory stimulation (study 
2.2). 
With the possible exception of CaMKIIa, changes in gene expression did not correlate 
closely with plasticity of nociceptive behaviour induced by daily repeated carrageenan 
treatment. Spinal mechanisms represent only one component of the central adaptive 
response to injury, and it is highly likely that that spinal mechanisms alone did not mediate 
the tachyphylaxis of hyperalgesia observed in study 2.2 (discussed in chapter 2). 
An enormous number of candidate genes have been implicated in the induction and 
maintenance of synaptic plasticity in the central nervous system. Even in higher centres, 
where there is an infinitely greater level of understanding of the molecular basis and 
functional relevance of synaptic plasticity than exists at present in the spinal cord, many 
important issues remain unresolved (reviewed by Morris, 1997). In the hippocampus, 
where synaptic plasticity has been most extensively studied, experiments remain 
predominantly at the stage of recording gene regulation associated with plasticity, rather 
than directly manipulating expression of individual genes and recording the effect on 
neuronal function. The significance of synergistic or parallel expression of key genes in 
relation to the ultimate modulation of neuronal excitability is not understood. The 
importance of post-transcriptional processes in regulating gene expression at the mRNA 
level during functional plasticity is similarly poorly understood. 
The selection of target genes for in-situ hybridisation analysis in studies 3.1 and 3.2 was 
hypothesis-driven, based on existing knowledge of the molecular mediators of synaptic 
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plasticity in higher centres. An alternative non hypothesis-driven approach to 
identification of genes that modulate or maintain the capacity for neuronal plasticity, using 
molecular screening techniques, may help to identify additional important target genes, 
which could then be studied in greater detail using in-situ hybridisation techniques to 
highlight the specific location of their regulation in the spinal cord. Several techniques 
have recently evolved to permit isolation of genes, known and unknown, which are 
involved in synaptic plasticity and other neuronal processes (reviewed by Befort & 
Costigan, 1999). These include differential display techniques, expressed sequence tags 
(random sequencing of clones from a cDNA library), serial analysis of gene expression 
(SAGE), subtractive cloning techniques, gene grids and microarrays. 
Differential display uses a polymerase chain reaction (PCR)-based protocol to produce a 
molecular 'bar-code' of a cDNA sample. If all reaction conditions are maintained constant 
between control and treated animals, then it is proposed that any differences in the 
fingerprint are the result of differentially regulated genes (reviewed by Matz & Lukyanov, 
1998). Differential display is inexpensive and relatively simple to perform, but is prone to 
a high false positive rate due to the fact that PCR is an amplification process. 
Microarray and gene grid techniques use high-density arrays of oligonucleotides, which 
are generated onto silica microchips. Control and treatment RNA samples are hybridised 
with separate oligonucleotide microarrays, and the gene chips are then scanned to identify 
differential expression of specific genes. While highly sensitive, micro arrays and gene 
grids are highly expensive and remain at present within the domain of pharmaceutical 
companies rather than the general research environment. 
EST and SAGE techniques produce cDNA libraries for control and treated populations, 
which are then sequenced using an automatic sequencer. As with microarrays, these 
techniques are highly sensitive but highly expensive. 
While these techniques may be invaluable in the identification of genes implicated in 
physiological and pathophysiological pain transmission, any genes identified will require 
thorough investigation using techniques such as in-situ hybridisation within models of 
inflammatory injury such as those used in studies 3.1 and 3.2, in order to confirm a 
significant role in the mechanisms that operate to produce physiological or 
pathophysiological pain. A combination of behavioural studies, high-sensitivity gene 
isolation techniques, and high-resolution molecular biology techniques such as in-situ 
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hybridisation promise to unlock the holy grail of the molecular basis of nociceptive 
plasticity in the future, providing thorough understanding of the molecular basis of 
synaptic plasticity in the dorsal hom and its contribution to physiological and 
pathophysiological pain transmission. This knowledge should help to identify new targets 
and strategies for the prevention and treatment of post-injury hyperalgesia and persistent 
pain states. 
226 
CHAPTER 4: CHARACTERISATION OF A METHOD FOR ORGANOTYPIC 
SLICE CULTURE OF SPINAL CORD 
Science is magic that works 
Vonnegut 
4.1 INTRODUCTION 
4.1.1. Principles of organotypic culture 
As our knowledge about molecular mechanisms regulating central nociceptive 
transmission increases, we require more sensitive means of investigating and manipulating 
these mechanisms. A variety of culture systems have been developed to study the 
structure and behaviour of spinal neurons (reviewed by Morrison et al., 1998). Primary 
neuronal cultures permit the study of either a single cell population or a heterogeneous cell 
population, allowing the exploration of molecular changes induced by specific stimuli, and 
interactions between neurons (e.g. Vartianen et al., 1999; Crain et al., 2000; Ma et al., 
1999). However, they are limited in their usefulness in the investigation of central 
nociceptive transmission, which is mediated through co-ordinated activity of a network of 
neurons located in different laminae of the dorsal hom. 
Organotypic slice cultures of spinal cord provide a potentially valuable tool for the 
investigation of intracellular and inter-cellular processes responsible for the control and 
integration of neurotransmission in the spinal cord, providing an 'in-vitro' preparation of 
living tissue in which anatomical structure and local neuronal circuitry are preserved. Two 
types of system have evolved for organotypic culture of nervous tissue (reviewed by 
Gahwi1er et a!., 1997), namely the 'roller-tube' technique, and the 'interface' (semi-
permeable membrane) technique. 
Roller-tube culture systems were first described by Hogue(1947) and subsequently 
characterised in detail by Gahwiler(1988). Sections of CNS tissue are stabilised in a 
plasma clot (Hogue, 1947) or in a collagen matrix on glass coverslips (Costero & Pomerat 
1951; Crain & Peterson, 1963), which are rotated slowly to provide continuously 
alternating oxygenation and nutrition to cultured tissue. 
An 'interface' system for organotypic culture of nervous tissue was first described by 
Yamamoto et al.(1989) using 'transwell' semiporous membranes, and by Stoppini et 
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al. (1991), using 'millicell' semiporous membranes. In interface systems cultures are 
continuously nourished by culture medium from below and oxygenated from above. 
Tissue cultured using roller-tube or interface culture systems display slightly different 
properties (reviewed by Gahwiler et aI., 1997). Irrespective of the original thickness of the 
slice preparation, roller-tube cultures flatten to a greater degree than interface cultures to 
provide a thin near-monolayer of cells. Roller tube cultures have been used preferentially 
in experimental procedures such as imaging and electrophysiological recordings that 
demand optimum access to, and visualisation of, individual neurons. However, CNS slices 
cultured using roller tube techniques are embedded in plasma or collagen for the first 36-
48 hours so that there is some delay before they can be used in experiments. Interface 
cultures are more easily prepared than roller-tube cultures and can be observed and 
manipulated at all stages of culturing. A novel technique for 'thin slice culture' of CNS 
tissue (sections up to 150 j.lm thick) on collagen-coated glass coverslips or culture dishes 
has recently been described (Parsley & Cheng, 1998), which offered the advantages of 
superior microscopic visualisation, enhanced tissue oxygenation and cost-effectiveness 
compared to previously reported methods of interface slice culture. 
All organotypic culture systems share certain environmental requirements (reviewed by 
Gahwiler et al., 1997), that include strict sterility and stable incubation conditions 
(standardly 37°C in an atmosphere containing 5% CO2), Culture media used in 
organotypic culture of neuronal tissue typically consist of a combination of 25% serum 
(typically horse, donkey or foetal calf), 50% synthetic medium, such as basal medium 
(Eagle) or modified Dulbecco's medium and 25% balanced salt solution enriched with 
glucose to a final concentration of 5.6mM. Certain experiments requiring precise control 
of the initial composition of the medium, particularly those studies which investigate 
embryonic development of the CNS, utilise complex serum-free media. For example, 
Annis et al.(1990) defined a complex serum-free medium for use in the investigation of 
axonal connectivity and development in cerebral cortex and forebrain organotypic culture 
systems, reporting that precise control of the composition of the culture medium provided 
superior neuronal metabolism and process outgrowth. 
The characteristics and viability of an organotypic culture system are critically influenced 
by the age (or stage of developmental) of the tissue from which the cultures are derived, 
and the thickness of the slice placed in culture (reviewed by Gahwiler et ai., 1997). 
Organotypic cultures of embryonic central nervous tissue have been well characterised and 
are reported to display superior resistance to oxidative stress relative to post-natal nervous 
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tissue. However, neurogenesis and neuronal migration of sensory neurons in the dorsal 
hom occurs throughout embryonic development and continues into the early post-natal 
period (reviewed by Bayer & Altman, 1995). This is of particular relevance when using 
organotypic culture systems to study spinal mechanisms involved in nociceptive 
transmission where it is important to localise the laminar arrangement of the spinal cord 
and ascending and descending tracts in spinal white matter. In addition, considerable 
ongoing cell differentiation and migration in embryonic organotypic culture systems can 
lead to distortion of the organotypic organisation of the cultured tissue. 
The thickness of tissue sections placed in culture also critically influences their survival in 
culture and suitability for morphological, immunohistochemical and electrophysiological 
investigations (reviewed by Morrison et al., 1998). Parsley et al., (1998) compared the 
viability of 80 /lm, 150 /lm and 300 /lm organotypic spinal cord cultures, reporting 
survival of 78 ± 7%, 95 ± 3% and 50 ± 7% of cells respectively after 14 days in culture. 
They observed that 300 /lm thick sections were too thick to permit visualisation of 
individual cells, while considerable cell death was apparent in 80 /lm sections, associated 
with trauma during the sectioning procedure, and concluded that 150 /lm sections offered 
optimal visualisation of individual neurons and viability in culture. 
4.1.2. Organotypic culture of spinal cord 
Organotypic culture of embryonic and neonatal rat spinal cord has been described 
previously in both roller-tube systems (Crain & Peterson, 1963; Bunge et al., 1965; Hosli 
& Hosli, 1987; Braschler et al., 1989; Delfs et al., 1989) and interface systems (Rothstein 
et al., 1993; Rothstein & Kuncl 1995; Manabe et al., 1999). In the spinal cord, 
organotypic culture techniques have been used to investigate a variety of neuronal 
processes and transmitter pathways including: cellular receptor location (Hosli & Hosli, 
1987); transcription factor expression (Manabe et at., 1999); neuroprotective strategies in 
spinal neurons (Rothstein & Kuncl, 1995) and glutamate neurotoxicity in ventral motor 
neurons (Rothstein et at., 1993). Previously reported techniques for organotypic culture of 
post-natal rat spinal cord typically cultured 350-500 /lm sections of spinal cord, which 
required fixation and further sectioning prior to further histochemical procedures. 
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4.1.3. Aims and Objectives 
Despite its considerable potential, the technique of organotypic culture has not yet been 
widely used to investigate aspects of central nociceptive transmission. The objective of this 
study was to characterise a simple 'interface' technique for organotypic culture of post-
natal spinal cord which would facilitate investigation of molecular mechanisms involved in 
central nociceptive transmission. 
Since the superficial dorsal hom plays a dominant role in nociceptive transmission, it was 
of particular interest to evaluate viability and activity of neurons in this location in 
organotypic cultures of spinal cord. 
4.2 MATERIALS AND METHODS 
4.2.1. Culturing procedure 
A sterile 3% solution of agar (A-6549, SIGMA, UK), was melted, set in petri dishes, and 
stored at 4°C to provide a stable mount against which stabilised sections of spinal cord 
could be sectioned. 
Sprague-Dawley or Wistar rat pups were used in all experiments. In preliminary studies, 
spinal cord collected from embryonic rats (embryonic day 17-19) and neonatal rat pups 
(aged 5-14 days post-natum[PN] was sectioned, and placed in organotypic culture. 
However, embryonic tissue and early post-natal tissue (day 5-7 PN) was difficult to 
stabilise and section, and consequently, all subsequent studies were performed on neonatal 
rat pups aged 10-14 days PN. Rat pups were euthanased using an overdose of 
pentobarbitone sodium (Sagatal, Rhone-Merieux, 0.25ml) administered by intraperitoneal 
injection. Following dissection of the spinal column, the spinal cord was ejected by high-
pressure hydraulic injection using a method described by Meikle et al. (1981). The spinal 
cord was immersed in ice-cold Hank's balanced salt solution (HBSS, GIBCO, 24020-091, 
UK) and the pia mater teased off whenever possible by fine dissection. 
A 6-8mm section of lumbar spinal cord was excised, stabilised in agar and sectioned using 
a modification of the method described by Pickering et al.(1994). A sterile 2% solution of 
agar was prepared and melted, then poured into a custom-made mould and cooled to 35-37 
0c. The excised section of spinal cord was placed in the melted agar solution, the mould 
was transferred to ice-cold HBSS and allowed to set. Once set, the stabilised section of 
spinal cord was placed against a solid 3% agar mount, fixed on the base of a vibratome, 
and bathed in ice-cold HBSS. With the vibratome set at slow speed and high vibration 
frequency, transverse slices of diameter 150-300 )..tm were collected, transferred to a sterile 
environment, and washed three times in sterile HBSS. Slices were transferred to sterile 
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culture wells [4 em diameter pet-track -etched membrane cell culture inserts (Becton 
Dickenson, UK) placed in NUNCLON surface disposable culture wells], containing 1 ml 
of sterile culture medium composed of(100 ml): 
49.6ml Dulbecco's modified Eagles medium (D-MEM) containing 4500mgll D-Glucose 
and GlutaMAX I™, without sodium pyruvate.( 61965-026, GIBCO, UK) 
24.8ml HBSS 
24.6 ml foetal calf serum (heat inactivated) (10108-157, GIBCO, UK) 
1ml 1M penicillin/Streptomycin (15140-114, GIBCO, UK) 
Cultures were incubated for up to 14 days at 35°C in a humidified incubator supplied with 
95% oxygen and 5% carbon dioxide and inspected daily using a light microscope for 
evidence of cell death and contamination. Culture medium was completely replaced at 36 h 
intervals. 
4.2.2. Histochemical analyses 
Histochemical procedures were performed on freshly harvested spinal cord sections and on 
cultured slices after 1-5 days in culture. Slices were fixed in an ice-cold solution of 4% 
paraformaldehyde (PF A), and washed three times (for 5 minutes) in phosphate-buffered 
saline (PBS) prior to NADPH-d staining and immunocytochemical analysis. All sections 
were mounted after processing using Histomount (HS-l 03, National Diagnostics, UK). 
4.2.2.1 MTT Assay 
The 3-(4,5-dimethyl-2-thiazolyl)- 2,5-diphenyl-2H tetrazolium bromide (MTT) assay was 
used as a simple and rapidly visualised colorimetric method of assessing cell viability, 
proliferation and cytotoxicity in culture systems (Leeder et at., 1988; Liu et at., 1997). A 
stock solution of 5mglml MTT in sterile 0.9% saline was prepared, stored at -20°C and 
diluted in culture medium to a working concentration of 500I-Lglml. Cultures were 
incubated for 2 h in MTT solution. Light microscopy was used for qualitative assessment 
of the intensity and localisation of MTT staining. 
4.2.2.2. NADPH diaphorase assay 
The reduced nicotinamide adenine dinucleotide phosphate diaphorase (NADPHd) assay in 
paraformaldehyde-fixed tissue was used to identify nitric oxide synthase (NOS) expression 
in the central nervous system. NADPH-d staining was performed according to the method 
of Valtschanoff et at., (1992). Sections were incubated in O.lM PBS containing 0.25% 
Triton X-I 00 for 10 minutes then transferred to a lightproof container containing a freshly 
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prepared solution of 0.1 M PBS, 0.25% Triton X-IOO, 0.5mg/ml ~-NADPH (N3886, 
SIGMA UK) and 0.2mglml nitro blue tetrazolium (NBT, 35H5043, SIGMA, UK). 
Sections were incubated in this solution at 37°C for 12-18 hours. Following incubation, 
sections were rinsed in O.lM PBS, dehydrated in serial solutions of ethanol (70-100%) and 
histoclear mounted. Light microscopy was used to assess the intensity and localisation of 
NADPH-d staining. 
4.2.2.3. Immunocytochemistry 
Fixed slice cultures were incubated at room temperature in IX PBS containing 5% Triton 
X-IOO for 30 minutes, followed by blocking solution [IX PBS containing 15% normal 
goat serum (NGS) ] for 60 minutes, then incubated overnight at 4°C with specific 
antibodies ( prepared in lXPBS with 3% NGS and 0.5% Triton X-I 00) against: 
opioid fJ-receptor (Oncogene Research, PCI65L, UK), used at a dilution of 1:2000 (l0~ 
glml) 
calcium-calmodulin lanase IIa (CaMKlla) (Boehringer-Mannheim 1481 703, UK), used at 
a dilution of 1: 2000 (10~g/ml) 
methionine-enkephalin (met-enk) (Affiniti Research products EA1150, UK), used at a 
dilution of 1 :5000 (10~g/ml) 
After rinsing, cultures were incubated with 0.5% biotinylated secondary antibody (Vector, 
UK) in a PBS solution containing 1.5% NGS for 1 hour, rinsed three times in PBS and 
then incubated with ABC-conjugated horseradish-peroxidase (ABC Elite kit, Vector, UK), 
in accordance with manufacturer's instructions. The peroxidase was visualised using VIP 
peroxidase substrate kit (VIP) according to manufacturer's instructions, producing a violet 
reaction product 2-8 minutes after the addition of peroxidase substrate solution. Cultures 
were rinsed and dehydrated in serial solutions of ethanol (70-100%) and histoclear before 
coverslipping. 
Quantitative analysis of CaMKIIa and met-enkephalin expression in the superficial dorsal 
hom was performed under light microscopy. Sections immunostained on day 1 and day 5 
of culture (n = 3 on each day) were examined. In each section, three regions of fixed size 
were selected in the left and the right superficial laminae (IIII). The number of positively 
labelled cells in each field was counted by visual inspection. ANOV A analysis was used 
to compare the number of positively labelled cells. 
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4.3 RESULTS 
4.3.1. Viability and topographical assessment of organotypically cultured spinal cord 
4.3.1.1. Selection of optimal age range of subjects for collection of spinal cord 
In preliminary studies, spinal cords were collected from a range of ages of embryonic and 
neonatal rats. Spinal cord harvested from embryonic and early neonatal rats were 
extremely fragile and difficult to stabilise and section. Spinal cord harvested from older 
rat pups aged 10-14 days was markedly more robust, was easily stabilised, and provided a 
good yield of anatomically intact transverse slices of spinal cord. For this reason, the 
majority of subsequent immunohistochemical studies were performed on organotypic 
cultures harvested from 10-14 day old rat pups. 
4.3.1.2. Selection of optimal thickness of transverse slicesfor organotypic culture 
The viability of cultured slices of spinal cord was qualitatively assessed using MTT and 
NADPH-d staining. Spinal cord slices were cultured for 5 days with minimal 
contamination (less than 1% of cultures were contaminated on day 5 of culture). All 
sections flattened (thinned) during the culture period. 
150 /lm sections were fragile and it was difficult to completely remove the surrounding 
agar prior to their transfer into culture wells. 150 /lm sections were of inferior anatomical 
integrity when compared with thicker sections. From a total of forty 150 /lm sections 
placed in culture, only 15 (37.5%) were suitable for further histochemical processing on 
day 5 of culture, as externsive cell death was evident in many slices. 150 /lm sections 
were also more susceptible than thicker sections to disintegration during fixation and 
immunocytochemical analysis. 
300 /lm sections displayed excellent anatomical integrity when examined under light 
microscopy and appeared on visual inspection under light microscopy to survive well in 
culture: from 20 sections placed in culture, 18 (90%) were considered on visual inspection 
to be suitable for immunocytochemical analysis. However, poor results were obtained 
from immunocytochemical procedures performed on 300 /lm sections: many sections 
failed to give positive staining, while in those sections in which positive immunostaining 
was observed, individual neurons could not be identified due to the thickness of the slice. 
Sections cut at 200 /lm displayed excellent anatomical integrity when examined under 
light microscopy and appeared to survive well in culture: from forty 200 /lm sections 
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placed in culture, 36 (95%) were suitable (following visual inspection under light 
microscopy) for processing for immunocytochemical analysis. 
4.2.2. Qualitative assessment of cell survival in 200 ~m organotypic cultures 
4.3.2.1. MTT staining 
MTT staining of cultured 200 ~m sections of spinal cord is shown in Figure 4.1. Dense 
positive MTT staining was observed in freshly harvested spinal cord and on days 1-5 of 
culture. On visual inspection of 4 sections that were MTT stained on day 5 of culture, 80-
90% of each cultured section showed positive MTT staining (indicating cell viability). 
4.3.2.2. NADPH-diaphorase staining 
NADPH-d staining of cultured 200 ~m sections of spinal cord is shown in figure 4.2. 
NADPH-d positive neurons were identified throughout the grey matter of the spinal cord 
on days 1-5 of culture. Bipolar neurons with long, branching dendrites and profuse 
terminal arborisation, and neurons with shorter curving dendrites, were observed in 
superficial laminae. Positive staining of bipolar and multipolar neurons was also observed 
in lamina X adjacent to the central canal. Sparse NADPH-d positive neurons were also 
observed in laminae III-V and in the ventral hom. On visual inspection, the pattern of 
expression of NOS in cultured spinal cord did not change dramatically from that observed 
in freshly harvested spinal cord, while the number of NADPH diaphorase-positive cells 
appeared to diminish over time. 
4.3.2.3. Expression of CaMKIla immunoreactivity in cultured spinal cord 
CaMKIla-IR in cultured 200 ~m sections of spinal cord is shown in figures 4.3 and 4.4. 
CaMKIla-IR cells were identified in the grey matter of cultured spinal cord in freshly 
harvested tissue and on days 1-5 of culture. CaMKIIa-IR was expressed intensely in small 
neurons in the superficial laminae of the dorsal hom (Figure 4.3). Positively stained 
bipolar and multipolar neurons were also identified in deeper laminae of the dorsal hom, 
particularly adjacent to the central canal (figure 4.4). On day 1, 58 ± 4.8 CaMKIla-IR 
immunopositive cells were counted in each field of view in the superficial laminae, while 
on day 5, CaMKIla-IR 23 ± 7.8 immunopositive cells/field of view were detected on day 5 
(F[1,8] = 86.67, P < 0.001). 
Figure 4.1 234 
MTT staining of 200 11m transverse sections of lumbar spinal cord (10-14 days PN). 
Immediately post-euthanasia (A), or following l(B) or 5 (C) days in culture, 
sections were incubated in MTT solution (500 I1g/ml) for 2 hours. 
Mitochondrial activity in live cells was indicated by a colour change from yellow to 
purple. Non-viable cultures remained yellow. 
Dense positive staining was observed on days 1-5 of culture. 
Scale bar represents 0.5mm 
A 
B 
c 
Figure 4.2 235 
NADPH-d staining of 200 )lm transverse sections of lumbar spinal cord (10-14 days 
PN), after 1 (A, B) and 5 (C, D) days in organotypic culture. NOS positive neurons 
were identified in both the dorsal horn (A, C) and ventral (B, D) horns. 
Scale bar = 50 )lm 
A c 
B D 
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While the total number of CaMKlla.-IR cells decreased in culture, the morphology and 
location of CaMKlla. immunopositive cells identified on day 5 of culture appeared on 
visual inspection to be closely similar to that identified in CaMKlla. immunopositive cells 
in tissue sections prepared from freshly harvested spinal cord. 
4.3.3.4. Expression of /l-opioid receptor and met-enkephalin immunoreactivity in 
cultured spinal cord 
Expression of /lOR-IR and of met-enkephalin-IR in organotypic culture of 200 /lm 
sections of spinal cord is shown in figures 4.5 and 4.6. /lOR immunoreactive cells were 
identified in the grey matter of cultured spinal cord on days 1-5 of culture. Expression of 
/lO-IR was intense in the superficial dorsal hom (laminae IIII), identified in both the cell 
bodies of small neurons, and their extensively arborising dendrites (Figure 4.5). Scattered 
positively stained bipolar and multipolar neuronal cell bodies and axons were also 
identified in deeper laminae of the dorsal hom, particularly immediately adjacent to the 
central canal (Figure 4.6). On visual inspection under light microscopy, the morphology of 
/lOR-IR positive cells identified in cultured tissue appeared to be identical to that 
identified in /lOR-IR positive cells in tissue sections prepared from freshly harvested 
spinal cord. 
Met-enkephalin-IR was also identified in the grey matter of cultured spinal cord on days 1-
5 of culture. Met-enkephalin-IR was most intense in the superficial dorsal hom (laminae 
IIII), identified in both neuronal cell bodies and in their axons (Figure 4.5) but was also 
present in laminae IV-VII (Figure 4.6). On day 1, 31 ± 6.9 immunopositive cells were 
counted in each field of view in the superficial laminae, significantly greater than 19± 4.1 
immunopositive cells/field of view quantified on day 5 (F[I,8] = 13.42, P < 0.01). On 
visual inspection under light microscopy, the morphology of met-enkephalin-IR positive 
cells identified in spinal cord sections on day 5 of culture appeared to be identical to that 
identified in met-enkephalin-IR positive cells in tissue sections prepared from freshly 
harvested spinal cord. 
Figure 4. 3 
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CaMKIla immunoreactvity(IR) in 200 ~m transverse sections of lumbar spinal cord 
(10-14 days PN) in fresh (A) and cultured (B- D) spinal cord sections. Sections B,C 
and D were cultured for 24h, 3 days and 5 days respectively. 
Scale bar = 250 !lm 
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Figure 4.4 
CaMKIIa immunoreactivity (IR) in laminae IV-VII of the dorsal horn of 
the spinal cord in 200 /lm sections cultured for 5 days 
Scale bar = 40 /lm 
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Figure 4.5 
A, B: fl-opioid receptor (fl- OR) immunoreactivity (IR) in superficial laminae of the 
dorsal horn following 24h (A) or 3 days (B) of organotypic culture. 
Scale bar = 25 flm 
C, D: fl-OR -IR in lamina V (C) and lamina X (D). Scale bar = 50 flm 
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Figure 4.6 
Examples of met-enkephalin immunoreactive cells in laminae IV -VII in 
organotypic slice cultures. Scale bar = 50!lm 
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4.4. DISCUSSION 
This study demonstrates that 200 ~m transverse slices of postnatal spinal cord can be 
cultured successfully using a simple interface culture system. Histochemical and 
immunocytochemical assays indicated that the architecture of organotypically cultured 
spinal cord closely resembles that observed in-vivo, and, in contrast to previous methods of 
organotypic culture of post-natal spinal cord (Rothstein et al., 1993; Manabe et al., 1999), 
the organotypic spinal cord cultures prepared in study 4 did not require further processing 
or sectioning prior to immunocytochemical analysis. The method described in study 4 
thus provides a simple and extremely useful technique for the investigation of molecular 
mechanisms of spinal nociceptive transmission. 
4.4.1. Age-based selection of spinal cord tissue 
The selection of 10-14 day old rat pups for organotypic slice culture of spinal cord was 
based on a number of criteria. From a practical perspective, it was considerably more easy 
to harvest intact spinal cord from older rat pups than from foetal rats; preliminary studies 
with foetal spinal cord provided low numbers of poor-quality transverse sections of spinal 
cord compared with the consistent harvest of 15-20 anatomically intact sections of spinal 
cord obtained from each spinal cord derived from 10-14 day old rat pups. 
It has been reported previously that viability of organotypic culture declines as the 
maturity of the tissue from which the cultures are prepared increases (reviewed by 
Gahwiler et al., 1997). However, continued differentiation and maturation of embryonic 
and early neonatal spinal cord in organotypic culture is likely to disrupt the anatomical 
integrity of cultured slices and hinder research into molecular aspects of pain research, in 
which an accurate in-vitro representation of adult in-vivo spinal cord is the ideal objective. 
The selection of spinal cord harvested from 10-14 day old rat pups for use in organotypic 
culture studies was based on a compromise between these two conflicting factors. Delfs et 
al. (1989) investigated the effect of maturity on the viability of organotypic cultures of 
400 ~m sections of spinal cord (assessed qualitatively using phase contrast microscopy) 
maintained in-vitro for several weeks using a modified roller-tube culture technique. Delfs 
et aI., reported that organotypic cultures derived from younger animals (2-9 days old) 
survived better than those derived from older animals (12-16 days old); after 2 weeks in 
culture, 97% of cultures from 2-9 day old animals survived compared with 66% from older 
animals, while after 4 weeks in culture, 60% of cultures from 2-9 day old animals survived 
compared to only 4% from older animals. Rothstein et aI.(1993; 1994) and Rothstein & 
Kuncl (1995) reported that 95% of 300-350 ~m cultured sections of spinal cord harvested 
from 8 day old rat pups survived for at least 3 months in culture with maintenance of 
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excellent organotypic cellular organisation. Manabe et ai.(1999) successfully cultured 500 
!..Lm sections of spinal cord harvested from 11 day old rat pups. Thus there was a precedent 
for organotypic culture of spinal cord obtained from 10-14 day old rat pups, although all 
previous reports cultured sections which were considerably thicker than those used in 
study 4. 
Delfs et al.(1989) measured choline acetyltransferase immunoreactivity (CHAT-IR) and 
acetylcholinesterase (AChE) activity in organotypically-cultured sections derived from 
spinal cords harvested from 2-16 day old rat pups. They observed a disparity in AChE 
activity and CHAT-IR expression between dorsal and ventral horns in the early stages of 
culture which disappeared in sections cultured for longer periods. While AChE activity is 
present in the ventral hom at 5 days post-natum, it is does not develop in the dorsal hom 
until 2 weeks post-natum (Schenen, 1987). This observation demonstrates the 
continuation of maturation and differentiation of spinal cord harvested in the early post-
natal period in organotypic culture, and highlights the advantages of culturing spinal cord 
tissue harvested from more mature animals when cultures are destined for use in 
investigation of molecular aspects of pain transmission. 
4.4.2. Development of methodology for harvesting transverse sections of spinal cord 
The method used in study 4 for the preparation of organotypic culture of post-natal spinal 
cord was adapted from a method described by Pickering et ai., (1) for preparation of spinal 
cord slices (from 7-18 day old rat pups) to be used in acute patch-clamp 
electrophysiological studies. In the present study, stabilisation of the spinal cord in agar 
prior to sectioning, and use of a vibratome to collect transverse spinal cord sections, 
enabled the collection of anatomically intact 150-300 !..Lm sections suitable for organotypic 
culture. Although one recent study has described a similar technique, harvesting agarose-
embedded foetal and postnatal (8-16 days PN) spinal cord using a vibratome, the majority 
of previous reports of organotypic culture of postnatal spinal cord typically harvested 
considerably thicker transverse sections of spinal cord (300 !..Lm-1 mm) using a McIlwain 
tissue chopper. Since the thickness of the spinal cord slice critically determines its 
subsequent viability in culture and suitability for manipUlation and use in histochemical 
and immunocytochemical procedures, this technique for harvesting transverse sections of 
200!..Lm or less offers distinct advantages to the McIlwain technique described previously. 
4.4.3. Viability and topographical assessment of cultured spinal cord 
4.4.3.1. MTT Assay 
The MTT reduction assay, in which 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide is reduced to an insoluble purple formazan by the mitochondria of viable cells, 
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provides a simple and rapid colorimetric method of assessing cell viability, proliferation 
and cytotoxicity in culture systems (Leeder et al., 1988; reviewed by Liu et al., 1997) . 
The MTT assay has been used to assess cell survival in numerous dissociated cell culture 
systems, including neoplastic cells (Higashi et al., 2000; Padille et al., 2000), primary 
neuronal culture systems (Zhu et al., 19971; Blanc et al., 1998; Suuronin et al., 2000) and 
primary astrocyte culture systems (de Groot et a!., 1997). A strong MTT reaction was 
present in cultured sections of spinal cord on days 1-5 of culture, indicating a high level of 
cell survival in the culture system. This assay thus provided a simple and effective means 
of confirming culture viability prior to time-consuming selective immunocytochemical 
procedures. 
4.4.3.2. NADPH-diaphorase staining 
The reduced nicotinamide adenine dinucleotide phosphate diaphorase (NADPHd) assay in 
paraformaldehyde-fixed tissue has been reported previously as a useful marker of NOS 
expression in the central nervous system, providing highly detailed visualisation of NOS-
positive neurons down to their finest processes (Dawson et al., 1991; Hope et al., 1991; 
Valtschanoff et a!., 1991; Matsumoto et al., 1993). 
The location and morphology ofNADPH-d positive neurons in the spinal cord of the adult 
rat has been thoroughly described by Valtschanoff et al., (1991); Saito et al., (1994) and 
Nakamura (1997). These groups identified NADPHd activity in laminae I-VI of the dorsal 
hom, in the dorsal commisure, in lamina X adjacent to the central canal, and in the ventral 
hom. In study 4, the pattern of NADPH-d staining and the morphology of positively 
stained neurons in cultured spinal cord slices appeared (upon qualititative visual inspection 
using light microscopy) to closely resembled that described in freshly fixed tissue 
collected from adult rats (Valtschanoff et al., 1992). While there appeared to be a gradual 
decline in the number ofNADPH-d positive neurons over time in cultured spinal cord, the 
basic pattern of NADPH-d activity observed on day 5 of culture did not differ from that 
observed on day 1 of culture. Nitric oxide plays an important role in nociceptive 
transmission (Haley et al., 1992; Meller et al., 1992a,b) and has also been implicated in the 
induction and maintenance of synaptic plasticity in the central nervous system (Bohme et 
a!., 1991; O'Dell et al., 1991). This assay may, therefore, subsequently provide a useful 
technique for in-vitro investigation of the role of NO in spinal nociceptive transmission 
and central sensitisation. 
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4.4.3.3. Expression ojCaMKIla, JL-opioid receptor and met-enkephalin immunoreactivity 
Immunocytochemical techniques have been extensively used to investigate molecular 
aspects of receptor and transmitter behaviour in organotypic slice cultures of brain tissue 
(e.g. Dickie et al., 1996; Wevers et al., 1998; Gomez-Urquiho et al., 1999). In organotypic 
cultures of spinal cord sections, immunocytochemical techniques have been used 
previously to evaluate choline acetyltransferase expression (Delfs et al., 1989; Rothstein et 
al., 1993; Wetts & Vaughn, 1998) and cFos expression (Manatabe et al., 1999). No 
comprehensive immunocyctochemical assays of the expression of receptors or transmitters 
imlicated in nociceptive transmission in the spinal cord have been performed thus far in 
organotypically cultured spinal cord tissue. 
Since the superficial dorsal hom plays a dominant role in nociceptive transmission, it was 
of particular interest to evaluate viability and activity of neurons in this location in 
organotypic cultures of spinal cord. CaMKIla, ~-OR receptors, and met-enkephalin, a 
signal transduction agent, a neurotransmitter receptor and its ligand respectively, are all 
expressed in the dorsal hom of the spinal cord and contribute to the regulation of 
nociceptive transmission (discussed in chapters 1 and 3). Immunocytochemical analysis of 
CaMKIla, met-enkephalin and ~-OR receptor expression in organotypic cultures of spinal 
cord provided a useful method of assessing the viability and activity of 'nociceptive' 
neurons in organotypic cultures of spinal cord. 
CaMKIla immunoreactivity was clearly identified in the dorsal hom of organotypically-
cultured spinal cord. While concentrated in the superficial laminae of the dorsal hom, 
CaMKIla-IR cells were also identified in the lateral funiculus (immediately lateral to the 
dorsal hom), in laminae III-VI and in laminae X adjacent to the central canal, locations 
which correlate closely with the location of cell bodies of several ascending nociceptive 
tracts including the spinothalamic tract, the spinoreticular tract and the spinomesencephalic 
tract (Willis et al., 1995). a-CaMKII immunopositive cells were also identified in the 
dorsal and ventral corticospinal tracts in cultured spinal cord on days 1-5. The pattern of 
expression of CaMKIla in cultured spinal cord correlates closely with that observed in 
freshly fixed sections derived from adult rats (Terishima et aI., 1994). This group reported 
strong CaMKIla expression in neurons in laminae I-IV, while laminae IV-X and the 
ventral hom were CaMKIla immunonegative. CaMKIla immunoreactivity was ascribed 
by Terishima et al. (1994) to three locations: presynaptic terminals, central processes of 
dorsal root ganglia, and dendritic processes of dorsal hom neurons. 
~-OR and met-enkephalin-immunopositive cells were identified in organotypically 
cultured sections of spinal cord on days 1-5 of culture, concentrated in the superficial 
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laminae and in lamina X adjacent to the central canal. While there was a gradual decline 
in the number of immunopositive cell numbers identified in the dorsal hom over time, the 
pattern of ~-OR and met-enkephalin immunoreactivity on day 1 of culture was closely 
similar to that observed on day 5 of culture, and appeared on visual inspection to closely 
resemble the pattern of expression in freshly harvested spinal cord tissue, fixed 
immediately post-euthanasia. 
The pattern of expression of met-enkephalin and ~-OR in the dorsal hom of organotypic 
cultures of spinal cord correlates closely to that which has been reported previously in 
fixed spinal cord derived from adult animals. The immunohistochemical localisation of 
the ~-opioid receptor has been thoroughly characterised. While ~-OR's are concentrated 
in laminae I and II (Arvidsson et al., 1995; Mansour et al., 1994; 1995), they are also 
located in deeper laminae of the dorsal horn (Mansour et al., 1994; 1995; Gouarderes et 
al., 1985). The morphological localisation of ~-OR immunoreactivity in the dorsal hom in 
organotypic culture was consistent with previous reports of ~-OR in freshly fixed adult 
spinal cord (reviewed by Coggeshall & Carlton, 1997), where ~-OR immunoreactivity has 
been further localised to neuronal cell membranes, proximal dendrites and axonal fibres in 
the superficial dorsal horn (Arvidsson et ai., 1995), and predominantly to cell bodies in 
deeper laminae (Mansour et al., 1995). Similarly, the morphological localisation of met-
enkephalin expression identified in organotypic culture was consistent with previous 
reports of met-enkephalin expression in freshly fixed adult spinal cord (reviewed by 
Merchentaler et at, 1986), where met-enkephalin expression has been further localised to 
neuronal cell bodies and dendrites in the dorsal hom (Hokfelt et al., 1977a; b;1979; Finley 
et at., 1981; Merchentaler et at., 1986). 
4.5 CONCLUSIONS 
This study describes a method of organotypic culture of post-natal spinal cord using an 
interface culture system which permits easy visualisation of individual neurons and easy 
environmental manipulation of these neurons. Such a culture system offers great potential 
for future in-vitro investigation of molecular mechanisms involved in central nociceptive 
transmission. There are many potential applications of this technique to numerous 
disciplines of pain research, including the potential for combining electrophysiological 
techniques and electrical stimulation, with molecular biology techniques. For example, 
techniques used in hippocampal slice culture systems to investigate the molecular basis of 
synaptic plasticity in higher centres can be applied to investigate the molecular basis of 
synaptic plasticity in the spinal cord, with the distinct advantage over existing techniques 
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that specific stimuli can be applied over a prolonged or intermittent time scale. The 
expression of molecular agents implicated in pathophysiological pain transmission can be 
studied in a sensitive system which permits the evaluation of the effects of stimulation 
with specific neuromodulatory agents on the function of individual spinal neurons. 
Organotypic slice cultures should also facilitate evaluation of time-dependent changes in 
spinal neuronal behaviour, such as immediate early gene expression, and facilitate more 
detailed evaluation of the molecular consequences of repetitive noxious (chemical or 
electrical) stimulation of varying intensity. 
F or the purposes of the present study, maintenance of spinal cord sections in culture for 5 
days demonstrated the suitability of these cultures for use in investigations into molecular 
mechanisms of rapidly induced spinal neuroplasticity. In previous reports, organotypic 
cultures of thicker sections of spinal cord derived from neonatal rat pups have been 
successfully maintained in culture for up to 3 months (Rothstein et at., 1993; 1995; 
Rothstein & Kuncl, 1995). It should be possible to maintain these sections of spinal cord 
for a prolonged period, which may be of use in studies into the molecular basis of 
persistent pain conditions. 
CHAPTER 5: GENERAL DISCUSSION 
Pain only exists ill the understanding 
Descartes 
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This study presents a new approach to the investigation of neuronal plasticity associated 
with tissue injury and inflammation. Wall (1999) recently speculated that classical dogma 
of a hard-wired, modality-dedicated relatively static pain transmission system had been 
superceded by the concept of pain perception as a considerably more complex 'need state' 
in which higher centres analyse and integrate nociceptive input, reacting in an appropriate 
manner through a battery of descending inhibitory and facilitatory pathways. In order to 
fully embrace this new concept of the 'pain system', strategies must be developed to 
facilitate investigation of every aspect of the central response to injury, not only those 
responses (predominantly excitatory) induced by severe injury. 
5.1 Characterisation of nociceptive plasticity associated with mild inflammatory 
injury 
Research into mechanisms of central nociceptive plasticity induced by inflammatory injury 
has classically concentrated on 'excitatory' plasticity of central nociceptive transmission, 
induced by induced by intense inflammatory injury resulting in extensive research into 
mechanisms underlying central sensitisation (reviewed by Dubner & Ruda, 1992; Yaksh, 
1999). Although spinal and supraspinal mechanisms of pro-nociceptive and anti-
nociceptive plasticity have been well characterised, existing knowledge about endogenous 
'anti-hyperalgesic' mechanisms which the body engages to restore 'nociceptive 
homeostasis' has not yet been integrated into a clinically useful context and interpreted in 
parallel with those mechanisms which trigger pathophysiological maladaptation associated 
with central sensitisation and persistent hyperalgesia. 
Millan (1999) speculated that the traditional emphasis on research into mechanisms 
underlying the induction of pathological pain sensation, rather than into endogenous 
mechanisms which adapt to or attenuate nociceptive transmission, reflected general 
frustration with attempts to develop novel analgesic or anti-hyperalgesic strategies based 
on the principle of engagement of endogenous antinociceptive mechanisms. Such 
frustration, in tum, could reflect the limitations of the high-intensity inflammatory model 
for facilitating evaluation of the endogenous adaptive response to injury. Improved 
understanding of the mechanisms underlying the engagement of endogenous 
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antinociceptive pathways may lead to the development of new strategies to combat 
persistent and other pathophysiological pain states. 
The present studies demonstrate that plasticity of nociceptive responses induced by mild 
repetitive inflammatory challenge differs in several respects from the plasticity induced by 
intense acute inflammatory injury. 
Mild inflammation induced by a dose of 0.25 mg carrageenan induced consistent 
inflammation, accompanied by thermal and mechanical hyperalgesic behaviour of similar 
magnitude to that induced by the doses of carrageenan (2-6 mg) standardly used to 
investigate nociceptive plasticity induced by inflammatory injury. This observation 
suggests that high-intensity models of inflammatory injury are unnecessary- and, from an 
animal welfare perspective, highly undesirable. Moreover, different mechanisms 
underlying plasticity of nociceptive responses may be induced by high intensity as opposed 
to low-intensity injury. High intensity injury may disable the engagement of effective 
endogenous adaptive mechanisms, making further investigations into physiological 
adaptation to injury impossible. 
5.2 Investigation of molecular mediators implicated in the induction and maintenance 
of nociceptive plasticity 
Knowledge of the molecular basis of central nociceptive plasticity is constantly evolving, 
reflecting the enormous number of interacting neurotransmitter and receptor systems that 
orchestrate the nociceptive response. In-situ hybridisation studies were performed to 
investigate the potential involvement of numerous molecular agents, previously implicated 
in neuronal plasticity in higher centres, in plasticity of nociceptive transmission in the 
spinal cord. The in-situ hybridisation studies presented in this thesis indicate that changes 
in the expression of CaMKlla, COX-2 and enkephalin mRNA in laminae IIII of the dorsal 
hom may contribute to the induction and/or maintenance of central nociceptive plasticity 
induced by mild inflammatory injury. 
As a signal transduction enzyme capable of regulating activity of many intracellular 
processes, CaMKlla gene regulation clearly offers the potential to enhance or attenuate 
ascending nociceptive transmission, and it is highly likely that the consequences of 
CaMKIla gene regulation are critically influenced by the intensity of the original stimulus. 
Low-dose carrageenan treatment dose-dependently induced unilateral upregulation of 
CaMKIla gene expression. A significant reduction in the magnitude of ipsilateral CaMKlI 
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a gene expression coincided with tachyphylaxis of hyperalgesic behaviour following daily 
repeated low-dose carrageenan treatment. Since enhanced CaMKIla expression is a 
hallmark of L TP in higher centres, this evidence suggests that the development of 
hyperalgesia following inflammatory injury may in part reflect L TP of spinal nociceptive 
. transmission. Since CaMKIla has the potential to modulate both excitatory and inhibitory 
nociceptive transmission, further studies are clearly indicated to identify the pathways 
targeted by altered CaMKIla gene expression in association with differing intensities of 
inflammatory injury. 
Simultaneous upregulation ofCOX-2, an enzyme which synthesises 'excitatory' 
neuromodulatory prostaglandin molecules, and of proenkephalin, a classical 
'antinociceptive' neurotransmitter illustrates the inherent duality of the central nociceptive 
response to injury, and its capacity for fine-tuned modulation of nociceptive responses in 
response to stimulations of differing intensity. 
While a clear dose-dependent relationship between COX-2 gene expression in laminae IIII 
and hyperalgesic behaviour associated with inflammatory injury was evident following 
weekly carrageenan treatment (0.25 mg and 0.05 mg), no clear relationship was observed 
between COX-2 mRNA expression and the observed plasticity of nociceptive responses 
induced by daily low-dose (0.05 mg) carrageenan treatment. Similarly, proenkephalin 
mRNA was unilaterally upregulated in response to mild inflammatory injury in an 
intensity-dependent fashion, but no clear relationship was observed between proenkephalin 
mRNA expression and the observed plasticity of nociceptive responses induced by daily 
repeated low-dose carrageenan treatment. The involvement of COX-II (prostaglandin) and 
enkephalin-mediated mechanisms in nociceptive plasticity would thus appear to depend 
critically upon the intensity and frequency or duration of injury. 
The in-situ hybridisation studies presented in this thesis identified a pattern of gene 
induction associated with mild inflammatory injury, which differed from that reported in 
association with high-intensity injury. Prodynorphin and immediate early gene mRNA 
induction associated with mild inflammatory injury was markedly lower than that 
previously reported following intense inflammatory injury. The magnitude of ipsilateral 
upregulation oftPA,junD, zif268; COX-I; prodynorphin; and GAD 67 identified in the 
present study did not appear to be directly related to the intensity of inflammatory injury or 
to the intensity of hyperalgesic behaviour, since a similar magnitude of up regulation was 
observed following saline or carrageenan treatment. 
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With the exception of CaMKIIa, no close correlation was identified between the 
attenuation of hyperalgesic behaviour induced by daily repetitive mild inflammatory 
stimulation, and gene expression investigated using in-situ hybridisation studies. While it 
is possible that the limited time-points at which target genes were analysed could have led 
to failure to identify transient alterations in expression of certain genes, particularly 
immediate early genes, as potential mediators of the observed nociceptive plasticity, it is 
also highly likely that tachyphylaxis of hyperalgesia observed in following daily repeated 
carrageenan treatment was mediated through alternative spinal neuromodulatory pathways 
or indeed through supraspinal (or peripheral) mechanisms, that were beyond the scope of 
the present study. 
In conclusion, the present study indicated that mild inflammatory injury induced changes 
in expression of certain molecular mediators of neuronal plasticity (most notably CaMKII 
a, COX-2 and potentially proenkephalin), but not of immediate early genes, GAD 67 or 
prodynorphin. Having identified a potential role for CaMKIIa, COX-2 and enkephalin in 
the mediation of central nociceptive plasticity induced by mild inflammatory injury, the 
contribution of these agents clearly warrants further investigation. 
While the role ofCOX-2 in the mediation of nociceptive transmission (as distinct to its 
role in the generation of inflammation) has been extensively investigated in the past, 
associated with the development of non-steroidal anti-inflammatory drugs as analgesic 
agents, it is only relatively recently that the involvement of COX-2 in modulation of 
central nociceptive plasticity has been recognised. Numerous research strategies offer the 
potential for more thorough evaluation of the roles of these, and other newly identified, 
agents in mediating central plasticity following mild inflammatory injury, including 
administration of highly specific agonistsl antagonists and studies using transgenic mice 
(in which the effects of specific gene deletion or gene over-expression on nociceptive 
responses may be investigated) 
Linking observations of behavioural plasticity, and plasticity of gene expression, 
associated with repetitive inflammatory injury 
A primary aim of the research presented in this thesis was to investigate and identify 
similarities between central plasticity of neuronal transmission in higher centres- most 
notably the hippocampus- which have been heavily implicated in the development of 
'memory', and central plasticity of nociceptive transmission in the spinal cord as a 
mechanism for the development of a 'memory of pain' (persistently enhanced pain 
251 
perception) or physiological adaptation to mild injury (persistently attenuated pain 
perception). Further investigation into the mechanisms underlying nociceptive plasticity 
induced by mild inflammatory injury may provide valuable new insights into endogenous 
'anti-hyperalgesic'mechanisms. However, extensive characterisation of the mediation of 
endogenous 'anti-hyperalgesia' is clearly indicated. 
In the first instance, the sites- spinal, supraspinal or peripheral- at which modulation of 
hyperalgesia induced by mild repetitive inflammatory injury occurs- must be identified. 
Studies on spinalised rats using a model oflow-dose repetitive carrageenan model may be 
indicated to facilitate identification of the role of descending modulatory pathways in the 
induction of tachyphylaxis of hyperalgesia. Having identified these sites, and using the 
results of the present in-situ hybridisation studies as indicators of certain molecular agents 
implicated in the mediation of this tachyphylaxis, techniques such as differential display, 
microarrays and gene grid analysis may provide new insights into the pharmacological 
basis of adaptive nociceptive plasticity induced by mild injury, while facilitating more 
thorough analysis of the regulation of transiently-expressed genes (including immediate 
early genes) over a prolonged time span so that their involvement in the induction and 
maintenance of central nociceptive plasticity can be assessed more thoroughly. 
Tachyphylaxis of nociceptive transmission associated with mild repetitive inflammatory 
injury potentially provides a behavioural correlate for LTD of central nociceptive 
transmission. If, as has been hypothesised (Sandkuhler, 2000), therapeutic TENS achieves 
pain relief in persistent pain conditions through the induction of LTD of pain transmission 
in primary afferent fibres and spinal projection neurons in the dorsal hom, then it is 
reasonable to speculate that similar endogenous mechanisms may mediate physiological 
'anti-hyperalgesia' following mild inflammatory injury. Further investigation of this 
hypothesis is clearly indicated, potentially using electrophysiological studies to identify 
changes in responsiveness of neurons in the spinal cord and in higher centres associated 
with mild repetitive inflammatory injury. 
Sherrington apocryphally described a human patient suffering from chronic pain as 'a slice 
preparation that could talk'; conversely, a 'living' slice preparation could offer valuable 
insights into mechanisms underlying conscious pain sensation, and could identify new 
pharmacological targets for pain control. The method for organotypic slice culture of 
neonatal rat spinal cord tissue described in this study provides a means of investigating the 
responses and interaction of individual spinal neurons following stimulation with specific 
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neuromodulatory agents or electrical stimuli. This technique should also facilitate analysis 
of the interaction of mediators involved in central nociceptive. 
In conclusion, this thesis provides a new perspective on the approach to understanding 
plasticity of pain transmission, and a novel technique for the study of molecular processes 
involved in nociceptive transmission in the spinal cord. The nature of pain remains a 
mystery. Improved understanding of the nature of pain transmission is of universal 
importance. It is to be hoped that this study may have taken some steps towards 
elucidating 'the truth' of the mystery of pain transmission, which - if complex- is still out 
there ... 
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